angiotensin ii has been researched along with Heart Failure in 991 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 169 (17.05) | 18.7374 |
| 1990's | 225 (22.70) | 18.2507 |
| 2000's | 321 (32.39) | 29.6817 |
| 2010's | 195 (19.68) | 24.3611 |
| 2020's | 81 (8.17) | 2.80 |
| Authors | Studies |
|---|---|
| Agra, RM; Almengló, C; Álvarez, E; Couselo-Seijas, M; Eiras, S; García-Acuña, JM; González-Juanatey, JR; González-Peteiro, M; Varela-Román, A | 1 |
| Chen, Y; Gong, W; Liu, L; Meng, G; Shen, J; Wang, Y; Zhang, S | 1 |
| Chen, L; Geng, Q; Jiang, W; Li, N; Wang, B; Wang, W; Xiong, R | 1 |
| Cao, JW; Gao, J; Hu, LL; Huang, ZR; Ji, Y; Song, TY; Wang, ZY; Xie, LP; Zhao, S | 1 |
| Feng, Y; Geng, C; Li, Z; Tang, Y; Wang, J; Yang, H; Yang, Y; Zhao, H | 1 |
| Bajpai, G; Bredemeyer, A; Feng, G; Förster, I; Koenig, A; Kreisel, D; Lai, L; Lavine, KJ; Leuschner, F; Lokshina, I; Ma, P | 1 |
| Lin, L; Liu, A; Mei, Y; Xun, S; Zhang, Y; Zhou, G | 1 |
| Liu, X; Tu, Y; Warusawitharana, HK; Xia, C; Yang, Y; Zhou, H | 1 |
| Hu, J; Liu, Y; Wang, Q; Wang, W | 1 |
| Guo, S; Qian, W; Shen, L; Yang, Y; Yao, Y; Zhou, G; Zhou, J | 1 |
| Han, X; Li, G; Liang, G; Liang, S; Long, X; Luo, W; Sun, J; Wang, M; Yu, T; Zhang, Y | 1 |
| Subbaiah, KCV; Tang, WHW; Wu, J; Yao, P | 1 |
| Dong, R; Du, T; Ferrucci, L; Hu, X; Jin, Y; Liu, H; Pang, H; Sun, L; Tanaka, T; Tang, X; Tian, R; Tian, Z; Wang, H; Wang, L; Xiao, S; Xiao, Y; Yang, X; Ye, Y; Zhang, S; Zhang, Y | 1 |
| Chattipakorn, N; Chen, R; Chen, Y; Dai, C; Huang, W; Liang, G; Luo, W; Shen, S; Wang, J; Wang, Z | 1 |
| Chen, R; Das, S; Jin, B; Li, G; Li, J; Sha, Z; Wang, S; Wang, Z; Xiao, J; Xu, J; Xu, W; Yan, Y; Yang, L; Yang, T; Yao, J; Yuan, W; Zhu, X | 1 |
| Abdelhamid, M; Adamopoulos, S; Anker, SD; Bayes-Genis, A; Ben Gal, T; Böhm, M; Chioncel, O; Coats, AJS; Filippatos, G; Jankowska, EA; Lopatin, Y; Lund, L; Metra, M; Milicic, D; Moura, B; Mullens, W; Piepoli, M; Rakisheva, A; Ristic, A; Rosano, G; Savarese, G; Seferovic, P; Thum, T | 1 |
| Cheng, G; Li, X; Liao, S; Lu, W; Wu, J; Zhu, H | 1 |
| Cai, Z; He, B; Li, Y; Shen, L; Sun, Z; Wang, X; Xiao, Q; Xu, K; Xu, L; Yang, W; Yang, X; Yin, A; Yuan, R; Zhang, W; Zhou, B; Zhuang, F | 1 |
| Gao, Y; Guo, X; Hu, L; Li, Y; Liu, Y; Ma, S; Tang, J; Wang, Z; Wei, J; Zhang, Q; Zhang, X; Zhang, Y | 1 |
| Hu, TT; Tang, QZ; Wan, Y; Wu, QQ; Xie, QW; Yao, Q; Yuan, Y; Zhao, JH | 1 |
| Li, G; Liang, G; Liang, S; Luo, W; Sun, J; Wang, M; Yu, T; Zou, C | 1 |
| Ji, M; Li, Y; Liu, Y; Ma, G | 1 |
| Chen, M; Lu, Y; Ma, L; Wang, Z; Xu, H; Zheng, L | 1 |
| Liang, G; Luo, W; Shan, P; Wang, M; Wang, Y; Wu, G; Xu, D; Yang, N; Zou, C | 1 |
| Červenka, L; Gawrys, O; Jíchová, Š; Kala, P; Kompanowska-Jezierska, E; Maxová, H; Miklovič, M; Sadowski, J; Škaroupková, P; Táborský, M; Vaněčková, I; Vaňourková, Z; Veselka, J; Walkowska, A | 1 |
| Bottermann, K; Deenen, R; Fischer, JW; Gödecke, A; Grandoch, M; Harris, TE; Hemmers, A; Herebian, D; Kalfhues, L; Köhrer, K; Leitner, LM; Nederlof, R; Nemmer, J; Oenarto, V; Petzsch, P; Pfeffer, M; Raje, V; Reichert, AS; Stegbauer, J; Zabri, H | 1 |
| Akiba, Y; Fukuda, K; Funahashi, A; Hashimoto, H; Katsuki, T; Kimura, M; Komuro, J; Kuoka, T; Kusumoto, D; Nakamura, T; Seki, T; Tokuoka, Y; Yamada, T; Yuasa, S | 1 |
| Dai, C; Huang, W; Li, W; Li, X; Liang, G; Luo, W; Shen, S; Wu, G | 1 |
| Ahmed, MM; Bavry, AA; Mahmoud, A; Meece, LE; Taha, Y | 1 |
| Cui, Y; Song, X; Zhu, T | 1 |
| Barthuber, C; Boege, F; Dechend, R; Heidecke, H; Karschnia, M; Kaufmann, S; Kelm, M; Roden, M; Scheiber, D; Szendrödi, J; Westenfeld, R; Zweck, E | 1 |
| An, Y; Chen, L; Liu, D; Liu, G; Liu, Y; Miao, M; Wang, W; Wei, M; Yang, L; Yin, Y; Zheng, M | 1 |
| Dong, Z; Li, T; Lu, J; Sheng, S; Shi, Y; Yuan, M; Yue, L | 1 |
| Nguyen, J; Vandemark, C; Zhao, ZQ | 1 |
| Achenbach, S; Bosch, A; Kannenkeril, D; Kolwelter, J; Ott, C; Poglitsch, M; Rauh, M; Schiffer, M; Schmieder, RE; Striepe, K | 1 |
| Fu, G; Gong, Y; Han, X; Huang, H; Huang, W; Liang, G; Long, X; Luo, W; Wang, Y; Wu, L; Ye, S; Ye, Y; Zhao, X | 1 |
| Kopkan, L; Kratky, V; Sykora, M; Szeiffova Bacova, B; Tribulova, N | 1 |
| Althammer, F; Biancardi, VC; Campos-Lira, E; Danh, J; Davis, S; Feresin, R; Ferreira-Neto, HC; Kirchner, MK; Montanez, J; Parent, MB; Roy, RK; Stern, JE; Whitley, KE; Zafar, U | 1 |
| Chen, A; Fei, X; Fu, H; Han, Y; Xu, Y; Zhang, F; Zhu, X | 1 |
| Kokkonen-Simon, K; Kovacs, A; Li, T; Matkovich, SJ; Matsiukevich, D; Oladipupo, SS; Ornitz, DM | 1 |
| Li, A; Liang, G; Luo, W; Wang, M; Wei, J; Xu, J; Xu, X; Yu, T | 1 |
| Cai, L; Chen, S; Chen, X; Ding, Y; Li, J; Li, X; Li, Y; Liu, S; Lu, X; Wei, Y; Wu, X; Xu, J; Zhou, G | 1 |
| Bizé, A; Boucher, P; Brehat, J; Chiaroni, PM; Corboz, D; Dai, J; de Pommereau, A; Denormandie, P; Gallet, R; Germain, S; Ghaleh, B; Lacampagne, A; Marbán, E; Mouri, N; Pallot, G; Panel, M; Sambin, L; Su, JB; Teiger, E; Thery, G | 1 |
| Abassi, Z; Aronson, D; Cohen-Segev, R; Hamoud, S; Kabala, A; Karram, T; Kinaneh, S; Nativ, O | 1 |
| Chen, J; Ma, E; Peng, L; Ren, DN; Wo, D; Wu, C; Yan, H; Zhu, W | 1 |
| Alcalai, R; Arad, M; Guetta, T; Hochhauser, E; Kornowski, R; Ofek, E; Petrover, Z; Seidman, CE; Seidman, J; Yadin, D | 1 |
| Fan, D; Hu, C; Kong, CY; Ma, ZG; Song, P; Tang, QZ; Teng, T; Wei, WY; Yuan, YP; Zhang, X | 1 |
| Červenka, L; Honetschlägerová, Z; Kompanowska-Jezierska, E; Kujal, P; Maxová, H; Sadowski, J; Táborský, M | 1 |
| Bin, J; Chen, L; He, M; Li, M; Liao, W; Liao, Y; Lin, H; Lu, W; Ma, S; Shen, M; Xie, J; Xiu, J; Zheng, C; Zhu, Y | 1 |
| Alla, JA; Langer, A; Nerger, E; Quitterer, U | 1 |
| Bangwei, Z; Bin, S; Huan, P; Jiming, W; Jing, J; Jinlai, G; Shihui, L; Xiaochun, Z; Xiaoqin, Z; Xinyi, F; Yi, H; Zhouqi, L; Ziyue, L | 1 |
| Han, X; Liang, G; Luo, W; Tu, Y; Wang, M; Wang, Q; Wang, Y; Xu, J; Yu, T | 1 |
| Aubdool, A; Baliga, RS; Bedi, KC; D'Amico, G; Dukinfield, M; Hobbs, A; Hodivala-Dilke, K; Maiques, O; Maniati, E; Margulies, KB; Reynolds, LE; Sanz-Moreno, V; Wang, J | 1 |
| Červenka, L; Imig, JD; Kikerlová, S; Kolář, F; Kompanowska-Jezierska, E; Melenovsky, V; Sadowski, J; Vacková, Š | 1 |
| Filippatos, G; Mancia, G; Manolis, A; Marathias, KP; Papademetriou, V; Tsioufis, C; Vlahakos, DV | 1 |
| Červenka, L; Husková, Z; Kikerlová, S; Kolář, F; Krátký, V; Sadowski, J | 1 |
| Bishop, E; Bordas, M; Chowdhury, SR; Cossette, SM; Gupta, A; Harmann, LM; Kumar, SN; Lu, Q; Pan, AY; Ramchandran, R; Simpson, PM; Sonin, DL; Spearman, AD; Strande, JL; Thirugnanam, K; Zou, MH | 1 |
| Chen, W; Gao, G; Liu, J; Luo, H; Wang, C; Yan, M; Yang, P | 1 |
| Gong, X; He, J; Li, Y; Lu, Y; Song, X | 1 |
| Guo, X; Jiang, X; Lu, C; Qu, F; Zhang, Y | 1 |
| Tao, L; Yang, X; Zhang, S; Zhu, J | 1 |
| Finger, S; Garlapati, V; Karbach, SH; Knopp, T; Knorr, M; Kossmann, S; Lagrange, J; Molitor, M; Münzel, T; Nguyen, TS; Rudi, WS; Ruf, W; Schüler, R; Wenzel, P; Wild, J | 1 |
| Gotoh, T; Hoshizaki, M; Imai, Y; Inagaki, T; Koyota, S; Kuba, K; Minato, T; Motoyama, S; Nakahara, K; Nakaoka, Y; Natsui, M; Nirasawa, S; Ozawa, R; Penninger, JM; Sato, T; Takahashi, S; Watanabe, H; Yamaguchi, T; Yokota, S; Yoshihashi, T; Yoshiya, T; Yoshizawa-Kumagaye, K | 1 |
| Guo, H; Lu, T; Wang, C; Wang, H; Xing, D; Yang, J; Zhong, S | 1 |
| Gao, L; Guo, S; Li, Y; Liu, Y; Shen, J; Shi, Q; Xiao, F; Xing, S; Yang, F; Zhang, W; Zhao, L | 1 |
| Aslam, N | 1 |
| Azizi, M; Balavoine, F; Boitard, SE; Llorens-Cortes, C; Marc, Y | 1 |
| Birner, C; Dietl, A; Domenig, O; Hirt, S; Jungbauer, C; Luchner, A; Maier, LS; Messmann, R; Schmid, C; Schopka, S; Wagner, S | 1 |
| Bao, Y; Dai, Y; Jia, K; Jin, Q; Li, X; Liu, A; Lu, L; Wu, L | 1 |
| Dong, Z; Ge, J; Hu, K; Li, W; Sun, A; Sun, X; Wu, J; Yin, L | 1 |
| Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J | 1 |
| Li, Y; Liu, L; Ruan, Z; Wang, G; Wang, R; Zhu, L | 1 |
| Bianchi, K; Crespo-Leiro, MG; Domenech, N; Eaton, P; Eykyn, TR; Fernandez-Caggiano, M; Francois, AA; Kamynina, A; Krasemann, S; Morales, V; Prysyazhna, O; Vieites, MG | 1 |
| Barreto-Chaves, MLM; Couto, GK; Fontes, MT; Lino, CA; Mill, JG; Paula, SM; Rossoni, LV; Senger, N | 1 |
| Choy, A; Chung, MK; Khodadadi-Jamayran, A; Lin, X; Narke, D; Offerman, E; Park, DS; Shaheen, D; Shekhar, A; Van Wagoner, DR; Wass, SY; Xiao, J; Yamaguchi, N | 1 |
| Bers, DM; Bossuyt, J; Hegyi, B; Ko, CY | 1 |
| Gu, J; Ji, Y; Lu, Y; Qian, Z; Qiu, M; Sun, W | 1 |
| Červenka, L; Gawrys, O; Hejnová, L; Honetschlagerová, Z; Husková, Z; Jíchová, Š; Kikerlová, S; Kolář, F; Kompanowska-Jezierska, E; Kujal, P; Melenovský, V; Novotný, J; Sadowski, J; Škaroupková, P; Vaňourková, Z | 1 |
| Carubelli, V; Di Pasquale, M; Garrafa, E; Inciardi, R; Lombardi, C; Metra, M; Oriecuia, C; Peveri, G; Specchia, C; Tomasoni, D | 1 |
| De Pergola, G; Giagulli, VA; Guastamacchia, E; Iovino, M; Lisco, G; Pesce, A; Triggiani, V; Vanacore, A | 1 |
| Alexis, JD; Ashton, JM; Burke, RM; Dirkx, RA; Lighthouse, JK; Mohan, A; O'Brien, M; Phipps, RP; Quijada, P; Small, EM; Woeller, CF; Wojciechowski, W | 1 |
| Arfsten, H; Bartko, PE; Domenig, O; Goliasch, G; Hengstenberg, C; Hülsmann, M; Mascherbauer, J; Pavo, N; Poglitsch, M; Prausmüller, S; Spinka, G; Strunk, G; Uyanik-Ünal, K; Wurm, R; Zuckermann, A | 1 |
| Alam, A; Burkhoff, D; Enter, DH; Jermyn, R | 1 |
| Ding, H; Li, J; Li, Y; Mei, Y; Wang, W; Zhang, R; Zhou, H | 1 |
| Chen, S; Daugherty, A; Lin, Y; Lu, HS; Mullick, AE; Ning, L; Rong, J; Shi, P; Tao, X; Wang, J; Xu, Y; Zhang, Z; Zheng, H | 1 |
| Cambrón-Mora, D; Garcia-Garduño, TC; Padilla-Gutierrez, JR; Valle, Y | 1 |
| Boroviak, K; Chavkin, N; Domingues, AF; Doviak, H; Evans, MA; Horitani, K; Katanasaka, Y; Min, KD; Miura-Yura, E; Ogawa, H; Philippos, G; Polizio, AH; Sano, M; Sano, S; Vassiliou, G; Walsh, K; Wang, Y; Yura, Y | 1 |
| Cheng, T; Fan, P; Hua, C; Wang, J; Xia, Q; Zhang, L; Zhao, L; Zhou, J | 1 |
| Fukamizu, A; Ho, L; Imai, Y; Ishida, J; Ito, H; Kadowaki, A; Kimura, A; Kuba, K; Penninger, JM; Reversade, B; Sato, C; Sato, T; Watanabe, H; Yamaguchi, T | 1 |
| Allen, BG; Chatenet, D; Fournier, A; Harada, M; Merlen, C; Nattel, S; Naud, P; Qi, X; Surinkaew, S; Tadevosyan, A; Xiao, J | 1 |
| Arkell, AM; Brunt, KR; Eadie, AL; Foster, AJ; Gillis, TE; Huber, JS; Murrant, CL; Platt, MJ; Romanova, N; Simpson, JA; Wright, DC | 1 |
| Gao, Y; Hu, D; Li, J; Li, Y; Shang, H; Xing, Y; Zhang, Y | 1 |
| Kittana, N | 1 |
| Fraidenburg, DR; Han, Y; Ren, X; Sun, S; Tang, H; Zhang, F; Zhao, M; Zhao, Z | 1 |
| Ahmad, S; Ferrario, CM; Groban, L; Lin, M; Sun, X; Varagic, J; Wang, H; Zapata-Sudo, G | 1 |
| He, B; He, W; Hu, H; Jiang, H; Liu, S; Lu, Z; Luo, D; Ma, R; Qin, Z; Xie, J; Yu, X | 1 |
| He, R; Sun, B; Sun, Y | 1 |
| Gao, J; Goodchild, TT; Kapusta, DR; Lefer, DJ; Li, Z; Polhemus, DJ; Scarborough, AL; Smart, FW; Trivedi, RK; Varner, KJ; Xia, H | 1 |
| Bach, D; Bode, D; Doerr, R; Guthof, T; Heinzel, FR; Hohendanner, F; Jeuthe, S; Pieske, BM; Primessnig, U; Reimers, S; Wakula, P; Zhang, K | 1 |
| Bai, J; Cao, HJ; Du, J; Guan, XM; Li, HH; Lin, QY; Liu, Y; Ma, XL; Wang, L; Xia, YL; Zhang, YL | 1 |
| E, X; Feng, Y; Gitau, SC; Li, T; Li, X; Liang, H; Liu, X; Qian, M; QiLi, M; Shan, H; Shen, Z; Wang, G; Xu, B; Zhang, Y; Zhao, D | 1 |
| Felder, RB; Wei, SG; Weiss, RM; Yu, Y | 1 |
| Du, W; Li, X; Xiao, X; Zhang, F; Zhang, S; Zhang, Y; Zhu, M | 1 |
| Meng, F; Tian, Z; Yan, M; Yang, P; Yang, S; Zhao, Z | 1 |
| Frank, DU; Saucerman, JJ; Sutcliffe, MD | 1 |
| Accornero, F; Dorn, LE; Petrosino, JM; Wright, P | 1 |
| Cai, YY; Chen, HY; He, JH; Jiang, W; Lan, J; Li, H; Li, RL; Li, X; Tang, CS; Wang, W; Wang, XX; Wu, SS; Wu, Y; Xin, JJ; Xue, KY; Zhang, HY; Zhuo, CL | 1 |
| Luo, X; Ma, Q; Wu, Y; Yu, J; Zhang, L; Zhang, Y | 1 |
| Agarwal, H; Barthwal, MK; Reddy, SS | 1 |
| Cornelissen, G; El-Kilany, G; Fedacko, J; Hristova, K; Singh, RB | 1 |
| Cheng, M; Hu, S; Huang, CX; Jiang, H; Liu, BL; Tu, X; Wang, L; Wang, S; Wu, G | 1 |
| Beak, JY; Bowles, DE; Huang, W; Jensen, BC; Jetten, AM; Kang, HS; Myers, PH | 1 |
| Brenes-Castro, D; Castillo, EC; García-Rivas, G; Torre-Amione, G; Vázquez-Garza, E | 1 |
| Cervenka, L; Huskova, Z; Kikerlova, S; Kolar, F; Kopkan, L; Kratky, V; Sadowski, J; Taborsky, M | 1 |
| Danhof, M; Giraudel, J; Mochel, JP; Peyrou, M; Rigel, DF; Teng, CH | 1 |
| Chen, C; Li, HH; Liu, Y; Xia, YL; Yan, X; Zhang, L; Zhang, YL; Zou, LX | 1 |
| Shah, AM; Zoccarato, A | 1 |
| Ba, L; Cao, Y; E, M; Fu, B; Qi, H; Ren, J; Shi, P; Song, C; Sun, H; Zhang, Q | 1 |
| Chen, P; Deng, Y; Feng, H; Huang, L; Ouyang, W; Wang, J; Wu, J; Xian, J; Zhu, G | 1 |
| Imai, Y; Ito, H; Kadowaki, A; Kuba, K; Sato, T; Suzuki, T; Watanabe, H | 1 |
| Chen, W; Fassett, J; Li, W; Liu, Z; Lu, Y; Qi, X; Tang, K; Weng, X; Xu, D; Xu, Y; Zhang, Y; Zhao, Y; Zheng, J | 1 |
| Ames, MK; Atkins, CE; Pitt, B | 1 |
| Becirovic-Agic, M; Ericsson, M; Hultström, M; Jönsson, S; Karlsen, TV; Leh, S; Lidén, Å; Nilsson, SK; Reed, RK; Skogstrand, T; Tveitarås, MK | 1 |
| Bi, HL; Cao, HJ; Han, L; Lai, S; Li, HH; Li, N; Wang, HX; Xie, X; Zhang, YL | 1 |
| Becirovic-Agic, M; Hultström, M; Jönsson, S | 1 |
| Li, Y; Lou, X; Lu, Y; Nasi-Er, BG; Sun, H; Tang, B; Zhang, J; Zhang, Y; Zhou, Q; Zhou, X | 1 |
| Chan, P; Chen, X; Cheng, Y; Li, Y; Liu, J; Liu, Z; Morrisey, E; Pi, J; Reilly, M; Shen, Y; Tomlinson, B; Wang, H; Yu, Z; Zhang, L; Zhang, Q; Zhang, Y; Zheng, X; Zhuang, T | 1 |
| Cao, C; Chang, J; Chen, X; Gao, E; Han, D; Li, J; Shen, D; Tang, J; Wang, B; Xiao, Y; Zhang, J; Zhao, W | 1 |
| Feng, YQ; Geng, QS; Hu, ZQ; Huang, L; Huang, YQ; Shan, ZX; Yu, XJ; Zhu, JN | 1 |
| Benedict, C; Cheng, Z; Cimini, M; de Lucia, C; Garikipati, VNS; Goukassian, DA; Kishore, R; Koch, WJ; Lucchese, AM; Roy, R; Truongcao, MM; Wang, C | 1 |
| Du, Y; Ge, W; Han, J; Jiang, L; Xu, J; Zhang, H | 1 |
| Alam, S; Barnes, GD; Carter, G; Cruden, NL; Hubbard, TJ; Huson, L; Japp, AG; Jeong, H; Lee, KM; Newby, DE; Pedersen, CM; Veitch, S; White, A | 1 |
| Gao, G; Guo, P; Luo, Y; Ma, Q; Sablok, G; Yang, M; Zhang, Y; Zhou, F | 1 |
| Chen, SA; Chen, YC; Chen, YJ; Chung, CC; Kao, YH; Kuo, CC; Lien, GS | 1 |
| Azuma, J; Ito, T; Schaffer, S | 1 |
| Hirose, M; Ishigami, A; Kobayashi, A; Kubota, I; Misaka, T; Miyata, M; Saitoh, S; Shishido, T; Suzuki, S; Takeishi, Y | 1 |
| Delafontaine, P; Galvez, S; Higashi, Y; Rezk, BM; Semprun-Prieto, L; Sukhanov, S; Tiwari, S; Yablonka-Reuveni, Z; Yoshida, T | 1 |
| Llewellyn, TL; Patel, KP; Sharma, NM; Zheng, H | 2 |
| Lopaschuk, GD; Mori, J; Oudit, GY; Zhang, L | 1 |
| Aiello, EA; Cingolani, HE; Ennis, IL; Perez, NG | 1 |
| Bigagli, E; Lodovici, M; Manni, ME; Musilli, C; Raimondi, L; Zazzeri, M | 1 |
| Higashimori, M; Ikeya, Y; Ishii, R; Kaneko, M; Komuro, I; Mano, T; Miwa, T; Ohtani, T; Omori, Y; Saito, Y; Sakata, Y; Takeda, Y; Tamaki, S; Tsukamoto, Y; Yamamoto, K | 1 |
| Fu, SY; Huang, Q; Jiang, J; Liu, FQ; Wang, JH; Xiu, CH; Xu, YS; Zhao, YJ | 1 |
| Chien, WM; Chin, MT; Liu, Y; Luchtel, DL; Medvedev, IO; Rosenfeld, ME; Weldy, CS | 1 |
| Banach, K; Burmeister, BT; Carnegie, GK; Conklin, BR; DeSantiago, J; Johnson, KR; Monasky, MM; Spindler, MJ; Taglieri, DM | 1 |
| Bucciarelli, L; Colombo, PC; Demmer, RT; Harxhi, A; Hayashi, Y; Jelic, S; Jorde, UP; Kebschull, M; LeJemtel, TH; Onat, D; Papapanou, P; Sabbah, HN; Schmidt, AM; Uriel, N | 1 |
| Bhat, G; Sayer, G | 1 |
| Burnett, JC; Cataliotti, A; Chen, HH; Ichiki, T; McKie, PM; Sangaralingham, SJ | 1 |
| Liu, K; Liu, Z; Yang, C; Yang, P | 1 |
| Alakoski, T; Kerkelä, R; Kivirikko, KI; Lipson, KE; Magga, J; Piuhola, J; Ruskoaho, H; Signore, P; Szabó, Z; Ulvila, J; Vainio, L; Vuolteenaho, O | 1 |
| Chen, D; Chen, LY; Gan, XB; Sun, HJ; Zhang, LL; Zhou, H; Zhou, YB | 1 |
| Cheng, W; Ge, J; Hou, Y; Hu, J; Li, Y; Lv, P; Niu, C; Wang, F; Yan, Y; Yang, Z | 1 |
| Cavasin, MA; Chen, B; Demos-Davies, KM; Ferguson, BS; Ferrara, C; Horn, TR; Jeong, MY; Mahaffey, JH; McKinsey, TA; Piroddi, N; Poggesi, C; Scellini, B; Schuetze, KB; Spiltoir, JI; Tesi, C; Williams, SM | 1 |
| Brum, PC; Casarini, DE; Couto, GK; de Oliveira, EM; Fernandes, FB; Fernandes, T; Ferreira-Filho, JC; Gomes-Santos, IL; Negrao, CE; Rossoni, LV; Salemi, VM | 1 |
| Calderone, A; Chabot, A; Dupuis, J; El Khoury, N; Fiset, C; Hertig, V; Jasmin, JF; Meus, MA; Nattel, S; Naud, P; Villeneuve, L | 1 |
| Ahmad, IM; Kabanov, AV; Manickam, DS; Rosenbaugh, EG; Savalia, K; Tian, J; Zimmerman, MC | 1 |
| Dai, Z; He, H; Huang, C; Meng, Y; Tang, Y; Wang, X; Xiao, J; Yu, S; Zhao, Q | 1 |
| Arutiunov, GP; Dragunov, DO; Sokolova, AV | 1 |
| Chai, X; Han, J; Li, C; Qiu, Q; Shi, T; Wang, W; Wang, Y; Wu, Y | 1 |
| Felder, RB; Wei, SG; Yu, Y; Zhang, ZH | 1 |
| Haack, KK; Zucker, IH | 1 |
| Cao, FF; Jiang, ZL; Li, YF; Liu, F | 1 |
| Chen, G; Ding, G; Jiang, R; Qian, X; Shen, B; Shen, M; Song, X; Wagner, MB | 1 |
| Re, RN | 2 |
| Frøkiær, J; Lütken, SC; Nielsen, S | 1 |
| Patel, KP; Schultz, HD; Wang, H; Zucker, IH | 1 |
| Esmaeli-Mahani, S; Masoomi, Y; Najafipour, H; Shahouzehi, B; Soltani Hekmat, A; Vakili, A; Yeganeh Hajahmadi, M | 1 |
| Asare, Y; Bruck, H; Heinze, G; Jankowski, J; Jankowski, V; Liehn, E; Machado, FB; Marx, N; Muñoz-Castañeda, JR; Pineda-Martos, C; Raya-Bermudez, A; Rodriguez, M; Salem, S; Staudt, M; Welker, P; Zidek, W | 1 |
| Li, YL; Liu, J; Muelleman, RL; Tu, H; Zhang, D; Zheng, H | 1 |
| Atar, D; Huang, L; Jordaan, P; Kompa, AR; Krum, H; von Lueder, TG; Wang, BH; Webb, R | 1 |
| De Mello, WC | 6 |
| Červenka, L; Husková, Z; Melenovský, V; Nishiyama, A; Sadowski, J; Škaroupková, P | 1 |
| Bürgelová, M; Červenka, L; Hammock, BD; Husková, Z; Hwang, SH; Imig, JD; Melenovský, V; Sadowski, J; Škaroupková, P; Sporková, A | 1 |
| Dai, Z; Huang, C; Huang, H; Tang, Y; Wang, X; Xiao, J; Yu, S; Zhao, Q | 1 |
| Guo, WX; Li, H; Li, YR; Lin, JM; Liu, Y; Wang, Y; Zhou, J | 1 |
| Abbate, A; Carbone, S; Gill, R; Marchetti, C; Mauro, AG; Mezzaroma, E; Regan, JA; Salloum, FN; Toldo, S; Valle Raleigh, J; Van Tassell, BW | 1 |
| Anand, IS; Carson, PE; Kao, DP; Komajda, M; Lewsey, JD; Lindenfeld, J; Massie, BM; McKelvie, RS; McMurray, JJ; Zile, MR | 1 |
| Benedict, C; Garikipati, VN; Gumpert, AM; Johnson, J; Khan, M; Kishore, R; Koch, WJ; Krishnamurthy, P; Nickoloff, E; Verma, SK | 1 |
| Akhter, SA; Li, J; Ludmer, N; Philip, JL; Razzaque, AM; Theccanat, T; Xu, X | 1 |
| Dong, Z; Huang, Q; Hultström, M; Lai, EY; Li, H; Qi, Y; Wang, H; Wang, R; Wei, X; Wilcox, CS; Wu, H; Zhou, R; Zhou, X | 1 |
| Cao, TN; Cordero-Reyes, AM; Gupte, AA; Hamilton, DJ; Li, S; Smith, JA; Torre-Amione, G; Vedula, I; Youker, KA; Zhang, A | 1 |
| Brandon-Warner, E; Bridges, CR; Fargnoli, AS; Hajjar, RJ; Katz, MG; Kendle, AP; Schrum, LW; Williams, RD | 1 |
| Bhimaraj, A; Celis, R; Cordero-Reyes, AM; Estep, JD; Flores-Arredondo, JH; Hamilton, DJ; Orrego, CM; Torre-Amione, G; Trevino, AR; Youker, KA | 1 |
| Dawn, B; Samanta, A | 1 |
| Boateng, SY; de Tombe, PP; Dewan, S; Ikie, C; Paudyal, A; Whalley, BJ | 1 |
| Flatt, DM; Gerling, IC; Heckle, MR; Mancarella, S; Marion, TN; Sun, Y; Weber, KT | 1 |
| Chen, L; Deng, K; Huang, J; Ji, Y; Jiang, X; Li, H; Ma, G; Wang, P; Zhang, X | 1 |
| Chen, YH; Guo, K; Hou, JW; Li, CY; Li, YG; Wang, YP; Yang, LC; Zhou, Q | 1 |
| Bai, J; Ding, L; Gu, R; Li, Q; Li, R; Wang, B; Wang, L; Xie, J; Xu, B | 1 |
| Aoki, T; Ikeda, S; Kadomatsu, K; Kikuchi, N; Kurosawa, R; Miyata, S; Mukherjee, R; Nogi, M; Numano, K; Omura, J; Otsuki, T; Satoh, K; Satoh, T; Shimokawa, H; Spinale, FG; Sugimura, K; Sunamura, S; Suzuki, K; Tatebe, S | 1 |
| Beqqali, A; Bitsch, N; de Windt, LJ; Hermans-Beijnsberger, S; Heymans, S; Nakagawa, S; Peters, T; Prasanth, KV; Schroen, B; van Oort, RJ | 1 |
| Brunt, KR; Eadie, AL; Simpson, JA | 1 |
| Chu, ML; Dong, H; Joyce, J; Khan, SA; Sasaki, T; Tsuda, T | 1 |
| Lionetti, V | 1 |
| Chang, H; Lin, CM; Shyu, KG; Wang, BW | 1 |
| Ishimoto, Y; Saitoh, H; Tanemoto, M | 1 |
| Aoyama, M; Bando, YK; Kawase, H; Monji, A; Murohara, T; Nishimura, K | 1 |
| Dobashi, S; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Oka, T | 1 |
| Bhuiyan, MS; Fukunaga, K; Hasegawa, H; Kanai, H; Shinoda, Y; Tagashira, H | 1 |
| Billia, F; Grothe, D; Hauck, L | 1 |
| Ding, H; Ding, S; Gao, L; He, B; Pu, J; Xu, L; Yao, T; Ying, X; Yuan, A; Zhao, Y | 1 |
| Chang, CP; Chen, HS; Cheng, W; Feng, X; Han, P; Lin, CH; Quertermous, T; Shang, C; Yang, J; Zhou, Q | 1 |
| Goliasch, G; Gyöngyösi, M; Hülsmann, M; Novak, JF; Pavo, N; Poglitsch, M; Säemann, MD; Strunk, G; Wurm, R | 1 |
| Alkhattabi, A; Fulford, L; Gao, X; Jiang, M; Jones, S; Karani, R; Koch, SE; Lasko-Roiniotis, VM; Lorenz, JN; Mann, A; Nieman, M; Robbins, N; Rubinstein, J; Worley, MC | 1 |
| Chen, X; Gao, X; Lu, G; Luo, C; Luo, J; Peng, L; Zuo, Z | 1 |
| D'Elia, E; Emdin, M; Senni, M; Vergaro, G | 1 |
| Han, F; Li, J; Liu, M; Mao, C; Yang, P | 1 |
| Choo, SJ; Kim Kwon, Y; Kim, JJ; Kim, MS; Kim, YM; Lee, BW; Lee, GH; Nam, HY; Sim, UC; Who Kim, S; Yu, SW | 1 |
| Bond Lau, W; Du, J; Li, P; Li, Y; Li, Z; Ma, XL; Wang, C; Wu, Y; Zhang, C | 1 |
| Akazawa, H; Ikeda, Y; Isobe, M; Komuro, I; Koriyama, H; Kumagai, H; Maejima, Y; Morishita, R; Nakagami, H; Shimamura, M; Suzuki, JI; Wakayama, K; Watanabe, R | 1 |
| Jugdutt, BI; Konig, A; Liu, P; Moe, G | 1 |
| Cornish, KG; Gao, L; Liu, D; Roy, SK; Zucker, IH | 1 |
| Felder, RB; Wei, SG; Weiss, RM; Yu, Y; Zhang, ZH | 1 |
| Agnew, C; Ding, Y; Li, YL; Schultz, HD | 1 |
| De Mello, WC; Gerena, Y | 1 |
| Arumugham, PS; Cotter, G; Cotter, OM; Kaluski, E; Sasimangalam, AN; Weatherley, B | 1 |
| Miller, JD; Stickland, MK | 1 |
| Crozier, I; Ikram, H | 1 |
| Fleck, E; Holzmeister, J; Neuss, M; Regitz-Zagrosek, V | 1 |
| Cherfa, A; Delcayre, C; Di Zhang, A; Escoubet, B; Jaisser, F; Messaoudi, S; Nguyen Dinh Cat, A; Samuel, JL; Soukaseum, C | 1 |
| Endoh, M | 1 |
| Blaxall, BC; Bonnin, P; Callebert, J; Debbabi, H; Doly, S; Jaffré, F; Launay, JM; Maroteaux, L; Mettauer, B; Monassier, L; Setola, V | 1 |
| Sun, Y | 1 |
| Dohi, K; Fujimoto, N; Imanaka-Yoshida, K; Ito, M; Kurita, T; Nobori, T; Onishi, K; Takamura, T; Tanigawa, T; Wada, H | 1 |
| Banba, K; Fuke, S; Kusano, KF; Morita, H; Murakami, M; Nagase, S; Nakamura, K; Nikaido, A; Nishii, N; Ohe, T; Sakuragi, S; Tada, T | 1 |
| Shyu, KG | 1 |
| Böhm, M; Werner, CM | 1 |
| Brum, PC; Bueno, CR; Ferreira, JC; Irigoyen, MC; Krieger, JE; Mattos, KC; Oliveira, EM; Pereira, MG; Rosa, KT | 1 |
| Chen, YX; Nie, RQ; Wang, JF; Yao, YJ; Zhou, SX | 1 |
| Fukumoto, M; Hayashi, T; Ikeda, T; Jin, D; Kitaura, Y; Miyazaki, M; Oku, H; Sugiyama, T; Takai, S | 1 |
| Preobrazhenksiĭ, DV | 1 |
| Szczepanska-Sadowska, E; Ufnal, M; Zera, T | 1 |
| Afzal, R; Floras, J; McKelvie, RS; Rouleau, JL; White, M; Yusuf, S | 1 |
| Kato, K; Kemuriyama, T; Maruyama, S; Nishida, Y; Ohta, H; Sato, Y; Tandai-Hiruma, M | 1 |
| Bjurgert, E; Cuthbertson, A; Hofstra, L; Indrevoll, B; Kindberg, GM; Krasieva, TB; Lovhaug, D; Narula, J; Narula, N; Petersen, LB; Petrov, AD; Reutelingsperger, CP; Solbakken, M; Tromberg, BJ; Vannan, MA; Verjans, JW | 1 |
| Baertschi, AJ; Isidoro Tavares, N; Lerch, R; Montessuit, C; Philip-Couderc, P | 1 |
| Delbridge, L; Palomeque, J; Petroff, MV | 1 |
| Ma, Q; Ning, Y; Sun, M; Wu, S; Yang, L; Yang, T | 1 |
| Huang, BS; Leenen, FH | 1 |
| Ahokas, RA; Bhattacharya, SK; Gerling, IC; Holewinski, JP; Kamalov, G; Sun, Y; Weber, KT | 1 |
| Li, YF; Patel, KP; Wang, W; Zheng, H | 1 |
| Gao, L; Patel, KP; Schultz, HD; Wang, W; Zucker, IH | 1 |
| Kurose, H; Nakaya, M; Nishida, M; Sato, Y | 1 |
| Abdallah, Y; Schlüter, KD; Schreckenberg, R; Tastan, I; Wenzel, S | 1 |
| Dhalla, NS; Rehsia, NS | 1 |
| Frøkiaer, J; Jonassen, T; Kim, SW; Knepper, MA; Kwon, TH; Lütken, SC; Marples, D; Nielsen, S | 1 |
| Fortin, D; Garnier, A; Geny, B; Lefebvre, F; Mettauer, B; N'Guessan, B; Veksler, V; Ventura-Clapier, R; Zoll, J | 1 |
| Baklanova, NA; Belenkov, IuN; Bolotina, MG; Lapina, IuV; Mareev, VIu; Masenko, VP; Narusov, OIu; Shestakova, MV | 1 |
| Bibevski, S; Fakhry, I; Mazgalev, TN; Popovic, ZB; Sica, DA; Van Wagoner, DR; Zhang, Y | 1 |
| Savvatis, K; Schultheiss, HP; Tschöpe, C; Westermann, D | 1 |
| Finch, M; Gao, L; Li, Y; Schultz, HD; Smith, LM; Wang, W; Wang, WZ; Zucker, IH | 1 |
| Escher, F; Qian, C; Reudelhuber, TL; Roks, AJ; Schoemaker, RG; Schultheiss, HP; Schumacher, SM; Tschöpe, C; van Gilst, WH; Walther, T; Wang, Y; Westermann, D | 1 |
| Brubaker, PH; Kitzman, DW; Moore, JB; Stewart, KP; Wesley, DJ | 1 |
| Carpini, SD; Casamassima, N; Gatti, G; Hamlyn, JM; Manunta, P; Messaggio, E; Zagato, L | 1 |
| Sadoshima, J; Zablocki, D | 2 |
| Erol, A | 1 |
| Li, D; Ma, S; Sun, M; Tan, Y; Tang, B; Yang, D; Yang, Y; Zhang, X | 1 |
| Ceconi, C; Ferrari, R; Guardigli, G | 1 |
| Chen, CX; Gao, JP; Gu, WL; Li, X; Wu, Q | 1 |
| Cao, Y; Duan, H; He, L; Zhan, Y; Zhang, Y | 1 |
| Biala, A; Finckenberg, P; Kaheinen, P; Levijoki, J; Louhelainen, M; Luft, FC; Martonen, E; Merasto, S; Mervaala, E; Muller, DN | 1 |
| Ding, Y; Li, YL; Schultz, HD | 1 |
| Domenighetti, AA; Egger, M | 1 |
| Fitzgerald, RS | 1 |
| Basu, R; Bodiga, S; Guo, D; Holland, SM; Kassiri, Z; Liu, GC; Lo, J; Oudit, GY; Penninger, JM; Scholey, JW; Wang, W; Zhong, JC | 1 |
| Chen, T; Chin, MT; Dai, DF; Dorn, GW; Johnson, SC; Kang, YJ; Marcinek, DJ; Nieves-Cintrón, M; Prolla, TA; Rabinovitch, PS; Santana, LF; Villarin, JJ | 1 |
| Buyandelger, B; Gunkel, S; Knöll, R; Ku, CH; Miocic, S; Ng, KE; Piotrowska, I | 1 |
| Cai, H; Cao, SP; Gu, N; Qian, CF; Song, YH; Zhao, ZM | 1 |
| Cai, J; Li, X; Lu, X; Niu, K; Xin, W | 1 |
| Dai, DF; Rabinovitch, P | 1 |
| Carretero, OA; D'Ambrosio, M; González, GE; Harding, P; Leung, P; Nakagawa, P; Peng, H; Peterson, EL; Rhaleb, NE; Xu, J; Yang, XP | 1 |
| Bodiga, S; Das, SK; Lo, J; Oudit, GY; Patel, V; Wang, W | 1 |
| Dorn, GW; Duan, X; Gold, JI; Koch, WJ; Matkovich, SJ; Zhang, Y | 1 |
| Huke, S; Knollmann, BC | 1 |
| Dell'Italia, LJ | 1 |
| Nishida, M | 1 |
| Hirooka, Y; Kishi, T; Ogawa, K; Sunagawa, K | 1 |
| Li, YF; Mehta, PP; Patel, KP; Sharma, NM; Zheng, H | 1 |
| Belatti, DA; Curry, PL; Gao, L; Kar, S; Zucker, IH | 1 |
| Chu, M; Heroux, AL; Iyengar, R; Kim, T; Koshman, YE; Martin, JL; Robia, SL; Russell, B; Samarel, AM | 1 |
| Cui, BP; Duan, YC; Gan, XB; Gao, XY; Li, P; Xiong, XQ; Zhu, GQ | 1 |
| Gao, L; Lazartigues, E; Xiao, L; Zucker, IH | 1 |
| Pan, H; Sun, X; Tan, H; Yu, Y | 1 |
| Barrick, CJ; Caron, KM; Dackor, RT; Lenhart, PM; Nagle, E | 1 |
| An, L; Guo, X; He, L; Jia, J; Wu, J; Zhao, X; Zhu, H; Zou, Y | 1 |
| Cornish, KG; Fahim, M; Gao, L; Liu, D; Mousa, TM; Zucker, IH | 1 |
| Anand, IS; Carson, PE; Komajda, M; Kuskowski, M; Massie, BM; McKelvie, RS; McMurray, JJ; Rector, TS; Zile, MR | 1 |
| Araujo, AS; Barreto-Chaves, ML; Belló-Klein, A; Diniz, GP; Fernandes, RO; Ludke, AR; Ribeiro, MF; Schenkel, PC; Tavares, AM | 1 |
| Collier, P; McDonald, KM | 1 |
| Anderson, ME; Band, H; Binkley, P; Bonilla, IM; Carnes, CA; Curran, J; Felder, RB; Gudmundsson, H; Hund, TJ; Kashef, F; Mohler, PJ; Smith, SA; Snyder, JS; Vargas-Pinto, P; Weiss, RM | 1 |
| Lerch, R; Montessuit, C; Papageorgiou, I; Pedrazzini, T; Pellieux, C | 1 |
| Patel, KP; Schultz, HD | 1 |
| Becher, PM; Lindner, D; Miteva, K; Savvatis, K; Schmack, B; Schultheiss, HP; Tschöpe, C; Van Linthout, S; Westermann, D; Zietsch, C | 1 |
| Hamada, J; Kobara, M; Nakata, T; Noda, K; Shiraishi, T; Tanaka, T; Toba, H; Wang, J; Yoshifuji, Y | 1 |
| Azibani, F; Chatziantoniou, C; Delcayre, C; Fazal, L; Samuel, JL | 1 |
| Basu, R; Das, SK; Kassiri, Z; Lopaschuk, GD; McLean, BA; Mori, J; Oudit, GY; Patel, VB; Wagg, CS; Zhang, L | 1 |
| Liu, X; Patel, KP; Sharma, NM; Zheng, H | 1 |
| Cambi, GE; Djeokeng, MM; Faggian, G; Fiaschi, T; Lucchese, G; Modesti, A; Modesti, PA; Sani, G | 1 |
| Ghigo, A; Hirsch, E; Perino, A; Shah, AM; Zhang, M | 1 |
| Engler, CW; Haack, KK; Papoutsi, E; Patel, KP; Pipinos, II; Zucker, IH | 1 |
| Creteur, J; De Backer, D; Donadello, K; Favory, R; Ortiz, JA; Rocco, JR; Salgado, DR; Silva, E; Vincent, JL | 1 |
| Becher, PM; Fröhlich, M; Hoffmann, S; Lindner, D; Savvatis, K; Schultheiss, HP; Tschöpe, C; Westermann, D; Xia, Y | 1 |
| Chen, B; Chen, Y; Dong, Y; Liu, D; Ma, Y; Xiong, Z; Yang, Y; Zhang, C | 1 |
| Bao, CY; Kang, YM; Liu, W; Qin, DN; Zang, WJ; Zheng, M | 1 |
| Golledge, J; Seto, SW; Wang, Y | 1 |
| Chen, C; Dong, DL; Guo, WT; Huo, R; Li, CB; Li, N; Li, Y; Liu, HB; Sheng, Y; Sun, B; Xie, X; Yang, BF; Zhu, JX | 1 |
| Akahashi, Y; Ambartsumian, N; Horie, T; Inuzuka, Y; Iwanaga, Y; Kato, T; Kawashima, T; Kimura, T; Kobuke, K; Koshimizu, TA; Lukanidin, E; Miyazaki, S; Morooka, H; Niizuma, S; Ono, K; Sheikh, SP; Shioi, T; Takase, T; Tamaki, Y | 1 |
| Chen, YJ; Chung, CC; Kao, YH | 1 |
| Wang, W; Zhu, GQ; Zucker, IH | 1 |
| Guo, C; Qi, F; Ren, L; Shi, Y; Wang, X; Yang, L; Yang, Y; Zhu, S | 1 |
| Dell'Italia, LJ; Husain, A | 1 |
| Hamada, M; Hara, Y; Hiwada, K; Ohtsuka, T; Shigematsu, Y | 1 |
| Angelini, A; Calvani, M; Dalla Libera, L; Della Barbera, M; Dona, M; Gobbo, V; Mosconi, L; Peluso, G; Ravara, B; Sandri, M; Vescovo, G | 1 |
| Colombo, PC; Jorde, UP; Katz, SD; Latif, F; Le Jemtel, TH; Vittorio, T | 1 |
| Morena Valenzuela, Gde L; Nicolás Ruiz, F; Pascual Figal, DA; Ruipérez Abizanda, JA; Tovar Zapata, I; Valdés Chávarri, M | 1 |
| Carvalho, RT; Creager, MA; Kopel, L; Lage, SG; Medeiros, CC | 1 |
| Abraham, MR; Beck, KC; Johnson, BD; Joyner, MJ; Olson, LJ; Turner, ST | 1 |
| Bilezikian, JP; Furuse, Y; Hisatome, I; Igawa, O; Kato, M; Kinugasa, Y; Kinugawa, T; Ogino, K; Ogura, K; Osaki, S; Shigemasa, C; Shimoyama, M; Tomikura, Y; Uchida, K | 1 |
| Anguita Sánchez, M | 1 |
| Cicha, MZ; Kopp, UC; Smith, LA | 1 |
| Anand, I; Cohn, JN; Gottlieb, SO; Latini, R; Maggioni, AP; Tognoni, G | 1 |
| Greenberg, BH | 1 |
| Inagaki, K; Iwanaga, Y; Kihara, Y; Mochly-Rosen, D; Onozawa, Y; Sarai, N; Takenaka, H | 1 |
| Ahn, S; Duprez, D; Galanti, L; Gurné, O; Ketelslegers, JM; Robert, A; Rousseau, MF; Van Mieghem, W | 1 |
| Frohlich, ED; Varagic, J | 1 |
| Doggrell, SA | 1 |
| Gould, PA; Kaye, DM | 1 |
| Fujita, T; Goto, A; Kobayashi, N; Matsuoka, H; Onozato, ML; Tojo, A | 1 |
| Hasebe, N; Ido, A; Ihara, T; Jin, YT; Kikuchi, K; Matsuhashi, H; Matsusaka, T; Natori, S | 1 |
| Hörl, WH | 1 |
| Jorde, UP; Katz, SD; Lang, CC; Mancini, DM; Packer, M; Vittorio, TJ | 1 |
| Force, T; Haq, S; Kilter, H; Michael, A | 1 |
| Boerrigter, G; Burnett, JC; Cataliotti, A; Costello-Boerrigter, LC; Harty, GJ; Lapp, H; Stasch, JP; Tsuruda, T | 1 |
| An, HY; Huang, LJ; Jin, JS | 1 |
| Patterson, JH | 1 |
| Baartscheer, A; Balt, JC; Belterman, CN; Mathy, MJ; Nap, A; Pfaffendorf, M; Van Zwieten, PA | 1 |
| Manohar, P; Piña, IL | 1 |
| Bech, JN; Bentzen, H; Nyvad, O; Pedersen, EB; Pedersen, RS | 1 |
| Pliquett, RU; Zucker, IH | 1 |
| Komajda, M | 1 |
| Bilińska, ZT; Grzybowski, J; Janas, J; Michalak, E; Ruzyłło, W; Skwarek, M | 1 |
| Morita, H; Sabbah, HN; Sharov, VG; Suzuki, G; Tanhehco, EJ; Todor, A | 1 |
| Bouvy, ML; Heerdink, ER; Hoes, AW; Leufkens, HG | 1 |
| Alegria, E; Arens, HA; Dabrowski, M; Dukát, A; Kiowski, W; Lenz, K; Marks, DS; Miric, M; Mitrovic, V; Seferovic, P; Spinar, J; Willenbrock, R | 1 |
| Charles, CJ; Lainchbury, JG; Nicholls, MG; Rademaker, MT; Richards, AM; Troughton, RW | 1 |
| Burnett, JC; Cataliotti, A; Chen, HH; Nordstrom, LJ; Redfield, MM | 1 |
| Isono, T; Kinoshita, M; Matsumoto, T; Ohnishi, M; Tsutamoto, T; Wada, A | 1 |
| Kitakaze, M; Sanada, S | 1 |
| Kinugawa, K; Nagai, R; Takahashi, T | 1 |
| Kokkonen, JO; Kovanen, PT; Lindstedt, KA | 1 |
| Buksa, M; Gerc, V | 1 |
| DiBona, GF; Sawin, LL | 1 |
| Buikema, H; de Zeeuw, D; Gschwend, S; Henning, RH; Pinto, YM; van Gilst, WH | 1 |
| Kaaja, R; Kokkonen, JO; Kovanen, PT; Kuoppala, A; Leskinen, HK; Liesmaa, I; Lindstedt, KA; Luodonpää, M; Ruskoaho, H; Rysä, J; Shiota, N | 1 |
| JOHNSTON, CI; JOSE, AD | 1 |
| LARAGH, JH | 2 |
| Egashira, K; Hayashidani, S; Ikeuchi, M; Matsusaka, H; Shiomi, T; Suematsu, N; Takeshita, A; Tsutsui, H; Wen, J | 1 |
| DiBianco, R | 1 |
| Inagaki, K; Iwanaga, Y; Izumi, T; Kihara, Y; Kita, T; Noma, A; Onozawa, Y; Sarai, N; Takenaka, H; Yoneda, T | 1 |
| Kamper, AL; Karlsen, FM | 1 |
| Cardin, S; Leung, TK; Li, D; Nattel, S; Thorin, E; Thorin-Trescases, N | 1 |
| Cohn, JN; Franciosa, JA; Loscalzo, J | 1 |
| Balt, JC; Belterman, CN; Mathy, MJ; Nap, A; Pfaffendorf, M; van Zwieten, PA | 1 |
| Matos, L | 1 |
| Ellis, GR; Taylor, JS | 1 |
| Doi, M; Kobayashi, S; Kohno, M; Matsuzaki, M; Oda, T; Ohkusa, T; Okuda, S; Tokuhisa, T; Yamamoto, T; Yano, M | 1 |
| Bentzen, H; Nyvad, O; Pedersen, EB; Pedersen, RS | 1 |
| McKelvie, RS | 1 |
| Cerbai, E; Mugelli, A | 1 |
| Anzai, T; Hashimoto, K; Himeno, H; Imai, K; Kawana, M; Kitakaze, M; Koretsune, Y; Maruyama, S; Masaoka, Y; Matsubara, H; Matsuoka, T; Miyao, Y; Miyatake, K; Miyauchi, T; Nakamura, Y; Nomura, F; Okamoto, H; Ozono, K; Sekiya, M; Shinohara, H; Shintani, U; Shiraki, T; Takaoka, H; Tsutamoto, T; Yasumura, Y; Yokoya, K; Yokoyama, H | 1 |
| Roig Minguell, E | 1 |
| Cruden, NL; Fox, KA; Newby, DE; Webb, DJ; Witherow, FN | 1 |
| Akiyama, H; Arimoto, T; Fukui, A; Hirono, O; Kubota, I; Minamihaba, O; Miyamoto, T; Nitobe, J; Nozaki, N; Okada, A; Okuyama, M; Tachibana, H; Takahashi, H; Takahashi, K; Takeishi, Y; Yamauchi, S | 1 |
| Lei, Y; Lu, ZZ; Ma, L; Wang, SW; Xue, Q; Yang, DY | 1 |
| Chen, CX; Shen, YH | 1 |
| Gallagher, G; Huang, Y; Hunyor, SN; Ikeda, Y; Jiang, L; Kawaguchi, O; Shirota, K; Yuasa, T; Zeng, B; Zheng, X | 1 |
| Iigaya, K; Kumagai, H; Onami, T; Saruta, T; Takimoto, C | 1 |
| Azizi, M; Ménard, J | 1 |
| Angeli, F; Verdecchia, P | 1 |
| Nattel, S | 1 |
| Castro-Chaves, P; Leite-Moreira, AF | 1 |
| Dor, V | 1 |
| Doi, K; Francis, GS; Fukamachi, K; Hail, MD; Hoercher, KJ; McCarthy, PM; Ootaki, Y; Schenk, S; Starling, RC; Young, JB | 1 |
| Gao, L; Qian, ZM; Tan, W; Wang, W; Zhu, GQ | 1 |
| Li, YF; Patel, KP; Pliquett, RU; Schultz, HD; Wang, W; Zucker, IH | 1 |
| Cardin, S; Hanna, N; Leung, TK; Nattel, S | 1 |
| Cuppoletti, A; Ferrer, E; Jiménez, W; Llancaqueo, M; Pérez-Villa, F; Roig, E; Sanz, G | 1 |
| Fujita, M; Hirata, A; Hori, M; Kitakaze, M; Liao, Y; Minamino, T; Nagamachi, Y; Nakatani, T; Ogawa, S; Okada, K; Ozawa, K; Takashima, S; Tomoike, H; Tsukamoto, O; Tsukamoto, Y; Yutani, C | 1 |
| Hasebe, N; Izawa, K; Jin, YT; Kido, S; Kikuchi, K; Natori, S; Ohta, T; Sato, M; Tsuji, S | 1 |
| Abassi, ZA; Hoffman, A; Winaver, J | 1 |
| Jin, H; Schwall, R; Wyss, JM; Yang, R | 1 |
| Boomsma, F; de Boer, RA; Flesch, M; Pinto, YM; Pokharel, S; Suurmeijer, AJ; van Gilst, WH; van Kampen, DA; van Veldhuisen, DJ | 1 |
| Burkhoff, D; Dickstein, M; Gu, A; He, KL; Maurer, M; Sabbah, HN; Wang, J; Wei, CM; Yi, GH | 1 |
| Arneja, AS; Dhalla, NS; Ganguly, PK; Netticadan, T; Shah, KR | 1 |
| Cornish, KG; Gao, L; Li, YL; Liu, D; Schultz, HD; Wang, W; Zucker, IH | 1 |
| Harada, E; Ito, T; Mizuno, Y; Yasue, H | 1 |
| Eto, T; Kato, J; Tsuruda, T | 1 |
| Kotooka, N; Node, K; Watanabe, T | 1 |
| Fowler, MB; Tang, WH; Vagelos, RH; Yee, YG | 1 |
| Berezin, AE | 1 |
| Dzau, VJ; McMurray, JJ; Pfeffer, MA; Swedberg, K | 1 |
| Dimayuga, CA; Homma, S; Jorde, UP; Katz, SD; Le Jemtel, TH; Rizkala, A; Vittorio, TJ | 1 |
| Bos, R; Findji, L; Lechat, P; Médiani, O; Mougenot, N; Vanhoutte, PM | 1 |
| Kára, T; Soucek, M; Spinarová, L; Stejfa, M; Toman, J; Tomandlová, M; Zatloukal, B | 1 |
| Delafontaine, P; Du, J; Li, Y; Mitch, WE; Rosenthal, N; Song, YH | 1 |
| Bertolozzi, I; Coppo, M; Gamberi, T; Gensini, GF; Lucchese, G; Lumachi, C; Marchetta, M; Modesti, A; Modesti, PA; Moroni, F; Toscano, T | 1 |
| Burnier, M; Maillard, M; Meier, P | 1 |
| Tsutsui, H | 1 |
| Yoshimura, M | 2 |
| Matsumori, A | 1 |
| Li, J; Molenaar, P; Russell, FD; Wang, J | 1 |
| Anavekar, NS; Chen, HH; Mirzoyev, Z | 2 |
| Hartung, DM; Hunt, J; Miller, H; Siemienczuk, J; Touchette, DR | 1 |
| Backes, RJ; Bailey, KR; Burnett, JC; Frantz, RP; Grill, D; Hanna, RD; Heublein, D; Mookadam, F; Moualla, SK; Nelson, SM; Nobrega, TP; Olson, LJ | 1 |
| Abe, JI; Berk, BC; Blaxall, BC; Ding, B; Huang, Q; Molina, CA; Sadoshima, J; Walsh, RA; Wei, H; Yan, C; Zhao, A | 1 |
| Battegay, E; Zeller, A | 1 |
| Blanchet, M; Curnier, D; De Champlain, J; Ducharme, A; Lamoureux, MC; Racine, N; Sheppard, R; Sirois, P; Tardif, JC; White, M | 1 |
| Hemels, ME; Van den Berg, MP; Van Gelder, IC; Van Tintelen, JP; Van Veldhuisen, DJ; Wiesfeld, AC | 1 |
| Hein, L | 1 |
| Yang, YJ; Zhang, X; Zhou, XW; Zhu, WL; Zhu, ZM | 1 |
| Czuriga, I | 1 |
| Biagini, G; Blaschke, F; Fleck, E; Graf, K; Leitges, M; Lindschau, C; Margeta, C; Spencer-Hänsch, C; Stawowy, P | 1 |
| Goldsmith, SR | 2 |
| Deschamps, AM; Spinale, FG | 1 |
| Clarke, E; Coombes, E; Dawes, M; Gosling, O; Martin, M; Smith, A | 1 |
| Huang, WY; Sun, M; Zhou, HY | 1 |
| Alter, DA; Austin, PC; Chong, A; Juurlink, DN; Ko, DT; Laupacis, A; Lee, DS; Levy, D; Stukel, TA; Tu, JV | 1 |
| Brunton, LL | 1 |
| Arbolishvili, GN; Baklanova, NA; Belenkov, IuN; Mareev, VIu; Nasonova, SN; Skvortsov, AA; Sychev, AV | 1 |
| Liu, JL; Zucker, IH | 1 |
| Ma, R; Wang, W | 1 |
| Chen, LY; Chen, PM; Fan, LL; Leng, XG; Ma, J; Wang, YF | 1 |
| Abe, Y; Kimura, S | 1 |
| Alexander, D; Chinnaiyan, KM; McCullough, PA | 1 |
| Boomsma, F; Lok, DJ; Plokker, HW; van de Wal, RM; van der Horst, FA; van Gilst, WH; van Veldhuisen, DJ; Voors, AA | 1 |
| Suissa, S | 1 |
| Dixon, LJ; El-Sherbeeny, N; Hamilton, PB; Hanratty, CG; Johnston, GD; Leahey, WJ; McGrath, LT; McVeigh, GE; Morgan, DR | 1 |
| Bech, JN; Jensen, P; Nyvad, O; Pedersen, EB; Starklint, J | 1 |
| Heusch, G; Schulz, R | 1 |
| Gao, LJ; Lin, XY; Xiao, LZ; Zhang, HF | 1 |
| Aoki, R; Fukuyama, T; Orito, K; Shimizu, M; Tanaka, R; Yamane, Y | 1 |
| Dell'Oro, R; Grassi, G; Mancia, G; Quarti-Trevano, F; Scopelliti, F | 1 |
| Akao, M; Delafontaine, P | 1 |
| Calderone, A; Caron, A; Dupuis, J; Jasmin, JF; Lefebvre, F; Préfontaine, A; Villeneuve, L | 1 |
| Gao, L; Li, YF; Li, YL; Liu, D; Patel, KP; Schultz, HD; Wang, W; Xia, XH; Zheng, H | 1 |
| Abe, Y; Guo, P; Ishizawa, M; Kimura, S; Kohno, M; Miyatake, A; Mizushige, K; Murakami, K; Nagai, Y; Namba, T; Nishiyama, A; Noma, T; Ohmori, K; Rahman, M | 1 |
| Hwang, GS; Koo, HN; Lee, BH; Oh, KS; Seo, HW; You, KH | 1 |
| Li, YL; Schultz, HD | 2 |
| Garaliene, V | 1 |
| Guo, WG; Xie, MJ; Yu, ZB | 1 |
| Leung, PS | 2 |
| Devereux, RB; Krauser, DG | 1 |
| Cameron, VA; Collins, RP; Frampton, CM; Palmer, BR; Pilbrow, AP; Richards, AM; Skelton, L; Troughton, RW; Yandle, TG | 1 |
| Lopaschuk, GD | 1 |
| Gibbons, RJ; Johnson, BD; O'Malley, K; Olson, T; Somers, VK; Wolk, R | 1 |
| Conlin, PR; Crivaro, M; Solomon, SD; Williams, JS | 1 |
| Iwanaga, Y; Kihara, Y; Kita, T; Takenaka, H | 1 |
| Iwanaga, Y; Kihara, Y; Kita, T; Onozawa, Y; Takenaka, H; Toyokuni, S | 1 |
| Chen, AF; Du, YH | 1 |
| Zucker, IH | 1 |
| Aries, A; Dali-Youcef, N; Nemer, M; Paradis, P; Wang, H | 1 |
| Hori, M; Mano, T; Masuyama, T; Miwa, T; Nishio, M; Nonaka, Y; Ohta, M; Ohtani, T; Okamoto, M; Sakata, Y; Takeda, Y; Yamamoto, K; Yoshida, J | 1 |
| Henderson, BC; Tyagi, SC | 1 |
| Guo, CM; Guo, RW; Qi, F; Shi, YK; Wang, Y; Wei, L; Yang, LX | 1 |
| Dai, M; He, JR; Wen, QX | 1 |
| Hood, SG; May, CN; Watson, AM | 1 |
| Alonso, M; Suri, D; Weiss, RE | 1 |
| Cohn, JN | 2 |
| Szczepańska-Sadowska, E | 1 |
| Dilsizian, V; Eckelman, WC; Narula, J; Narula, N; Shirani, J | 1 |
| Cingolani, HE; Ennis, IL | 1 |
| Butler, C; Jugdutt, BI | 1 |
| Athyros, VG; Kakafika, AI; Karagiannis, A; Mikhailidis, DP; Tziomalos, K | 1 |
| Gao, L; Li, YL; Schultz, HD; Zucker, IH | 1 |
| Mitsuyama, S | 1 |
| Okura, T | 1 |
| Fujii, M; Horie, M; Ohnishi, M; Sakai, H; Tanaka, T; Tsutamoto, T; Wada, A; Yamamoto, T | 1 |
| Díez, J; Fortuño, MA; López, N; Varo, N | 1 |
| Dorn, GW; Liao, JK; Matter, CM; Ogita, H; Satoh, M; Takeshita, K; Wang, CY | 1 |
| Belardinelli, R | 1 |
| Feng, N; Hoover, DB; Paolocci, N | 1 |
| Cui, W; Li, M; Lu, XY; Wang, SR; Wang, ZT; Zhao, MJ; Zhu, LQ | 1 |
| Gao, XY; Han, Y; Shi, Z; Wang, W; Yu, Y; Zhang, F; Zhong, MK; Zhu, GQ | 1 |
| Anderson, NR; Cornish, KG; Hackley, JF; Hiser, BA; Irwin, ED; Kieval, R; Peuler, JD; Rossing, MA; Serdar, DJ; Zucker, IH | 1 |
| Bobillier, A; Gardner, R; Hillier, C; MacFadyen, R; Mann, J; McDonagh, T; McMurray, J; Murdoch, D; Seed, A | 1 |
| Bissessor, N; White, H | 1 |
| Bacurau, AV; Brum, PC; Casarini, DE; Coelho, MA; Evangelista, FS; Ferreira, JC; Krieger, JE; Oliveira, EM | 1 |
| Figtree, G; Rasmussen, HH | 1 |
| Cornish, KG; Liu, D; Mousa, TM; Zucker, IH | 1 |
| Middlekauff, HR; Negrão, CE | 1 |
| Schiffrin, EL | 1 |
| Felder, RB; Gomez-Sanchez, E; Wei, SG; Weiss, RM; Yu, Y; Zhang, ZH | 1 |
| Afzal, R; Gunasinghe, HR; Liu, PP; McKelvie, RS; Spinale, FG; Stroud, RE; Yan, AT; Yan, RT | 1 |
| Backx, PH; Crackower, MA; Dawood, F; Kassiri, Z; Liu, PP; Liu, QC; Oudit, GY; Penninger, JM; Scholey, JW; Zhou, J | 1 |
| Inoue, T; Morooka, T; Nishimura, Y; Node, K | 1 |
| Felder, RB; Kang, YM; Weiss, RM; Xue, B; Zhang, ZH | 1 |
| Kjekshus, J | 1 |
| Aarsland, T; Abrahamsen, AM; Dickstein, K; Kremer, D; Woie, L | 1 |
| Brenner, BM; Hostetter, TH; Ichikawa, I; Pfeffer, JM; Pfeffer, MA | 1 |
| Cushman, DW; Ondetti, MA | 1 |
| Davies, RO; Gomez, HJ; Irvin, JD; Walker, JF | 1 |
| Espiner, EA; Fitzpatrick, D; Ikram, H; Nicholls, MG | 2 |
| Blaine, EH; Gaul, SL; Reitz, PM; Ribeiro, LT; Sweet, CS | 1 |
| Espiner, EA; Ikram, H; Maslowski, AH; Nicholls, MG | 1 |
| Cohn, JN; Francis, GS; Goldsmith, S; Levine, TB | 1 |
| Espiner, EA; Ikram, H; Maslowski, AH; Nicholls, MG; Turner, JG | 1 |
| Dipalma, JR | 1 |
| Cohn, JN; Levine, TB | 1 |
| Sullivan, JM | 1 |
| Cody, RJ | 4 |
| Materson, BJ | 1 |
| Colucci, WS; Curfman, G; Dzau, VJ; Hollenberg, NK; Meggs, L; Williams, GH | 1 |
| Barger, AC | 2 |
| Denham, IM; Johnston, CI; McGrath, BP | 1 |
| Antonaccio, MJ | 1 |
| Brunner, HR; Turini, GA; Waeber, B | 1 |
| Cody, RJ; Covit, AB; Laragh, JH; Schaer, GL | 1 |
| Brown, JJ; Fraser, R; Lever, AF; Robertson, JI | 1 |
| Dzau, VJ; Hollenberg, NK; Williams, GH | 1 |
| Forslund, T; Fyhrquist, F; Grönhagen-Riska, C; Hortling, L; Immonen, I; Tikkanen, I | 1 |
| Punzengruber, C; Silberbauer, K; Sinzinger, H | 1 |
| Decoodt, P; Devriendt, J; Staroukine, M; Verniory, A | 1 |
| Ball, S; Cleland, J; Dargie, H; Ford, I; Hodsman, P; Semple, P | 1 |
| Mareev, VIu | 1 |
| Lee, CL; Walsh, WF | 1 |
| Gross, F | 1 |
| Espiner, EA; Ikram, H; Maslowski, AH; Nicholls, MG; Penman, T; Scandrett, MS | 1 |
| Colassin, R; Franken, P; Henuzet, C; Polis, O | 1 |
| Kubo, S; Nishimura, H; Nishioka, A; Sonotani, N; Takatsu, T | 1 |
| Chan, W; Espiner, EA; Ikram, H; Nicholls, MG | 1 |
| Colucci, WS; Dzau, VJ; Hollenberg, NK; Williams, GH | 1 |
| Avery, GS; Brogden, RN; Heel, RC; Speight, TM | 1 |
| Creager, MA; Faxon, DP; Gavras, H; Halperin, JL; Ryan, TJ; Schick, EC | 1 |
| Espiner, EA; Ikram, H; Lun, S; Maslowski, AH; Nicholls, MG; Scandrett, MS | 1 |
| Espiner, EA; Julius, S; Miles, KD; Nicholls, MG; Zweifler, AJ | 1 |
| Brenner, BM; Skorecki, KL | 1 |
| Jezek, V; Schrijen, F | 2 |
| Böhm, M; Langheinrich, M; Liefeldt, L; Paul, M; Schönfelder, G; Stock, P | 1 |
| Hu, TH; Song, YC; Wan, LL; Zhang, YH; Zhu, J | 1 |
| Francischetti, EA | 1 |
| Brilla, CG; Maisch, B; Rupp, H; Weber, KT; Zhou, G | 1 |
| Majewski, H; Minatoguchi, S | 1 |
| Dzau, VJ; Gibbons, GH; Pratt, R | 1 |
| Parker, TG | 1 |
| Abassi, ZA; Keiser, HR; Pieruzzi, F | 1 |
| Bravo, E; Hobbs, RE; James, KB; McCarthy, PM; Sapp, S; Thomas, JD; Vargo, R | 1 |
| Adamiak, D; Kregel, KC; Mott, A; Redlich, T; Stauss, HM; Unger, T; Zhu, YC | 1 |
| Chang, PI; Pitt, B | 1 |
| Lorell, BH | 1 |
| Lie, KI; van Zwieten, PA | 2 |
| Boehm, KD; Bumpus, FM; Gabrovsek, J; Husain, A; Kinoshita, A; Philip, A; Urata, H | 1 |
| Bloom, SR; Clark, P; Cleland, JG; Crossman, D; Ghatei, MA; Good, JM; Nihoyannopoulos, P; Oakley, CM | 1 |
| Brunner, HR; Nussberger, J; Waeber, B | 2 |
| Rucinska, EJ; Sweet, CS | 1 |
| Ganten, D; Hoffmann, S; Urata, H | 1 |
| Smith, RD; Timmermans, PB | 1 |
| Cleland, JG; Hubbard, WN; Pittard, J; Poole-Wilson, PA; Sutton, GC | 1 |
| Baur, LH; Cats, VM; de Groot, A; Frölich, M; Keirse, MJ; Schipperheyn, JJ; Souverijn, JH; van der Laarse, A; Voogd, PJ; Vroom, TF | 1 |
| Amtorp, O; Gundersen, T; Nilsson, B; Remes, J; Sigurdsson, A; Swedberg, K | 1 |
| Awan, N; Cleland, J; Crozier, I; Dickstein, K; Frey, M; Ikram, H; Klinger, G; Makris, L; Stephen, N; Young, J | 1 |
| Fox, M; Panchal, BC; Trippodo, NC | 1 |
| Falkenhahn, M; Gohlke, P; Paul, M; Stoll, M; Unger, T | 1 |
| Dietz, R; Hänlein, D; Osterziel, KJ | 1 |
| Abraham, WT | 1 |
| Morgan, K | 1 |
| Sigurdsson, A; Swedberg, K | 1 |
| Fleck, E; Hildebrandt, A; Neuss, M; Regitz-Zagrosek, V | 1 |
| Chappell, MC; Ferrario, CM | 1 |
| Sigurdsson, A; Swedberg, K; Ullman, B | 1 |
| Brady, AJ; Cleland, JG; Good, JM; Noormohamed, FH; Oakley, CM | 1 |
| Alhenc-Gelas, F; Arnal, JF; Challah, M; Corvol, P; Huang, H; Llorens-Cortes, C; Michel, JB | 1 |
| Kawamura, K; Kubota, J; Nishimura, H; Ueyama, M | 1 |
| Pratt, NG | 1 |
| Andreotti, F; Bradshaw, A; Cleland, JG; Oakley, CM; Sbarouni, E; Tuddenham, E | 1 |
| Holmer, SR; Riegger, G; Schunkert, H | 1 |
| Bakris, GL; Riley, DJ; Weir, M | 1 |
| Fenwick, MK; Morton, JJ; Motwani, JG; Struthers, AD | 2 |
| Wu, H; Zhao, HY | 1 |
| Cattaneo, BM; Giannattasio, C; Grassi, G; Mancia, G; Perondi, R; Saino, A; Seravalle, G | 1 |
| Held, P; Sigurdsson, A; Swedberg, K | 1 |
| Eberhardt, RT; Frishman, WH; Kang, PM; Kevak, RM | 1 |
| Remme, WJ | 1 |
| Foote, EF; Halstenson, CE | 1 |
| Fukunami, M; Hori, M; Houki, N; Sato, H | 1 |
| Takeda, T; Takeuchi, K | 1 |
| Diamant, D; Dzau, VJ; Ingelfinger, JR; Litwin, SE; Riegger, G; Schunkert, H; Tang, SS | 1 |
| Fabris, B; Johnston, CI; Yoshida, K | 1 |
| Goldsmith, SR; Hasking, GJ; Miller, E | 1 |
| Burnett, JC; Cavero, PG; Fett, DL | 1 |
| DeKock, M; Dickstein, K; Fleck, E; Gottlieb, SS; Kostis, J; LeJemtel, T; Levine, TB | 1 |
| Bøtker, HE; Jensen, HK; Krusell, LR; Sørensen, EV | 1 |
| Ford, NF; Fulmor, IE; Hui, KK; Natarajan, C; Smith, RA | 1 |
| Asakuma, S; Fujiwara, M; Iwasaki, T; Nakamura, K; Nakamura, T | 1 |
| Matsuo, H | 1 |
| Awan, NA; Mason, DT | 1 |
| al-Subaili, M; Cleland, JG; Dutka, DP; Impallomeni, M; Nihoyannopoulos, P; Oakley, CM; Olivotto, I; Ward, S | 1 |
| Cheng, CP; Little, WC; Ohno, M; Ohte, N; Suzuki, M; Wang, ZM | 1 |
| Clarkson, PB; MacDonald, TM; MacFadyen, RJ; Pringle, SD; Wheeldon, NM | 1 |
| Dietz, R; Höhnel, K; Luft, FC; Scheuermann, M; Willenbrock, R | 1 |
| Cosín Aguilar, J; Cruz Fernández, JM; de Teresa Galván, E; Ferreira Montero, IJ; López-Sendón, J; Soler Soler, J; Tamargo Menéndez, J | 1 |
| Bakovic-Alt, R; Bonzel, T; Mitrovic, V; Mudra, H; Posvar, EL; Schmidt, W; Strand, JC | 1 |
| Campbell, SE; Sun, Y; Weber, KT | 1 |
| Ganten, D; Nishimura, H; Urata, H | 1 |
| Katz, AM | 1 |
| Matsumori, A; Sasayama, S | 1 |
| Burri, M; Kehtari, R; Metzger, J; Reuge, L | 1 |
| Ball, SG; Hall, AS | 1 |
| Bailey, JE; Borgeson, DD; Burnett, JC; Heublein, DM; Luchner, A; Redfield, MM; Sandberg, SM; Stevens, TL | 1 |
| Ahmmed, GU; Hisatome, I; Kato, M; Kinugawa, T; Miyakoda, H; Ogino, K; Omodani, H; Osaki, S; Thames, MD | 1 |
| Cleland, JG; Morgan, K | 1 |
| Lee, MA; Lee, YA; Liang, CS; Lindpaintner, K | 1 |
| Kageyama, Y; Matsumoto, A; Murakami, M; Naitoh, M; Saruta, T; Suzuki, H; Tsujimoto, G | 1 |
| Häggström, J; Hansson, K; Karlberg, BE; Kvart, C; Madej, A; Olsson, K | 1 |
| Krasnikova, TL | 1 |
| Carayon, A; Grenier, O; Guerot, C; Isnard, R; Kalotka, H; Komajda, M; Lechat, P; Maistre, G; Pousset, F; Thomas, D | 1 |
| Häggström, J; Hansson, K; Karlberg, BE; Kvart, C; Olsson, K; Vuolteenaho, O | 1 |
| Nasa, Y; Okumura, Y; Sanbe, A; Takeo, S; Toga, W | 1 |
| Abe, K; Jiang, ZL; Johnston, CI; Kamimoto, M; Kanazawa, M; Kohzuki, M; Sato, T; Wu, XM; Yasujima, M; Yoshida, K | 1 |
| Aliot, E; Chati, Z; Mertès, PM; Zannad, F | 1 |
| Abraham, WT; Asano, K; Bohlmeyer, TJ; Bristow, MR; Bush, EW; Dutcher, DL; Jenkin, MJ; Minobe, WA; Perryman, MB; Port, JD; Raynolds, MV; Roden, RL; Tremmel, KD; Zisman, LS | 1 |
| Devaux, B; Henry, JP; Macé, B; Mulder, P; Richard, V; Thibout, E; Thuillez, C; Wimart, MC | 1 |
| Bonzel, T; Mitrovic, V; Mudra, H; Schlepper, M; Schmidt, W | 1 |
| Yamazaki, T; Yazaki, Y | 2 |
| Takeshita, A | 1 |
| Lerch, R; Montessuit, C | 1 |
| Fukai, D; Kinoshita, M; Maeda, Y; Tsutamoto, T; Wada, A | 1 |
| Bing, OH; Lakatta, EG; Li, Z; Long, X; Robinson, KG | 1 |
| Dickstein, K; Hall, C; Klinge, R; Polis, A | 1 |
| Gavras, H | 1 |
| Carugo, S; Cattaneo, BM; Grassi, G; Lanfranchi, A; Mancia, G; Morganti, A; Pozzi, M; Seravalle, G | 1 |
| Curzen, NP; Fox, KM | 1 |
| Abassi, ZA; Gurbanov, K; Haramati, A; Hoffman, A; Mulroney, SE; Opgenorth, TJ; Potlog, C; Winaver, J | 1 |
| Fukai, D; Hisanaga, T; Kinoshita, M; Mabuchi, N; Maeda, K; Maeda, Y; Ohnishi, M; Tsutamoto, T; Wada, A | 1 |
| Weber, KT | 1 |
| Hunyady, L; Nagy, L | 1 |
| Avezum, A; Held, P; Latini, R; Lindgren, E; Maggioni, AP; McKelvie, RS; Pogue, J; Probstfield, J; Rouleau, JL; Teo, KK; Tsuyuki, RT; Wang, Y; White, M; Wiecek, EM; Yusuf, S | 1 |
| Baba, T; Komamura, K; Miyatake, K; Noguchi, T; Ohmori, F; Sasaki, T; Tomimoto, S | 1 |
| Charles, CJ; Espiner, EA; Kosoglou, T; Nicholls, MG; Rademaker, MT; Richards, AM | 1 |
| Pitt, B | 1 |
| DiBona, GF; Jones, SY; Sawin, LL | 1 |
| Lechat, P | 1 |
| Crow, MT; Gluzband, YA; Janicki, JS; Kass, DA; Pak, PH; Senzaki, H | 1 |
| Asano, M; Maehara, J; Momose, K; Saitoh, C; Saitoh, M; Sato, S; Taguchi, K; Tanaka, H; Usuda, S | 1 |
| Kanatsu, K; Kawai, C; Liang, P; Muso, E; Ono, T; Sasayama, S; Sekita, K; Shimada, T; Sugiyama, T; Takeuchi, E; Yashiro, M; Yoshida, H | 1 |
| Bartels, GL; Kruijssen, DA; Remme, WJ; Van Den Heuvel, AF; van der Ent, M; van Veldhuisen, DJ | 1 |
| Artner-Dworzak, E; Belenkov, J; Fuchs, D; Lopatin, J; Mareev, V; Nassonov, E; Samsonov, M; Tilz, GP; Wachter, H | 1 |
| Agnello, D; Anesini, A; Bevilacqua, M; Catania, A; Ghezzi, P; Latini, R; Maggioni, AP; Masson, S; Moccetti, T; Pasotti, E; Salio, M; Santoro, L; Sessa, F; Torri, M; Vago, T | 1 |
| Pacher, R | 1 |
| Agarwal, M; Nicholls, MG; Richards, AM | 1 |
| Endo, A; Hamada, T; Hisatome, I; Kato, M; Kato, T; Kinugawa, T; Miyakoda, H; Mori, M; Noguchi, N; Ogino, K; Omodani, H; Osaki, S; Shigemasa, C | 1 |
| Inada, M; Masaki, H; Matsubara, H; Mori, Y | 1 |
| Francis, G | 1 |
| Ogilvie, RI; Zborowska-Sluis, D | 1 |
| Berezin, AE; Fushteĭ, IM | 1 |
| Drexler, H; Schaufelberger, M; Schieffer, E; Swedberg, K | 1 |
| Struthers, AD | 1 |
| Finkel, MS; Johnson, LA; Kan, H | 1 |
| Ambrosio, GB; Ceconi, C; Dalla Libera, L; Facchin, L; Leprotti, C; Serafini, F; Vescovo, G; Volterrani, M | 1 |
| Greenland, BD; Grossman, W; Lynch, JJ; Shen, YT; Wiedmann, RT | 1 |
| Kokkonen, JO; Kovanen, PT; Saarinen, J | 1 |
| Boon, NA; Flapan, AD; Fox, KA; Goodfield, NE; Newby, DE; Webb, DJ | 1 |
| Sasayama, S | 1 |
| Bartels, GL; de Leeuw, PW; Remme, WJ; van der Ent, M | 1 |
| Dietz, R; Gross, M; Gulba, D; Krämer, J; Osterziel, KJ; von Harsdorf, R; Willenbrock, R | 1 |
| Konstam, MA; Pitt, B | 1 |
| Bastien, N; Lambert, C | 1 |
| Dec, GW; Hajjar, RJ; Narula, J | 1 |
| Eichhorn, EJ | 1 |
| Garr, M; Goldsmith, SR; McLaurin, M | 1 |
| Clair, MJ; de Gasparo, M; Hebbar, L; Hendrick, JW; Houck, WV; Kribbs, SB; Krombach, RS; Mukherjee, R; Rios, G; Spinale, FG; Whitebread, S | 1 |
| de Gasparo, M; Iannini, JP; Melton, DM; Mukherjee, R; Spinale, FG | 1 |
| Fujii, M; Hayashi, M; Hisanaga, T; Kinoshita, M; Mabuchi, N; Maeda, K; Ohnishi, M; Sawaki, M; Tsutamoto, T; Wada, A | 1 |
| Burkhoff, D; Gu, AG; Popilskis, S; Wang, J; Yi, GH; Zhang, H; Zhu, SM | 1 |
| Carraway, JW; Holycross, BJ; McCune, SA; Park, S; Radin, MJ | 1 |
| Brenner, BM; Dietz, R; Höhnel, K; Mackenzie, HS; Pagel, I; Scheuermann, M; Willenbrock, R | 1 |
| Aakvaag, A; Djøseland, O; Hall, C; Hystad, M; Karlberg, BE; Kjekshus, J; Klinge, R | 1 |
| Col, V; de Cannière, L; Donckier, J; Messaoudi, L; Michel, L | 1 |
| Brunner-La Rocca, HP; Esler, MD; Vaddadi, G | 1 |
| Crespo, MJ | 1 |
| Mimran, A; Ribstein, J | 1 |
| Brunner, HR; Burnier, M | 1 |
| Leary, AC; Lim, PO; MacDonald, TM; McMahon, AD; Shiels, P | 1 |
| Mitrovic, V; Schönburg, M; Schulz, O; Thormann, J | 1 |
| Baan, J | 1 |
| Cazaubon, C; Domergue, V; Fornes, P; Giudicelli, JF; Nisato, D; Richer, C | 1 |
| Barbe, F; Crozatier, B; Guyene, TT; Hittinger, L; Houël, R; Su, J | 1 |
| Isoyama, S; Kagaya, Y; Namiuchi, S; Otani, H; Shirato, K; Tanikawa, T | 1 |
| Burrell, CJ; Knightingale, AK; Marshall, AJ | 1 |
| Huang, BS; Leenen, FH; Zhang, W | 1 |
| Ingenito, AJ; McConnaughey, JS; McConnaughey, MM | 1 |
| Dahlström, U; Jansson, K; Karlberg, BE; Karlberg, KE; Karlsson, E; Nylander, E; Nyquist, O | 1 |
| Baba, T; Goto, Y; Miyazaki, S; Noguchi, T; Nonogi, H; Sumida, H; Yasuda, S | 1 |
| Lee, AF; MacFadyen, RJ; Morton, JJ; Pringle, SD; Struthers, AD | 1 |
| Kirk, JK | 1 |
| Bishop, VS; Liu, JL; Murakami, H; Sanderford, M; Zucker, IH | 1 |
| Harrison, DG; Münzel, T | 1 |
| Rydén, L | 1 |
| Domínguez, J; García-Escribano, JR; Paule, A; Rodríguez-García, JL; Vázquez, M | 1 |
| Braith, RW; Feigenbaum, MS; Kluess, HA; Pepine, CJ; Welsch, MA | 1 |
| Bohlender, J; Dietz, R; Haass, M; Höhnel, K; Luft, FC; Scheuermann, M; Thibault, G; Willenbrock, R | 1 |
| Willenheimer, R | 1 |
| Arnold, JM; Azevedo, ER; Baird, MG; Butt, RW; Humen, DP; Moe, GW; Parker, AB; Parker, JD; Parker, JO; Smith, SJ | 1 |
| Barbe, F; Campbell, DJ; Crozatier, B; Hittinger, L; Su, JB | 1 |
| Arens, H; Bouzo, H; George, M; Münz, J; Pethig, H; Petr, P; Riegger, GA; Spacek, R; von Behren, V | 1 |
| Cleland, JG; Cowburn, PJ; Dargie, HJ; Hillier, C; McGrath, JC; McMurray, JJ; Morton, JJ | 1 |
| Ezan, E; Fraser, C; Junot, C; MacFadyen, R; Morton, JJ; Robson, J; Struthers, AD | 1 |
| Weber, M | 1 |
| van Veldhuisen, DJ; Voors, AA | 1 |
| Heras, M; Jiménez, W; Morales, M; Orús, J; Perez-Villa, F; Roig, E; Sanz, G | 1 |
| Coca, A; Giner, V | 1 |
| Drexler, H; Wollert, KC | 1 |
| Califf, RM; Cohn, JN | 1 |
| Pfeffer, MA | 1 |
| Chung, O; Unger, T | 1 |
| Leary, AC; MacDonald, TM | 1 |
| Capogrossi, MC; Emanueli, C; Madeddu, P; Maestri, R; Minasi, A; Olivetti, G; Salis, MB | 1 |
| Farquharson, CA; Struthers, AD | 2 |
| Lim, PO; MacFadyen, RJ; Struthers, AD | 1 |
| Cukon, S; Ennezat, PV; Hammer, A; Infeld, J; Jorde, UP; Le Jemtel, TH; Lisker, J; Sonnenblick, EH; Suryadevara, V | 1 |
| González-Juanatey, JR | 1 |
| Berger, D | 1 |
| Arnold, JM; Barr, A; Charbonneau, L; de Champlain, J; Hall, C; Moe, GW; Packer, M; Proulx, G; Rouleau, JL; Sirois, P | 1 |
| Bertel, O; Clozel, M; Kiowski, W; Nicholls, MG; Rickenbacher, P; Sütsch, G; Yandle, TG | 1 |
| Berder, V; Juilliére, Y | 1 |
| Bonarjee, VV; Dickstein, K | 1 |
| Azqueta, M; Filella, X; Heras, M; Orús, J; Paré, C; Perez-Villa, F; Roig, E; Sanz, G | 1 |
| Cobelli, F; Febo, O | 1 |
| Just, H | 1 |
| Bond, BR; Cazaubon, C; Clair, MJ; Gay, DM; Goldberg, AT; Hendrick, JW; King, MK; Krombach, RS; McElmurray, JH; Morrison, AE; Nisato, D; Nisato, R; Spinale, FG | 1 |
| Inada, Y; Naka, T | 1 |
| Gerdes, AM; Harris, J; Lu, W; Said, S; Tamura, T | 1 |
| Badoer, E; McGrath, BP | 1 |
| Brown, NJ; Vaughan, DE | 1 |
| Lee, AF; MacFadyen, RJ; Struthers, AD | 1 |
| Cleland, JG; Cockburn, N; Richardson, M | 1 |
| Dickstein, K | 2 |
| Hall, AS; White, HL | 1 |
| Azuma, J; Lombardini, JB; Schaffer, SW | 1 |
| Berry, C | 1 |
| Kohno, Y; Oana, S; Ohnuma, N; Tanabe, M; Terai, M | 1 |
| Block, AJ; Isaac, D; Kerut, EK; Pfeffer, MA; Porter, CB; Proulx, G; Qian, C; Rouleau, JL; Sestier, F; Stewart, DJ | 1 |
| Burnett, JC; Chen, HH | 1 |
| Krum, H | 1 |
| Clair, MJ; de Gasparo, M; Hendrick, JW; King, MK; Mandel, J; McElmurray, JH; Mukherjee, R; New, RB; Sampson, AC; Spinale, FG | 1 |
| Kromer, EP | 1 |
| Fujii, M; Hayashi, M; Horie, H; Kinoshita, M; Mabuchi, N; Maeda, K; Matsumoto, T; Ohnishi, M; Sawaki, M; Sugimoto, Y; Tsutamoto, T; Tsutsui, T; Wada, A | 1 |
| Bosch, FH; Jacobs, EM; van Leusen, R | 1 |
| Irvine, S; Liu, JL; Patel, KP; Reid, IA; Zucker, IH | 1 |
| Bulagannawar, M; Carretero, OA; Cavasin, MA; Karumanchi, R; Liu, YH; Mehta, D; Yang, XP | 1 |
| Espiner, EA; Frampton, CM; Nicholls, MG; Powell, JD; Rademaker, MT; Richards, AM; Troughton, RW; Yandle, TG | 1 |
| Braunwald, E; Bristow, MR | 1 |
| Dixon, IM; Hao, J; Jassal, DS; Jones, SC; Wang, B | 1 |
| Anversa, P; Chimenti, C; Frustaci, A; Jakoniuk, I; Kajstura, J; Leri, A; Maseri, A; Nadal-Ginard, B | 1 |
| Littmann, L; Stell, LK | 1 |
| Hisaoka, T; Kobayashi, S; Kohno, M; Matsuzaki, M; Ohkusa, T; Ono, K; Suetsugu, M; Yamada, J; Yano, M | 1 |
| Anversa, P; Barlucchi, L; Dostal, DE; Fiordaliso, F; Hintze, TH; Kajstura, J; Leri, A; Nadal-Ginard, B; Tada, H | 1 |
| Rivey, MP; Struckman, DR | 1 |
| Fowler, MB; Jamali, AH; Khot, UN; Tang, WH | 1 |
| Kim, SD | 1 |
| Cheng, CP; Cheng, HJ; Igawa, A; Little, WC; Ohte, N; Onishi, K; Suzuki, M; Tachibana, H; Ukai, T; Zhang, ZS | 1 |
| Thürmann, PA | 1 |
| Connell, JM; Hillier, C; McDonald, JE; McMurray, JJ; Padmanabhan, N; Petrie, MC | 1 |
| Hayashida, W; Inagaki, K; Iwanaga, Y; Kihara, Y; Sasayama, S; Yasaka, A | 1 |
| Haghfelt, T | 1 |
| Opie, LH; Sack, MN | 1 |
| Dargie, HJ; Farmer, R; McDonagh, TA; McMurray, JJ; Morton, JJ; Murdoch, DR | 1 |
| Patterson, JH; Rodgers, JE | 1 |
| Angelini, A; Battista Ambrosio, G; Dalla Libera, L; Ravara, B; Rossini, K; Sandri, M; Thiene, G; Vescovo, G | 1 |
| Abraham, WT; Wagoner, LE | 1 |
| Miller, AB; Srivastava, P | 1 |
| McMurray, JJ | 1 |
| Draganov, B; Høieggen, A; Os, I | 1 |
| Inagaki, K; Iwanaga, Y; Kataoka, K; Kihara, Y; Onozawa, Y; Sasayama, S; Yoneda, T | 1 |
| Böhm, M; Schwaab, B | 1 |
| Maki, T; Nasa, Y; Takahashi, M; Takeo, S; Tanonaka, K; Yoshida, H | 1 |
| Goa, KL; Jarvis, B; Sharpe, M | 1 |
| Bennett, SR; Drew, P; Griffin, S; McKeown, J | 1 |
| Angelini, A; Betto, R; Dalla Libera, L; Ravara, B; Renken, C; Sabbadini, R; Sandri, M; Vescovo, G | 1 |
| Date, Y; Hosoda, H; Kangawa, K; Koh, H; Kojima, M; Nagaya, N; Nakazato, M; Okumura, H; Oya, H; Shimizu, W; Uematsu, M; Yamagishi, M; Yutani, C | 1 |
| Aicher, A; Dimmeler, S; Freyssinet, JM; Haase, A; Hoffmann, J; Hugel, B; Mallat, Z; Rössig, L; Tedgui, A; Zeiher, AM | 1 |
| Asai, S; Fujii, M; Hayashi, M; Kinoshita, M; Kuwahara, K; Mabuchi, N; Maeda, K; Matsumoto, T; Nakao, K; Ohnishi, M; Saito, Y; Tanaka, H; Tsuji, T; Tsutamoto, T; Tsutsui, T; Wada, A; Wang, X; Yamamoto, T | 1 |
| Basdew, M; Danser, AH; de Vries, R; Saxena, PR; Schoemaker, RG; Schuijt, MP; van Veghel, R | 1 |
| Cohen Solal, A; Garçon, P; Logeart, D; Salengro, E | 1 |
| Wang, Y | 1 |
| Cardin, S; Leung, TK; Li, D; Nattel, S; Pang, L; Shinagawa, K; Wang, Z | 1 |
| Aggarwal, A; Campbell, DJ; Esler, M; Kaye, D | 1 |
| Hesse, B; Kjaer, A | 1 |
| Achilli, F; Baglivo, J; Calchera, I; Capra, A; Failla, M; Gentile, G; Giannattasio, C; Grappiolo, A; Mancia, G; Meles, E; Sala, L; Vincenzi, A | 1 |
| Benedict, CR; Fowler, MB; Liss, CL; Tang, WH; Vagelos, RH; Willson, K; Yee, YG | 1 |
| Ditiatkov, AE; Radzevich, AE; Tikhonov, VA | 1 |
| Azuma, J; Schaffer, S; Solodushko, V | 1 |
| Cai, H; Dong, Y; Hu, W | 1 |
| Ambrosioni, E; Angelini, V; Borghi, C; Gatti, M; Giovagnorio, MT; Grippo, MC; Lepera, G; Maranga, SS; Melandri, F; Naccarella, F; Naccarelli, GV; Nisam, S; Pazzaglia, S; Spinelli, G | 1 |
| Aubert, ML; Blum, WF; Dietz, R; Höhnel, K; Langenickel, T; Nüssler, AK; Pagel, I; Philipp, S; Willenbrock, R | 1 |
| Charles, CJ; Cooper, GJ; Coy, DH; Espiner, EA; Lewis, LK; Nicholls, MG; Rademaker, MT; Richards, AM | 1 |
| Greenberg, B | 1 |
| Moore, MA | 1 |
| Andreuzzi, B; Gronda, E; Mangiavacchi, M; Municinò, A | 1 |
| Callahan, KS; Cheang, KI; Munger, MA; Ng, TM | 1 |
| Lapointe, N; Rouleau, JL | 1 |
| Gadsbøll, N; Henriksen, OM | 1 |
| Berezin, AE; Vizir, VA | 1 |
| de Denus, S; Spinler, SA | 1 |
| Burchardt, H; Davidsen, U; Heitmann, M; Petersen, EB; Rasmussen, K; Stokholm, KH | 1 |
| González-Juanatey, JR; Mazón Ramos, P | 1 |
| Bruni, F; Carerj, S; Luzza, F; Rizzo, F | 1 |
| Bhatnagar, RK; Lund, DD; McNamara, RF; Schmid, PG; Schmidt, JA | 1 |
| Atkinson, AB; Robertson, JI | 1 |
| Abboud, FM; Heistad, DD; Mark, AL; Mayer, HE; Schmid, PG | 2 |
| Barger, AC; Burton, JA; Cant, JR; Haber, E; Smith, FW; Watkins, L | 1 |
| Donald, RA; Espiner, EA; Nicholls, MG | 1 |
| Davis, JO; DeForrest, JM; Freeman, RH; Rowe, BP; Seymour, AA; Williams, GM | 2 |
| Cannon, PJ | 1 |
| DiBona, GF | 1 |
| Oelkers, W | 1 |
| Just, OH; Wiedemann, K | 1 |
| Burnett, JC | 2 |
| Arakawa, K; Kanaya, H | 1 |
| Brunner, HR; Faxon, DP; Flessas, A; Gavras, H; Gavras, I; Ryan, TJ | 1 |
| Brunner, HR; Ferguson, RK; Gavras, H; Rivier, JL; Turini, GA | 2 |
| Cohn, JN; Curtiss, C; Franciosa, JA; Vrobel, T | 1 |
| Haber, E | 1 |
| Ledingham, IM | 1 |
| Davis, JO; Freeman, RH; Stephens, GA; Watkins, BE; Williams, GM | 1 |
| Davis, JO; Morris, BJ; Williams, GM; Zatzman, ML | 1 |
| McNay, JL | 1 |
| Galla, JH; Hayslett, JP; Kotchen, TA; Schneider, G | 1 |
| Espiner, EA; Hughes, H; Nicholls, MG; Rogers, T | 1 |
| Doi, K; Hata, T; Ichihara, K; Kumahara, Y; Ogihara, T; Yamamoto, T | 1 |
| Carriére, S | 1 |
| Davis, JO; Freeman, RH | 1 |
| Ramsay, DJ; Rolls, BJ; Wood, RJ | 2 |
| Davis, JO; Freeman, RH; Lohmeier, TE; Spielman, WS | 1 |
| DiBona, GF; Kaloyanides, GJ; Slick, GL | 1 |
| del Greco, F | 1 |
| Kondo, K | 1 |
| Brockmeier, D; Heintz, B; Kierdorf, H; Kirsten, R; Lückel, G; Maigatter, S; Nelson, K; Rangoonwala, B; Sieberth, HG; Verho, M | 1 |
| Coutie, WJ; Lang, CC; Motwani, JG; Rahman, AR; Struthers, AD | 1 |
| Packer, M | 3 |
| Armstrong, PW; Forster, C; Larosa, G | 1 |
| Charles, CJ; Espiner, EA; Fitzpatrick, MA; Ikram, H; Nussberger, J; Rademaker, MT; Yandle, TG | 1 |
| Bagger, JP; Eiskjaer, H; Mogensen, CE; Pedersen, EB; Schmitz, A | 1 |
| Davies, E; Edwards, CR; Flapan, AD; Shaw, TR; Williams, BC | 2 |
| Han, YL; Miao, ZL; Tong, M | 1 |
| Brilla, C; Tan, LB; Weber, KT | 1 |
| Fisher, ML; Gottlieb, SS; Krichten, CM; Robinson, S; Weir, MR | 1 |
| Burnett, JC; Margulies, KB; McKinley, LJ; Perrella, MA | 1 |
| Davies, E; Edwards, CR; Flapan, AD; Gow, IF; Morris, M; Padfield, PL; Shaw, TR; Williams, BC | 1 |
| Dietz, R; Fischer, T; Haberbosch, W; Hauck, S; Osterziel, KJ; Süsselbeck, T; Waas, W | 1 |
| Beermann, B; Cederholm, T; Hildebrand, IL; Jansson, E; Sylvén, C | 1 |
| Bann, J; Baur, LH; Bruschke, AV; Buis, B; Manger Cats, V; Schipperheyn, JJ; van der Laarse, A; van der Wall, EE; van Dijk, AD | 1 |
| Gorbacheva, ON; Karpov, IuA; Masenko, VP; Nasonov, EL; Samoriadova, OS; Zharova, EA | 1 |
| Guo, SP; Liu, YZ | 1 |
| Riegger, AJ | 2 |
| Brunner, H; Doering, W; Kleber, FX; Niemöller, L; Nussberger, J | 1 |
| Davies, E; Edwards, CR; Flapan, AD; Shaw, TR; Waugh, C; Williams, BC | 1 |
| Bruzzone, F; Canale, C; Caponnetto, S; Licciardello, L; Marchetti, GV; Masperone, MA; Pastorino, L; Terrachini, V | 1 |
| Finckh, M; Holtz, J | 1 |
| Arnolda, L; Johnston, CI; McGrath, BP | 1 |
| Ma, C; Qin, S | 1 |
| Matsuo, H; Nishida, M; Obata, H; Sano, H; Yasuda, H | 1 |
| Brunner, HR | 1 |
| Gohlke, P; Unger, T | 1 |
| Dzau, VJ; Hirsch, AT | 1 |
| Fogo, A; Ichikawa, I; Kon, V; Yoshioka, T | 1 |
| Akhmedov, ShD; Chernov, VI; Lishmanov, IuB; Rezapov, BR; Travkov, IuA; Usov, VIu | 1 |
| Nicholls, MG | 1 |
| Brunner, HR; Hofbauer, KG; Nicod, P; Nussberger, J; Waeber, B | 1 |
| Dargie, HJ; McAlpine, HM; Morton, JJ | 1 |
| Dargie, HJ; Leckie, B; McAlpine, HM; Morton, JJ | 1 |
| Cockcroft, JR; Webb, DJ | 1 |
| Dzau, VJ; Ingelfinger, JR | 1 |
| Francis, GS | 2 |
| Broqvist, M; Dahlström, U; Karlberg, BE; Karlsson, E; Marklund, T | 1 |
| Hasegawa, K; Inoue, S; Kakumae, S; Kawahara, Y; Nakamura, T; Nakao, M; Nezuo, S; Sawayama, T; Tadaoka, S | 1 |
| Corvol, P | 1 |
| Lopes, MR | 1 |
| Autenrieth, G; Göldel, N; Knesewitsch, P; Werdan, K; Wilmanns, W | 1 |
| Schiffrin, EL; St-Louis, J | 1 |
| Belz, GG; Kirch, W; Kleinbloesem, CH | 1 |
| Wyvratt, MJ | 1 |
| Ganten, D; Gohlke, P; Lang, RE; Unger, T | 1 |
| Edwards, CR; Padfield, PL | 1 |
| Blaine, EH; Frederick, CM; Ludden, CT; Nussberger, J; Ribeiro, LG; Slater, EE; Sweet, CS | 1 |
| Fyhrquist, F; Tikkanen, I | 1 |
| Esser, H; Heck, I; Kikis, D; Stumpe, KO | 1 |
| Chambers, S; Espiner, EA; Ikram, H; Livesey, JH; Nicholls, MG | 1 |
| Ball, SG; Cleland, JG; Dargie, HJ; East, BW; Ford, I; Gillen, G; Hodsman, GP; Morton, JJ; Robertson, I; Robertson, JI | 1 |
| Arnolda, L; Jackson, B; Jennings, G; Johnston, CI; Kiat, H; Matthews, PG; McGrath, BP | 1 |
| Hollenberg, NK | 1 |
| Jia, L | 1 |
| Grönhagen-Riska, C | 1 |
| Hall, C; Karlberg, BE | 1 |
| Danielsen, H; Jensen, T; Madsen, M; Pedersen, EB; Sørensen, SS; Thomsen, OO | 1 |
| Andersen, AR; Barry, DI; Paulson, OB; Pedersen, EV; Schmidt, JF; Vorstrup, S; Waldemar, G | 1 |
| Eliseev, OM | 2 |
| Brenner, BM; Stanton, RC | 1 |
| Brenner, BM; Ichikawa, I; Kon, V; Pfeffer, JM; Pfeffer, MA | 1 |
| Punzengruber, C; Silberbauer, K; Sinzinger, H; Stanek, B | 1 |
| de Jonge, A; van Zwieten, PA | 1 |
| Hayes, JS; Hood, WB; Imai, N; Liang, CS; Stone, CK | 1 |
| Glogar, DH; Kaindl, F; Silberbauer, K; Stummvoll, HK; Templ, H; Wittels, P | 1 |
| Kiseleva, ZM; Serebrovskaia, IuA; Uchitel', IA | 1 |
| Benevent, J; Cibault, G; Danvy, F; Isorni, P | 1 |
| Agrest, A; Finkielman, S; Massani, ZM; Paladini, AC; Worcel, M | 1 |
| Lucchelli, PD; Natangelo, R; Santambrogio, S | 1 |
| Grütte, E; Schröder, R; Schüren, KP | 1 |
| Blaise, BH; Düsterdieck, G; Jahnecke, J; Kobayashi, T; Krück, F; Lommer, D; Schieffer, H; Wolff, HP | 1 |
| Berkmen, R | 1 |
| Kritcher, EM; Luchi, RJ | 1 |
| Heizmann, A; Klaus, D; Sadowski, P | 1 |
| Lenzi, S; Sotgiu, G | 1 |
| Tatsumi, S | 1 |
| Wolff, HP | 1 |
| Clauss, RH; Ray, JF | 1 |
| Davis, JO; Howards, SS; Johnston, CI; Wright, FS | 1 |
| Kelly, DT | 1 |
| Boucher, R; De Champlain, J; Genest, J; Granger, P | 1 |
| Imai, M; Sokabe, H | 1 |
| Boucher, R; de Champlain, J; Genest, J; Koiw, E; Veyrat, R | 1 |
| Bergan, JJ; Conn, J; Haid, SP | 1 |
| Truniger, B | 1 |
| Dimich, D; Manca, P; Morandini, G; Spanedda, M | 1 |
| Mach, RS; Muller, AF; Veyrat, R | 1 |
| Kadioğlu, A; Ozen, M; Oztekin, G | 1 |
| Kuroda, M; Morimoto, S; Murakami, M | 1 |
| Gordon, RD; Vandongen, R | 1 |
| Veyrat, R | 1 |
| Lahovaara, S; Paasonen, MK; Peltola, P | 1 |
| Baumber, JS; Davis, JO; Johnson, JA; Schneider, EG | 1 |
| Kashii, C; Takatsu, T | 1 |
| Bajusz, E; Cantin, M; Leone, A | 1 |
| Baum, GL; Castillo, C; Llamas, R; Schwartz, A | 1 |
| Klug, P; Samec, HJ; Sterz, H; Zalaudek, G | 1 |
| Kaufmann, W; Rosskamp, E | 1 |
| Greenway, CV; Murthy, VS | 1 |
| Coleman, TG; Granger, HJ; Guyton, AC | 1 |
| Blaine, EH; Davis, JO; Harris, PD | 1 |
| Kaufmann, W; Krause, DK; Meurer, KA; Rosskamp, E | 1 |
| Barjon, P; Fourcade, J | 1 |
| Davis, JO; Johnson, JA; Prewitt, RL; Shade, RE; Witty, RT | 1 |
| Alvisi, R; Alvisi, V; Baggioni, GF; Pipani, A; Ripa, R; Salzano, S | 1 |
| Kiil, F | 1 |
| Hidaka, H; Ito, T; Kato, T; Yoshitoski, Y | 1 |
| Haber, E; Oparil, S | 1 |
| Kinoshita, M; Kusukawa, R | 1 |
| Yamazaki, N | 1 |
268 review(s) available for angiotensin ii and Heart Failure
| Article | Year |
|---|---|
Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Death, Sudden, Cardiac; Defibrillators, Implantable; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Neprilysin; Norepinephrine; Primary Prevention; Receptors, Angiotensin; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left | 2022 |
Effect of Angiotensin II Antagonism on Gastrointestinal Bleeding in Patients With Left Ventricular Assist Devices: A Systematic Review and Meta-Analysis.
Topics: Angiotensin II; Arteriovenous Malformations; Gastrointestinal Hemorrhage; Heart Failure; Heart-Assist Devices; Humans; Retrospective Studies | 2022 |
Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update.
Topics: Angiotensin II; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Heart Failure; Humans; Hypertension; Hypoglycemic Agents; Liraglutide | 2023 |
Inhibition of the renin-angiotensin system in the cardiorenal syndrome with anaemia: a double-edged sword.
Topics: Anemia; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardio-Renal Syndrome; Glomerular Filtration Rate; Heart Failure; Humans; Renin-Angiotensin System | 2019 |
Targeting Brain Aminopeptidase A: A New Strategy for the Treatment of Hypertension and Heart Failure.
Topics: Angiotensin II; Angiotensin III; Animals; Antihypertensive Agents; Brain; Clinical Trials as Topic; Disulfides; Glutamyl Aminopeptidase; Heart Failure; Humans; Hypertension; Myocardial Infarction; Renin-Angiotensin System; Sulfonic Acids | 2020 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Angiotensin II-Vasopressin Interactions in The Regulation of Cardiovascular Functions. Evidence for an Impaired Hormonal Sympathetic Reflex in Hypertension and Congestive Heart Failure.
Topics: Angiotensin II; Animals; Cardiovascular Physiological Phenomena; Cardiovascular System; Heart Failure; Humans; Hypertension; Receptor Cross-Talk; Reflex, Abnormal; Sympathetic Nervous System; Vasopressins | 2021 |
RAAS: A Convergent Player in Ischemic Heart Failure and Cancer.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Myocardial Infarction; Myocardial Ischemia; Neoplasms; Renin; Renin-Angiotensin System | 2021 |
Angiotensin-converting enzyme 2-Angiotensin 1-7/1-9 system: novel promising targets for heart failure treatment.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Cardiovascular Agents; Heart Failure; Humans; Molecular Mimicry; Molecular Targeted Therapy; Peptide Fragments; Peptidyl-Dipeptidase A; Signal Transduction; Treatment Outcome | 2018 |
Chronic heart failure: a disease of the brain.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Baroreflex; Brain; Cardiomegaly; Chronic Disease; Heart; Heart Failure; Humans; Inflammation; Natriuretic Peptide, Brain; Neuroimmunomodulation; Norepinephrine; Oxidative Stress; Paraventricular Hypothalamic Nucleus; Peptide Fragments; Renin-Angiotensin System; Sympathetic Nervous System; Vagus Nerve Stimulation | 2019 |
Temporal Frame of Immune Cell Infiltration during Heart Failure Establishment: Lessons from Animal Models.
Topics: Angiotensin II; Animals; Aorta; B-Lymphocytes; Cardiomegaly; Cell Movement; Constriction, Pathologic; Cytokines; Disease Models, Animal; Endomyocardial Fibrosis; Heart Failure; Humans; Hypertension; Mice; Monocytes; T-Lymphocytes; Time Factors; Ventricular Dysfunction, Left | 2018 |
The renin-angiotensin-aldosterone system and its suppression.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cat Diseases; Cats; Dog Diseases; Dogs; Heart Failure; Hypertension; Kidney Diseases; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System | 2019 |
The effect of taurine on chronic heart failure: actions of taurine against catecholamine and angiotensin II.
Topics: Angiotensin II; Animals; Catecholamines; Chronic Disease; Heart Failure; Humans; Renin-Angiotensin System; Taurine | 2014 |
Impact of the renin-angiotensin system on cardiac energy metabolism in heart failure.
Topics: Angiopoietins; Angiotensin II; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Animals; Carbohydrate Metabolism; Energy Metabolism; Fatty Acids; Heart; Heart Failure; Humans; Insulin Resistance; Mitochondria; Myocardium; Oxidation-Reduction; Peptidyl-Dipeptidase A; Renin; Renin-Angiotensin System | 2013 |
The autocrine/paracrine loop after myocardial stretch: mineralocorticoid receptor activation.
Topics: Angiotensin II; Autocrine Communication; Calcium; Cardiomegaly; Cardiovascular Diseases; Heart Failure; Humans; Myocardial Contraction; Myocardium; Paracrine Communication; Reactive Oxygen Species; Receptors, Mineralocorticoid; Sodium-Calcium Exchanger; Sodium-Hydrogen Exchangers; Thyroid Hormones | 2013 |
The renin-angiotensin-aldosterone system and heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Renin; Renin-Angiotensin System; Treatment Outcome; Ventricular Remodeling | 2014 |
Central mechanisms for exercise training-induced reduction in sympatho-excitation in chronic heart failure.
Topics: Angiotensin II; Brain; Chronic Disease; Exercise Therapy; Heart Failure; Humans; Nitric Oxide; Oxidative Stress; Quality of Life; Sympathetic Nervous System | 2015 |
A possible mechanism for the progression of chronic renal disease and congestive heart failure.
Topics: Angiotensin II; Disease Progression; Heart Failure; Humans; Neurodegenerative Diseases; Renal Insufficiency, Chronic; Renin-Angiotensin System; Up-Regulation | 2015 |
Modulation of angiotensin II signaling following exercise training in heart failure.
Topics: Angiotensin II; Animals; Exercise Therapy; Heart Failure; Humans; Renin-Angiotensin System; Signal Transduction | 2015 |
Intracellular angiotensin II disrupts chemical communication and impairs metabolic cooperation between cardiac myocytes.
Topics: Angiotensin II; Animals; Cell Communication; Heart Failure; Humans; Hyperglycemia; Myocardial Ischemia; Myocytes, Cardiac; Renin-Angiotensin System | 2015 |
Atrophied cardiomyocytes and their potential for rescue and recovery of ventricular function.
Topics: Angiotensin II; Antioxidants; Heart Failure; Humans; Myocardial Contraction; Myocytes, Cardiac; Myofibroblasts; Oxidative Stress; Signal Transduction; Ventricular Function | 2016 |
An Expanded View of Progressive Cardiorenal Disorders.
Topics: Angiotensin II; Angiotensinogen; Cardio-Renal Syndrome; Disease Progression; Heart Failure; Humans; Parathyroid Hormone-Related Protein; Peptidyl-Dipeptidase A; Renal Insufficiency, Chronic; Renin; Renin-Angiotensin System; Signal Transduction; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2016 |
Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction.
Topics: Adrenomedullin; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; beta-N-Acetyl-Galactosaminidase; Biomarkers; C-Reactive Protein; Cardio-Renal Syndrome; Catecholamines; Chromogranin A; Creatinine; Galectin 3; Glycopeptides; Growth Differentiation Factor 15; Heart Failure; Hepatitis A Virus Cellular Receptor 1; Humans; Interleukin-1; Interleukin-1 Receptor-Like 1 Protein; Interleukin-18; Interleukin-6; Lipocalin-2; MicroRNAs; Natriuretic Peptide, Brain; Peptide Fragments; Renin; Renin-Angiotensin System; Stroke Volume; Troponin; Troponin T; Tumor Necrosis Factor-alpha | 2017 |
Cardiac Ca2+ signaling and Ca2+ sensitizers.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Angiotensin II; Animals; Azocines; Calcium; Calcium Signaling; Cardiotonic Agents; Cholinergic Agonists; Dihydropyridines; Endothelins; Heart Failure; Humans; Hydrazones; Myocardial Contraction; Myocardium; Phosphodiesterase Inhibitors; Pyridazines; Quinolines; Simendan; Thiadiazines; Troponin C | 2008 |
Myocardial repair/remodelling following infarction: roles of local factors.
Topics: Angiotensin II; Animals; Cell Death; Fibrosis; Heart Failure; Humans; Inflammation; Myocardial Infarction; Myocardium; Oxidative Stress; Prognosis; Reactive Oxygen Species; Signal Transduction; Ventricular Remodeling | 2009 |
The therapeutic role of RAS blockade in chronic heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Heart Failure; Humans; Hypertrophy, Left Ventricular; Renin-Angiotensin System | 2008 |
Angiotensin II: a regulator of cardiomyocyte function and survival.
Topics: Angiotensin II; Animals; Apoptosis; Calcium Signaling; Cell Survival; Heart Failure; Humans; Models, Cardiovascular; Myocardial Contraction; Myocytes, Cardiac; p38 Mitogen-Activated Protein Kinases; Signal Transduction | 2009 |
The brain renin-angiotensin-aldosterone system: a major mechanism for sympathetic hyperactivity and left ventricular remodeling and dysfunction after myocardial infarction.
Topics: Angiotensin II; Brain; Heart Failure; Humans; Myocardial Infarction; Renin-Angiotensin System; Sympathetic Nervous System; Ventricular Dysfunction, Left; Ventricular Remodeling | 2009 |
Nutrient dyshomeostasis in congestive heart failure.
Topics: Angiotensin II; Animals; Antioxidants; Biomarkers; Black or African American; Heart Failure; Homeostasis; Humans; Neurotransmitter Agents; Nutrition Disorders; Oxidative Stress | 2009 |
Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Chronic Disease; Exercise; Heart; Heart Failure; Humans; Medulla Oblongata; Neurons; Oxidative Stress; Peptide Fragments; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Signal Transduction; Sympathetic Nervous System; Transcription Factor AP-1; Transcription, Genetic; Up-Regulation | 2009 |
Regulation of cardiac hypertrophy by the formation of G protein-coupled receptor--TRPC channel protein complex.
Topics: Angiotensin II; Animals; Calcium; Calcium Signaling; Cardiomegaly; Diglycerides; Drug Design; Heart Failure; Humans; Multiprotein Complexes; Receptors, G-Protein-Coupled; TRPC Cation Channels; TRPC6 Cation Channel | 2009 |
Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure.
Topics: Angiotensin II; Animals; Antidiuretic Agents; Antihypertensive Agents; Benzazepines; Biomarkers; Bosentan; Catecholamines; Drug Therapy, Combination; Endothelin-1; Heart Failure; Humans; Peptides, Cyclic; Renin-Angiotensin System; Sulfonamides; Sympathetic Nervous System; Tolvaptan; Treatment Outcome; Vasopressins | 2010 |
Rational of the use of aliskiren in hypertension and beyond.
Topics: Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseases; Diabetic Nephropathies; Diuretics; Drug Therapy, Combination; Europe; Fumarates; Germany; Heart Failure; Humans; Hydrochlorothiazide; Hypertension; Irbesartan; Japan; Prevalence; Prorenin Receptor; Protein Precursors; Randomized Controlled Trials as Topic; Receptors, Cell Surface; Renin; Renin-Angiotensin System; Risk Factors; Tetrazoles; Time Factors; World Health Organization | 2009 |
Endogenous ouabain in renal Na(+) handling and related diseases.
Topics: Adrenal Glands; Angiotensin II; Animals; Cell Proliferation; Diuretics; Drosophila; Epinephrine; Heart Failure; Homeostasis; Humans; Hypertension; Kidney; Myocytes, Cardiac; Myocytes, Smooth Muscle; Ouabain; Renal Insufficiency; Sodium; Sodium-Calcium Exchanger; Sodium-Potassium-Exchanging ATPase; Vasoconstriction | 2010 |
Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium.
Topics: Acute Coronary Syndrome; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Apoptosis; Atherosclerosis; Bradykinin; Cardiotonic Agents; Coronary Artery Disease; Disease Progression; Endothelial Cells; Endothelium, Vascular; Heart Failure; Humans; Hypertension; Peptidyl-Dipeptidase A; Perindopril; Plaque, Atherosclerotic; Randomized Controlled Trials as Topic; Secondary Prevention; Stem Cells | 2010 |
Novel aspects of angiotensin II action in the heart. Implications to myocardial ischemia and heart failure.
Topics: Angiotensin II; Animals; Cell Size; Heart; Heart Failure; Humans; Mechanoreceptors; Myocardial Ischemia; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Ventricular Remodeling | 2011 |
Adaptive and maladaptive remodeling of cardiomyocyte excitation-contraction coupling by angiotensin II.
Topics: Adaptation, Physiological; Angiotensin II; Animals; Cardiomegaly; Excitation Contraction Coupling; Heart Failure; Humans; Mice; Mice, Knockout; Myocytes, Cardiac; Renin-Angiotensin System; Ventricular Remodeling | 2010 |
Genetics of mechanosensation in the heart.
Topics: Angiotensin II; Animals; Cardiomyopathies; Connectin; Heart Failure; Humans; Intermediate Filaments; Mechanotransduction, Cellular; Muscle Proteins; Mutation; Myocardium; Polymorphism, Genetic; Protein Kinases; Renin-Angiotensin System; Sarcomeres; Sensation; Stress, Mechanical | 2011 |
Role of ACE2 in diastolic and systolic heart failure.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Heart Failure; Humans; Hypertension; Peptide Fragments; Peptidyl-Dipeptidase A; Renin-Angiotensin System; Signal Transduction | 2012 |
Translational success stories: angiotensin receptor 1 antagonists in heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Drug Design; Heart Failure; Humans; Myocardium; Renin-Angiotensin System; Signal Transduction; Translational Research, Biomedical; Ventricular Function, Left | 2011 |
Roles of heterotrimeric GTP-binding proteins in the progression of heart failure.
Topics: Angiotensin II; Calcium Channels; Diglycerides; Disease Progression; Heart Failure; Heterotrimeric GTP-Binding Proteins; Humans; Signal Transduction | 2011 |
Angiotensin peptides and nitric oxide in cardiovascular disease.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Cardiovascular Diseases; Heart Failure; Humans; Nitric Oxide; Peptide Fragments; Peptides; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Renin-Angiotensin System | 2013 |
NADPH oxidases in heart failure: poachers or gamekeepers?
Topics: Aldosterone; Angiotensin II; Animals; Apoptosis; Arrhythmias, Cardiac; Enzyme Activation; Fibroblasts; Fibrosis; Heart Failure; Humans; Hydrogen Peroxide; Hypertrophy, Left Ventricular; Leukocytes; Membrane Glycoproteins; Mice; Models, Cardiovascular; Molecular Targeted Therapy; Myocytes, Cardiac; NADPH Oxidase 2; NADPH Oxidases; Neovascularization, Pathologic; Oxidative Stress; Protein Isoforms; Reactive Oxygen Species; Subcellular Fractions | 2013 |
Angiotensin II, sympathetic nerve activity and chronic heart failure.
Topics: Angiotensin II; Chronic Disease; Heart; Heart Failure; Humans; Sympathetic Nervous System | 2014 |
Androgen modulates cardiac fibrosis contributing to gender differences on heart failure.
Topics: Androgens; Angiotensin II; Female; Fibrosis; Heart Failure; Humans; Male; Myocardium; Oxidative Stress; Sex Factors; Taiwan; Transforming Growth Factor beta; Young Adult | 2013 |
Dissecting the role of chymase in angiotensin II formation and heart and blood vessel diseases.
Topics: Angiotensin I; Angiotensin II; Arteriosclerosis; Cardiomegaly; Cardiovascular Diseases; Chymases; Heart Diseases; Heart Failure; Humans; Hypertension; Peptidyl-Dipeptidase A; Serine Endopeptidases | 2002 |
[Prevention and treatment of congestive heart failure in diabetic patients].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Carbazoles; Cardiotonic Agents; Carvedilol; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Lisinopril; Male; Meta-Analysis as Topic; Metoprolol; Prognosis; Propanolamines; Risk Factors; Time Factors | 2002 |
Local cardiac renin-angiotensin system: hypertension and cardiac failure.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihypertensive Agents; Heart; Heart Failure; Hemodynamics; Humans; Hypertension; Hypertrophy, Left Ventricular; Myocardium; Organ Specificity; Rats; Rats, Inbred SHR; Renin-Angiotensin System; Vascular Resistance; Ventricular Remodeling | 2002 |
Angiotensin AT-1 receptor antagonism: complementary or alternative to ACE inhibition in cardiovascular and renal disease?
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Cough; Diabetes Complications; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney Diseases; Myocardial Infarction; Receptor, Angiotensin, Type 1 | 2002 |
Clinical treatment regimens for chronic heart failure: a review.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiotonic Agents; Digoxin; Diuretics; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Pacemaker, Artificial; Spironolactone; Vasodilator Agents | 2002 |
Stretch-activated pathways and left ventricular remodeling.
Topics: Angiotensin II; Animals; Endothelin-1; GTP-Binding Proteins; Heart Failure; Humans; Insulin-Like Growth Factor I; Integrins; Interleukin-6; Myocardial Contraction; Myocytes, Cardiac; Signal Transduction; Ventricular Remodeling | 2002 |
Angiotensin II receptor blockers in heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Heart Failure; Humans | 2003 |
Therapeutic role of angiotensin II receptor blockers in the treatment of heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Heart Failure; Humans; Renin-Angiotensin System; Ventricular Dysfunction, Left | 2003 |
Novel mechanisms of sympatho-excitation in chronic heart failure.
Topics: Angiotensin II; Baroreflex; Endothelin-1; Excitatory Postsynaptic Potentials; Heart Failure; Humans; Nitric Oxide; Sympathetic Nervous System | 2002 |
Adrenomedullin and the renin-angiotensin-aldosterone system.
Topics: Adrenomedullin; Angiotensin II; Animals; Heart Failure; Hemodynamics; Humans; Nitroprusside; Norepinephrine; Peptides; Renin-Angiotensin System | 2003 |
[Renin-angiotensin system as a potential target for the treatment with heart failure: ACE inhibitors, angiotensin-II receptor blockers and aldosterone antagonists].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Drug Therapy, Combination; Evidence-Based Medicine; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Treatment Outcome | 2003 |
[Treatment for diastolic failure].
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Calcium Channel Blockers; Diastole; Heart Failure; Humans; Losartan; Practice Guidelines as Topic; Receptor, Angiotensin, Type 1; Tetrazoles | 2003 |
[Angiotensin II antagonists in the treatment of cardiac decompensation].
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans | 2003 |
Update on therapy for heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Spironolactone | 2003 |
[Blockade of the renin-angiotensin system. ACE inhibitors, angiotensin II antagonists or both?].
Topics: Albuminuria; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Drug Therapy, Combination; Heart Failure; Humans; Kidney Failure, Chronic; Myocardial Infarction; Proteinuria; Receptors, Angiotensin; Renin-Angiotensin System | 2003 |
[New possibilities in clinical use of angiotensin II receptor inhibitors].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Ramipril; Renin-Angiotensin System; Survival Analysis; Telmisartan; Treatment Outcome | 2003 |
Racial differences in responses to drug treatment: implications for pharmacotherapy of heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Black People; Cardiotonic Agents; Cardiovascular Agents; Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Racial Groups; White People | 2002 |
The therapeutic potential of angiotensin II receptor blockers in the treatment of heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Clinical Trials as Topic; Diastole; Heart; Heart Failure; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
[Clinical use of markers of neurohormonal activation in heart failure].
Topics: Angiotensin II; Atrial Natriuretic Factor; Biomarkers; Endothelins; Heart Failure; Humans; Interleukin-6; Natriuretic Peptide, Brain; Neurotransmitter Agents; Norepinephrine; Renin; Tumor Necrosis Factor-alpha | 2004 |
[The bioactivity of angiotensin II and the effects of related Chinese Herbs].
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cardiomegaly; Drugs, Chinese Herbal; Heart Failure; Humans; Hypertension; Myocardial Reperfusion Injury; Plants, Medicinal; Receptor, Angiotensin, Type 2 | 2003 |
[Organ protection by angiotensin II receptor blockers].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cognition Disorders; Heart Failure; Humans; Hypertension; Kidney Diseases; Losartan; Membrane Proteins; Mineralocorticoid Receptor Antagonists; Proteins; Proteinuria; Randomized Controlled Trials as Topic; Stroke; Tetrazoles | 2004 |
Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists.
Topics: Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiovascular Agents; Diabetic Nephropathies; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Heart Failure; Humans; Hypertension; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Proteinuria; Rats; Renin-Angiotensin System; Ventricular Dysfunction, Left | 2004 |
Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Dose-Response Relationship, Drug; Heart Failure; Humans; Hypertension; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2004 |
[Renin-angiotensin system and its role in cardiovascular physiopathology and therapy].
Topics: Angiotensin II; Cardiovascular Diseases; Heart Failure; Humans; Receptors, Angiotensin; Renin-Angiotensin System; Signal Transduction; Time Factors | 2004 |
Baroreceptor reflex in heart failure.
Topics: Angiotensin II; Animals; Baroreflex; Cardiac Output; Chemoreceptor Cells; Exercise; Heart Failure; Humans; Reactive Oxygen Species; Sympathetic Nervous System; Vascular Resistance | 2004 |
Exercise training and sympathetic regulation in experimental heart failure.
Topics: Angiotensin II; Animals; Baroreflex; Disease Models, Animal; Heart Failure; Nitric Oxide; Nitric Oxide Synthase; Physical Conditioning, Animal; Rabbits; Receptor, Angiotensin, Type 1; Sympathetic Nervous System | 2004 |
Large A-V fistula: pathophysiological consequences and therapeutic perspectives.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Arginine Vasopressin; Arteriovenous Fistula; Atrial Natriuretic Factor; Endothelins; Heart Failure; Humans; Nitric Oxide; Renin-Angiotensin System; Sympathetic Nervous System | 2003 |
The therapeutic potential of hepatocyte growth factor for myocardial infarction and heart failure.
Topics: Angiotensin II; Animals; Disease Models, Animal; Heart Failure; Hepatocyte Growth Factor; Humans; Myocardial Infarction | 2004 |
[Renin-angiotensin-aldosterone system and natriuretic peptide system--reference to cardiovascular diseases].
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Cardiovascular Diseases; Drug Design; Heart Failure; Humans; Hypertension; Kidney Tubules, Distal; Natriuresis; Natriuretic Peptides; Renin-Angiotensin System; Sodium; Sodium, Dietary; Water-Electrolyte Balance | 2004 |
[Effect of adrenomedullin on cardiac myocytes and fibroblasts].
Topics: Adrenomedullin; Angiotensin II; Animals; Apoptosis; Calcium; Cardiomegaly; Cell Division; Cyclic AMP; Endothelin-1; Heart Failure; Humans; Myoblasts, Cardiac; Myocardial Contraction; Myocytes, Cardiac; Nitric Oxide; Peptides; Protein Kinase C; Signal Transduction; Tumor Necrosis Factor-alpha; Ventricular Remodeling | 2004 |
[Cardio-protective effects of nitric oxide].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Heart Failure; Humans; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Oxidative Stress; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Renin-Angiotensin System | 2004 |
Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Heart Failure; Humans; Hypotension; Mineralocorticoid Receptor Antagonists; Multicenter Studies as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Spironolactone; Ventricular Dysfunction, Left | 2004 |
The future of angiotensin II inhibition in cardiovascular medicine.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Arteriosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Hypertension; Kidney Diseases; Myocardial Infarction; Protease Inhibitors; Renin; Risk Factors | 2005 |
[Molecular mechanism in heart failure].
Topics: Angiotensin II; Calcium; Calcium-Transporting ATPases; Collagen; Extracellular Signal-Regulated MAP Kinases; Gene Expression; Genes, Immediate-Early; Heart Failure; Humans; Microtubules; Myocardial Contraction; Oxidative Stress; Protein Kinase C; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Ribosomal Protein S6 Kinases; Ryanodine Receptor Calcium Release Channel; Transforming Growth Factor beta; Ventricular Remodeling | 2005 |
[Heart failure and renin-angiotensin-aldosterone system: studies on aldosterone].
Topics: Aldosterone; Angiotensin II; Animals; Apoptosis; Dehydroepiandrosterone; Gene Expression Regulation, Enzymologic; Heart Failure; Humans; Myocardium; Peptidyl-Dipeptidase A; Renin-Angiotensin System | 2005 |
[Cytokine antagonists and endothelin antagonists for therapy of heart failure].
Topics: Angiotensin II; Animals; Antibodies, Monoclonal; Bosentan; Clinical Trials as Topic; Cytokines; Endothelins; Etanercept; Genetic Therapy; Heart Failure; Humans; Immunoglobulin G; Infliximab; Interleukin-10; Mast Cells; NF-kappa B; Proto-Oncogene Proteins c-kit; Pyridazines; Receptors, Tumor Necrosis Factor; Sulfonamides | 2005 |
Renal and humoral pathophysiological actions of angiotensin II in congestive heart failure.
Topics: Angiotensin II; Animals; Heart Failure; Humans; Kidney; Receptors, Angiotensin; Renal Circulation; Renin-Angiotensin System | 2005 |
Renal and humoral pathophysiological actions of angiotensin II in congestive heart failure.
Topics: Angiotensin II; Blood Pressure; Cardiovascular System; Heart Failure; Humans; Kidney; Receptors, Angiotensin; Renin-Angiotensin System | 2005 |
[Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dogs; Drug Therapy, Combination; Female; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Myocardial Infarction; Placebos; Rabbits; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors; Stroke; Tetrazoles; Time Factors | 2005 |
Genetic aspects of atrial fibrillation.
Topics: Aged; Angiotensin II; Atrial Fibrillation; Connexins; Coronary Disease; Gap Junction alpha-5 Protein; Heart Conduction System; Heart Failure; Humans; Polymorphism, Genetic | 2005 |
[Chronic heart failure--the epidemic of the 21st century].
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Defibrillators, Implantable; Digitalis Glycosides; Diuretics; Endothelin Receptor Antagonists; Erythropoietin; Heart Failure; Heart-Assist Devices; Humans; Hungary; Immunologic Factors; Mineralocorticoid Receptor Antagonists; Pacemaker, Artificial; Peptide Hydrolases; Primary Prevention; Risk Factors; Severity of Illness Index; Vasopressins | 2005 |
Interactions between the sympathetic nervous system and the RAAS in heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Sympathetic Nervous System | 2004 |
Disruptions and detours in the myocardial matrix highway and heart failure.
Topics: Angiotensin II; Disease Progression; Endothelin-1; Extracellular Matrix; Heart Failure; Humans; Hypertrophy, Left Ventricular; Integrins; Matrix Metalloproteinases; Myocardial Infarction; Myocardium; Transforming Growth Factor beta; Ventricular Remodeling | 2005 |
Angiotensin II--nitric oxide interactions in the control of sympathetic outflow in heart failure.
Topics: Angiotensin II; Animals; Baroreflex; Cardiac Output, Low; Disease Models, Animal; Excitatory Postsynaptic Potentials; Exercise; Heart Failure; Hemodynamics; Humans; NG-Nitroarginine Methyl Ester; Nitric Oxide; Rabbits; Risk Factors; Sensitivity and Specificity; Sympathetic Nervous System | 2000 |
Cardiac sympathetic afferent reflexes in heart failure.
Topics: Afferent Pathways; Angiotensin II; Animals; Baroreflex; Bradykinin; Capsaicin; Cardiac Output, Low; Disease Models, Animal; Dogs; Heart; Heart Failure; Nitric Oxide; Reference Values; Sensitivity and Specificity; Sympathetic Nervous System | 2000 |
Role of angiotensin II in the evolution of diastolic heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Mineralocorticoid Receptor Antagonists; Prognosis; Renal Insufficiency; Renin-Angiotensin System; Treatment Outcome | 2005 |
[Aldosterone in heart failure].
Topics: Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Animals; Apoptosis; Cytochrome P-450 CYP11B2; Dehydroepiandrosterone; Gene Expression Regulation, Enzymologic; Heart Failure; Humans; Hydrocortisone; Myocardium; Oxidative Stress; Peptidyl-Dipeptidase A; Receptors, Mineralocorticoid; Renin-Angiotensin System | 2005 |
Angiotensin II in the failing heart. Short communication.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Heart Failure; Humans; Myocardium; Myocytes, Cardiac | 2005 |
Angiotensin-sympathetic system interactions in cardiovascular and metabolic disease.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Heart Failure; Humans; Hypertension; Insulin Resistance; Metabolic Syndrome; Renin-Angiotensin System; Sympathetic Nervous System | 2006 |
Angiotensin II as candidate of cardiac cachexia.
Topics: Angiotensin II; Cachexia; Heart Failure; Humans; Insulin-Like Growth Factor I; Muscle, Skeletal; Muscular Atrophy | 2006 |
[The main determinants of endothelial dysfunction].
Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Arteriosclerosis; Biological Availability; Diabetes Mellitus; Endothelium, Vascular; Free Radicals; Heart Failure; Homocysteine; Humans; Hypertension; Hypolipidemic Agents; Middle Aged; Models, Biological; Muscle, Smooth, Vascular; Nitric Oxide; Oxidative Stress; Potassium Channels; Reactive Oxygen Species; Renal Insufficiency; Risk Factors; Vasodilation | 2006 |
Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
Topics: Adrenergic Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Carbazoles; Carvedilol; Chi-Square Distribution; Cohort Studies; Coronary Disease; Death, Sudden, Cardiac; Diuretics; Drug Therapy, Combination; Echocardiography; Electroencephalography; Enalapril; Female; Follow-Up Studies; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Indapamide; Logistic Models; Losartan; Male; Multivariate Analysis; Prognosis; Propanolamines; Prospective Studies; Randomized Controlled Trials as Topic; Risk; Risk Assessment; Risk Factors; Sex Factors; Stroke; Survival Analysis; Telmisartan | 2006 |
Novel mechanisms of sympathetic regulation in chronic heart failure.
Topics: Angiotensin II; Animals; Baroreflex; Central Nervous System; Chronic Disease; Heart Failure; Humans; Oxidative Stress; Reactive Oxygen Species; Reflex; Renin-Angiotensin System; Sympathetic Nervous System | 2006 |
Oxidative mechanism and homeostasis of proteinase/antiproteinase in congestive heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Heart Failure; Homeostasis; Humans; Models, Cardiovascular; Oxidation-Reduction; Oxidative Stress; Peptide Hydrolases; Protease Inhibitors; Rats | 2006 |
Mechanisms of sympathetic activation in heart failure.
Topics: Angiotensin II; Animals; Baroreflex; Heart Failure; Humans; Neurotransmitter Agents; Sympathetic Nervous System | 2006 |
Rationale for angiotensin II receptor blocker therapy in chronic heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Heart Failure; Humans; Long-Term Care; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2000 |
Neuropeptides in neurogenic disorders of the cardiovascular control.
Topics: Angiotensin II; Brain; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Cytokines; Heart Failure; Humans; Hypertension; Nerve Net; Neuropeptides; Neurosecretory Systems; Stress, Psychological; Vasopressins | 2006 |
Mechanisms of protective effects induced by blockade of the renin-angiotensin system: novel role of the pancreatic islet angiotensin-generating system in Type 2 diabetes.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypertension; Insulin Resistance; Islets of Langerhans; Renin-Angiotensin System; Vasoconstrictor Agents | 2007 |
Early imaging in heart failure: exploring novel molecular targets.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Captopril; Fluorine Radioisotopes; Heart Failure; Humans; Imidazoles; Lisinopril; Positron-Emission Tomography; Pyridines; Radiopharmaceuticals; Renin-Angiotensin System; Ventricular Remodeling | 2007 |
Sodium-hydrogen exchanger, cardiac overload, and myocardial hypertrophy.
Topics: Amiloride; Angiotensin II; Animals; Calcium Signaling; Carbonic Anhydrase II; Cardiomegaly; Cation Transport Proteins; Cells, Cultured; Endothelins; Heart Failure; Hormones; Humans; Hydrogen; Hydrogen-Ion Concentration; Hypertrophy, Left Ventricular; MAP Kinase Signaling System; Mice; Mitochondria, Heart; Models, Cardiovascular; Myocytes, Cardiac; Phosphorylation; Protein Processing, Post-Translational; Rabbits; Rats; Rats, Inbred SHR; Reactive Oxygen Species; Signal Transduction; Sodium; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Stress, Mechanical; Swine | 2007 |
Carotid body function in heart failure.
Topics: Angiotensin II; Animals; Carotid Body; Chemoreceptor Cells; Heart; Heart Failure; Humans; Hypoxia; Nitric Oxide; Paraventricular Hypothalamic Nucleus; Reflex; Sympathetic Nervous System | 2007 |
Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?
Topics: Administration, Oral; Aldosterone; Amides; Angiotensin II; Animals; Antihypertensive Agents; Enzyme Activation; Enzyme Reactivators; Fumarates; Heart Failure; Humans; Hypertension; Randomized Controlled Trials as Topic; Renin; Renin-Angiotensin System; Vasoconstrictor Agents | 2007 |
[Role of oxidative stress in angiotensin II-induced heart failure].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Heart Failure; Oxidative Stress; Rats; Rats, Inbred Dahl | 2007 |
[Angiotensin II and heart failure].
Topics: Angiotensin II; Heart Failure; Humans; Ventricular Remodeling | 2007 |
Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Infarction; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction, Left | 2007 |
ACE Inhibitors in heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Coronary Circulation; Heart Failure; Hemodynamics; Humans; Physical Exertion; Renin; Renin-Angiotensin System | 1984 |
Angiotensin-converting enzyme inhibitors: biochemical properties and biological actions.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen; Animals; Disease Models, Animal; Heart Failure; Humans; Hypertension; Kidney; Oligopeptides; Peptidyl-Dipeptidase A; Receptors, Angiotensin; Renin; Structure-Activity Relationship; Substrate Specificity | 1984 |
An overview of the clinical pharmacology of enalapril.
Topics: Aldosterone; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Bradykinin; Dipeptides; Drug Administration Schedule; Enalapril; Enalaprilat; Heart Failure; Heart Rate; Humans; Hydrochlorothiazide; Hypertension; Kidney; Kidney Failure, Chronic; Norepinephrine; Prostaglandins; Renal Circulation; Renin | 1984 |
Neurohumoral control mechanisms in congestive heart failure.
Topics: Angiotensin II; Animals; Heart Failure; Hemodynamics; Humans; Neurotransmitter Agents; Renin; Sympathetic Nervous System; Vasoconstriction; Vasodilator Agents; Vasopressins | 1981 |
Drug suppression of the angiotensin system in congestive heart failure.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Captopril; Heart Failure; Hemodynamics; Humans; Myocardial Contraction; Renin-Angiotensin System; Saralasin; Teprotide | 1983 |
Haemodynamic responses to specific renin-angiotensin inhibitors in hypertension and congestive heart failure. A review.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen; Captopril; Dipeptides; Enalapril; Heart Failure; Hemodynamics; Humans; Hypertension; Hypertension, Pulmonary; Kinetics; Liver Cirrhosis; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Renin; Renin-Angiotensin System; Teprotide | 1984 |
Monotherapy of hypertension with angiotensin-converting enzyme inhibitors.
Topics: Acute Kidney Injury; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Clinical Trials as Topic; Dipeptides; Enalapril; Heart Failure; Humans; Hypertension; Proline; Racial Groups; Teprotide; Time Factors | 1984 |
Angiotensin converting enzyme (ACE) inhibitors.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Heart Failure; Humans; Hypertension; Kallikreins; Kidney; Kinins; Prostaglandins; Renin | 1982 |
[Use of captopril in circulatory failure].
Topics: Angiotensin II; Animals; Captopril; Chronic Disease; Drug Evaluation; Heart Failure; Hemodynamics; Humans; Proline; Renin; Renin-Angiotensin System | 1982 |
Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.
Topics: Aldosterone; Angiotensin II; Captopril; Drug Interactions; Heart Failure; Hemodynamics; Humans; Hypertension; Kallikreins; Kinetics; Kinins; Proline; Prostaglandins; Renin; Scleroderma, Systemic | 1980 |
Body fluid homeostasis in congestive heart failure and cirrhosis with ascites.
Topics: Aldosterone; Angiotensin II; Blood Volume; Body Fluids; Body Water; Cardiac Volume; Heart Failure; Homeostasis; Humans; Kidney; Kinins; Liver Cirrhosis; Prostaglandins; Renin; Sodium | 1982 |
Role of the cardiac renin-angiotensin system in human heart failure.
Topics: Angiotensin II; Heart; Heart Failure; Humans; Renin-Angiotensin System | 1995 |
[Alternative pathways of angiotensin I. The glimpse of new possibilities in the treatment of hypertension and heart failure].
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Circulation; Blood Pressure; Heart Failure; Humans; Hypertension; Renin-Angiotensin System | 1995 |
Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antibody Formation; Collagen; Collagenases; Connective Tissue; Dinoprostone; Endomyocardial Fibrosis; Fibroblasts; Heart Failure; Humans; Hypertension; Matrix Metalloproteinase 1; Myocardial Infarction; Myocardium; Neurotransmitter Agents; Renin-Angiotensin System; Ventricular Dysfunction, Left | 1995 |
The clinical potential of renin inhibitors and angiotensin antagonists.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Dipeptides; Heart Failure; Hemodynamics; Humans; Mineralocorticoid Receptor Antagonists; Renin; Renin-Angiotensin System; Sodium | 1994 |
Angiotensin as local modulating factor in ventricular dysfunction and failure due to coronary artery disease.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Coronary Disease; Heart; Heart Failure; Humans; Myocardial Contraction; Renin-Angiotensin System; Ventricular Dysfunction, Left | 1994 |
Molecular biology of myocardial hypertrophy and failure: gene expression and trophic signaling.
Topics: Angiotensin II; Animals; Calcium; Cardiomegaly; Fibroblast Growth Factors; Gene Expression; Heart Failure; Hemodynamics; Humans; Muscle Proteins; Proto-Oncogenes; Signal Transduction; Transcription Factors; Transforming Growth Factors | 1995 |
The cardiac renin-angiotensin system: its possible role in cell communication and impulse propagation.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Communication; Heart; Heart Failure; Humans; Myocardium; Rats; Renin-Angiotensin System | 1995 |
Dose-response relationships of ACE inhibitors and angiotensin II blockers.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Dose-Response Relationship, Drug; Heart Failure; Hemodynamics; Humans; Hypertension; Receptors, Angiotensin | 1994 |
Losartan in heart failure: preclinical experiences and initial clinical outcomes.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Disease Models, Animal; Drug Evaluation, Preclinical; Heart Failure; Hemodynamics; Humans; Imidazoles; Losartan; Rats; Receptors, Angiotensin; Sheep; Tetrazoles | 1994 |
Tissue angiotensin II system in the human heart.
Topics: Angiotensin II; Animals; Atrial Function; Chymases; Heart Failure; Heart Ventricles; Hemodynamics; Humans; Hypertension; Peptidyl-Dipeptidase A; Receptors, Angiotensin; Renin-Angiotensin System; Serine Endopeptidases | 1994 |
Angiotensin II receptor subtypes: selective antagonists and functional correlates.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Endothelium, Vascular; Heart Failure; Hemodynamics; Humans; Hypertension; Receptors, Angiotensin | 1994 |
The renin-angiotensin system in the heart and vascular wall: new therapeutic aspects.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomegaly; Coronary Disease; Endothelium, Vascular; Heart Failure; Humans; Hypertension; Myocardial Infarction; Myocardium; Peptidyl-Dipeptidase A; Renin-Angiotensin System | 1994 |
New neurohormonal antagonists and atrial natriuretic peptide in the treatment of congestive heart failure.
Topics: Angiotensin II; Arginine Vasopressin; Atrial Natriuretic Factor; Heart Failure; Humans; Neurotransmitter Agents; Renin; Renin-Angiotensin System | 1994 |
[Neurohormonal compensation processes in chronic heart failure: the effect of drugs].
Topics: Adrenergic beta-Agonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Cardiac Glycosides; Cardiotonic Agents; Deoxyepinephrine; Diuretics; Dobutamine; Heart Failure; Humans; Receptors, Cell Surface; Renin-Angiotensin System; Sympathetic Nervous System | 1994 |
Diverse factors influencing angiotensin metabolism during ACE inhibition: insights from molecular biology and genetic studies.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Endothelium, Vascular; Gene Expression; Heart Failure; Humans; Myocardial Infarction; Peptidyl-Dipeptidase A; Renin-Angiotensin System | 1994 |
Is neurohormonal activation a major determinant of the response to ACE inhibition in left ventricular dysfunction and heart failure?
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Sympathetic Nervous System; Ventricular Dysfunction, Left | 1994 |
A new myocardial conversion of angiotensin I.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Chymases; Coronary Artery Disease; Heart Failure; Humans; Hypertension; Myocardium; Renin-Angiotensin System; Serine Endopeptidases | 1994 |
Neurohormonal response to ventricular failure: pharmacologic management.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Constriction, Pathologic; Digoxin; Heart Failure; Heart Ventricles; Hemodynamics; Humans; Norepinephrine; Survival Rate; Vasodilator Agents; Vasopressins | 1993 |
[Growth stimulating properties of angiotensin II on the heart: consequences for therapy of heart failure].
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen; Animals; Bradykinin; Gene Expression Regulation; Heart Failure; Hemodynamics; Humans; Hypertrophy, Left Ventricular; Peptidyl-Dipeptidase A; Renin-Angiotensin System | 1993 |
Renal adaptation to the failing heart. Understanding the cascade of responses.
Topics: Adaptation, Physiological; Aldosterone; Angiotensin II; Arginine Vasopressin; Atrial Natriuretic Factor; Blood Volume; Endothelins; Heart Failure; Hemodynamics; Homeostasis; Humans; Kidney Diseases; Norepinephrine; Prostaglandins; Renal Circulation; Renin-Angiotensin System; Systole | 1994 |
RAA system and cardiovascular control in normal subjects, hypertensives and patients with congestive heart failure.
Topics: Angiotensin II; Animals; Blood Pressure; Cardiovascular Physiological Phenomena; Heart Failure; Humans; Hypertension; Renin-Angiotensin System | 1993 |
Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiovascular Diseases; Heart Failure; Homeostasis; Humans; Hypertension; Imidazoles; Losartan; Receptors, Angiotensin; Renin-Angiotensin System; Saralasin; Tetrazoles | 1993 |
Pathophysiology and therapy of heart failure, new insights and developments. Part II. Cardiac and peripheral alterations during progressive heart failure.
Topics: Adaptation, Physiological; Angiotensin II; Cyclic AMP; Heart Failure; Hemodynamics; Homeostasis; Humans; Myocardial Contraction; Norepinephrine; Oxygen Consumption; Phosphoric Diester Hydrolases; Pressoreceptors; Renal Circulation | 1993 |
New therapeutic agents in the management of hypertension: angiotensin II-receptor antagonists and renin inhibitors.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Dipeptides; Heart Failure; Humans; Hypertension; Imidazoles; Losartan; Renin; Tetrazoles | 1993 |
[Pathophysiology of cytoskeleton and extracellular matrix in failing myocardium].
Topics: Angiotensin II; Calcium; Collagen; Cytoskeleton; Extracellular Matrix; Fibroblasts; Fibrosis; Heart Failure; Humans; Myocardial Contraction; Myocardium; Norepinephrine | 1993 |
[Effect of angiotensin-converting enzyme inhibitors in congestive heart failure].
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Catecholamines; Collagen; Depression, Chemical; Heart Failure; Humans; Renin-Angiotensin System; Survival Rate; Sympathetic Nervous System | 1993 |
The cardiac renin-angiotensin system in heart failure.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Heart Failure; Humans; Myocardium; Renin-Angiotensin System | 1993 |
[Clinical evaluation of ACE inhibitors for therapy of chronic congestive heart failure].
Topics: Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Flow Velocity; Chronic Disease; Clinical Trials as Topic; Coronary Circulation; Heart Failure; Humans; Middle Aged; Renin; Ultrasonography | 1995 |
Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Bradykinin; Heart Failure; Humans; Hypertension; Imidazoles; Losartan; Prostaglandin Antagonists; Receptors, Angiotensin; Tetrazoles | 1996 |
[Neurohormonal factors in heart failure. I].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aldosterone; Angiotensin II; Autonomic Nervous System; Clinical Trials as Topic; Female; Heart; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Male; Middle Aged; Receptors, Adrenergic; Renin-Angiotensin System; Vasodilator Agents | 1996 |
Structural remodelling of the heart by fibrous tissue: role of circulating hormones and locally produced peptides.
Topics: Aldosterone; Angiotensin II; Cardiac Volume; Catecholamines; Diastole; Endocardium; Endomyocardial Fibrosis; Heart Failure; Hemodynamics; Humans; Myocardium; Peptides; Peptidyl-Dipeptidase A; Wound Healing | 1995 |
Mechanisms of angiotensin II formation in humans.
Topics: Angiotensin II; Animals; Cardiomegaly; Cardiovascular System; Chymases; Heart Failure; Hemodynamics; Homeostasis; Humans; Peptidyl-Dipeptidase A; Renin-Angiotensin System; Serine Endopeptidases; Species Specificity; Tissue Distribution | 1995 |
The cardiomyopathy of overload: an unnatural growth response.
Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Bradykinin; Cardiomyopathy, Hypertrophic; Cell Division; Growth Substances; Heart Failure; Hemodynamics; Humans; Myocardium; Nitrates; Vasodilator Agents | 1995 |
Immunomodulating agents for the management of heart failure with myocarditis and cardiomyopathy--lessons from animal experiments.
Topics: Adjuvants, Immunologic; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Cardiomyopathy, Dilated; Cardiotonic Agents; Cardiovirus Infections; Cytokines; Encephalomyocarditis virus; Heart Failure; Humans; Mice; Myocarditis; Prodrugs; Pyrazines; Quinolines; Tetrazoles; Tumor Necrosis Factor-alpha | 1995 |
[Chronic cardiac insufficiency: current treatment and future outlook].
Topics: Adrenergic Antagonists; Aldosterone; Angiotensin II; Cardiotonic Agents; Cardiovascular Agents; Clinical Protocols; Deoxyepinephrine; Digitalis Glycosides; Diuretics; Heart Failure; Humans; Vasoconstrictor Agents | 1996 |
Clinical background to the use of ACE inhibitor therapy after myocardial infarction.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Clinical Trials as Topic; Coronary Circulation; Heart Failure; Hemodynamics; Humans; Long-Term Care; Myocardial Infarction; Recurrence; Survival Rate | 1995 |
Inhibition of the renin-angiotensin-aldosterone system in heart failure: new insights from basic clinical research.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atrial Natriuretic Factor; Contraindications; Cough; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Polymorphism, Genetic; Receptors, Angiotensin; Renin; Renin-Angiotensin System; Ventricular Dysfunction, Left | 1996 |
[Losartan, an angiotensin II receptor blocker: a new trend in cardiovascular chemotherapy].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Heart Failure; Humans; Hypertension; Hypertension, Renovascular; Imidazoles; Kidney Diseases; Losartan; Myocardial Infarction; Rats; Receptors, Angiotensin; Renin-Angiotensin System; Tetrazoles; Time Factors | 1996 |
The integrated effects of angiotensin II.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Vessels; Cardiovascular Diseases; Endothelium, Vascular; Fibrinolysis; Heart Failure; Humans; Renin-Angiotensin System | 1997 |
[Heart failure and circulatory control peptides].
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Heart Failure; Humans; Kidney; Renin-Angiotensin System; Sodium; Vasopressins | 1994 |
[Hypertrophy due to left cardiac insufficiency: role of the neurohumoral system].
Topics: Aldosterone; Angiotensin II; Arginine Vasopressin; Atrial Natriuretic Factor; Heart Failure; Humans; Hypertrophy, Left Ventricular; Neurotransmitter Agents; Norepinephrine; Renin; Stroke Volume; Systole; Ventricular Dysfunction, Left | 1997 |
[Molecular mechanism of cardiac hypertrophy and dysfunction].
Topics: Angiotensin II; Animals; Calcium-Calmodulin-Dependent Protein Kinases; Cardiomyopathy, Hypertrophic; Endothelin-1; Heart Failure; Humans; Hypertension; Proto-Oncogene Proteins c-raf; Rats; Signal Transduction; Stress, Mechanical | 1997 |
Angiotensin II antagonism: a new avenue of hypertension management.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Heart Failure; Humans; Hypertension; Imidazoles; Losartan; Tetrazoles | 1997 |
Do ACE inhibitors modulate atherosclerosis?
Topics: Angioplasty, Balloon, Coronary; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin; Cell Division; Coronary Artery Disease; Heart Failure; Humans; Muscle, Smooth, Vascular; Secondary Prevention | 1997 |
Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation.
Topics: Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Collagen; Female; Fibrosis; Heart Failure; Humans; Myocardial Infarction; Myofibrils; Peptidyl-Dipeptidase A; Ventricular Dysfunction, Left | 1997 |
[AT1 angiotensin receptor inhibition as a new therapeutic possibility].
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Female; Heart Failure; Humans; Hypertension; Losartan; Renin-Angiotensin System | 1997 |
Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Pilot Projects; Renin-Angiotensin System; Ventricular Dysfunction, Left | 1997 |
[Significance of neuroendocrine parameters in heart failure].
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Endothelins; Heart Failure; Hemodynamics; Humans; Neurosecretory Systems; Survival Rate; Sympathetic Nervous System | 1998 |
The importance of the renin-angiotensin system in cardiovascular disease.
Topics: Angiotensin II; Animals; Cardiovascular Diseases; Diabetic Nephropathies; Heart Failure; Humans; Hypertension; Renin-Angiotensin System; Sensitivity and Specificity | 1998 |
[Pathophysiological function of angiotensin II AT1 and AT2 receptors and clinical application of AT1 antagonists].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium; Captopril; Cardiovascular System; Clinical Trials as Topic; Heart Failure; Humans; Kidney; Losartan; Protein Kinase C; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Signal Transduction | 1998 |
Captopril and angiotensin II receptor antagonist therapy in a pacing model of heart failure.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Cardiac Pacing, Artificial; Disease Models, Animal; Dogs; Heart Failure; Humans | 1998 |
[Losartan--a nonpeptide antagonist of angiotensin-II receptors in the treatment of heart failure].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Cardiovascular Agents; Drug Evaluation, Preclinical; Heart Failure; Humans; Losartan; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Renin-Angiotensin System | 1998 |
Fighting fire with fire.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Enalaprilat; Endothelium, Vascular; Heart Failure; Humans; Renin; Shock, Septic | 1998 |
Angiotensin II formation in the human heart: an ACE or non-ACE-mediated pathway?
Topics: Angiotensin II; Animals; Heart Failure; Humans; In Vitro Techniques; Myocardium; Peptidyl-Dipeptidase A; Research Design; Sensitivity and Specificity | 1998 |
[Mechanism involved in the onset of heart failure].
Topics: Angiotensin II; Animals; Calcium; Cardiomegaly; Endothelin-1; Heart Failure; Humans; Interleukin-1; Neurotransmitter Agents; Receptors, Adrenergic, beta; Ventricular Remodeling | 1998 |
Angiotensin II and coronary artery disease, congestive heart failure, and sudden cardiac death.
Topics: Angiotensin II; Coronary Disease; Death, Sudden, Cardiac; Heart Failure; Humans; Models, Cardiovascular | 1998 |
Overview of angiotensin II-receptor antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Heart Failure; Humans; Hypertension; Renin-Angiotensin System | 1998 |
Effect of treatment on survival in an animal model of chronic heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cricetinae; Disease Models, Animal; Heart Failure; Humans; Isoquinolines; Quinapril; Renin-Angiotensin System; Tetrahydroisoquinolines | 1998 |
Apoptosis in the failing heart.
Topics: Angiotensin II; Animals; Apoptosis; Cytokines; Heart Failure; Humans; Myocardium; Norepinephrine | 1998 |
Medical therapy of chronic heart failure. Role of ACE inhibitors and beta-blockers.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Down-Regulation; Heart Failure; Humans; Myocardium; Norepinephrine; Renin-Angiotensin System; Ventricular Remodeling | 1998 |
Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bradykinin; Dose-Response Relationship, Drug; Fibrinolysis; Follow-Up Studies; Heart Failure; Humans; Prognosis; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2 | 1999 |
Angiotensin receptor blockers: pharmacology and clinical significance.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Dose-Response Relationship, Drug; Heart Failure; Humans; Hypertension; Rats; Receptors, Angiotensin; Renal Circulation | 1999 |
Comparative antihypertensive effects of angiotensin II receptor antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Dose-Response Relationship, Drug; Heart Failure; Humans; Hypertension | 1999 |
Practical considerations of the pharmacology of angiotensin receptor blockers.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Heart Failure; Humans; Hypertension | 1999 |
Angiotensin-II receptor antagonists: their place in therapy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Clinical Trials as Topic; Drug Administration Schedule; Drug Interactions; Heart Failure; Humans; Hypertension; Irbesartan; Losartan; Renin-Angiotensin System; Telmisartan; Tetrazoles; Valine; Valsartan | 1999 |
Angiotensin II and sympathoactivation in heart failure.
Topics: Angiotensin II; Animals; Clinical Trials as Topic; Disease Models, Animal; Heart Failure; Hemodynamics; Humans; Prognosis; Rats; Renin-Angiotensin System; Vasoconstrictor Agents | 1999 |
Emerging treatments for hypertension: potential role for vasopeptidase inhibition.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Biomarkers; Blood Pressure; Heart Failure; Humans; Hypertension; Pyridines; Renin; Survival Rate; Thiazepines; Treatment Outcome; Vasodilation | 1999 |
[Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topic; Heart Diseases; Heart Failure; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 1999 |
The renin-angiotensin system and experimental heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Aortic Valve Stenosis; Cardiomegaly; Coronary Disease; Heart Failure; Mice; Mice, Transgenic; Myocardium; Rats; Receptors, Angiotensin; Renin-Angiotensin System; Signal Transduction | 1999 |
Cardiac protection: evolving role of angiotensin receptor blockers.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Middle Aged; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2000 |
Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Myocardial Infarction; Prognosis; Receptors, Angiotensin; Renin-Angiotensin System; Risk Factors; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2000 |
Angiotensin II receptor blockade and end-organ protection.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Blood Pressure; Glomerular Filtration Rate; Heart Failure; Humans; Hypertension; Myocardial Contraction; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Sodium; Vascular Diseases | 1999 |
Angiotensin II type 1 receptor blockade: a new development in cardiovascular pharmacology.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiovascular Diseases; Cardiovascular System; Heart Failure; Humans; Hypertension; Losartan; Receptors, Angiotensin; Renin-Angiotensin System | 1998 |
[Do angiotensin II receptor antagonists substitute angiotensin converting enzyme inhibitors in the treatment of high blood pressure?].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Diabetic Angiopathies; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Vasoconstriction | 2000 |
[Use of angiotensin II receptor blockaders in heart failure].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Therapy, Combination; Heart Failure; Humans; Irbesartan; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2000 |
[Exercise test in the evaluation of the efficacy of drug therapy].
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiotonic Agents; Clinical Trials as Topic; Deoxyepinephrine; Digitalis; Evaluation Studies as Topic; Exercise Test; Follow-Up Studies; Heart Failure; Humans; Oxygen Consumption; Plants, Medicinal; Plants, Toxic; Time Factors; Vasodilator Agents; Xamoterol | 2000 |
Heart failure drugs: what's new?
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Drug Therapy, Combination; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Receptors, Angiotensin; Spironolactone | 2000 |
[Therapy for heart failure].
Topics: Acute Disease; Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Cardiotonic Agents; Chronic Disease; Diuretics; Heart Failure; Humans; Vasodilator Agents | 2000 |
[Candesartan cilexetil: pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Heart Failure; Humans; Kidney Diseases; Rats; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles | 2000 |
Angiotensin II antagonists are superior to ACE inhibitors; David vs. Goliath.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Heart Failure; Humans | 2000 |
'ACE inhibitors are better than AT(1) receptor blockers (ARBs)' - controversies in heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Bradykinin; Heart Failure; Humans; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Survival Rate | 2000 |
Interaction between the actions of taurine and angiotensin II.
Topics: Angiotensin II; Animals; Calcium; Cardiomegaly; Cell Size; Diuretics; Heart Failure; Humans; MAP Kinase Signaling System; Myocardium; Receptors, Angiotensin; Sodium-Calcium Exchanger; Taurine | 2000 |
Natriuretic peptides in the pathophysiology of congestive heart failure.
Topics: Amino Acid Sequence; Angiotensin II; Animals; Atrial Natriuretic Factor; Heart; Heart Failure; Humans; Natriuresis; Natriuretic Peptide, Brain; Natriuretic Peptide, C-Type; Prognosis; ROC Curve; Sensitivity and Specificity; Signal Transduction | 2000 |
Recent advances in the management of chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Cytokines; Disease Progression; Endothelin-1; Heart Failure; Humans | 2000 |
[Angiotensin-II-receptor antagonists for cardiac insufficiency].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Captopril; Dose-Response Relationship, Drug; Drug Therapy, Combination; Heart Failure; Humans; Losartan; Randomized Controlled Trials as Topic; Tetrazoles | 2000 |
[Acute renal insufficiency due to vomiting or diarrhea: the Achilles heel of medical support for heart failure].
Topics: Acute Kidney Injury; Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Volume; Diarrhea; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Renal Dialysis; Treatment Outcome; Vomiting | 2000 |
Combined therapy with an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor in heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Drug Therapy, Combination; Heart Failure; Humans | 2001 |
The role of angiotensin receptor blockers in the management of chronic heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Bradykinin; Chronic Disease; Clinical Trials as Topic; Forecasting; Heart Failure; Humans; Losartan | 2001 |
Measurement of the renin-angiotensin system in heart failure.
Topics: Angiotensin II; Disease Progression; Heart Failure; Hemodynamics; Humans; Peptidyl-Dipeptidase A; Receptors, Angiotensin; Renin; Renin-Angiotensin System | 2000 |
Valsartan: a novel angiotensin type 1 receptor antagonist.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Hypertension; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 2000 |
Enhanced angiotensin II activity in heart failure: reevaluation of the counterregulatory hypothesis of receptor subtypes.
Topics: Angiotensin II; Animals; Apoptosis; Disease Models, Animal; Heart; Heart Failure; Humans; Mice; Myocardium; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Signal Transduction | 2001 |
Angiotensin II-receptor blockers: clinical relevance and therapeutic role.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Diabetic Neuropathies; Heart Failure; Humans; Hypertension | 2001 |
Medical management of mild-to-moderate heart failure before the advent of beta blockers.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Anticoagulants; Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Hypertension; Isosorbide Dinitrate; Randomized Controlled Trials as Topic; Severity of Illness Index; Vasodilator Agents | 2001 |
Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Captopril; Heart Failure; Humans; Hypertension; Losartan; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone; Tetrazoles; Valine; Valsartan | 2001 |
Angiotensin receptor blockers for chronic heart failure and acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Therapy, Combination; Heart Failure; Humans; Losartan; Models, Cardiovascular; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles | 2001 |
Telmisartan: a review of its use in hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressure; Calcium Channel Blockers; Drug Interactions; Heart Failure; Humans; Hypertension; Randomized Controlled Trials as Topic; Telmisartan; Treatment Outcome | 2001 |
Signal transduction in cardiac hypertrophy--dissecting compensatory versus pathological pathways utilizing a transgenic approach.
Topics: Angiotensin II; Animals; Animals, Genetically Modified; Antigens, CD; Calcineurin; Calcium-Calmodulin-Dependent Protein Kinases; Cardiomegaly; Cytokine Receptor gp130; GTP-Binding Protein alpha Subunits, Gq-G11; Heart Failure; Heterotrimeric GTP-Binding Proteins; Membrane Glycoproteins; Mitogen-Activated Protein Kinases; Monomeric GTP-Binding Proteins; Myocardial Contraction; Protein Kinase C; Receptor Protein-Tyrosine Kinases; Receptors, Angiotensin; Signal Transduction; Transcription, Genetic | 2001 |
Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Biomarkers; Diagnosis, Differential; Endothelins; Heart Failure; Humans; Mortality; Natriuretic Peptide, Brain; Neurosecretory Systems; Prognosis; Renin-Angiotensin System; Tumor Necrosis Factor-alpha | 2001 |
Taurine-deficient cardiomyopathy: role of phospholipids, calcium and osmotic stress.
Topics: Angiotensin II; Animals; Calcium; Cardiomyopathies; Heart Failure; Humans; Muscle Proteins; Myocardium; Phospholipids; Taurine; Water-Electrolyte Balance | 2000 |
Do ACE inhibitors or angiotensin II antagonists reduce total mortality and arrhythmic mortality? A critical review of controlled clinical trials.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Combined Modality Therapy; Defibrillators, Implantable; Heart Failure; Humans; Prevalence; Randomized Controlled Trials as Topic | 2002 |
Improving the managed care of hypertension with angiotensin II antagonists.
Topics: Angiotensin II; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Managed Care Programs; Renin-Angiotensin System | 2002 |
[Arrhythmia risk stratification in patients with heart failure according to drug treatment and its effects].
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiotonic Agents; Death, Sudden, Cardiac; Diuretics; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Pacemaker, Artificial; Prognosis; Randomized Controlled Trials as Topic; Risk; Risk Assessment; Spironolactone; Vasodilator Agents | 2001 |
[Is heart rate reduction beneficial to patients with heart insufficiency? Focus on beta-blockade].
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Controlled Clinical Trials as Topic; Heart Failure; Heart Rate; Humans; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Vasodilator Agents | 2002 |
[Pathophysiology of congestive heart failure].
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Atrial Natriuretic Factor; Cytokines; Heart Failure; Humans; Natriuretic Peptide, Brain; Neurosecretory Systems; Neurotransmitter Agents; Prognosis; Rats; Renin-Angiotensin System; Risk Factors; Swine; Ventricular Dysfunction, Left | 2002 |
Captopril in the treatment of clinical hypertension and cardiac failure.
Topics: Administration, Oral; Angiotensin II; Blood Pressure; Captopril; Diuretics; Drug Therapy, Combination; Heart Failure; Humans; Hypertension; Hypertension, Renal; Hyponatremia; Kidney Failure, Chronic; Proline; Renal Artery Obstruction | 1979 |
Converting enzyme inhibition and blood pressure regulation.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Dogs; Heart Failure; Homeostasis; Hypertension; Rats; Renal Artery; Renin; Sodium | 1976 |
The kidney in heart failure.
Topics: Aldosterone; Angiotensin II; Animals; Cardiac Output; Dogs; Edema; Edema, Cardiac; Glomerular Filtration Rate; Heart; Heart Failure; Humans; Kidney; Kidney Tubules; Natriuresis; Prostaglandins; Regional Blood Flow; Renin; Sodium; Sympathetic Nervous System; Water | 1977 |
Neurogenic regulation of renal tubular sodium reabsorption.
Topics: Angiotensin II; Animals; Denervation; Dogs; Electric Stimulation; Glomerular Filtration Rate; Heart Failure; Histocytochemistry; Humans; Inulin; Kidney; Kidney Function Tests; Kidney Tubules; Natriuresis; Sodium | 1977 |
[Pathophysiological aspects of the renin-angiotensin-aldosterone system].
Topics: Adrenal Insufficiency; Aldosterone; Angiotensin II; Bartter Syndrome; Contraceptives, Oral; Half-Life; Heart Failure; Humans; Hyperaldosteronism; Hypertension; Kidney Diseases; Renin | 1977 |
George C. Griffith lecture. The role of renin in normal and pathological cardiovascular homeostasis.
Topics: Angiotensin II; Angiotensinogen; Animals; Antibodies; Blood Pressure; Cardiovascular Physiological Phenomena; Dogs; Feedback; Heart Failure; Homeostasis; Humans; Hypertension, Renal; Posture; Rats; Renin; Water-Electrolyte Balance | 1976 |
Heart failure in experimental refractory shock.
Topics: Angiotensin II; Animals; Catecholamines; Coronary Disease; Endotoxins; Gastrointestinal Hemorrhage; Heart; Heart Failure; Heart Ventricles; Peptides; Shock, Hemorrhagic | 1976 |
Angiotensin II blockade and the functions of the renin-angiotensin system.
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Dogs; Heart Failure; Hypertension, Renal; Kidney; Rats; Regional Blood Flow; Renin; Saralasin; Species Specificity; Time Factors | 1976 |
Factors affecting renal cortical blood flow. A review.
Topics: Acetylcholine; Acute Kidney Injury; Angiotensin II; Animals; Bradykinin; Diuretics; Dogs; Dopamine; Electric Stimulation; Epinephrine; Heart Failure; Hemorrhage; Humans; Hypotension; Isoproterenol; Kidney Cortex; Kidney Transplantation; Liver Cirrhosis; Norepinephrine; Oxytocin; Prostaglandins; Regional Blood Flow; Transplantation, Homologous; Ureter; Vasomotor System; Vasopressins; Vena Cava, Inferior; Water-Electrolyte Balance | 1975 |
Mechanisms regulating renin release.
Topics: Aldosterone; Angiotensin II; Animals; Aortic Diseases; Blood Pressure; Brain; Calcium; Catecholamines; Chemoreceptor Cells; Dogs; Glomerular Filtration Rate; Heart Failure; Hemorrhage; Hormones; Humans; Hyponatremia; Ischemia; Juxtaglomerular Apparatus; Kidney; Kidney Tubules, Distal; Peptides; Potassium; Pressoreceptors; Rabbits; Receptors, Adrenergic; Renal Artery; Renal Artery Obstruction; Renin; Sodium; Sympathetic Nervous System | 1976 |
Pathophysiology of chronic heart failure.
Topics: Angiotensin II; Catecholamines; Chronic Disease; Energy Metabolism; Heart Failure; Hemodynamics; Humans; Myocardial Contraction; Neurosecretory Systems; Sodium; Vasoconstriction | 1992 |
Prevention of structural changes in the heart in hypertension by angiotensin converting enzyme inhibition.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomegaly; Diastole; Heart Failure; Humans; Hypertension; Myocardium; Rats; Rats, Inbred SHR | 1992 |
Role of neuroendocrine mechanisms in the pathogenesis of heart failure.
Topics: Aldosterone; Angiotensin II; Animals; Atrial Natriuretic Factor; Disease Models, Animal; Dogs; Heart Failure; Renin; Sympathetic Nervous System | 1991 |
[Pathophysiology of cardiorenal regulatory mechanisms in heart failure].
Topics: Angiotensin II; Animals; Glomerular Filtration Rate; Heart Failure; Homeostasis; Humans; Myocardial Contraction; Receptors, Angiotensin; Renal Circulation | 1991 |
The renin-angiotensin system in hypertension: an update.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Bradykinin; Heart Failure; Humans; Hypertension; Renin; Renin-Angiotensin System | 1990 |
Tissue renin-angiotensin systems in the heart and vasculature: possible involvement in the cardiovascular actions of converting enzyme inhibitors.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Cardiomegaly; Cardiovascular Physiological Phenomena; Cardiovascular System; Heart Failure; Humans; Peptidyl-Dipeptidase A; Renin-Angiotensin System | 1990 |
Emerging role of the tissue renin-angiotensin systems in congestive heart failure.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Heart; Heart Failure; Humans; Kidney; Rats; Renin-Angiotensin System | 1990 |
New angiotensin converting enzyme inhibitors. Their role in the management of hypertension.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Cerebrovascular Disorders; Heart Failure; Humans; Hypertension; Potassium; Renin; Renin-Angiotensin System; Risk Factors | 1990 |
Inhibition of the renin-angiotensin system in the treatment of heart failure: why, when, and where.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Digoxin; Diuretics; Dogs; Drug Therapy, Combination; Heart Failure; Hemodynamics; Humans; Kidney; Renin-Angiotensin System; Risk | 1985 |
The relationship of the sympathetic nervous system and the renin-angiotensin system in congestive heart failure.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Propanolamines; Receptors, Adrenergic, beta; Renin-Angiotensin System; Sympathetic Nervous System; Xamoterol | 1989 |
New therapeutic prospects of renin-angiotensin system inhibition.
Topics: Angiotensin II; Angiotensin III; Angiotensin-Converting Enzyme Inhibitors; Animals; Heart Failure; Humans; Hypertension; Renin-Angiotensin System | 1989 |
[Congestive heart insufficiency. Prophylactic aspects].
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Circulation; Heart Failure; Humans | 1989 |
Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics.
Topics: Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Drug Interactions; Heart Failure; Humans; Hypertension; Kidney Failure, Chronic; Liver Diseases; Metabolic Clearance Rate; Peptidyl-Dipeptidase A | 1988 |
Evolution of angiotensin-converting enzyme inhibitors.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Trials as Topic; Drug Design; Enalapril; Heart Failure; Humans; Hypertension; Renin-Angiotensin System | 1988 |
[The renin-angiotensin system: systemic and local function].
Topics: Angiotensin II; Cardiomegaly; Coronary Disease; Heart Failure; Humans; Hypertension; Peptidyl-Dipeptidase A; Renin-Angiotensin System | 1988 |
Angiotensin-converting enzyme inhibitors: past, present, and bright future.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Captopril; Dipeptides; Drug Eruptions; Drug Interactions; Enalapril; Heart Failure; Humans; Hyperaldosteronism; Hypertension; Hypertension, Renal; Kidney Diseases; Neutropenia; Proline; Taste Disorders | 1985 |
Neurohumoral mechanisms involved in congestive heart failure.
Topics: Angiotensin II; Animals; Arginine Vasopressin; Blood Vessels; Epinephrine; Heart Failure; Humans; Neurotransmitter Agents; Norepinephrine; Receptors, Neurotransmitter; Renin; Renin-Angiotensin System; Sympathetic Nervous System | 1985 |
Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Cyclooxygenase Inhibitors; Drug Interactions; Glomerular Filtration Rate; Heart Failure; Humans; Kidney; Prostaglandins; Renal Circulation; Renin-Angiotensin System | 1988 |
[Some advances in angiotensin converting enzyme inhibitors].
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Heart Failure; Humans; Hypertension; Oligopeptides; Prostaglandins; Scleroderma, Systemic; Structure-Activity Relationship; Teprotide | 1985 |
Adaptive and maladaptive actions of angiotensin II in patients with severe congestive heart failure.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Enalapril; Glomerular Filtration Rate; Heart Failure; Humans; Renin-Angiotensin System; Risk | 1987 |
Clinical applications of antimineralocorticoids.
Topics: Aldosterone; Angiotensin II; Ascites; Glucose; Heart Failure; Humans; Hypertension; Liver Cirrhosis; Mineralocorticoids; Renin; Water-Electrolyte Balance | 1988 |
Role of angiotensin in autoregulation of cerebral blood flow.
Topics: Angiotensin II; Animals; Captopril; Cerebrovascular Circulation; Heart Failure; Homeostasis; Humans; Renin-Angiotensin System | 1988 |
[Pharmacological and immunological approaches to inhibiting the renin-angiotensin system].
Topics: Angiotensin II; Animals; Antibodies; Antibodies, Monoclonal; Antihypertensive Agents; Depression, Chemical; Heart Failure; Humans; Hypertension; Immunization, Passive; Immunotherapy; Renin; Renin-Angiotensin System | 1987 |
Interaction between the adrenergic and renin-angiotensin-aldosterone-systems.
Topics: Angiotensin II; Animals; Heart Failure; Humans; Rats; Renin; Renin-Angiotensin System; Sympathetic Nervous System | 1986 |
Aldosterone in clinical medicine.
Topics: Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Heart Failure; Humans; Hyperaldosteronism; Hypertension, Malignant; Hypokalemia; Hypotension; Liver Cirrhosis; Metabolic Clearance Rate; Natriuresis; Nephrotic Syndrome; Posture; Renal Artery Obstruction; Renin; Secretory Rate | 1968 |
Pharmacologic assistance to the failing circulation.
Topics: Adenosine Triphosphatases; Aminophylline; Angiotensin II; Blood Gas Analysis; Blood Pressure; Cardiac Output; Chlorpromazine; Digitalis Glycosides; Heart Failure; Humans; Myocardial Infarction; Phenoxybenzamine; Pulmonary Edema; Shock, Hemorrhagic; Shock, Septic; Sympatholytics; Sympathomimetics; Vascular Resistance; Water-Electrolyte Balance | 1968 |
Endocrine factors in congestive heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Animals; Blood Pressure; Body Weight; Diet, Sodium-Restricted; Dogs; Endocrine Glands; Heart Atria; Heart Failure; Humans; Male; Middle Aged; Mitral Valve Insufficiency; Renal Veins; Renin; Sodium; Vasopressins; Water-Electrolyte Balance | 1968 |
[Early diagnosis and treatment of hypertension and renal vascular hypertension].
Topics: Adolescent; Adult; Age Factors; Angiotensin II; Cardiomyopathies; Cerebrovascular Disorders; Diagnosis, Differential; Female; Heart Failure; Humans; Hypertension; Hypertension, Renal; Kidney Function Tests; Male; Middle Aged; Radioisotope Renography; Renin | 1969 |
[Changes in renal hemodynamics and function in cardiac insufficiency].
Topics: Aldosterone; Angiotensin II; Animals; Arteriovenous Anastomosis; Cardiac Volume; Catecholamines; Diuretics; Heart Failure; Hemodynamics; Hypertension; Kidney; Kidney Tubules; Oxygen; Sodium; Vascular Resistance; Vasomotor System; Vasopressins; Veins; Water-Electrolyte Balance | 1969 |
[Congestive heart failure and aldosterone].
Topics: Adolescent; Aldosterone; Angiotensin II; Heart Failure; Humans; Male; Renin | 1971 |
Circulation: overall regulation.
Topics: Aldosterone; Angiotensin II; Blood Circulation; Blood Pressure; Body Fluids; Cardiac Output; Heart Failure; Homeostasis; Hypertension; Hypertension, Renal; Kidney; Models, Biological; Natriuresis; Nephrosis; Oxygen; Physical Exertion; Pressoreceptors; Reflex; Renin; Systems Analysis | 1972 |
[Control systems of arterial pressure].
Topics: Angiotensin II; Animals; Blood Pressure; Blood Volume; Cardiac Output; Cats; Central Nervous System; Cerebrovascular Circulation; Chemoreceptor Cells; Dogs; Heart; Heart Failure; Humans; Hypertension; Hypotension; Ischemic Attack, Transient; Kidney; Posture; Pressoreceptors; Reflex; Renin; Vascular Resistance; Venous Pressure | 1972 |
[Congestive heart failure].
Topics: Acetazolamide; Aldosterone; Angiotensin II; Benzothiadiazines; Catecholamines; Diuretics; Ethacrynic Acid; Furosemide; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Organomercury Compounds; Renin; Sodium Chloride Symporter Inhibitors; Vasopressins; Water-Electrolyte Balance | 1974 |
97 trial(s) available for angiotensin ii and Heart Failure
| Article | Year |
|---|---|
Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chromatography, Liquid; Heart Failure; Humans; Receptors, Angiotensin; Sodium; Tandem Mass Spectrometry | 2023 |
Three-vessel coronary infusion of cardiosphere-derived cells for the treatment of heart failure with preserved ejection fraction in a pre-clinical pig model.
Topics: Angiotensin II; Animals; Fibrosis; Heart Failure; Hypertrophy, Left Ventricular; Stroke Volume; Swine; Ventricular Function, Left | 2023 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Sustained cardiovascular actions of APJ agonism during renin-angiotensin system activation and in patients with heart failure.
Topics: Aged; Angiotensin II; Apelin Receptors; Blood Pressure; Cardiography, Impedance; Cardiovascular System; Cross-Over Studies; Female; Forearm; Heart Failure; Hemodynamics; Humans; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Plethysmography; Receptors, G-Protein-Coupled; Renin-Angiotensin System; Sodium; Vascular Resistance | 2013 |
Effects of exercise training on SFO-mediated sympathoexcitation during chronic heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Heart; Heart Failure; Heart Rate; Kidney; Losartan; Male; Physical Exertion; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Subfornical Organ; Sympathetic Nervous System | 2014 |
[Effect of loop diuretics with different elimination half-lives on natriuresis changes and indicators characterizing the state of renal tubulointerstitial tissue].
Topics: Adult; Angiotensin II; Chronic Disease; Delayed-Action Preparations; Female; Half-Life; Heart Failure; Humans; Hypertension; Kidney Tubules; Male; Middle Aged; Natriuresis; Sodium Potassium Chloride Symporter Inhibitors; Sulfonamides; Torsemide | 2014 |
Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response.
Topics: Aged; Aged, 80 and over; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cause of Death; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heart Failure; Humans; Irbesartan; Male; Middle Aged; Prognosis; Prospective Studies; Stroke Volume; Survival Rate; Tetrazoles; United Kingdom; United States | 2015 |
[Irbasartan in patients with hart failure and preserved left-ventricular systolic function. Results of the I-PRESERVE study].
Topics: Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Female; Follow-Up Studies; Heart Failure; Humans; Irbesartan; Male; Retrospective Studies; Systole; Tetrazoles; Treatment Outcome; Ventricular Function, Left | 2009 |
Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Drug Therapy, Combination; Enalapril; Endothelin-1; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Norepinephrine; Peptide Fragments; Radionuclide Angiography; Stroke Volume; Tetrazoles; Treatment Outcome; Ventricular Function, Left | 2009 |
[Plasma tissue factor and serum angiotensin II and the therapeutic effect of different dosages of fosinopril on chronic heart failure].
Topics: Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Female; Fosinopril; Heart Failure; Humans; Male; Middle Aged; Thromboplastin | 2009 |
Endurance exercise training in older patients with heart failure: results from a randomized, controlled, single-blind trial.
Topics: Aged; Aldosterone; Anaerobic Threshold; Angiotensin II; Cardiac Output, Low; Cardiac Volume; Echocardiography; Exercise; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Oxygen; Physical Endurance; Prospective Studies; Quality of Life; Single-Blind Method; Stroke Volume; Treatment Failure; Ventricular Dysfunction, Left; Ventricular Function, Left | 2009 |
Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial.
Topics: Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Female; Follow-Up Studies; Heart Failure; Hospital Mortality; Humans; Irbesartan; Male; Minnesota; Stroke Volume; Surveys and Questionnaires; Survival Rate; Systole; Tetrazoles; Time Factors; Treatment Outcome; Ventricular Function, Left | 2012 |
Beneficial effect of replacing of angiotensin-converting enzyme inhibitor with angiotensin II antagonist for heart failure patients.
Topics: Adult; Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Treatment Outcome; Ventricular Dysfunction, Left | 2002 |
Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure.
Topics: Aldosterone; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Chronic Disease; Enzyme Activation; Female; Heart Failure; Humans; Male; Middle Aged; Peptidyl-Dipeptidase A; Radial Artery; Sodium, Dietary; Tonometry, Ocular; Treatment Outcome | 2002 |
Angiotensin II contributes to arterial compliance in congestive heart failure.
Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Brachial Artery; Carotid Arteries; Compliance; Elasticity; Enalaprilat; Female; Heart Failure; Humans; Male; Manometry; Middle Aged | 2002 |
Angiotensin-converting enzyme genotype modulates pulmonary function and exercise capacity in treated patients with congestive stable heart failure.
Topics: Angiotensin II; Atrial Natriuretic Factor; Echocardiography; Exercise Test; Exercise Tolerance; Female; Genotype; Heart Failure; Humans; Lung; Male; Middle Aged; Natriuretic Peptide, Brain; Peptidyl-Dipeptidase A; Pulmonary Gas Exchange; Regression Analysis; Respiratory Function Tests; Stroke Volume | 2002 |
Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy.
Topics: Aged; Aged, 80 and over; Angiotensin II; Atrial Natriuretic Factor; Endothelin-1; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Spironolactone; Treatment Outcome | 2002 |
Vasopressor response to angiotensin II infusion in patients with chronic heart failure receiving beta-blockers.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Carbazoles; Carvedilol; Chronic Disease; Diuretics; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Infusions, Intravenous; Male; Metoprolol; Middle Aged; Propanolamines | 2003 |
[Preliminary exploration on effect of yiqi wenyang huoxue lishui treatment on neuroendocrine system in patients with congestive heart failure].
Topics: Adult; Aged; Angiotensin II; Atrial Natriuretic Factor; Coronary Disease; Drugs, Chinese Herbal; Female; Heart Failure; Humans; Male; Middle Aged; Neurosecretory Systems; P-Selectin; Phytotherapy | 2002 |
[Level of angiotensin II and aldosterone in plasma is often elevated in patients with heart failure treated with converting enzyme inhibitors--preliminary results].
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Diastole; Heart Failure; Humans; Male; Middle Aged; Prognosis; Stroke Volume | 2002 |
Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.
Topics: Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Atrial Natriuretic Factor; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Hemodynamics; Hormones; Humans; Male; Middle Aged; Placebos; Prodrugs; Regression Analysis; Renin; Tetrazoles; Treatment Outcome | 2003 |
Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Cross-Over Studies; Diuretics; Double-Blind Method; Drug Therapy, Combination; Furosemide; Glomerular Filtration Rate; Heart Failure; Humans; Kidney; Kidney Diseases; Losartan; Receptor, Angiotensin, Type 1; Renal Circulation; Renin | 2003 |
Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Drug Synergism; Drug Therapy, Combination; Exercise Tolerance; Female; Heart Failure; Heart Function Tests; Humans; Losartan; Male; Middle Aged; Natriuretic Peptide, Brain; Receptors, Angiotensin; Renin; Tetrazoles; Valine; Valsartan | 2004 |
Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Bradykinin; Bradykinin Receptor Antagonists; Cardiac Output; Cross-Over Studies; Double-Blind Method; Enalapril; Female; Forearm; Heart Failure; Heart Rate; Hemodynamics; Humans; Losartan; Male; Middle Aged; Peptidyl-Dipeptidase A; Regional Blood Flow; Vasodilation | 2004 |
Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Enalapril; Female; Genotype; Heart Failure; Humans; Male; Middle Aged; Neurotransmitter Agents; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Renin | 2004 |
Comparison of suppression of the circulating and vascular renin-angiotensin system by enalapril versus trandolapril in chronic heart failure.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Double-Blind Method; Enalapril; Endothelium, Vascular; Exercise Tolerance; Female; Heart Failure; Humans; Indoles; Male; Middle Aged; Renin-Angiotensin System | 2004 |
[Physical training in patients with chornic heart failure: haemodynamics, effects].
Topics: Angiotensin II; Endothelins; Exercise Therapy; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Natriuretic Peptides; Thromboxane B2 | 2001 |
Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure.
Topics: Adrenergic alpha-Antagonists; Angiotensin II; Atrial Natriuretic Factor; Biomarkers; Carbazoles; Carvedilol; Endothelin-1; Endothelins; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Propanolamines | 2005 |
Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Double-Blind Method; Drug Therapy, Combination; Enalapril; Exercise Tolerance; Female; Heart Failure; Humans; Irbesartan; Lactic Acid; Male; Middle Aged; Norepinephrine; Prospective Studies; Rest; Tetrazoles | 2005 |
[Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect o
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Norepinephrine; Quinapril; Renin; Tetrahydroisoquinolines; Tetrazoles; Valine; Valsartan | 2005 |
Effects of dietary omega-3 fatty acid supplementation on endothelium-dependent vasodilation in patients with chronic heart failure.
Topics: Acetylcholine; Aged; Angiotensin II; Cross-Over Studies; Dietary Supplements; Double-Blind Method; Endothelium-Dependent Relaxing Factors; Fatty Acids, Omega-3; Female; Forearm; Heart Failure; Humans; Male; NG-Nitroarginine Methyl Ester; Nitroprusside; Olive Oil; Plant Oils; Plethysmography | 2006 |
Increased urinary aquaporin-2 excretion in response to furosemide in patients with chronic heart failure.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Aquaporin 2; Arginine Vasopressin; Atrial Natriuretic Factor; Blood Pressure; Chronic Disease; Cross-Over Studies; Female; Furosemide; Glomerular Filtration Rate; Heart Failure; Humans; Male; Middle Aged; Natriuresis; Natriuretic Peptide, Brain; Renin | 2006 |
[Effects of carvedilol on neurohormone and magnesium metabolism in patients with chronic heart failure].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aldosterone; Angiotensin II; Carbazoles; Carvedilol; Female; Heart Failure; Humans; Magnesium; Male; Middle Aged; Natriuretic Peptide, Brain; Norepinephrine; Propanolamines | 2005 |
Dietary sodium intake modulates myocardial relaxation responsiveness to angiotensin II.
Topics: Adult; Angiotensin II; Cross-Over Studies; Diastole; Female; Heart Failure; Humans; Male; Myocardial Contraction; Prospective Studies; Renal Circulation; Sodium, Dietary | 2006 |
[Effects of xinshuai mistura on plasma angiotensin II, atrial natriuretic peptide and N terminal pro-brain natriuretic peptide in patients with heart failure].
Topics: Adult; Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Captopril; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Phytotherapy; Single-Blind Method; Treatment Outcome | 2006 |
Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure.
Topics: Aged; Aldosterone; Amides; Analysis of Variance; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Female; Fumarates; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Ramipril; Renin; Statistics, Nonparametric; Treatment Outcome | 2007 |
Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Chromatography, High Pressure Liquid; Endothelin-1; Extracellular Matrix; Female; Heart Failure; Humans; Male; Matrix Metalloproteinases; Middle Aged; Neurotransmitter Agents; Tissue Inhibitor of Metalloproteinases | 2008 |
Haemodynamic, hormonal, and electrolyte responses to captopril in resistant heart failure.
Topics: Aged; Angiotensin II; Captopril; Clinical Trials as Topic; Heart Failure; Hemodynamics; Humans; Middle Aged; Potassium; Proline; Renin; Sodium | 1981 |
Monotherapy of hypertension with angiotensin-converting enzyme inhibitors.
Topics: Acute Kidney Injury; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Captopril; Clinical Trials as Topic; Dipeptides; Enalapril; Heart Failure; Humans; Hypertension; Proline; Racial Groups; Teprotide; Time Factors | 1984 |
Effects of enalapril on heart rate variability in patients with congestive heart failure.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cross-Over Studies; Double-Blind Method; Enalapril; Female; Heart Failure; Heart Rate; Humans; Linear Models; Male; Middle Aged | 1995 |
Effect of the implantable left ventricular assist device on neuroendocrine activation in heart failure.
Topics: Adult; Angiotensin II; Atrial Natriuretic Factor; Catecholamines; Female; Heart Failure; Heart-Assist Devices; Hemodynamics; Humans; Male; Middle Aged; Neurosecretory Systems; Prostheses and Implants; Renin; Vasopressins; Ventricular Function, Left | 1995 |
Elevated plasma endothelin concentrations in heart failure; an effect of angiotensin II?
Topics: Adult; Aged; Angiotensin II; Cardiac Output, Low; Coronary Disease; Endothelins; Female; Heart Failure; Humans; Male; Middle Aged; Prospective Studies | 1994 |
Combining salicylate and enalapril in patients with coronary artery disease and heart failure.
Topics: Adult; Aged; Angiotensin II; Blood Pressure; Coronary Disease; Creatinine; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Enalapril; Female; Heart Failure; Humans; Male; Middle Aged; Norepinephrine; Peptidyl-Dipeptidase A; Salicylates; Salicylic Acid | 1995 |
Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Double-Blind Method; Exercise Tolerance; Female; Heart Failure; Humans; Male; Middle Aged; Norepinephrine; Peptidyl-Dipeptidase A; Prognosis; Ramipril; Time Factors | 1994 |
Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Double-Blind Method; Female; Heart Failure; Hemodynamics; Humans; Imidazoles; Losartan; Male; Middle Aged; Norepinephrine; Renin; Tetrazoles | 1995 |
Interactions between the renin-angiotensin system and the parasympathetic nervous system in heart failure.
Topics: Age Factors; Angiotensin II; Baroreflex; Blood-Brain Barrier; Heart Failure; Heart Transplantation; Hemodynamics; Humans; Longitudinal Studies; Parasympathetic Nervous System; Prognosis; Radioimmunoassay; Regression Analysis; Renin; Renin-Angiotensin System; Stroke Volume | 1994 |
Effects of ramipril on the neurohormonal response to exercise in patients with mild or moderate congestive heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Double-Blind Method; Exercise Test; Female; Heart Failure; Hemodynamics; Hormones; Humans; Male; Middle Aged; Norepinephrine; Prospective Studies; Ramipril | 1994 |
Effect of intense angiotensin II suppression on the diuretic response to furosemide during chronic ACE inhibition.
Topics: Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Captopril; Diuresis; Drug Synergism; Female; Furosemide; Heart Failure; Humans; Kidney; Male; Middle Aged | 1994 |
Determinants of the initial effects of captopril on blood pressure, glomerular filtration rate, and natriuresis in mild-to-moderate chronic congestive heart failure secondary to coronary artery disease.
Topics: Aged; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Blood Pressure; Captopril; Coronary Disease; Double-Blind Method; Female; Glomerular Filtration Rate; Heart Failure; Humans; Male; Natriuresis; Norepinephrine; Placebos; Renal Plasma Flow; Sodium | 1994 |
Angiotensin II and sympathetic activity in patients with congestive heart failure.
Topics: Adult; Aged; Analysis of Variance; Angiotensin II; Blood Pressure; Chronic Disease; Double-Blind Method; Enalaprilat; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Norepinephrine; Sympathetic Nervous System | 1993 |
Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Female; Heart Failure; Hemodynamics; Humans; Imidazoles; Losartan; Male; Middle Aged; Norepinephrine; Renin-Angiotensin System; Tetrazoles | 1993 |
Renal effects of xamoterol in patients with moderate heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Diuresis; Double-Blind Method; Female; Heart Failure; Hemodynamics; Humans; Kidney; Male; Middle Aged; Potassium; Sodium; Xamoterol | 1993 |
Effects of brain natriuretic peptide on exercise hemodynamics and neurohormones in isolated diastolic heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Blood Pressure; Cross-Over Studies; Diastole; Exercise Test; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Pulmonary Artery; Pulmonary Wedge Pressure; Single-Blind Method | 1996 |
Hemodynamic and hormonal effects of quinaprilat in patients with congestive heart failure.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Failure; Hemodynamics; Humans; Injections, Intravenous; Isoquinolines; Male; Middle Aged; Peptidyl-Dipeptidase A; Renin; Tetrahydroisoquinolines | 1996 |
Captopril does not acutely modulate plasma endothelin-1 concentration in human congestive heart failure.
Topics: Adult; Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Captopril; Double-Blind Method; Endothelin-1; Female; Heart Failure; Humans; Male; Middle Aged; Radioimmunoassay; Renin; Stroke Volume | 1996 |
[Hemodynamic and humoral effects of parenteral therapy with intravenously administered ACE inhibitor quinaprilat in patients with advanced heart failure].
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Catecholamines; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Heart Failure; Hemodynamics; Hormones; Humans; Infusions, Intravenous; Isoquinolines; Male; Middle Aged; Peptidyl-Dipeptidase A; Renin; Tetrahydroisoquinolines | 1996 |
Effects of angiotensin II receptor blockade on N-terminal proatrial natriuretic factor plasma levels in chronic heart failure.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Atrial Natriuretic Factor; Biphenyl Compounds; Double-Blind Method; Female; Heart Failure; Hemodynamics; Humans; Imidazoles; Losartan; Male; Middle Aged; Protein Precursors; Tetrazoles | 1997 |
Digitalis increases brain natriuretic peptide in patients with severe congestive heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Cardiotonic Agents; Deslanoside; Female; Guanosine Monophosphate; Heart Failure; Hemodynamics; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardium; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Norepinephrine; Renin | 1997 |
[AT1 angiotensin receptor inhibition as a new therapeutic possibility].
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Female; Heart Failure; Humans; Hypertension; Losartan; Renin-Angiotensin System | 1997 |
Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Pilot Projects; Renin-Angiotensin System; Ventricular Dysfunction, Left | 1997 |
Within-patient variability of hormone and cytokine concentrations in heart failure.
Topics: Aldosterone; Analysis of Variance; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Case-Control Studies; Creatinine; Cytokines; Endothelins; Female; Heart Failure; Hormones; Humans; Interleukin-6; Male; Middle Aged; Norepinephrine; Receptors, Tumor Necrosis Factor; Renin; Time Factors | 1998 |
Effects of a new angiotensin-converting enzyme inhibitor, alacepril, on changes in neurohormonal factors and arterial baroreflex sensitivity in patients with congestive heart failure.
Topics: Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Arteries; Atrial Natriuretic Factor; Baroreflex; Blood Pressure; Body Weight; Captopril; Dose-Response Relationship, Drug; Epinephrine; Female; Heart Failure; Heart Rate; Hemodynamics; Humans; Male; Middle Aged; Neuropeptides; Neurotransmitter Agents; Norepinephrine; Renin; Tilt-Table Test; Ventricular Function, Left | 1998 |
Emerging data from heart failure trials: clinical application.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Calcium Channel Blockers; Endothelin Receptor Antagonists; Heart Failure; Humans | 1998 |
Angiotensin-converting enzyme gene expression in skeletal muscle in patients with chronic heart failure.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Biopsy; Capillaries; Citrate (si)-Synthase; Enalapril; Endothelium, Vascular; Female; Gene Expression Regulation, Enzymologic; Heart Failure; Humans; Immunohistochemistry; Male; Middle Aged; Muscle, Skeletal; Peptidyl-Dipeptidase A; RNA, Messenger; Transcription Factors | 1998 |
Improved exercise tolerance after losartan and enalapril in heart failure: correlation with changes in skeletal muscle myosin heavy chain composition.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Enalapril; Exercise Tolerance; Heart Failure; Humans; Losartan; Male; Middle Aged; Muscle, Skeletal; Myosin Heavy Chains | 1998 |
Regulation of peripheral vascular tone in patients with heart failure: contribution of angiotensin II.
Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Endothelin-1; Female; Forearm; Heart Failure; Humans; Infusions, Intra-Arterial; Losartan; Lower Body Negative Pressure; Male; Middle Aged; Norepinephrine; Plethysmography; Regional Blood Flow; Vascular Resistance; Vasoconstrictor Agents | 1998 |
Angiotensin II receptor subtype I antagonism and diastolic cardiac filling in man.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Cardiovascular Agents; Cross-Over Studies; Diastole; Double-Blind Method; Echocardiography; Heart Failure; Hemodynamics; Humans; Male; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan | 1999 |
Angiotensin-converting enzyme inhibition restores hepatocyte growth factor production in patients with congestive heart failure.
Topics: Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Female; Heart Failure; Heparin; Hepatocyte Growth Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction | 1999 |
Neuroendocrine activation in heart failure is modified by endurance exercise training.
Topics: Aged; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Coronary Disease; Exercise; Female; Heart Failure; Humans; Male; Middle Aged; Neurosecretory Systems; Physical Endurance; Prognosis; Stroke Volume; Treatment Outcome; Vasopressins | 1999 |
ARCTIC: assessment of haemodynamic response in patients with congestive heart failure to telmisartan: a multicentre dose-ranging study in Canada.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Benzimidazoles; Benzoates; Canada; Catheterization, Peripheral; Coronary Care Units; Dose-Response Relationship, Drug; Double-Blind Method; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Norepinephrine; Renin; Safety; Telmisartan; Treatment Outcome | 1999 |
Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Dyspnea; Exercise Test; Exercise Tolerance; Fatigue; Female; Heart Failure; Humans; Hypotension; Male; Middle Aged; Prospective Studies; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin; Severity of Illness Index; Tetrazoles | 1999 |
Nonadherence with angiotensin-converting enzyme inhibitor therapy: a comparison of different ways of measuring it in patients with chronic heart failure.
Topics: Aged; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Chronic Disease; Diuretics; Drug Therapy, Combination; Echocardiography; Furosemide; Heart Failure; Humans; Lisinopril; Oligopeptides; Peptidyl-Dipeptidase A; Radionuclide Ventriculography; Treatment Outcome; Treatment Refusal | 1999 |
Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.
Topics: Aged; Angiotensin I; Angiotensin II; Chronic Disease; Cross-Over Studies; Diuretics; Double-Blind Method; Endothelium, Vascular; Enzyme Inhibitors; Forearm; Heart Failure; Humans; Male; Middle Aged; Nitric Oxide; omega-N-Methylarginine; Spironolactone; Vasodilation | 2000 |
Is there a role for renin profiling in selecting chronic heart failure patients for ACE inhibitor treatment?
Topics: Aged; Aged, 80 and over; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Patient Selection; Renin; Renin-Angiotensin System; Sodium | 2000 |
Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan.
Topics: Aged; Angiotensin II; Atrial Natriuretic Factor; Cause of Death; Cohort Studies; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Norepinephrine; Prognosis; Protein Precursors; Quinolines; Survival Rate; Vasodilator Agents | 2000 |
Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins.
Topics: Aldosterone; Angiotensin II; Antihypertensive Agents; Bosentan; Double-Blind Method; Endothelin Receptor Antagonists; Endothelins; Heart Failure; Humans; Middle Aged; Sulfonamides | 2000 |
Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Double-Blind Method; Endothelin-1; Exercise Tolerance; Female; Heart Failure; Humans; Lisinopril; Male; Middle Aged; Neprilysin; Norepinephrine; Prospective Studies; Pyridines; Radionuclide Ventriculography; Severity of Illness Index; Survival Rate; Thiazepines; Treatment Outcome | 2000 |
Use of placebo in heart failure research.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Heart Failure; Helsinki Declaration; Humans; Patient Compliance; Placebos; Tetrazoles | 2000 |
ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
Topics: Acrylates; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atrial Natriuretic Factor; Biomarkers; Catheterization, Swan-Ganz; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Hemodynamics; Humans; Imidazoles; Male; Middle Aged; Norepinephrine; Prognosis; Prospective Studies; Radionuclide Ventriculography; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin; Safety; Thiophenes | 2001 |
Angiotensin in cardiac surgery: efficacy in patients on angiotensin converting enzyme inhibitors.
Topics: Analysis of Variance; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Cardiac Surgical Procedures; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Phenylephrine; Vascular Resistance; Vasoconstrictor Agents | 2001 |
Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aldosterone; Angiotensin II; Body Mass Index; Cachexia; Chronic Disease; Energy Metabolism; Female; Ghrelin; Growth Hormone; Heart Failure; Humans; Male; Middle Aged; Norepinephrine; Peptide Hormones; Peptides; Predictive Value of Tests; Renin; Tumor Necrosis Factor-alpha | 2001 |
Vitamin C inhibits endothelial cell apoptosis in congestive heart failure.
Topics: Administration, Oral; Adult; Aged; Angiotensin II; Apoptosis; Ascorbic Acid; Biomarkers; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Administration Schedule; Endothelium, Vascular; Enzyme Inhibitors; Female; Heart Failure; Humans; Injections, Intravenous; Male; Middle Aged; Oxidative Stress; Prospective Studies; Thiobarbituric Acid Reactive Substances; Tumor Necrosis Factor-alpha | 2001 |
Radial artery flow-mediated dilatation in heart failure patients: effects of pharmacological and nonpharmacological treatment.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Flow Velocity; Drug Administration Schedule; Echocardiography, Doppler; Enalapril; Exercise Test; Exercise Therapy; Female; Heart Failure; Humans; Losartan; Male; Middle Aged; Radial Artery; Vasodilation | 2001 |
Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure.
Topics: Adult; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Enalapril; Epinephrine; Female; Heart Failure; Humans; Male; Middle Aged; Norepinephrine; Prospective Studies; Ultrasonography | 2002 |
Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure.
Topics: Aged; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Vessels; Chronic Disease; Cross-Over Studies; Cross-Sectional Studies; Double-Blind Method; Female; Heart Failure; Humans; Lisinopril; Longitudinal Studies; Male; Middle Aged; Time Factors | 2002 |
[Effect of long-term treatment with enalapril, losartan and their combination on the quality of life of patients with congestive heart failure].
Topics: Adult; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Losartan; Middle Aged; Quality of Life; Receptor, Angiotensin, Type 1 | 2002 |
Renal and cardiac function during alpha1-beta-blockade in congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Carbazoles; Cardiac Output; Carvedilol; Diuretics; Drug Therapy, Combination; Glomerular Filtration Rate; Heart; Heart Failure; Heart Rate; Humans; Kidney; Middle Aged; Propanolamines; Renal Circulation | 2002 |
Influence of ramipril on plasma atrial natriuretic peptide, antidiuretic hormone, angiotensin II and aldosterone in patients with chronic congestive heart failure.
Topics: Aged; Aged, 80 and over; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Female; Heart Failure; Humans; Male; Middle Aged; Radioimmunoassay; Ramipril; Sodium; Vasopressins | 1992 |
Effect of angiotensin-converting enzyme inhibition on plasma brain natriuretic peptide levels in patients with heart failure.
Topics: Aged; Angiotensin II; Atrial Natriuretic Factor; Blood Pressure; Captopril; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Nerve Tissue Proteins; Radioimmunoassay; Single-Blind Method | 1992 |
[Effect of captopril on the exercise performance in patients with congestive heart failure].
Topics: Adult; Aged; Angiotensin II; Captopril; Dinoprostone; Double-Blind Method; Epoprostenol; Exercise Tolerance; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged | 1992 |
Furosemide-induced natriuresis is augmented by ultra-low-dose captopril but not by standard doses of captopril in chronic heart failure.
Topics: Aged; Angiotensin II; Captopril; Double-Blind Method; Female; Furosemide; Glomerular Filtration Rate; Heart Failure; Humans; Male; Natriuresis; Renal Circulation; Renin-Angiotensin System | 1992 |
Skeletal muscle depressed calcium and phosphofructokinase in chronic heart failure are upregulated by captopril--a double-blind, placebo-controlled study.
Topics: Aged; Angiotensin II; Calcium; Captopril; Chronic Disease; Double-Blind Method; Heart Failure; Humans; Middle Aged; Muscles; Phosphofructokinase-1; Serum Albumin | 1991 |
[Development of heart failure after myocardial infarct: changes in plasma renin activity, angiotensin II, catecholamines and atrial natriuretic peptide].
Topics: Angiotensin II; Atrial Natriuretic Factor; Captopril; Catecholamines; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Myocardial Infarction; Renin; Ventricular Function, Left | 1991 |
Hemodynamic, hormonal, and pharmacokinetic aspects of treatment with lisinopril in congestive heart failure.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Enalapril; Female; Heart Failure; Hemodynamics; Hormones; Humans; Kinetics; Lisinopril; Male; Middle Aged; Peptidyl-Dipeptidase A; Random Allocation; Renin | 1987 |
Evolution of angiotensin-converting enzyme inhibitors.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Captopril; Clinical Trials as Topic; Drug Design; Enalapril; Heart Failure; Humans; Hypertension; Renin-Angiotensin System | 1988 |
Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Double-Blind Method; Electrolytes; Enalapril; Heart Failure; Humans; Physical Exertion; Potassium; Renin | 1985 |
Controlled trial of enalapril in congestive cardiac failure.
Topics: Angiotensin II; Blood Pressure; Clinical Trials as Topic; Creatinine; Double-Blind Method; Enalapril; Exercise Test; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Norepinephrine; Peptidyl-Dipeptidase A; Potassium | 1985 |
631 other study(ies) available for angiotensin ii and Heart Failure
| Article | Year |
|---|---|
Soluble angiotensin-converting enzyme levels in heart failure or acute coronary syndrome: revisiting its modulation and prognosis value.
Topics: Acute Coronary Syndrome; ADAM17 Protein; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Enalapril; Female; Heart Failure; Human Umbilical Vein Endothelial Cells; Humans; Kaplan-Meier Estimate; Losartan; Male; Metoprolol; Middle Aged; Peptidyl-Dipeptidase A; Prognosis | 2021 |
Hydrogen Sulfide Attenuates Angiotensin II-Induced Cardiac Fibroblast Proliferation and Transverse Aortic Constriction-Induced Myocardial Fibrosis through Oxidative Stress Inhibition via Sirtuin 3.
Topics: Actins; Angiotensin II; Animals; Cell Proliferation; Collagen; Dynamins; Fibroblasts; Heart Failure; Hydrogen Sulfide; Membrane Potential, Mitochondrial; Mice; Mice, Knockout; Myocardium; Oxidative Stress; Rats; Rats, Sprague-Dawley; RNA Interference; RNA, Small Interfering; Sirtuin 3; Transcription, Genetic | 2021 |
STING protects against cardiac dysfunction and remodelling by blocking autophagy.
Topics: Angiotensin II; Animals; Apoptosis; Autophagy; Autophagy-Related Protein-1 Homolog; Cardiomegaly; Disease Models, Animal; Gene Expression Regulation; Heart Failure; Humans; Membrane Proteins; Mice; Myocytes, Cardiac; Protective Agents; Signal Transduction; Sirolimus | 2021 |
S-nitrosylation of Hsp90 promotes cardiac hypertrophy in mice through GSK3β signaling.
Topics: Angiotensin II; Animals; Cardiomegaly; Glycogen Synthase Kinase 3 beta; Heart Failure; HSP90 Heat-Shock Proteins; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Rats; Signal Transduction | 2022 |
Allergic asthma aggravates angiotensin Ⅱ-induced cardiac remodeling in mice.
Topics: Angiotensin II; Animals; Asthma; Bronchoalveolar Lavage Fluid; Cardiovascular Diseases; Disease Models, Animal; Heart Failure; Immunoglobulin E; Mice; Mice, Inbred BALB C; Nutrition Surveys; Ovalbumin; Ventricular Remodeling | 2022 |
CCL17 Aggravates Myocardial Injury by Suppressing Recruitment of Regulatory T Cells.
Topics: Angiotensin II; Animals; Chemokine CCL17; Diphtheria Toxin; Heart Failure; Humans; Inflammation; Ligands; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Phenylephrine; T-Lymphocytes, Regulatory; Ventricular Remodeling | 2022 |
Fibroblast growth factor 12 attenuated cardiac remodeling via suppressing oxidative stress.
Topics: Angiotensin II; Animals; Collagen; Fibroblast Growth Factors; Fibronectins; Fibrosis; Heart Failure; Mice; Myocardial Infarction; Myocardium; Oxidative Stress; Ventricular Remodeling | 2022 |
The Prevention Role of Theaflavin-3,3'-digallate in Angiotensin II Induced Pathological Cardiac Hypertrophy via CaN-NFAT Signal Pathway.
Topics: Angiotensin II; Antioxidants; Biflavonoids; Calcineurin; Cardiomegaly; Catechin; Heart Failure; Humans; Myocytes, Cardiac; Signal Transduction | 2022 |
MircroRNA-145 Attenuates Cardiac Fibrosis Via Regulating Mitogen-Activated Protein Kinase Kinase Kinase 3.
Topics: Angiotensin II; Animals; Collagen; Fibrosis; Heart Failure; MAP Kinase Kinase Kinase 3; Mice; MicroRNAs; Myocardial Infarction; Myocardium; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2023 |
MicroRNA-384-5p protects against cardiac hypertrophy via the ALPK3 signaling pathway.
Topics: Angiotensin II; Animals; Cardiomegaly; Heart Failure; Humans; MicroRNAs; Muscle Proteins; Myocytes, Cardiac; Protein Kinases; Signal Transduction | 2022 |
Corynoline protects ang II-induced hypertensive heart failure by increasing PPARα and Inhibiting NF-κB pathway.
Topics: Angiotensin II; Animals; Berberine Alkaloids; Fibrosis; Heart Failure; Hypertension; Inflammation; Mice; Mice, Inbred C57BL; NF-kappa B; PPAR alpha; RNA | 2022 |
FAM114A1 influences cardiac pathological remodeling by regulating angiotensin II signaling.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin II; Animals; Heart Failure; Mice; Myocardium; Ventricular Remodeling | 2022 |
CCL17 acts as a novel therapeutic target in pathological cardiac hypertrophy and heart failure.
Topics: Angiotensin II; Animals; Cardiomegaly; Chemokine CCL17; Chemokines; Fibrosis; Heart Failure; Humans; Ligands; Mice; Mice, Inbred C57BL; Myocardium; Myocytes, Cardiac; Proteomics | 2022 |
Tabersonine attenuates Angiotensin II-induced cardiac remodeling and dysfunction through targeting TAK1 and inhibiting TAK1-mediated cardiac inflammation.
Topics: Angiotensin II; Animals; Cardiomegaly; Fibrosis; Heart Failure; Indole Alkaloids; Inflammation; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Quinolines; Rats; Signal Transduction; Ventricular Remodeling | 2022 |
Targeting miR-30d reverses pathological cardiac hypertrophy.
Topics: Angiotensin II; Animals; Cardiomegaly; China; Heart Failure; Humans; Intracellular Signaling Peptides and Proteins; Mice; MicroRNAs; Myocytes, Cardiac; Protein Serine-Threonine Kinases; Rats | 2022 |
Rhein attenuates angiotensin II-induced cardiac remodeling by modulating AMPK-FGF23 signaling.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Animals; Anthraquinones; Fibroblast Growth Factor-23; Fibrosis; Heart Failure; Hypertrophy; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Rats; Ventricular Remodeling | 2022 |
Exercise-derived peptide protects against pathological cardiac remodeling.
Topics: Angiotensin II; Animals; China; Extracellular Matrix Proteins; Heart; Heart Failure; Humans; Hypertension; Mice; Myocytes, Cardiac; Ventricular Remodeling | 2022 |
ANGPTL8 is a negative regulator in pathological cardiac hypertrophy.
Topics: Angiopoietin-Like Protein 8; Angiopoietin-like Proteins; Angiotensin II; Animals; Antigens, CD; Cardiomegaly; Disease Models, Animal; Glycogen Synthase Kinase 3 beta; Heart Failure; Humans; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Peptide Hormones; Proto-Oncogene Proteins c-akt; Rats; Receptors, Immunologic; Signal Transduction | 2022 |
Tax1 banding protein 1 exacerbates heart failure in mice by activating ITCH-P73-BNIP3-mediated cardiomyocyte apoptosis.
Topics: Angiotensin II; Animals; Antiviral Agents; Apoptosis; Diabetes Mellitus, Experimental; Heart Failure; Membrane Proteins; Mice; Mice, Knockout; Mice, Transgenic; Mitochondrial Proteins; Myocytes, Cardiac; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Rats; Stroke Volume; Ubiquitin-Protein Ligases; Ventricular Function, Left | 2022 |
Diacerein alleviates Ang II-induced cardiac inflammation and remodeling by inhibiting the MAPKs/c-Myc pathway.
Topics: Angiotensin II; Animals; Anthraquinones; Cardiomegaly; Cardiomyopathies; Fibrosis; Heart Failure; Hypertension; Inflammation; Mice; Mice, Inbred C57BL; Myocardium; Myocytes, Cardiac; RNA; Ventricular Remodeling | 2022 |
Vaspin Ameliorates Cardiac Remodeling by Suppressing Phosphoinositide 3-Kinase/Protein Kinase B Pathway to Improve Oxidative Stress in Heart Failure Rats.
Topics: Angiotensin II; Animals; Atrial Natriuretic Factor; Collagen; Fibrosis; Heart Failure; Myocardial Infarction; Myocytes, Cardiac; NADPH Oxidases; Natriuretic Peptide, Brain; Oxidative Stress; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Ventricular Remodeling | 2022 |
CCL24/CCR3 axis plays a central role in angiotensin II-induced heart failure by stimulating M2 macrophage polarization and fibroblast activation.
Topics: Angiotensin II; Animals; Chemokine CCL24; Fibroblasts; Heart Failure; Humans; Macrophages; Mice; Mice, Inbred C57BL; Receptors, CCR3 | 2023 |
Sclareol attenuates angiotensin II-induced cardiac remodeling and inflammation via inhibiting MAPK signaling.
Topics: Angiotensin II; Animals; Fibrosis; Heart Failure; Hypertension; Inflammation; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Myocardium; Myocytes, Cardiac; Ventricular Remodeling | 2023 |
Endothelin type A receptor blockade attenuates aorto-caval fistula-induced heart failure in rats with angiotensin II-dependent hypertension.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrasentan; Endothelin-1; Endothelins; Fistula; Heart Failure; Hypertension; Rats; Rats, Transgenic; Receptor, Angiotensin, Type 1; Receptor, Endothelin A | 2023 |
Cardiomyocyte p38 MAPKα suppresses a heart-adipose tissue-neutrophil crosstalk in heart failure development.
Topics: Adipose Tissue; Angiotensin II; Animals; Cardiomegaly; Fatty Acids; Heart Failure; Inflammation; Lipase; Lipids; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Neutrophils; p38 Mitogen-Activated Protein Kinases; Tamoxifen | 2022 |
Development of non-bias phenotypic drug screening for cardiomyocyte hypertrophy by image segmentation using deep learning.
Topics: Angiotensin II; Animals; Cardiomegaly; Cells, Cultured; Cholesterol; Deep Learning; Drug Evaluation, Preclinical; Endothelin-1; Ezetimibe; Heart Failure; Mice; Myocytes, Cardiac; Rats | 2022 |
Leonurine attenuates angiotensin II-induced cardiac injury and dysfunction via inhibiting MAPK and NF-κB pathway.
Topics: Angiotensin II; Animals; Fibrosis; Heart Failure; Mice; Mitogen-Activated Protein Kinases; Myocytes, Cardiac; NF-kappa B; Rats | 2023 |
MicroRNA-19 upregulation attenuates cardiac fibrosis via targeting connective tissue growth factor.
Topics: Angiotensin II; Animals; Connective Tissue Growth Factor; Fibroblasts; Fibrosis; Heart Failure; MicroRNAs; Myocardial Infarction; Myocardium; Rats; Transforming Growth Factor beta1; Up-Regulation | 2023 |
Receptor autoantibodies: Associations with cardiac markers, histology, and function in human non-ischaemic heart failure.
Topics: Angiotensin II; Autoantibodies; Heart Failure; Humans; Immunoglobulin G; Inflammation; Receptors, G-Protein-Coupled | 2023 |
Compound Kushen injection attenuates angiotensin II‑mediated heart failure by inhibiting the PI3K/Akt pathway.
Topics: Angiotensin II; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Heart Failure; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction | 2023 |
HypERlnc attenuates angiotensin II-induced cardiomyocyte hypertrophy via promoting SIRT1 SUMOylation-mediated activation of PGC-1α/PPARα pathway in AC16 cells.
Topics: Angiotensin II; Cardiomegaly; Heart Failure; Humans; Myocytes, Cardiac; Peptide Hormones; PPAR alpha; Sirtuin 1; Sumoylation | 2023 |
Dectin-1 Acts as a Non-Classical Receptor of Ang II to Induce Cardiac Remodeling.
Topics: Angiotensin II; Animals; Fibrosis; Heart Failure; Hypertension; Lectins, C-Type; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocytes, Cardiac; NF-kappa B; Ventricular Remodeling | 2023 |
Anti-Fibrotic Potential of Angiotensin (1-7) in Hemodynamically Overloaded Rat Heart.
Topics: Angiotensin II; Animals; Connexin 43; Fibrosis; Heart; Heart Failure; Hypertension; Male; Rats; Rats, Transgenic | 2023 |
Angiotensin II-Mediated Neuroinflammation in the Hippocampus Contributes to Neuronal Deficits and Cognitive Impairment in Heart Failure Rats.
Topics: Angiotensin II; Animals; Cognitive Dysfunction; Heart Failure; Hippocampus; Humans; Neuroinflammatory Diseases; Rats | 2023 |
Upregulated expression of a TOR2A gene product-salusin-β in the paraventricular nucleus enhances sympathetic activity and cardiac sympathetic afferent reflex in rats with chronic heart failure induced by coronary artery ligation.
Topics: Angiotensin II; Animals; Blood Pressure; Coronary Vessels; Heart Failure; Immunoglobulin G; NADPH Oxidases; Paraventricular Hypothalamic Nucleus; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Reflex; Sympathetic Nervous System | 2023 |
Characterization of a robust mouse model of heart failure with preserved ejection fraction.
Topics: Angiotensin II; Animals; Cardiomyopathies; Disease Models, Animal; Fibrosis; Heart Failure; Mice; Phenylephrine; Stroke Volume; Ventricular Function, Left | 2023 |
Ginsenoside Rg5 alleviates Ang II-induced cardiac inflammation and remodeling by inhibiting the JNK/AP-1 pathway.
Topics: Angiotensin II; Animals; Arrhythmias, Cardiac; Heart Failure; Hypertension; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Transcription Factor AP-1 | 2023 |
Integrin beta-like 1 mediates fibroblast-cardiomyocyte crosstalk to promote cardiac fibrosis and hypertrophy.
Topics: Angiotensin II; Animals; Cardiomegaly; Fibroblasts; Fibrosis; Heart Failure; Integrins; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Rats; Ventricular Remodeling | 2023 |
Effects of Angiotensin 1-7 and Mas Receptor Agonist on Renal System in a Rat Model of Heart Failure.
Topics: Angiotensin I; Angiotensin II; Animals; Cardiomegaly; Heart Failure; Kidney; Peptide Fragments; Rats; Renin-Angiotensin System | 2023 |
Resveratrol prevents Ang II-induced cardiac hypertrophy by inhibition of NF-κB signaling.
Topics: Angiotensin II; Animals; Cardiomegaly; Heart Failure; Mice; Myocytes, Cardiac; NF-kappa B; Rats; Resveratrol; Signal Transduction | 2023 |
Effect of pharmacological heart failure drugs and gene therapy on Danon's cardiomyopathy.
Topics: Angiotensin II; Animals; Cardiomegaly; Fibrosis; Genetic Therapy; Glycogen Storage Disease Type IIb; Heart Failure; Humans; Mice; Ramipril; Reactive Oxygen Species; Spironolactone | 2023 |
IRX2 regulates angiotensin II-induced cardiac fibrosis by transcriptionally activating EGR1 in male mice.
Topics: Angiotensin II; Animals; Fibroblasts; Heart; Heart Failure; Homeodomain Proteins; Male; Mice; Mice, Knockout; Peptide Hormones; Transcription Factors | 2023 |
Impaired renal autoregulation and pressure-natriuresis: any role in the development of heart failure in normotensive and angiotensin II-dependent hypertensive rats?
Topics: Angiotensin II; Animals; Blood Pressure; Heart Failure; Homeostasis; Hypertension; Kidney; Natriuresis; Rats; Rats, Transgenic; Renal Circulation; Sodium | 2023 |
Pregnancy-induced physiological hypertrophic preconditioning attenuates pathological myocardial hypertrophy by activation of FoxO3a.
Topics: Angiotensin II; Animals; Aortic Valve Stenosis; Cardiomegaly; Female; Glycogen Synthase Kinase 3 beta; Heart; Heart Failure; Mice; Peptide Hormones; Pregnancy | 2023 |
Identification of membrane palmitoylated protein 1 (MPP1) as a heart-failure-promoting protein triggered by cardiovascular risk factors and aging.
Topics: Angiotensin II; Animals; Cardiovascular Diseases; Heart Failure; Humans; Mice; Mice, Transgenic; Myocardium; Receptor, Angiotensin, Type 1; Risk Factors; Stroke Volume; Ventricular Function, Left | 2023 |
SOX4 as a potential therapeutic target for pathological cardiac hypertrophy.
Topics: Angiotensin II; Animals; Cardiomegaly; Heart Failure; Mice; Myocytes, Cardiac; Rats; Sirtuin 3; SOXC Transcription Factors | 2023 |
20(S)-ginsenoside Rh2 inhibits angiotensin-2 mediated cardiac remodeling and inflammation associated with suppression of the JNK/AP-1 pathway.
Topics: Angiotensin II; Animals; Heart Failure; Hypertension; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Transcription Factor AP-1; Ventricular Remodeling | 2023 |
Repurposing an anti-cancer agent for the treatment of hypertrophic heart disease.
Topics: Angiotensin II; Animals; Cardiomegaly; Cardiovascular Agents; Case-Control Studies; Cells, Cultured; Disease Models, Animal; Drug Repositioning; Fibrosis; Gene Expression Regulation; Heart Failure; Humans; Integrin alphaVbeta3; Male; Mice; Myocytes, Cardiac; Neovascularization, Physiologic; Recovery of Function; Signal Transduction; Snake Venoms; Transcriptome | 2019 |
Altered Renal Vascular Responsiveness to Vasoactive Agents in Rats with Angiotensin II-Dependent Hypertension and Congestive Heart Failure.
Topics: Angiotensin II; Animals; Arterio-Arterial Fistula; Heart Failure; Hypertension; Pulmonary Artery; Rats; Rats, Transgenic; Renal Circulation; Vasoconstriction; Vasoconstrictor Agents; Vasodilation | 2019 |
Enhanced Renal Vascular Responsiveness to Angiotensin II and Norepinephrine: A Unique Feature of Female Rats with Congestive Heart Failure.
Topics: Angiotensin II; Animals; Female; Heart Failure; Norepinephrine; Rats; Rats, Sprague-Dawley | 2019 |
Cardiomyocyte-Specific
Topics: Angiotensin II; Animals; Cell Line; Endothelial Cells; Fibrosis; Heart; Heart Failure; In Vitro Techniques; Inflammation; Macrophages; Mice; Mice, Knockout; Myocardium; Myocytes, Cardiac; NF-kappa B; Protein Serine-Threonine Kinases; Vasoconstrictor Agents; Ventricular Dysfunction, Left | 2019 |
Rapamycin regulates the balance between cardiomyocyte apoptosis and autophagy in chronic heart failure by inhibiting mTOR signaling.
Topics: Angiotensin II; Animals; Apoptosis; Autophagy; Cell Line; Echocardiography; Endoplasmic Reticulum Stress; Fluorescent Antibody Technique; Heart Failure; Male; Myocytes, Cardiac; Rats; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2020 |
Inhibition of microRNA-146a attenuated heart failure in myocardial infarction rats.
Topics: Angiotensin II; Animals; Animals, Newborn; Antagomirs; Atrial Remodeling; Disease Models, Animal; Heart; Heart Failure; Humans; MicroRNAs; Myocardial Infarction; Myocardium; Myocytes, Cardiac; Natriuretic Peptide, Brain; Rats; Rats, Sprague-Dawley; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Protective effect of hyperoside on heart failure rats via attenuating myocardial apoptosis and inducing autophagy.
Topics: Angiotensin II; Animals; Apoptosis; Autophagy; Cardiotonic Agents; Cells, Cultured; Heart Failure; Male; Myocardium; Quercetin; Rats; Rats, Wistar | 2020 |
Long Noncoding RNA FTX Reduces Hypertrophy of Neonatal Mouse Cardiac Myocytes and Regulates the PTEN/PI3K/Akt Signaling Pathway by Sponging MicroRNA-22.
Topics: Actins; Angiotensin II; Animals; Animals, Newborn; Apoptosis; Cardiomegaly; Cells, Cultured; Heart Failure; Mice; Mice, Inbred C57BL; MicroRNAs; Myocardium; Myocytes, Cardiac; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA, Long Noncoding; Signal Transduction | 2019 |
Nox2+ myeloid cells drive vascular inflammation and endothelial dysfunction in heart failure after myocardial infarction via angiotensin II receptor type 1.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Disease Models, Animal; Endothelial Cells; Heart Failure; Leukocyte Rolling; Macrophages; Male; Mice, Inbred C57BL; Monocytes; Muramidase; Myeloid Cells; Myocardial Infarction; NADPH Oxidase 2; Oxidative Stress; Receptor, Angiotensin, Type 1; Signal Transduction; Telmisartan; Vasculitis | 2021 |
B38-CAP is a bacteria-derived ACE2-like enzyme that suppresses hypertension and cardiac dysfunction.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Carboxypeptidases; Cardiomegaly; Disease Models, Animal; Fibrosis; Heart Failure; Hypertension; Male; Mice; Mice, Inbred C57BL; Paenibacillus; Peptidyl-Dipeptidase A; Recombinant Proteins | 2020 |
Apelin-13 alleviated cardiac fibrosis via inhibiting the PI3K/Akt pathway to attenuate oxidative stress in rats with myocardial infarction-induced heart failure.
Topics: Angiotensin II; Animals; Disease Models, Animal; Echocardiography; Fibroblasts; Fibrosis; Heart; Heart Failure; Humans; Injections, Intraperitoneal; Intercellular Signaling Peptides and Proteins; Male; Myocardial Infarction; Myocardium; Oxidative Stress; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction | 2020 |
TBC1D25 Regulates Cardiac Remodeling Through TAK1 Signaling Pathway.
Topics: Angiotensin II; Animals; Aorta; Cardiomegaly; Echocardiography; Gene Expression Regulation; GTPase-Activating Proteins; Heart Failure; Hypertrophy; Male; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mice, Knockout; Myocytes, Cardiac; Phosphorylation; Protein Domains; Rats; Rats, Sprague-Dawley; Signal Transduction; Ventricular Remodeling | 2020 |
Increase in PKCα Activity during Heart Failure Despite the Stimulation of PKCα Braking Mechanism.
Topics: Angiotensin II; Diastole; Diglycerides; Heart; Heart Failure; Humans; Myocardial Contraction; Myocardial Infarction; Myocardium; Protein Kinase C-alpha; Quality of Life; Signal Transduction | 2020 |
Alterations of the renin angiotensin system in human end-stage heart failure before and after mechanical cardiac unloading by LVAD support.
Topics: Angiotensin I; Angiotensin II; beta-Arrestins; Female; Heart Failure; Heart-Assist Devices; Humans; Male; Middle Aged; Proto-Oncogene Mas; ras Proteins; Renin-Angiotensin System; Signal Transduction | 2020 |
Senolytic Agent Navitoclax Inhibits Angiotensin II-Induced Heart Failure in Mice.
Topics: Angiotensin II; Aniline Compounds; Animals; Apoptosis; Cardiac Pacing, Artificial; Cardiomegaly; Cells, Cultured; Cellular Senescence; Disease Models, Animal; Fibrosis; Heart Failure; Inflammation Mediators; Male; Mice, Inbred C57BL; Myocytes, Cardiac; Rats, Sprague-Dawley; Stroke Volume; Sulfonamides; Tachycardia, Ventricular; Ventricular Function, Left; Ventricular Remodeling | 2020 |
Alpha-lipoic acid protects against pressure overload-induced heart failure via ALDH2-dependent Nrf1-FUNDC1 signaling.
Topics: Aldehyde Dehydrogenase, Mitochondrial; Angiotensin II; Animals; Animals, Newborn; Aorta; Apoptosis; Base Sequence; Cardiotonic Agents; Constriction, Pathologic; Disease Models, Animal; Fibrosis; Heart Failure; Heart Ventricles; Hypertrophy, Left Ventricular; Male; Membrane Proteins; Mice, Inbred C57BL; Mitochondria; Mitochondrial Proteins; Myocytes, Cardiac; Nuclear Respiratory Factor 1; Pressure; Rats; Signal Transduction; Thioctic Acid | 2020 |
MicroRNA-132 attenuated cardiac fibrosis in myocardial infarction-induced heart failure rats.
Topics: Angiotensin II; Animals; Cardiotonic Agents; Cells, Cultured; Disease Models, Animal; Echocardiography; Fibroblasts; Fibrosis; Heart; Heart Failure; Humans; Male; MicroRNAs; Myocardial Infarction; Myocardium; Primary Cell Culture; Rats; Signal Transduction | 2020 |
Mitochondrial pyruvate carrier abundance mediates pathological cardiac hypertrophy.
Topics: Angiotensin II; Animals; Anion Transport Proteins; Cardiomegaly; Cell Proliferation; Citric Acid Cycle; Constriction, Pathologic; Female; Heart Failure; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Mitochondria, Heart; Mitochondrial Membrane Transport Proteins; Monocarboxylic Acid Transporters; Myocardium; Myocytes, Cardiac; Pyruvic Acid | 2020 |
Renin-angiotensin system overactivation in perivascular adipose tissue contributes to vascular dysfunction in heart failure.
Topics: Adipose Tissue; Angiotensin II; Animals; Aorta, Thoracic; Biological Availability; Endothelium, Vascular; Heart Failure; Hemodynamics; Male; Models, Biological; Myocardial Infarction; Nitric Oxide; Oxidative Stress; Peptidyl-Dipeptidase A; Rats, Wistar; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Vasoconstriction | 2020 |
Cardiac Pressure Overload Decreases ETV1 Expression in the Left Atrium, Contributing to Atrial Electrical and Structural Remodeling.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin II; Animals; Arrhythmias, Cardiac; Disease Models, Animal; DNA-Binding Proteins; Down-Regulation; Female; Heart Atria; Heart Failure; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Neuregulin-1; Receptor, Transforming Growth Factor-beta Type I; Transcription Factors; Ventricular Remodeling; Young Adult | 2021 |
Two-hit mechanism of cardiac arrhythmias in diabetic hyperglycaemia: reduced repolarization reserve, neurohormonal stimulation, and heart failure exacerbate susceptibility.
Topics: Action Potentials; Angiotensin II; Animals; Arrhythmias, Cardiac; Blood Glucose; Calcium Signaling; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Diabetes Mellitus; Disease Models, Animal; Heart Conduction System; Heart Failure; Heart Rate; Isoproterenol; Male; Mice, Inbred C57BL; Myocytes, Cardiac; Potassium Channels; Rabbits; Ryanodine Receptor Calcium Release Channel | 2021 |
Piperlongumine attenuates angiotensin-II-induced cardiac hypertrophy and fibrosis by inhibiting Akt-FoxO1 signalling.
Topics: Angiotensin II; Animals; Apoptosis; Cardiomegaly; Cardiomyopathies; Dioxolanes; Disease Models, Animal; Fibroblasts; Fibrosis; Heart Failure; Kruppel-Like Factor 4; Myocytes, Cardiac; Nerve Tissue Proteins; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction | 2021 |
Renal Sympathetic Denervation Attenuates Congestive Heart Failure in Angiotensin II-Dependent Hypertension: Studies with Ren-2 Transgenic Hypertensive Rats with Aortocaval Fistula.
Topics: Angiotensin II; Animals; Arteriovenous Fistula; Female; Heart Failure; Hypertension; Kidney; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Renin; Sympathectomy | 2021 |
Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta-blockers in patients hospitalized for acute heart failure.
Topics: Aftercare; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Patient Discharge; Retrospective Studies; Stroke Volume; Ventricular Function, Left | 2021 |
Prevention of Fibrosis and Pathological Cardiac Remodeling by Salinomycin.
Topics: Angiotensin II; Animals; Antifibrotic Agents; Cardiomegaly; Cell Survival; Disease Models, Animal; Extracellular Matrix; Fibrosis; Gene Expression; Heart Failure; Humans; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocardium; Myofibroblasts; NIH 3T3 Cells; p38 Mitogen-Activated Protein Kinases; Pyrans; rho-Associated Kinases; Ventricular Remodeling | 2021 |
Myocardial Angiotensin Metabolism in End-Stage Heart Failure.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Disease Progression; Female; Heart Failure; Heart Transplantation; Humans; Male; Mass Spectrometry; Middle Aged; Myocardium; Peptide Fragments; Renin-Angiotensin System; Stroke Volume | 2021 |
Underutilized Fuel: Angiotensin II for Vasoplegia in the Heart Failure Patient Population.
Topics: Angiotensin II; Heart Failure; Humans; Vasoplegia | 2021 |
Alarin alleviated cardiac fibrosis via attenuating oxidative stress in heart failure rats.
Topics: Angiotensin II; Animals; Fibrosis; Galanin-Like Peptide; Heart Failure; Male; Malondialdehyde; Myocardial Infarction; Oxidative Stress; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta; Vasoconstrictor Agents | 2021 |
Loss of Hepatic Angiotensinogen Attenuates Sepsis-Induced Myocardial Dysfunction.
Topics: Angiotensin II; Angiotensinogen; Animals; Heart Failure; Liver; Low Density Lipoprotein Receptor-Related Protein-1; Mice; Myocardium; NLR Family, Pyrin Domain-Containing 3 Protein; Sepsis | 2021 |
The Cancer Therapy-Related Clonal Hematopoiesis Driver Gene
Topics: Angiotensin II; Animals; Clonal Hematopoiesis; DNA Damage; Gain of Function Mutation; Heart Failure; Hematopoietic Stem Cells; Inflammasomes; Interleukin-18; Interleukin-1beta; Macrophages; Male; Mice; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Protein Phosphatase 2C | 2021 |
MiR-590-5p inhibits pathological hypertrophy mediated heart failure by targeting RTN4.
Topics: Angiotensin II; Animals; Apoptosis; Base Sequence; Biomarkers; Cardiomegaly; Cell Line; Disease Models, Animal; Down-Regulation; Heart Failure; Mice, Inbred C57BL; MicroRNAs; Nogo Proteins; Protein Binding | 2021 |
ELABELA-APJ axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage.
Topics: Angiotensin II; Animals; Aorta; Apelin Receptors; Arterial Pressure; Cardiotonic Agents; Constriction; Disease Models, Animal; Fibrosis; Forkhead Box Protein M1; Gene Expression Regulation; Heart Failure; HEK293 Cells; Humans; Hypertension; Hypertrophy, Left Ventricular; Infusions, Subcutaneous; Ligands; Male; Mice, Inbred C57BL; Mice, Knockout; Myocardial Contraction; Myocardium; Peptide Hormones; Peptidyl-Dipeptidase A; Signal Transduction; Transfection; Ventricular Dysfunction, Left; Ventricular Function, Left | 2017 |
Intracellular Angiotensin-II Interacts With Nuclear Angiotensin Receptors in Cardiac Fibroblasts and Regulates RNA Synthesis, Cell Proliferation, and Collagen Secretion.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Calcium; Cell Nucleus; Cell Proliferation; Collagen; Collagen Type I; Disease Models, Animal; Dogs; Fibroblasts; GTP-Binding Protein alpha Subunits, Gi-Go; GTP-Binding Protein alpha Subunits, Gq-G11; GTP-Binding Protein beta Subunits; Heart Atria; Heart Failure; Immunoblotting; Inositol 1,4,5-Trisphosphate Receptors; Microscopy, Fluorescence; Nitric Oxide; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Transcription, Genetic | 2017 |
Central-acting therapeutics alleviate respiratory weakness caused by heart failure-induced ventilatory overdrive.
Topics: Angiotensin II; Animals; Blood-Brain Barrier; Diaphragm; Eukaryotic Initiation Factor-2; Heart Failure; Lung; Male; Mice; Muscle Weakness; Phosphorylation; Respiration; Signal Transduction | 2017 |
The Inhibitory Effect of WenxinKeli on H9C2 Cardiomyocytes Hypertrophy Induced by Angiotensin II through Regulating Autophagy Activity.
Topics: Angiotensin II; Animals; Autophagy; Cardiomegaly; Heart Failure; Humans; Medicine, Chinese Traditional; Myocytes, Cardiac; Rats | 2017 |
Angiotensin-(1-7) in Paraventricular Nucleus Contributes to the Enhanced Cardiac Sympathetic Afferent Reflex and Sympathetic Activity in Chronic Heart Failure Rats.
Topics: Acetophenones; Angiotensin I; Angiotensin II; Animals; Arterial Pressure; Capsaicin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic N-Oxides; Heart Failure; Hemodynamics; Kidney; Male; NADPH Oxidases; NG-Nitroarginine Methyl Ester; Paraventricular Hypothalamic Nucleus; Peptide Fragments; Rats; Rats, Sprague-Dawley; Signal Transduction; Spin Labels; Superoxides; Sympathetic Nervous System | 2017 |
Blunting of estrogen modulation of cardiac cellular chymase/RAS activity and function in SHR.
Topics: Angiotensin II; Animals; Chymases; Estrogens; Female; Heart Failure; Myocardium; Myocytes, Cardiac; Peptide Fragments; Peptidyl-Dipeptidase A; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1 | 2018 |
Stimulation of ganglionated plexus attenuates cardiac neural remodeling and heart failure progression in a canine model of acute heart failure post-myocardial infarction.
Topics: Angiotensin II; Animals; Biomarkers; Disease Models, Animal; Disease Progression; Dogs; Electric Stimulation Therapy; GAP-43 Protein; Heart; Heart Failure; Male; Myocardial Infarction; Natriuretic Peptide, Brain; Nerve Growth Factor; Norepinephrine; Parasympathetic Nervous System; Proto-Oncogene Proteins c-fos; Random Allocation; Tyrosine 3-Monooxygenase | 2017 |
Effect of the changes of NMDA receptor in hypothalamic paraventricular nucleus on cardiac function and sympathetic nervous activity in rats with heart failure.
Topics: Angiotensin II; Animals; Glutamate Decarboxylase; Heart Failure; Male; Norepinephrine; Paraventricular Hypothalamic Nucleus; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Sympathetic Nervous System; Tyrosine 3-Monooxygenase; Ventricular Function, Left | 2017 |
Renal Sympathetic Denervation Protects the Failing Heart Via Inhibition of Neprilysin Activity in the Kidney.
Topics: Aminobutyrates; Angiotensin II; Animals; Biphenyl Compounds; Bisoprolol; Blood Pressure; Drug Combinations; Echocardiography; Heart Failure; Kidney; Myocardium; Neprilysin; Nitrites; Norepinephrine; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renal Artery; Renin; Reperfusion Injury; Sympathectomy; Tetrazoles; Valsartan; Ventricular Function, Left | 2017 |
Cellular mechanisms of metabolic syndrome-related atrial decompensation in a rat model of HFpEF.
Topics: Angiotensin II; Animals; Atrial Remodeling; Calcium; Calcium Signaling; Cell Nucleus; Cytosol; Disease Models, Animal; Excitation Contraction Coupling; Heart Atria; Heart Failure; Heart Ventricles; Hypertension; Metabolic Syndrome; Myocytes, Cardiac; Rats; Sarcoplasmic Reticulum; Stroke Volume | 2018 |
CXCL1-CXCR2 axis mediates angiotensin II-induced cardiac hypertrophy and remodelling through regulation of monocyte infiltration.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Animals; Cardiomegaly; Cell Movement; Chemokine CXCL1; Female; Fibrosis; Heart Failure; Humans; Male; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Monocytes; Myocardium; Receptors, Interleukin-8B; Signal Transduction; Up-Regulation | 2018 |
Aspirin Reduces Cardiac Interstitial Fibrosis by Inhibiting Erk1/2-Serpine2 and P-Akt Signalling Pathways.
Topics: Actins; Angiotensin II; Animals; Aspirin; beta Catenin; Cell Line; Collagen Type I; Disease Models, Animal; Fibroblasts; Fibrosis; Heart Failure; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocardium; Phosphorylation; Proto-Oncogene Proteins c-akt; Serpin E2; Signal Transduction | 2018 |
Angiotensin II Type 1a Receptors in the Subfornical Organ Modulate Neuroinflammation in the Hypothalamic Paraventricular Nucleus in Heart Failure Rats.
Topics: Angiotensin II; Animals; Heart Failure; Inflammation; Male; Paraventricular Hypothalamic Nucleus; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Subfornical Organ | 2018 |
Research on Q-markers of Qiliqiangxin capsule for chronic heart failure treatment based on pharmacokinetics and pharmacodynamics association.
Topics: Aconitine; Angiotensin II; Animals; Benzofurans; Biomarkers; Chromatography, High Pressure Liquid; Chronic Disease; Drugs, Chinese Herbal; Ginsenosides; Heart Failure; Isoflavones; Male; Medicine, Chinese Traditional; Quality Control; Rats, Sprague-Dawley; Tandem Mass Spectrometry | 2018 |
MicroRNA 199a-5p induces apoptosis by targeting JunB.
Topics: Angiotensin II; Animals; Apoptosis; Cell Line; Disease Models, Animal; Gene Expression Regulation; Heart Failure; MicroRNAs; Myocardial Infarction; Myocytes, Cardiac; Rats | 2018 |
Network-based predictions of in vivo cardiac hypertrophy.
Topics: Angiotensin II; Animals; Cardiomegaly; Computational Biology; Disease Models, Animal; Heart Failure; Humans; Mice; Mice, Transgenic; Myocardium; Myocytes, Cardiac; Signal Transduction | 2018 |
CTGF/CCN2 is an autocrine regulator of cardiac fibrosis.
Topics: Angiotensin II; Animals; Autocrine Communication; Connective Tissue Growth Factor; Fibrosis; Heart Failure; Humans; Mice; Myocytes, Cardiac; Myofibroblasts; Ventricular Remodeling | 2018 |
Irisin alleviates pressure overload-induced cardiac hypertrophy by inducing protective autophagy via mTOR-independent activation of the AMPK-ULK1 pathway.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Animals; Autophagy; Autophagy-Related Protein-1 Homolog; Benzamides; Cardiomegaly; Fibronectins; Heart Failure; Humans; Mice; Mice, Transgenic; Myocytes, Cardiac; Phenylephrine; Pressure; Pyrimidines; Signal Transduction; TOR Serine-Threonine Kinases | 2018 |
[Role of ACE2-Ang (1-7)-Mas receptor axis in heart failure with preserved ejection fraction with hypertension].
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Atrial Remodeling; Case-Control Studies; Enzyme-Linked Immunosorbent Assay; Heart Failure; Humans; Hypertension; Male; Peptide Fragments; Peptidyl-Dipeptidase A; Random Allocation; Rats; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled; Stroke Volume; Ventricular Function, Left; Ventricular Remodeling | 2018 |
Cilostazol ameliorates heart failure with preserved ejection fraction and diastolic dysfunction in obese and non-obese hypertensive mice.
Topics: Angiotensin II; Animals; Biomarkers; Biopsy; Blood Pressure; Cilostazol; Diastole; Disease Models, Animal; Disease Progression; Echocardiography; Energy Metabolism; Fibrosis; Heart Failure; Hypertension; Immunohistochemistry; Male; Mice; Renin; Stroke Volume; Vasodilator Agents; Ventricular Dysfunction, Left | 2018 |
Overexpression of miR-142-3p improves mitochondrial function in cardiac hypertrophy.
Topics: Angiotensin II; Animals; Apoptosis; Atrial Natriuretic Factor; Cardiomegaly; Carrier Proteins; Cells, Cultured; Heart Failure; Intracellular Signaling Peptides and Proteins; Male; MicroRNAs; Mitochondria, Heart; Myocardium; Natriuretic Peptide, Brain; Rats; Rats, Sprague-Dawley | 2018 |
The nuclear receptor RORα protects against angiotensin II-induced cardiac hypertrophy and heart failure.
Topics: Angiotensin II; Animals; Cardiomegaly; Cells, Cultured; Female; Fibroblasts; Heart Failure; Humans; Interleukin-6; Loss of Function Mutation; Mice; Mice, Inbred C57BL; Middle Aged; Mitochondria, Heart; Myocardial Contraction; Myocytes, Cardiac; Nuclear Receptor Subfamily 1, Group F, Member 1; Rats; Rats, Sprague-Dawley; STAT3 Transcription Factor | 2019 |
The Role of Renal Vascular Reactivity in the Development of Renal Dysfunction in Compensated and Decompensated Congestive Heart Failure.
Topics: Acetylcholine; Angiotensin II; Animals; Heart Failure; Male; Norepinephrine; Rats; Rats, Sprague-Dawley; Renal Artery; Renal Circulation; Vasoconstriction; Vasodilation | 2018 |
Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.
Topics: Aldosterone; Aminobutyrates; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cross-Over Studies; Cyclic GMP; Dogs; Dose-Response Relationship, Drug; Drug Combinations; Female; Heart Failure; Humans; Male; Natriuretic Peptides; Renin-Angiotensin System; Sodium, Dietary; Tetrazoles; Valsartan | 2019 |
Gallic Acid Suppresses Cardiac Hypertrophic Remodeling and Heart Failure.
Topics: Angiotensin II; Animals; Autophagy; Cardiomegaly; Cardiotonic Agents; Cell Enlargement; Cells, Cultured; Gallic Acid; Heart Failure; Male; Mice, Inbred C57BL; Myocarditis; Myocytes, Cardiac; Oxidative Stress; Rats, Sprague-Dawley; Signal Transduction | 2019 |
RORα nuclear receptors in protection against angiotensin II-induced cardiac hypertrophy.
Topics: Angiotensin II; Cardiomegaly; Heart Failure; Humans | 2019 |
MiR-103 inhibiting cardiac hypertrophy through inactivation of myocardial cell autophagy via targeting TRPV3 channel in rat hearts.
Topics: Angiotensin II; Animals; Autophagy; Beclin-1; Cardiomegaly; Cells, Cultured; Down-Regulation; Heart; Heart Failure; Male; MicroRNAs; Myocytes, Cardiac; Rats; Rats, Wistar; Signal Transduction; TRPV Cation Channels; Up-Regulation | 2019 |
MicroRNA-375-3p inhibitor suppresses angiotensin II-induced cardiomyocyte hypertrophy by promoting lactate dehydrogenase B expression.
Topics: Angiotensin II; Animals; Aorta; Cardiomegaly; Disease Models, Animal; Gene Expression Regulation; Gene Knockdown Techniques; Heart Failure; Humans; Isoenzymes; L-Lactate Dehydrogenase; MicroRNAs; Myocardium; Myocytes, Cardiac; Myosin Heavy Chains; Natriuretic Peptide, Brain; Primary Cell Culture; Rats; Signal Transduction | 2019 |
Loss of Apelin Augments Angiotensin II-Induced Cardiac Dysfunction and Pathological Remodeling.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Apelin; Biopsy; Cardiomegaly; Disease Models, Animal; Echocardiography; Fibrosis; Heart Failure; Hypertension; Mice; Mice, Knockout; Myocardial Contraction; Myocytes, Cardiac; Peptidyl-Dipeptidase A; Ventricular Dysfunction; Ventricular Remodeling | 2019 |
Novel role of mitochondrial GTPases 1 in pathological cardiac hypertrophy.
Topics: Angiotensin II; Animals; Cardiomegaly; Cardiomyopathy, Dilated; GTP Phosphohydrolases; Heart Failure; Humans; MAP Kinase Kinase Kinases; Mice; Mice, Knockout; Mitochondria; Myocytes, Cardiac; Oxidative Stress | 2019 |
Time course of decompensation after angiotensin II and high-salt diet in Balb/CJ mice suggests pulmonary hypertension-induced cardiorenal syndrome.
Topics: Angiotensin II; Animals; Blood Pressure; Cardio-Renal Syndrome; Diet; Heart Failure; Hypertension; Hypertension, Pulmonary; Male; Mice, Inbred BALB C; Myocardium; Sodium Chloride, Dietary; Time Factors; Water-Electrolyte Imbalance | 2019 |
The immunoproteasome catalytic β5i subunit regulates cardiac hypertrophy by targeting the autophagy protein ATG5 for degradation.
Topics: Aged; Aged, 80 and over; Angiotensin II; Animals; Autophagy; Autophagy-Related Protein 5; Cardiomegaly; Case-Control Studies; Catalytic Domain; Female; Heart Failure; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; Myocardium; Natriuretic Peptide, Brain; Proteasome Endopeptidase Complex; Rats; RNA Interference; RNA, Small Interfering; Up-Regulation | 2019 |
Quantitative trait loci associated with angiotensin II and high-salt diet induced acute decompensated heart failure in Balb/CJ mice.
Topics: Angiotensin II; Animals; Blood Pressure; Cardiomegaly; Chromosome Mapping; Diet; Disease Models, Animal; Echocardiography; Female; Genetic Linkage; Genetic Predisposition to Disease; Heart Failure; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred Strains; Oligonucleotide Array Sequence Analysis; Phenotype; Polymorphism, Single Nucleotide; Quantitative Trait Loci; Sodium Chloride, Dietary; Species Specificity; Thiobarbituric Acid Reactive Substances | 2019 |
Renal Sympathetic Denervation Improves Outcomes in a Canine Myocardial Infarction Model.
Topics: Angiotensin II; Animals; Blood Pressure; Denervation; Disease Models, Animal; Dogs; Echocardiography; Female; Heart; Heart Failure; Kidney; Male; Myocardial Infarction; Myocardium; Renal Artery; Renin-Angiotensin System; Sympathectomy; Sympathetic Nervous System; Ventricular Function, Left | 2019 |
Endothelial Forkhead Box Transcription Factor P1 Regulates Pathological Cardiac Remodeling Through Transforming Growth Factor-β1-Endothelin-1 Signal Pathway.
Topics: Angiotensin II; Animals; Aorta; Disease Models, Animal; Endothelin-1; Endothelium, Vascular; Fibrosis; Forkhead Transcription Factors; Heart Failure; Humans; Mice; Mice, Knockout; Myocardium; Nanotubes, Peptide; Repressor Proteins; RNA, Small Interfering; Signal Transduction; Transforming Growth Factor beta1; Ventricular Remodeling | 2019 |
Sodium (±)-5-bromo-2-(α-hydroxypentyl) benzoate ameliorates pressure overload-induced cardiac hypertrophy and dysfunction through inhibiting autophagy.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Animals; Autophagy; Cardiomegaly; Cell Line; Heart Failure; Male; Metformin; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Signal Transduction; TOR Serine-Threonine Kinases; Ventricular Remodeling | 2019 |
MicroRNA-92b-3p suppresses angiotensin II-induced cardiomyocyte hypertrophy via targeting HAND2.
Topics: 3' Untranslated Regions; Angiotensin II; Animals; Basic Helix-Loop-Helix Transcription Factors; Cardiomegaly; Cardiomyopathy, Hypertrophic; Disease Models, Animal; Heart Defects, Congenital; Heart Failure; Heart Ventricles; Mice; Mice, Inbred C57BL; MicroRNAs; Myocardium; Myocytes, Cardiac; RNA, Small Interfering; Signal Transduction; Up-Regulation | 2019 |
Podoplanin neutralization improves cardiac remodeling and function after acute myocardial infarction.
Topics: Angiotensin II; Animals; Antibodies, Neutralizing; Cardiomyopathies; Cell Survival; Cicatrix; Echocardiography; Fibrosis; Heart Failure; Heart Transplantation; Hemodynamics; Humans; Hypertrophy, Left Ventricular; Inflammation; Macrophages; Membrane Glycoproteins; Mice; Monocytes; Myocardial Infarction; Myocardial Ischemia; Myocytes, Cardiac; Regeneration; Vasoconstrictor Agents; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Kaempferol Prevents Against Ang II-induced Cardiac Remodeling Through Attenuating Ang II-induced Inflammation and Oxidative Stress.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Animals; Anti-Inflammatory Agents; Antioxidants; Cells, Cultured; Collagen; Disease Models, Animal; Fibroblasts; Fibrosis; Heart Failure; Inflammation Mediators; Kaempferols; Male; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Myocytes, Cardiac; NF-E2-Related Factor 2; NF-kappa B; Oxidative Stress; Rats, Sprague-Dawley; Signal Transduction; Ventricular Function, Left; Ventricular Remodeling | 2019 |
Clinical effects of Xinmailong therapy in patients with chronic heart failure.
Topics: Angiotensin II; C-Reactive Protein; Drugs, Chinese Herbal; Female; Heart Failure; Heart Ventricles; Humans; Male; Medicine, Chinese Traditional; Middle Aged; Treatment Outcome; Ventricular Function, Left | 2013 |
Heart failure and angiotensin II modulate atrial Pitx2c promotor methylation.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Azacitidine; Cell Line, Tumor; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Interactions; Enzyme Inhibitors; Heart Atria; Heart Failure; Homeobox Protein PITX2; Homeodomain Proteins; Isoproterenol; Losartan; Male; Promoter Regions, Genetic; Rats; RNA; Transcription Factors | 2013 |
Deficiency of senescence marker protein 30 exacerbates angiotensin II-induced cardiac remodelling.
Topics: Aging; Angiotensin II; Animals; Apoptosis; Ascorbic Acid; bcl-2-Associated X Protein; Biomarkers; Calcium-Binding Proteins; Cardiomegaly; Caspase 3; Disease Models, Animal; Fibrosis; Heart Failure; Intracellular Signaling Peptides and Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; Oxidative Stress; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Ventricular Remodeling | 2013 |
Angiotensin II inhibits satellite cell proliferation and prevents skeletal muscle regeneration.
Topics: Angiotensin II; Animals; Cell Count; Cell Cycle Proteins; Cell Proliferation; Disease Models, Animal; Heart Failure; Mice; Muscle, Skeletal; Receptor, Angiotensin, Type 1; Receptors, Notch; Regeneration; Satellite Cells, Skeletal Muscle; Signal Transduction; Wasting Syndrome | 2013 |
Angiotensin II-mediated posttranslational modification of nNOS in the PVN of rats with CHF: role for PIN.
Topics: Angiotensin II; Animals; Chronic Disease; Cytoplasmic Dyneins; Heart Failure; Male; Nitric Oxide; Nitric Oxide Synthase Type I; Paraventricular Hypothalamic Nucleus; Protein Processing, Post-Translational; Rats; Rats, Sprague-Dawley; Tissue Distribution; Up-Regulation | 2013 |
Exposure of cardiomyocytes to angiotensin II induces over-activation of monoamine oxidase type A: implications in heart failure.
Topics: Aldehyde Dehydrogenase; Angiotensin II; Animals; Biphenyl Compounds; Catalase; Enzyme Activation; Heart Failure; Hyperglycemia; Irbesartan; Losartan; Monoamine Oxidase; Myocytes, Cardiac; Rats; Tetrazoles | 2013 |
A novel heart failure mice model of hypertensive heart disease by angiotensin II infusion, nephrectomy, and salt loading.
Topics: Angiotensin II; Animals; Animals, Newborn; Blood Pressure; Cells, Cultured; Disease Models, Animal; Disease Progression; Fibrosis; Gene Expression Regulation; Heart Failure; Hypertension; Hypertrophy, Left Ventricular; Male; Mice; Mice, Inbred C57BL; Myocardium; Nephrectomy; Neuropeptides; Oxidative Stress; Pulmonary Edema; rac1 GTP-Binding Protein; Rats; Rats, Wistar; Sodium Chloride, Dietary; Time Factors; Ventricular Function, Left | 2013 |
The effects of high thoracic epidural anesthesia on sympathetic activity and apoptosis in experimentally induced congestive heart failure.
Topics: Anesthesia, Epidural; Anesthetics, Local; Angiotensin II; Animals; Apoptosis; Apoptosis Inducing Factor; DNA Repair; Endothelin-1; Heart Failure; Lidocaine; Male; Myocardium; Norepinephrine; Poly(ADP-ribose) Polymerases; Rats; Rats, Wistar; Sympathetic Nervous System; Thoracic Vertebrae; Tissue Fixation; Tumor Necrosis Factor-alpha; Ventricular Function, Left | 2014 |
Inhalation of diesel exhaust does not exacerbate cardiac hypertrophy or heart failure in two mouse models of cardiac hypertrophy.
Topics: Air Pollutants; Angiotensin II; Animals; Cardiomegaly; Disease Models, Animal; Disease Progression; Echocardiography; Heart Failure; Heart Rate; Inhalation Exposure; Male; Mice; Mice, Inbred C57BL; Particle Size; Particulate Matter; Time Factors; Vehicle Emissions | 2013 |
The C-terminus of the long AKAP13 isoform (AKAP-Lbc) is critical for development of compensatory cardiac hypertrophy.
Topics: A Kinase Anchor Proteins; Angiotensin II; Animals; Aorta; Apoptosis; Cardiomegaly; Collagen; Female; Gene Expression Regulation; Guanine Nucleotide Exchange Factors; Heart Failure; Histone Deacetylases; Male; Mice; Mice, Transgenic; Minor Histocompatibility Antigens; Myocardium; Phenylephrine; Protein Kinase C; Protein Structure, Tertiary; Signal Transduction | 2014 |
Peripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation.
Topics: Adult; Angiotensin II; Arm; Cytokines; Endothelial Cells; Endothelium, Vascular; Female; Healthy Volunteers; Heart Failure; Humans; Hyperemia; Male; Neuropeptides; Neurotransmitter Agents; RNA, Messenger; Vascular Cell Adhesion Molecule-1; Vasculitis | 2014 |
M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics.
Topics: Aldosterone; Angiotensin II; Animals; Arterial Pressure; Atrial Natriuretic Factor; Cardiac Pacing, Artificial; Disease Models, Animal; Dogs; Enzyme Activation; Enzyme Activators; Guanylate Cyclase; Heart Failure; Hypertension; Male; Natriuresis; Nitroglycerin; Pulmonary Wedge Pressure; Receptors, Cytoplasmic and Nuclear; Renal Circulation; Soluble Guanylyl Cyclase; Time Factors | 2014 |
Mechanisms of Ghrelin anti-heart failure: inhibition of Ang II-induced cardiomyocyte apoptosis by down-regulating AT1R expression.
Topics: Angiotensin II; Animals; Apoptosis; Case-Control Studies; Caspase 3; Down-Regulation; Female; Ghrelin; Heart Failure; Humans; Male; Middle Aged; Myocardium; Myocytes, Cardiac; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger | 2014 |
Connective tissue growth factor inhibition attenuates left ventricular remodeling and dysfunction in pressure overload-induced heart failure.
Topics: Angiotensin II; Animals; Antibodies, Monoclonal; Aorta, Thoracic; Collagen Type I; Connective Tissue Growth Factor; Constriction, Pathologic; Fibroblasts; Gene Expression; Heart; Heart Failure; Male; Matrix Metalloproteinase 2; Mice; Mice, Inbred C57BL; Myocardium; Myocytes, Cardiac; Plasminogen Activator Inhibitor 1; Pressure; Reverse Transcriptase Polymerase Chain Reaction; Ventricular Dysfunction, Left; Ventricular Remodeling; Weight-Bearing | 2014 |
Intermedin in the paraventricular nucleus attenuates cardiac sympathetic afferent reflex in chronic heart failure rats.
Topics: Adrenomedullin; Afferent Pathways; Angiotensin II; Animals; Blood Pressure; Calcitonin Gene-Related Peptide; Chronic Disease; Heart Failure; Heart Rate; Hemodynamics; Kidney; Male; Neuropeptides; Paraventricular Hypothalamic Nucleus; Peptide Fragments; Rats; Rats, Sprague-Dawley; Superoxides; Sympathetic Nervous System | 2014 |
A comparison of the efficacy of surgical renal denervation and pharmacologic therapies in post-myocardial infarction heart failure.
Topics: Adrenergic beta-Antagonists; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Denervation; Disease Models, Animal; Endothelins; Heart Failure; Heart Rate; Hemodynamics; Kidney; Male; Myocardial Infarction; Natriuretic Peptide, Brain; Norepinephrine; Rats; Rats, Wistar; Renin; Treatment Outcome; Ventricular Function, Left | 2014 |
HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling.
Topics: Angiotensin II; Animals; Cardiomegaly; Disease Models, Animal; Fibrosis; Heart Failure; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Hydroxamic Acids; Indoles; Male; Mice; Mice, Knockout; Muscle, Skeletal; Muscular Atrophy; Myocardium; Signal Transduction; Stroke Volume; Systole; Time Factors; Ventricular Function, Left; Ventricular Remodeling | 2014 |
Effects of exercise training on circulating and skeletal muscle renin-angiotensin system in chronic heart failure rats.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Heart Failure; Heart Function Tests; Male; Muscle, Skeletal; Peptidyl-Dipeptidase A; Physical Conditioning, Animal; Rats; Rats, Wistar; Renin-Angiotensin System | 2014 |
Nestin is a marker of lung remodeling secondary to myocardial infarction and type I diabetes in the rat.
Topics: Actins; Airway Remodeling; Angiotensin II; Animals; Biomarkers; Cell Differentiation; Collagen Type I; Diabetes Mellitus, Type 1; Fibroblasts; Heart Failure; Humans; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Male; MicroRNAs; Myocardial Contraction; Myocardial Infarction; Nestin; Pulmonary Fibrosis; Rats; Rats, Sprague-Dawley; RNA, Messenger; Streptozocin; Transforming Growth Factor beta | 2015 |
Neuronal uptake of nanoformulated superoxide dismutase and attenuation of angiotensin II-dependent hypertension after central administration.
Topics: Angiotensin II; Animals; Antioxidants; Cells, Cultured; Central Nervous System; Drug Delivery Systems; Electron Spin Resonance Spectroscopy; Free Radical Scavengers; Heart Failure; Hypertension; Male; Mice; Mice, Inbred C57BL; Nanoparticles; Polyethylene Glycols; Polymers; Superoxide Dismutase; Superoxides | 2014 |
Renal sympathetic denervation suppresses ventricular substrate remodelling in a canine high-rate pacing model.
Topics: Aldosterone; Angiotensin II; Animals; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Catheter Ablation; Disease Models, Animal; Disease Progression; Dogs; Female; Fibrosis; Heart Failure; Heart Ventricles; Kidney; Male; Natriuretic Peptide, Brain; Sympathectomy; Time Factors; Transforming Growth Factor beta; Ventricular Function, Left; Ventricular Pressure; Ventricular Remodeling | 2014 |
Qishenyiqi protects ligation-induced left ventricular remodeling by attenuating inflammation and fibrosis via STAT3 and NF-κB signaling pathway.
Topics: Angiotensin II; Animals; Captopril; Drugs, Chinese Herbal; Fibrosis; Heart Failure; Heart Ventricles; Hemodynamics; Inflammation; Interleukin-6; Ligation; Male; Matrix Metalloproteinases; NADPH Oxidases; NF-kappa B; Oxidative Stress; Protective Agents; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Signal Transduction; STAT3 Transcription Factor; Ventricular Remodeling | 2014 |
Central SDF-1/CXCL12 expression and its cardiovascular and sympathetic effects: the role of angiotensin II, TNF-α, and MAP kinase signaling.
Topics: Angiotensin II; Animals; Chemokine CXCL12; Heart Failure; Hemodynamics; Male; Mitogen-Activated Protein Kinases; Paraventricular Hypothalamic Nucleus; Rats; Rats, Sprague-Dawley; Signal Transduction; Sympathetic Nervous System; Tumor Necrosis Factor-alpha | 2014 |
Effects of olmesartan therapy on the expression of lung adrenoceptors in rats with chronic heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Proliferation; Chronic Disease; Heart Failure; Imidazoles; Lung; Male; Rats; Rats, Wistar; Receptors, Adrenergic; Renin; RNA, Messenger; Tetrazoles | 2015 |
Protein kinase C promotes cardiac fibrosis and heart failure by modulating galectin-3 expression.
Topics: Angiotensin II; Animals; Cell Line; Collagen Type I; Enzyme Activation; Fibronectins; Fibrosis; Galectin 3; Heart Failure; Male; Mice; Myocardium; Protein Kinase C; Pulmonary Artery; Rats, Sprague-Dawley; Ultrasonography | 2015 |
AVP-induced increase in AQP2 and p-AQP2 is blunted in heart failure during cardiac remodeling and is associated with decreased AT1R abundance in rat kidney.
Topics: Analysis of Variance; Angiotensin II; Animals; Aquaporin 2; Deamino Arginine Vasopressin; Echocardiography; Heart Failure; Immunoblotting; Immunohistochemistry; Kidney; Rats; Receptor, Angiotensin, Type 1; Receptors, Vasopressin | 2015 |
Investigation of changes in apelin receptor mRNA and protein expression in the myocardium and aorta of rats with two-kidney, one-clip (2K1C) Goldblatt hypertension.
Topics: Angiotensin II; Animals; Aorta; Apelin; Apelin Receptors; Blood Pressure; Disease Models, Animal; Heart Failure; Heart Ventricles; Hypertension, Renovascular; Intercellular Signaling Peptides and Proteins; Kidney; Male; Myocardium; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled; Reverse Transcriptase Polymerase Chain Reaction; Surgical Instruments | 2015 |
Identification of the Vasoconstriction-Inhibiting Factor (VIF), a Potent Endogenous Cofactor of Angiotensin II Acting on the Angiotensin II Type 2 Receptor.
Topics: Adrenal Glands; Amino Acid Sequence; Angiotensin II; Animals; Cattle; Cells, Cultured; Chromogranin A; Endothelial Cells; Heart Failure; Humans; Male; MAP Kinase Signaling System; Mice; Molecular Sequence Data; p38 Mitogen-Activated Protein Kinases; Peptides; Protein Processing, Post-Translational; Rats; Rats, Inbred WKY; Rats, Sprague-Dawley; Rats, Wistar; Receptor, Angiotensin, Type 2; Renal Insufficiency, Chronic; Renin-Angiotensin System; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Vasodilation | 2015 |
Effect of angiotensin II on voltage-gated sodium currents in aortic baroreceptor neurons and arterial baroreflex sensitivity in heart failure rats.
Topics: Angiotensin II; Animals; Aorta; Arteries; Baroreflex; Chronic Disease; Disease Models, Animal; Heart Failure; Losartan; Male; Neurons; Nodose Ganglion; Pressoreceptors; Rats; Rats, Sprague-Dawley; Sodium; Voltage-Gated Sodium Channels | 2015 |
Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Collagen; Heart Failure; Humans; Myocardium; Neprilysin | 2015 |
Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in Ren-2 transgenic hypertensive rats with aorto-caval fistula.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta; Blood Pressure; Cytochrome P-450 Enzyme System; Disease Progression; Enzyme Inhibitors; Epoxide Hydrolases; Fatty Acids, Monounsaturated; Female; Fistula; Heart Failure; Heart Rate; Hemodynamics; Kidney; Male; Peptide Fragments; Rats; Rats, Transgenic; Renin; Renin-Angiotensin System; Solubility; Time Factors; Vena Cava, Inferior | 2015 |
Inhibition of soluble epoxide hydrolase does not improve the course of congestive heart failure and the development of renal dysfunction in rats with volume overload induced by aorto-caval fistula.
Topics: 8,11,14-Eicosatrienoic Acid; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzoates; Disease Models, Animal; Drug Evaluation, Preclinical; Epoxide Hydrolases; Epoxy Compounds; Heart Failure; Kidney; Male; Myocardium; Peptide Fragments; Random Allocation; Rats; Renal Insufficiency; Renin-Angiotensin System; Ultrasonography; Urea | 2015 |
[Renal sympathetic denervation suppresses ventricular substrate remodeling in a canine high-rate pacing model].
Topics: Aldosterone; Angiotensin II; Animals; Cardiac Pacing, Artificial; Dogs; Enzyme-Linked Immunosorbent Assay; Heart Failure; Heart Ventricles; Hemodynamics; Models, Animal; Natriuretic Peptide, Brain; Sympathectomy; Ventricular Remodeling | 2015 |
[Qangxin Granule Intervened Chronic Heart Failure Rats with Xin-qi Deficiency Complicated Blood Stasis and Edema Syndrome: an Experimental Study].
Topics: Angiotensin II; Animals; C-Reactive Protein; Chronic Disease; Drugs, Chinese Herbal; Edema; Heart; Heart Failure; Heart Ventricles; Medicine, Chinese Traditional; Natriuretic Peptide, Brain; Qi; Rats; Rats, Sprague-Dawley; Syndrome; Thyrotropin; Ventricular Function, Left | 2015 |
A mouse model of heart failure with preserved ejection fraction due to chronic infusion of a low subpressor dose of angiotensin II.
Topics: Angiotensin II; Animals; Blood Pressure; Disease Models, Animal; Heart Failure; Infusions, Subcutaneous; Male; Mice; Stroke Volume | 2015 |
Interleukin-10 inhibits chronic angiotensin II-induced pathological autophagy.
Topics: Angiotensin II; Animals; Animals, Newborn; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cardiomegaly; Down-Regulation; Enzyme Activation; Gene Deletion; Heart Failure; Heart Ventricles; Interleukin-10; Mechanistic Target of Rapamycin Complex 1; Mice, Inbred C57BL; Mice, Knockout; Models, Biological; Multiprotein Complexes; Myocytes, Cardiac; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Rats, Sprague-Dawley; Signal Transduction; TOR Serine-Threonine Kinases | 2015 |
Regulation of cellular oxidative stress and apoptosis by G protein-coupled receptor kinase-2; The role of NADPH oxidase 4.
Topics: Acetophenones; Adrenergic beta-Agonists; Angiotensin II; Animals; Apoptosis; Arrestins; beta-Arrestins; Cell Line; Cyclic AMP; G-Protein-Coupled Receptor Kinase 2; Heart Failure; Isoproterenol; Membrane Glycoproteins; Microscopy, Confocal; Mitochondria; Myocytes, Cardiac; NADPH Oxidase 2; NADPH Oxidase 4; NADPH Oxidases; Oxidative Stress; Phosphorylation; Rats; Reactive Oxygen Species; Receptors, Adrenergic, beta; Rhodopsin; RNA Interference; RNA, Small Interfering; Signal Transduction | 2016 |
Sympathoexcitation in Rats With Chronic Heart Failure Depends on Homeobox D10 and MicroRNA-7b Inhibiting GABBR1 Translation in Paraventricular Nucleus.
Topics: 3' Untranslated Regions; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Binding Sites; Chronic Disease; Disease Models, Animal; Gene Expression Regulation; Heart Failure; HEK293 Cells; Homeodomain Proteins; Humans; Losartan; Male; Mice; MicroRNAs; Oligonucleotides, Antisense; Paraventricular Hypothalamic Nucleus; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptors, GABA-B; RNA Interference; Sympathetic Nervous System; Transcription Factors; Transfection | 2016 |
Combination of angiotensin II and l-NG-nitroarginine methyl ester exacerbates mitochondrial dysfunction and oxidative stress to cause heart failure.
Topics: Angiotensin II; Animals; Atrial Natriuretic Factor; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiomegaly; DNA, Mitochondrial; Electron Transport Complex I; Electron Transport Complex II; Enzyme Inhibitors; Gene Expression; Heart; Heart Failure; Hydrogen Peroxide; Mice; Mitochondria, Heart; Myocardium; Natriuretic Peptide, Brain; Natriuretic Peptide, C-Type; NG-Nitroarginine Methyl Ester; Nitric Oxide; Oxidative Stress; Protein Precursors; Pyruvate Dehydrogenase Complex; Reverse Transcriptase Polymerase Chain Reaction; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Vasoconstrictor Agents | 2016 |
Mitigation of myocardial fibrosis by molecular cardiac surgery-mediated gene overexpression.
Topics: Angiotensin II; Animals; Calcium; Cardiomyopathies; Collagen; Disease Models, Animal; Enzyme Induction; Fibronectins; Fibrosis; Genetic Therapy; Heart Failure; Hemodynamics; Male; Myocardial Infarction; Myocardium; Myofibroblasts; Receptor, Angiotensin, Type 1; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Sheep; Time Factors; Transforming Growth Factor beta | 2016 |
Full Expression of Cardiomyopathy Is Partly Dependent on B-Cells: A Pathway That Involves Cytokine Activation, Immunoglobulin Deposition, and Activation of Apoptosis.
Topics: Angiotensin II; Animals; Apoptosis; B-Lymphocytes; Cardiomyopathies; Collagen; Cytokines; Disease Models, Animal; Fibroblasts; Fibrosis; Genetic Predisposition to Disease; Heart Failure; Hypertrophy, Left Ventricular; Immunoglobulin G; Magnetic Resonance Imaging; Male; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, SCID; Myocardium; NG-Nitroarginine Methyl Ester; Phenotype; Sialic Acid Binding Ig-like Lectin 2; Signal Transduction; Sodium Chloride; Stroke Volume; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2016 |
IL-10 for cardiac autophagy modulation: New direction in the pursuit of perfection.
Topics: Angiotensin II; Animals; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cardiomegaly; Gene Expression Regulation; Heart Failure; Humans; Interleukin-10; Mice; Myocardium; Myocytes, Cardiac; Proto-Oncogene Proteins c-bcl-2; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Signal Transduction; Stroke Volume | 2016 |
Nuclear accumulation of myocyte muscle LIM protein is regulated by heme oxygenase 1 and correlates with cardiac function in the transition to failure.
Topics: Angiotensin II; Animals; Female; Guinea Pigs; Heart Failure; Heme Oxygenase-1; Histone Deacetylases; LIM Domain Proteins; Muscle Proteins; Myocardium; Myocytes, Cardiac; Rats, Sprague-Dawley | 2016 |
Tripartite motif 32 prevents pathological cardiac hypertrophy.
Topics: Angiotensin II; Animals; Cardiomegaly; Cell Differentiation; Cells, Cultured; Echocardiography; Heart Failure; Humans; Male; Mice, Knockout; Myocytes, Cardiac; Signal Transduction; Transcription Factors; Tripartite Motif Proteins; Ubiquitin-Protein Ligases | 2016 |
Dual-specificity phosphatase 14 protects the heart from aortic banding-induced cardiac hypertrophy and dysfunction through inactivation of TAK1-P38MAPK/-JNK1/2 signaling pathway.
Topics: Angiotensin II; Animals; Base Sequence; Cardiomegaly; Case-Control Studies; Cells, Cultured; Dual-Specificity Phosphatases; Heart Failure; HEK293 Cells; Humans; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice, Inbred C57BL; Mice, Transgenic; Mitogen-Activated Protein Kinase Phosphatases; Molecular Sequence Data; Myocytes, Cardiac; Rats | 2016 |
Overexpression of microRNA-99a Attenuates Cardiac Hypertrophy.
Topics: Angiotensin II; Animals; Cardiomegaly; Cell Enlargement; Cells, Cultured; Disease Models, Animal; Genetic Therapy; Heart Failure; Humans; Isoproterenol; Male; Mice; Mice, Inbred C57BL; MicroRNAs; Myocytes, Cardiac; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation | 2016 |
Basigin Promotes Cardiac Fibrosis and Failure in Response to Chronic Pressure Overload in Mice.
Topics: Angiotensin II; Animals; Animals, Newborn; Aortic Diseases; Basigin; Blood Proteins; Cells, Cultured; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Fibrosis; Heart Failure; Hypertrophy, Left Ventricular; Inflammation Mediators; JNK Mitogen-Activated Protein Kinases; Male; Matrix Metalloproteinases; Mechanotransduction, Cellular; Mice, Knockout; Myocardium; Myocytes, Cardiac; Oxidative Stress; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left | 2016 |
Long Non-Coding RNA Malat-1 Is Dispensable during Pressure Overload-Induced Cardiac Remodeling and Failure in Mice.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin II; Animals; Aorta, Thoracic; Cardiomegaly; Constriction, Pathologic; Crosses, Genetic; Fetal Proteins; Gene Expression Regulation; Heart Failure; Heterozygote; Ligation; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Pressure; Proteins; RNA Splicing; RNA, Long Noncoding; Ventricular Remodeling | 2016 |
"Fibroblast" pharmacotherapy - Advancing the next generation of therapeutics for clinical cardiology.
Topics: Angiotensin II; Chymases; Fibroblasts; Heart Failure; Humans | 2016 |
Fibulin-2 is essential for angiotensin II-induced myocardial fibrosis mediated by transforming growth factor (TGF)-β.
Topics: Angiotensin II; Animals; Calcium-Binding Proteins; Cardiomegaly; Disease Models, Animal; Extracellular Matrix Proteins; Fibrosis; Heart Failure; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Models, Cardiovascular; Myocardium; Signal Transduction; Transforming Growth Factor beta1; Ventricular Remodeling | 2016 |
Simultaneous exposure to nitric oxide inhibition and angiotensin II overload: is it a murine model of mitochondrial dysfunction in nonischemic heart failure?
Topics: Angiotensin II; Animals; Disease Models, Animal; Heart Failure; Mice; Mitochondria; NG-Nitroarginine Methyl Ester; Nitric Oxide; Oxidative Stress | 2016 |
Suppressive effect of epigallocatechin-3-O-gallate on endoglin molecular regulation in myocardial fibrosis in vitro and in vivo.
Topics: Angiotensin II; Animals; Anthracenes; Catechin; Cell Proliferation; Cells, Cultured; Endoglin; Fibrosis; Heart Failure; Immunohistochemistry; JNK Mitogen-Activated Protein Kinases; Male; Models, Biological; Myocardial Infarction; Myocardium; Promoter Regions, Genetic; Protein Binding; Rats, Wistar; RNA, Small Interfering; Signal Transduction; Transcription Factor AP-1 | 2016 |
AT1-pathway inhibition in aneurysm growth and cardiac failure.
Topics: Aneurysm; Angiotensin II; Angiotensin Receptor Antagonists; Heart Failure; Humans; Myocardium; Receptor, Angiotensin, Type 1 | 2016 |
A dipeptidyl peptidase-4 inhibitor ameliorates hypertensive cardiac remodeling via angiotensin-II/sodium-proton pump exchanger-1 axis.
Topics: Angiotensin II; Animals; Blood Pressure; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Echocardiography; Heart Failure; Hypertension; Male; Myocytes, Cardiac; Pyrazoles; Rats; Rats, Inbred SHR; Signal Transduction; Sodium-Hydrogen Exchangers; Thiazolidines; Vasodilation; Ventricular Remodeling | 2016 |
Serum angiotensin-converting enzyme 2 concentration and angiotensin-(1-7) concentration in patients with acute heart failure patients requiring emergency hospitalization.
Topics: Acute Disease; Adult; Aged; Aldosterone; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Blood Pressure; Case-Control Studies; Emergencies; Female; Heart Failure; Hospitalization; Humans; Japan; Male; Middle Aged; Peptide Fragments; Peptidyl-Dipeptidase A; Regression Analysis; Renin; Renin-Angiotensin System | 2017 |
Haloperidol aggravates transverse aortic constriction-induced heart failure via mitochondrial dysfunction.
Topics: Adenosine Triphosphate; Angiotensin II; Animals; Antipsychotic Agents; Aorta; Calcium; Constriction; Haloperidol; Heart Failure; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred ICR; Mitochondria, Heart | 2016 |
p21(CIP1/WAF1)-dependent inhibition of cardiac hypertrophy in response to Angiotensin II involves Akt/Myc and pRb signaling.
Topics: Angiotensin II; Animals; Cardiomegaly; Cyclin-Dependent Kinase Inhibitor p21; Gene Expression Regulation; Heart; Heart Failure; Humans; Mice; Mice, Knockout; Oncogene Protein v-akt; Proto-Oncogene Proteins c-myc; Retinoblastoma Protein | 2016 |
Novel Protective Role for Ubiquitin-Specific Protease 18 in Pathological Cardiac Remodeling.
Topics: Analysis of Variance; Angiotensin II; Animals; Cardiomegaly; Cells, Cultured; Disease Models, Animal; Gene Expression Regulation; Heart Failure; Mice; Mice, Knockout; Myocytes, Cardiac; Random Allocation; Role; Sensitivity and Specificity; Signal Transduction; Ubiquitin Thiolesterase; Ventricular Remodeling | 2016 |
Pathological Ace2-to-Ace enzyme switch in the stressed heart is transcriptionally controlled by the endothelial Brg1-FoxM1 complex.
Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Cardiomegaly; Disease Models, Animal; DNA Helicases; Endothelial Cells; Forkhead Box Protein M1; Heart Failure; Humans; Mice; Multiprotein Complexes; Myocardium; Nuclear Proteins; Peptidyl-Dipeptidase A; Thiostrepton; Transcription Factors | 2016 |
Renin-Angiotensin System Fingerprints of Heart Failure With Reduced Ejection Fraction.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Heart Failure; Humans; Renin-Angiotensin System; Stroke Volume | 2016 |
Transient receptor potential vanilloid 2 function regulates cardiac hypertrophy via stretch-induced activation.
Topics: Adrenergic beta-Agonists; Angiotensin II; Animals; Aorta; Calcium Channels; Constriction, Pathologic; Echocardiography; Heart; Heart Failure; Hypertension; Hypertrophy, Left Ventricular; Isoproterenol; Male; Mice; Mice, Knockout; Myocytes, Cardiac; Sarcolemma; TRPV Cation Channels; Up-Regulation; Vasoconstrictor Agents | 2017 |
Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cells, Cultured; Disease Models, Animal; Diuretics; Fibroblasts; Fibrosis; Furosemide; Heart Failure; Heart Ventricles; Hydrochlorothiazide; Male; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Recovery of Function; Signal Transduction; Smad2 Protein; Stroke Volume; Transforming Growth Factor beta1; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2017 |
Effects of the Activin A-Follistatin System on Myocardial Cell Apoptosis through the Endoplasmic Reticulum Stress Pathway in Heart Failure.
Topics: Activins; Angiotensin II; Animals; Apoptosis; Biomarkers; Caspase 3; Cell Line; Disease Models, Animal; Endoplasmic Reticulum Stress; Female; Follistatin; Heart Failure; Heart Ventricles; Hemodynamics; Immunohistochemistry; Myocytes, Cardiac; Natriuretic Peptide, Brain; Rats; Signal Transduction; Transcription Factor CHOP | 2017 |
Angiotensin II Causes Apoptosis of Adult Hippocampal Neural Stem Cells and Memory Impairment Through the Action on AMPK-PGC1α Signaling in Heart Failure.
Topics: AMP-Activated Protein Kinase Kinases; Angiotensin II; Animals; Apoptosis; Cells, Cultured; Female; Heart Failure; Hippocampus; Male; Memory Disorders; Neural Stem Cells; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Protein Kinases; Rats; Rats, Sprague-Dawley; Signal Transduction | 2017 |
Cardiac Fibroblast-Specific Activating Transcription Factor 3 Protects Against Heart Failure by Suppressing MAP2K3-p38 Signaling.
Topics: Acetylation; Activating Transcription Factor 3; Angiotensin II; Animals; Binding Sites; Cells, Cultured; Disease Models, Animal; Fibroblasts; Fibrosis; Genetic Predisposition to Disease; Heart Failure; Histone Deacetylase 1; Histones; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; MAP Kinase Kinase 3; Mice, Knockout; Myocardium; p38 Mitogen-Activated Protein Kinases; Phenotype; Promoter Regions, Genetic; Protein Kinase Inhibitors; Signal Transduction; Time Factors; Transforming Growth Factor beta; Ventricular Function, Left; Ventricular Remodeling | 2017 |
A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction.
Topics: Angiotensin II; Animals; Disease Models, Animal; Heart Failure; Myocardial Infarction; Rats; Treatment Outcome; Vaccines, Subunit; Vasoconstrictor Agents | 2017 |
Selective type 1 angiotensin II receptor blockade attenuates oxidative stress and regulates angiotensin II receptors in the canine failing heart.
Topics: Aldehydes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Dogs; Echocardiography; Heart Failure; Hemodynamics; Male; Oxidative Stress; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Ventricular Dysfunction, Left; Ventricular Remodeling | 2008 |
Role of oxidant stress on AT1 receptor expression in neurons of rabbits with heart failure and in cultured neurons.
Topics: Angiotensin II; Animals; Antioxidants; Cells, Cultured; Chronic Disease; Cyclic N-Oxides; Disease Models, Animal; Heart Failure; Male; MAP Kinase Kinase 4; NADPH Oxidases; Neurons; Oxidative Stress; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Rabbits; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; RNA, Messenger; Spin Labels; Superoxides; Transcription Factor AP-1 | 2008 |
Angiotensin II-triggered p44/42 mitogen-activated protein kinase mediates sympathetic excitation in heart failure rats.
Topics: Acute Disease; Analysis of Variance; Angiotensin II; Animals; Chronic Disease; Disease Models, Animal; Flavonoids; Fluorescent Antibody Technique; Heart Failure; Hemodynamics; Immunohistochemistry; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Random Allocation; Rats; Rats, Sprague-Dawley; Signal Transduction; Sympathetic Nervous System | 2008 |
Exercise training improves peripheral chemoreflex function in heart failure rabbits.
Topics: Action Potentials; Angiotensin II; Animals; Cardiac Pacing, Artificial; Carotid Body; Chronic Disease; Citrulline; Disease Models, Animal; Enzyme Inhibitors; Exercise Therapy; Heart Failure; Hemodynamics; Hypoxia; Kidney; Male; Nitric Oxide; Nitric Oxide Synthase Type I; Physical Exertion; Rabbits; Receptor, Angiotensin, Type 1; Reflex; Signal Transduction; Sympathetic Nervous System; Thiourea | 2008 |
Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium Signaling; Cardiomyopathies; Cricetinae; Eplerenone; Heart Failure; Mineralocorticoid Receptor Antagonists; Models, Cardiovascular; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Renin-Angiotensin System; Spironolactone | 2008 |
Diuretics - a panacea for acute heart failure? Different formulations, doses, and combinations.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Heart Failure; Humans; Prospective Studies | 2008 |
The best medicine: exercise training normalizes chemosensitivity and sympathoexcitation in heart failure.
Topics: Action Potentials; Angiotensin II; Animals; Carotid Body; Chronic Disease; Exercise Therapy; Heart Failure; Hemodynamics; Humans; Kidney; Nitric Oxide; Nitric Oxide Synthase Type I; Physical Exertion; Receptor, Angiotensin, Type 1; Reflex; Signal Transduction; Sympathetic Nervous System | 2008 |
The acute and chronic effects of losartan in heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Heart Failure; Heart Rate; Humans; Losartan; Pulmonary Wedge Pressure; Renin; Treatment Outcome; Vascular Resistance | 1995 |
Use of angiotensin II antagonists in human heart failure: function of the subtype 1 receptor.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Disease Models, Animal; Down-Regulation; Heart Failure; Humans; Losartan; Myocardium; Rats; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Renin-Angiotensin System | 1995 |
Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling.
Topics: Angiotensin II; Animals; Blood Pressure; Echocardiography; Female; Heart Failure; Humans; Hypertension; Male; Mice; Mice, Transgenic; Myocytes, Cardiac; Oxidative Stress; Pregnancy; Receptor Cross-Talk; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Signal Transduction; Vasoconstrictor Agents; Ventricular Remodeling | 2008 |
Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy.
Topics: Adult; Angiotensin II; Animals; Cells, Cultured; Cytokines; ErbB Receptors; Female; Fibroblasts; Heart Failure; Heparin-binding EGF-like Growth Factor; Humans; Hypertrophy, Left Ventricular; Intercellular Signaling Peptides and Proteins; Isoproterenol; Male; Mice; Mice, Knockout; Mice, Transgenic; Middle Aged; Myocardium; Myocytes, Cardiac; Norepinephrine; Protein Interaction Mapping; Receptor, Angiotensin, Type 1; Receptor, Serotonin, 5-HT2B; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Signal Transduction; src-Family Kinases | 2009 |
Conventional therapy with an ACE inhibitor diminishes left ventricular dyssynchrony during the progression of heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Comorbidity; Disease Progression; Dogs; Heart Failure; Hemodynamics; Male; Norepinephrine; Ventricular Dysfunction, Left | 2010 |
Clinical features of and effects of angiotensin system antagonists on amiodarone-induced pulmonary toxicity.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alveolar Epithelial Cells; Amiodarone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Apoptosis; Cells, Cultured; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Logistic Models; Lung Diseases; Male; Middle Aged; Multivariate Analysis; Pulmonary Alveoli; Retrospective Studies; Risk Factors; Survival Analysis | 2010 |
Serotonin 5-HT2B receptor in cardiac fibroblast contributes to cardiac hypertrophy: a new therapeutic target for heart failure?
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cardiomegaly; Cytokines; Drug Delivery Systems; ErbB Receptors; Fibroblasts; Heart Failure; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Isoproterenol; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Mice, Transgenic; Myocardium; Rats; Receptor, Angiotensin, Type 1; Receptor, Serotonin, 5-HT2B; Serotonin 5-HT2 Receptor Antagonists; Serotonin Antagonists; Signal Transduction | 2009 |
Exercise training reduces cardiac angiotensin II levels and prevents cardiac dysfunction in a genetic model of sympathetic hyperactivity-induced heart failure in mice.
Topics: Angiotensin II; Animals; Blood Pressure; Disease Models, Animal; Heart; Heart Failure; Heart Rate; Male; Mice; Mice, Congenic; Mice, Inbred C57BL; Mice, Knockout; Models, Genetic; Myocardium; Physical Conditioning, Animal; Receptors, Adrenergic, alpha-2; Renin-Angiotensin System; Sympathetic Nervous System; Ventricular Dysfunction | 2009 |
Angiotensin II vaccine promising for patients with chronic heart failure.
Topics: Angiotensin II; Chronic Disease; Heart Failure; Humans; Renin-Angiotensin System; Vaccines | 2009 |
Long-term angiotensin II blockade may improve not only hyperglycemia but also age-associated cardiac fibrosis.
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fibrosis; Heart Failure; Hyperglycemia; Male; Myocardium; Peptidyl-Dipeptidase A; Rats; Rats, Sprague-Dawley; Tetrazoles | 2009 |
Central TNF-alpha elevates blood pressure and sensitizes to central pressor action of angiotensin II in the infarcted rats.
Topics: Angiotensin II; Animals; Blood Pressure; Brain; Heart Failure; Heart Rate; Injections, Intraventricular; Male; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Tumor Necrosis Factor-alpha | 2008 |
Endogenous angiotensin II has fewer effects but neuronal nitric oxide synthase has excitatory effects on renal sympathetic nerve activity in salt-sensitive hypertension-induced heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Brain; Citrulline; Enzyme Inhibitors; Heart Failure; Hypertension; Kidney; Losartan; Male; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Pressoreceptors; Rats; Rats, Inbred Dahl; Renin-Angiotensin System; Sodium Chloride, Dietary; Sympathetic Nervous System; Thiourea | 2009 |
Noninvasive imaging of angiotensin receptors after myocardial infarction.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Binding Sites; Biomarkers; Disease Models, Animal; Feasibility Studies; Fluorescent Dyes; Heart Failure; Losartan; Male; Mice; Microscopy, Confocal; Microscopy, Fluorescence; Microscopy, Fluorescence, Multiphoton; Microscopy, Video; Myocardial Infarction; Myocardium; Radiopharmaceuticals; Receptors, Angiotensin; Technetium; Time Factors; Tomography, Emission-Computed, Single-Photon; Ventricular Remodeling; X-Ray Microtomography | 2008 |
Angiotensin II and tumour necrosis factor alpha as mediators of ATP-dependent potassium channel remodelling in post-infarction heart failure.
Topics: Action Potentials; Angiotensin II; Animals; ATP-Binding Cassette Transporters; Cells, Cultured; Diazoxide; Forkhead Transcription Factors; Gene Expression; Heart Failure; KATP Channels; Myocardial Infarction; Myocytes, Cardiac; Patch-Clamp Techniques; Potassium Channels, Inwardly Rectifying; Rats; Receptors, Drug; RNA, Messenger; Sulfonylurea Receptors; Tumor Necrosis Factor-alpha; Ventricular Remodeling | 2009 |
Cell swelling, impulse conduction, and cardiac arrhythmias in the failing heart. Opposite effects of angiotensin II and angiotensin (1-7) on cell volume regulation.
Topics: Angiotensin I; Angiotensin II; Animals; Arrhythmias, Cardiac; Cardiomyopathies; Cell Size; Cells, Cultured; Cricetinae; Electrophysiology; Heart Conduction System; Heart Failure; Heart Ventricles; Hypotonic Solutions; Male; Membrane Potentials; Myocytes, Cardiac; Peptide Fragments; Pulse | 2009 |
Enhanced angiotensin-mediated excitation of renal sympathetic nerve activity within the paraventricular nucleus of anesthetized rats with heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Disease Models, Animal; Heart Failure; Heart Rate; Kidney; Ligation; Losartan; Male; Paraventricular Hypothalamic Nucleus; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; RNA, Messenger; Sympathetic Nervous System; Unconsciousness; Vasoconstrictor Agents | 2009 |
Aldosterone improves contractile function of adult rat ventricular cardiomyocytes in a non-acute way: potential relationship to the calcium paradox of aldosteronism.
Topics: Aldosterone; Angiotensin II; Animals; Calcium; Cell Size; Heart Failure; Hyperaldosteronism; In Vitro Techniques; Myocardial Contraction; Myocytes, Cardiac; Parathyroid Hormone; Rats; Rats, Wistar; Reactive Oxygen Species | 2010 |
Changes of renal AQP2, ENaC, and NHE3 in experimentally induced heart failure: response to angiotensin II AT1 receptor blockade.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 2; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aquaporin 2; Benzimidazoles; Biphenyl Compounds; Body Water; Epithelial Sodium Channels; Heart Failure; Kidney; Kidney Cortex; Kidney Medulla; Phosphorylation; Potassium; Rats; Rats, Wistar; Sodium; Sodium-Hydrogen Exchanger 3; Sodium-Hydrogen Exchangers; Sodium-Potassium-Chloride Symporters; Solute Carrier Family 12, Member 1; Tetrazoles; Tissue Distribution | 2009 |
Control by circulating factors of mitochondrial function and transcription cascade in heart failure: a role for endothelin-1 and angiotensin II.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Down-Regulation; Endothelin-1; Female; Heart Failure; Heat-Shock Proteins; Humans; Male; Middle Aged; Mitochondria, Heart; Oxygen Consumption; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Rats; Transcription Factors | 2009 |
[Influence of chronic cardiac failure severity on the course of comorbid type 2 diabetes mellitus].
Topics: Aged; Angiotensin II; C-Peptide; Comorbidity; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Insulin; Male; Middle Aged; Natriuretic Peptide, Brain; Norepinephrine; Retrospective Studies; Severity of Illness Index | 2009 |
Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model.
Topics: Angiotensin II; Animals; Baroreflex; Biomarkers; Blood Pressure; C-Reactive Protein; Cardiac Pacing, Artificial; Disease Models, Animal; Dogs; Female; Heart Failure; Heart Rate; Male; Norepinephrine; Stroke Volume; Sympathetic Nervous System; Systemic Inflammatory Response Syndrome; Time Factors; Vagus Nerve; Vagus Nerve Stimulation; Ventricular Function, Left | 2009 |
Downregulated Kv4.3 expression in the RVLM as a potential mechanism for sympathoexcitation in rats with chronic heart failure.
Topics: Angiotensin II; Animals; Body Weight; Chronic Disease; Disease Models, Animal; Down-Regulation; Heart Failure; Hemodynamics; Male; Medulla Oblongata; p38 Mitogen-Activated Protein Kinases; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Shal Potassium Channels; Signal Transduction; Sympathetic Nervous System | 2010 |
Circulating rather than cardiac angiotensin-(1-7) stimulates cardioprotection after myocardial infarction.
Topics: Analysis of Variance; Angiotensin I; Angiotensin II; Animals; Bone Marrow Cells; Heart Failure; Hemodynamics; Immunohistochemistry; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocytes, Cardiac; Peptide Fragments; Proto-Oncogene Proteins c-kit; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A | 2010 |
The one-two punch: knocking out angiotensin II in the heart.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Chymases; Heart Failure; Humans; Myocardium; Renin-Angiotensin System | 2010 |
High-dose versus low-dose losartan in patients with heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Heart Failure; Humans; Losartan; Myocardium; Stem Cells | 2010 |
Increased expression of calpain and elevated activity of calcineurin in the myocardium of patients with congestive heart failure.
Topics: Adult; Angiotensin II; Blotting, Western; Calcineurin; Calpain; Female; Gene Expression Profiling; Heart Failure; Humans; Male; Middle Aged; Myocardium; Radioimmunoassay; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Effect of sodium houttuyfonate on inhibiting ventricular remodeling induced by abdominal aortic banding in rats.
Topics: Aldosterone; Alkanes; Angiotensin II; Animals; Aorta, Abdominal; Blood Pressure; Collagen; Constriction; Heart Failure; Male; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Sulfites; Tumor Necrosis Factor-alpha; Ventricular Function, Left; Ventricular Remodeling | 2010 |
Furanocoumarins-imperatorin inhibits myocardial hypertrophy both in vitro and in vivo.
Topics: Angiotensin II; Animals; Cardiomegaly; Cardiovascular Agents; Cells, Cultured; Furocoumarins; Heart Failure; Molecular Structure; Myocardium; Myocytes, Cardiac; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Sprague-Dawley | 2010 |
Levosimendan improves cardiac function and survival in rats with angiotensin II-induced hypertensive heart failure.
Topics: Angiotensin II; Angiotensinogen; Animals; bcl-2-Associated X Protein; Blood Pressure; Cardiotonic Agents; Disease Models, Animal; Heart; Heart Failure; Heart Rate; Humans; Hydrazones; Hypertension; Major Histocompatibility Complex; Male; Pyridazines; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Renin; Renin-Angiotensin System; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan | 2010 |
Role of blood flow in carotid body chemoreflex function in heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Flow Velocity; Cardiac Pacing, Artificial; Carotid Arteries; Carotid Body; Chemoreceptor Cells; Constriction; Disease Models, Animal; Heart Failure; Kidney; Male; Nitric Oxide; Nitric Oxide Donors; Nitric Oxide Synthase Type I; Potassium; Rabbits; Receptor, Angiotensin, Type 1; Reflex; Regional Blood Flow; Spectrometry, Fluorescence; Sympathetic Nervous System; Time Factors; Ventricular Function, Left | 2011 |
The cardiovascular mighty mini-ruler.
Topics: Angiotensin II; Animals; Blood Flow Velocity; Carotid Arteries; Carotid Body; Disease Models, Animal; Heart Failure; Hypoxia; Nitric Oxide; Nitric Oxide Synthase Type III; Physical Conditioning, Animal; Rabbits; Reactive Oxygen Species; Regional Blood Flow; Sympathetic Nervous System | 2011 |
Enhanced susceptibility to biomechanical stress in ACE2 null mice is prevented by loss of the p47(phox) NADPH oxidase subunit.
Topics: Analysis of Variance; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Blood Pressure; Cardiomyopathy, Dilated; Disease Models, Animal; Enzyme Activation; Extracellular Matrix; Heart Failure; Male; Matrix Metalloproteinases; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardium; NADPH Oxidases; Oxidative Stress; Peptide Fragments; Peptidyl-Dipeptidase A; Phosphorylation; Stress, Mechanical; Superoxides; Time Factors; Ventricular Function, Left; Ventricular Remodeling | 2011 |
Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure.
Topics: Angiotensin II; Animals; Cardiomegaly; Catalase; DNA Damage; DNA, Mitochondrial; Gene Expression Regulation; GTP-Binding Protein alpha Subunits, Gq-G11; Heart Failure; Mice; Mice, Transgenic; Mitochondria, Heart; Models, Animal; Myocytes, Cardiac; Oxidative Stress; Reactive Oxygen Species; Reverse Transcriptase Inhibitors; Zidovudine | 2011 |
Icariin attenuates cardiac remodelling through down-regulating myocardial apoptosis and matrix metalloproteinase activity in rats with congestive heart failure.
Topics: Angiotensin II; Animals; Apoptosis; Cardiotonic Agents; Disease Models, Animal; Down-Regulation; Flavonoids; Heart Failure; Hemodynamics; Isoproterenol; Male; Matrix Metalloproteinases; Mitochondria; Myocardium; Myocytes, Cardiac; Natriuretic Peptide, Brain; Norepinephrine; Rats; Rats, Sprague-Dawley; Tumor Necrosis Factor-alpha; Ventricular Remodeling | 2011 |
Improved cardiac function after sarcoplasmic reticulum Ca(2+)-ATPase gene transfer in a heart failure model induced by chronic myocardial ischaemia.
Topics: Adenoviridae; Angiotensin II; Animals; Disease Models, Animal; Endothelin-1; Fluorescent Dyes; Gene Transfer Techniques; Genetic Therapy; Green Fluorescent Proteins; Heart Failure; Interleukin-6; Male; Myocardial Infarction; Myocardium; Natriuretic Peptide, Brain; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Stroke Volume; Swine; Swine, Miniature; Tumor Necrosis Factor-alpha | 2011 |
Mitochondrial oxidative stress mediates induction of autophagy and hypertrophy in angiotensin-II treated mouse hearts.
Topics: Angiotensin II; Animals; Autophagy; Cardiomegaly; Catalase; Heart Failure; Mice; Mitochondria, Heart; Oxidative Stress; Peroxisomes; Reactive Oxygen Species | 2011 |
Angiotensin II-induced dilated cardiomyopathy in Balb/c but not C57BL/6J mice.
Topics: Angiotensin II; Animals; Blood Pressure; Cardiomyopathy, Dilated; Collagen; Fibrosis; Heart Failure; Heart Rate; Interferon-gamma; Interleukin-4; Liver; Lung; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Phenotype; Pulmonary Atelectasis; Stroke Volume; T-Lymphocytes, Helper-Inducer; Ventricular Remodeling | 2011 |
Intracrine action of angiotensin II in the intact ventricle of the failing heart: angiotensin II changes cardiac excitability from within.
Topics: Action Potentials; Angiotensin II; Animals; Cell Separation; Cricetinae; Heart Failure; Heart Ventricles; In Vitro Techniques; Intracellular Space; Losartan; Male; Myocytes, Cardiac; Signal Transduction | 2011 |
Nuclear effects of G-protein receptor kinase 5 on histone deacetylase 5-regulated gene transcription in heart failure.
Topics: Angiotensin II; Animals; Cell Nucleus; Cytoplasm; Disease Models, Animal; G-Protein-Coupled Receptor Kinase 5; Green Fluorescent Proteins; GTP-Binding Protein alpha Subunits, Gq-G11; Heart Failure; Histone Deacetylases; Humans; Mice; Mice, Knockout; Mice, Transgenic; Phosphorylation; Sequence Analysis, RNA; Transcription, Genetic | 2011 |
Oxidized CaMKII: a "heart stopper" for the sinus node?
Topics: Angiotensin II; Animals; Apoptosis; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cell Death; Electrophysiology; Heart Diseases; Heart Failure; Humans; Mice; Models, Biological; NADPH Oxidases; Oxygen; Sinoatrial Node | 2011 |
Brain AT1 receptor activates the sympathetic nervous system through toll-like receptor 4 in mice with heart failure.
Topics: Angiotensin II; Animals; Body Weight; Brain; Brain Stem; Electrocardiography; Heart; Heart Failure; Infusions, Intraventricular; Losartan; Male; Mice; Mice, Inbred ICR; Models, Biological; Myeloid Differentiation Factor 88; Myocardial Infarction; NF-kappa B; Norepinephrine; Organ Size; Receptor, Angiotensin, Type 1; Sympathetic Nervous System; Toll-Like Receptor 4; Ventricular Dysfunction, Left | 2011 |
Decreased nNOS in the PVN leads to increased sympathoexcitation in chronic heart failure: role for CAPON and Ang II.
Topics: Adaptor Proteins, Signal Transducing; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Line, Tumor; Chronic Disease; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Inhibitors; Heart Failure; Hemodynamics; Immunohistochemistry; Kidney; Losartan; Male; Microinjections; Nitric Oxide Synthase Type I; omega-N-Methylarginine; Paraventricular Hypothalamic Nucleus; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Receptors, N-Methyl-D-Aspartate; RNA Interference; RNA, Messenger; Sympathetic Nervous System; Time Factors | 2011 |
Central angiotensin (1-7) enhances baroreflex gain in conscious rabbits with heart failure.
Topics: Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Baroreflex; Chronic Disease; Consciousness; Disease Models, Animal; Heart Failure; Heart Rate; Infusions, Intraventricular; Kidney; Male; Metoprolol; Peptide Fragments; Rabbits; Sympathetic Nervous System; Vagus Nerve | 2011 |
Serine-910 phosphorylation of focal adhesion kinase is critical for sarcomere reorganization in cardiomyocyte hypertrophy.
Topics: Angiotensin II; Animals; Animals, Newborn; Blotting, Western; Cardiomyopathy, Dilated; Cells, Cultured; Dose-Response Relationship, Drug; Endothelin-1; Enzyme Activation; Fluorescence Recovery After Photobleaching; Focal Adhesion Kinase 1; Heart Failure; Humans; Immunoprecipitation; Insulin-Like Growth Factor I; Microscopy, Fluorescence; Mutation; Myocytes, Cardiac; Paxillin; Phenylephrine; Phosphorylation; Protein Kinase C-delta; Rats; Rats, Sprague-Dawley; Recombinant Fusion Proteins; Sarcomeres; Serine; Signal Transduction; src-Family Kinases; Time Factors; Transfection | 2011 |
Inhibition of cardiac sympathetic afferent reflex and sympathetic activity by baroreceptor and vagal afferent inputs in chronic heart failure.
Topics: Angiotensin II; Animals; Blood Pressure; Capsaicin; Chronic Disease; Heart; Heart Failure; Heart Rate; Kidney; Male; Microinjections; Neurons, Afferent; Paraventricular Hypothalamic Nucleus; Pressoreceptors; Rats; Rats, Sprague-Dawley; Reflex; Sodium Chloride; Sympathetic Nervous System; Vagus Nerve | 2011 |
Brain-selective overexpression of angiotensin-converting enzyme 2 attenuates sympathetic nerve activity and enhances baroreflex function in chronic heart failure.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Baroreflex; Enzyme Induction; Heart Failure; Humans; Male; Medulla Oblongata; Mice; Mice, Knockout; Myocardial Ischemia; Nerve Tissue Proteins; Nitric Oxide; Norepinephrine; Organ Specificity; Peptide Fragments; Peptidyl-Dipeptidase A; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptors, Angiotensin; Receptors, G-Protein-Coupled; Recombinant Fusion Proteins; Reflex, Abnormal; Sympathetic Nervous System | 2011 |
High free fatty acids level related with cardiac dysfunction in obese rats.
Topics: Angiotensin II; Animals; Biomarkers; Diet, High-Fat; Fatty Acids, Nonesterified; Fenofibrate; Heart Failure; Immunohistochemistry; Male; Myocardial Contraction; Myocardium; NF-kappa B; Nitric Oxide Synthase Type II; Obesity; Random Allocation; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Triglycerides | 2012 |
Loss of receptor activity-modifying protein 3 exacerbates cardiac hypertrophy and transition to heart failure in a sex-dependent manner.
Topics: Angiotensin II; Animals; Cardiomegaly; Cardiovascular Diseases; Disease Models, Animal; Female; Gene Expression; Gene Expression Profiling; Gene Knockout Techniques; Genetic Association Studies; Heart Failure; Hypertension; Hypertrophy, Right Ventricular; Kidney Diseases; Male; Mice; Mice, Knockout; Phenotype; Proto-Oncogene Proteins c-akt; Receptor Activity-Modifying Protein 3; Renin; Sex Factors | 2012 |
Involvement of autophagy in cardiac remodeling in transgenic mice with cardiac specific over-expression of human programmed cell death 5.
Topics: Angiotensin II; Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Cardiomegaly; Cardiomyopathy, Dilated; Heart Failure; Humans; Mice; Mice, Transgenic; Myocardium; Myosin Heavy Chains; Neoplasm Proteins; Organ Specificity; Survival Analysis; Ultrasonography; Up-Regulation; Ventricular Remodeling | 2012 |
Abnormal baroreflex function is dissociated from central angiotensin II receptor expression in chronic heart failure.
Topics: Angiotensin II; Animals; Baroreflex; Heart Failure; Hemodynamics; Kidney; Male; Membrane Glycoproteins; NADPH Oxidases; Rabbits; Receptor, Angiotensin, Type 1; Sympathetic Nervous System | 2012 |
Time course of hydrogen peroxide-thioredoxin balance and its influence on the intracellular signalling in myocardial infarction.
Topics: Angiotensin II; Animals; Antioxidants; Apoptosis Regulatory Proteins; Glutathione Disulfide; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Heart; Heart Failure; Hydrogen Peroxide; Male; MAP Kinase Kinase 4; MAP Kinase Signaling System; Myocardial Infarction; Myocardium; Oxidative Stress; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Signal Transduction; Thioredoxins; TOR Serine-Threonine Kinases; Ventricular Remodeling | 2012 |
The role of renin angiotensin system intervention in stage B heart failure.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetic Angiopathies; Heart Failure; Humans; Myocardial Infarction; Myocardial Ischemia; Renin-Angiotensin System; Signal Transduction; Stroke Volume; Ventricular Dysfunction, Left | 2012 |
Differential regulation of EHD3 in human and mammalian heart failure.
Topics: Angiotensin II; Animals; Carrier Proteins; Case-Control Studies; Cells, Cultured; Dogs; Gene Expression Regulation; Heart Failure; Heart Ventricles; Humans; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; NADPH Oxidases; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Sodium-Calcium Exchanger | 2012 |
Differential effects of high-fat diet on myocardial lipid metabolism in failing and nonfailing hearts with angiotensin II-mediated cardiac remodeling in mice.
Topics: Angiotensin II; Angiotensinogen; Animals; Diet, High-Fat; Dietary Fats; Fatty Acids; Heart Failure; Hypertrophy, Left Ventricular; Lipid Metabolism; Male; Mice; Mice, Transgenic; Models, Animal; Myocardial Contraction; Myocardium; Oxidation-Reduction; Palmitates; Triglycerides; Ventricular Remodeling | 2012 |
Angiotensin II and oxidative stress in the failing heart.
Topics: Angiotensin II; Animals; Cardiovascular Diseases; Heart Failure; Humans; Mitochondria; NADPH Oxidases; Oxidative Stress; Reactive Oxygen Species; Renin-Angiotensin System | 2013 |
Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and β-receptor blockade.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin II; Animals; Apoptosis; Benzazepines; Cyclic Nucleotide-Gated Cation Channels; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Heart Failure; Heart Rate; Immunohistochemistry; In Situ Nick-End Labeling; Ivabradine; Male; Metoprolol; Mice; Mice, Inbred C57BL; Multivariate Analysis; Random Allocation; Sensitivity and Specificity; Statistics, Nonparametric; Tachycardia; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Remodeling | 2012 |
Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cells, Cultured; Disease Models, Animal; Drug Therapy, Combination; Heart Failure; Hemodynamics; Imidazoles; Lipid Peroxidation; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardium; NADPH Oxidases; Oxidative Stress; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Spironolactone; Tetrazoles; Ventricular Function, Left | 2012 |
[Hypertension-induced fibrosis: a balance story].
Topics: Aldosterone; Angiotensin II; Animals; Bone Morphogenetic Proteins; Cardiomegaly; Disease Models, Animal; Fibrosis; Gene Expression Regulation; Heart Failure; Hypertension; Male; Mice; Mice, Transgenic; Myocytes, Cardiac; Natriuretic Peptide, Brain; Renin; Renin-Angiotensin System | 2012 |
Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fraction.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cardiomegaly; Cyclin-Dependent Kinases; E2F Transcription Factors; Energy Metabolism; Glucose; Heart Failure; Male; Mice; Mice, Inbred C57BL; Myocardium; Oxidation-Reduction; Phenylephrine; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Receptor, Angiotensin, Type 1; Receptors, Adrenergic, alpha; Retinoblastoma Protein; Signal Transduction; Stroke Volume; Time Factors; Ultrasonography; Ventricular Function | 2012 |
Exercise training normalizes enhanced sympathetic activation from the paraventricular nucleus in chronic heart failure: role of angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Heart Failure; Heart Rate; Kidney; Losartan; Neurons; Paraventricular Hypothalamic Nucleus; Physical Conditioning, Animal; Rats; Sympathetic Nervous System | 2012 |
Impaired JAK2-induced activation of STAT3 in failing human myocytes.
Topics: Angiotensin II; Blotting, Western; Cells, Cultured; Enzyme Inhibitors; Heart Failure; Humans; Interleukin-6; Janus Kinase 2; Muscle Cells; Phosphorylation; Signal Transduction; STAT3 Transcription Factor; Tyrphostins | 2012 |
Parallel changes in neuronal AT1R and GRK5 expression following exercise training in heart failure.
Topics: Angiotensin II; Animals; Cells, Cultured; Chronic Disease; Disease Models, Animal; G-Protein-Coupled Receptor Kinase 5; Heart Failure; Male; Medulla Oblongata; Neurons; NF-kappa B; Paraventricular Hypothalamic Nucleus; Physical Conditioning, Animal; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Up-Regulation | 2012 |
Microcirculatory effects of angiotensin II inhibitors in patients with severe heart failure.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Female; Heart Failure; Humans; Male; Microcirculation; Middle Aged; Prospective Studies; Renin-Angiotensin System | 2013 |
Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Apoptosis; Cyclic GMP-Dependent Protein Kinase Type I; Cyclic Nucleotide Phosphodiesterases, Type 5; Cytokines; Extracellular Matrix; Heart Failure; Heart Function Tests; Hydralazine; Male; Mice; Mice, Inbred C57BL; Myocarditis; Myocardium; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Sildenafil Citrate; Sulfones; Vasoconstrictor Agents; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2012 |
Proteasome inhibition attenuates heart failure during the late stages of pressure overload through alterations in collagen expression.
Topics: Angiotensin II; Animals; Cells, Cultured; Collagen; Disease Models, Animal; Down-Regulation; Fibrosis; Heart Failure; Heart Ventricles; Hypertension; Leupeptins; Male; Proteasome Inhibitors; Random Allocation; Rats; Rats, Sprague-Dawley; RNA, Messenger; Severity of Illness Index; Signal Transduction; Transforming Growth Factor beta1; Ubiquitin; Ventricular Dysfunction, Left | 2013 |
Inhibition of cyclooxygenase-2 reduces hypothalamic excitation in rats with adriamycin-induced heart failure.
Topics: Angiotensin II; Animals; Atrial Natriuretic Factor; Corticotropin-Releasing Hormone; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Doxorubicin; Heart Failure; Hypothalamus; Myocardium; Neurotransmitter Agents; Norepinephrine; Paraventricular Hypothalamic Nucleus; Rats | 2012 |
Bone morphogenetic protein-4 mediates cardiac hypertrophy, apoptosis, and fibrosis in experimentally pathological cardiac hypertrophy.
Topics: Angiotensin II; Animals; Apoptosis; Bone Morphogenetic Protein 4; Cardiomegaly; Fibrosis; Heart Failure; Humans; Mice; Myocardium; Myocytes, Cardiac; Physical Conditioning, Animal; Reactive Oxygen Species | 2013 |
Metastasis-associated protein, S100A4 mediates cardiac fibrosis potentially through the modulation of p53 in cardiac fibroblasts.
Topics: Angiotensin II; Animals; Cell Proliferation; Collagen; Connective Tissue Growth Factor; Fibrosis; Gene Expression Regulation; Gene Knockout Techniques; Heart Failure; Heart Ventricles; Hypertrophy, Left Ventricular; Male; Mice; Mice, Knockout; Myofibroblasts; Natriuretic Peptide, Brain; NIH 3T3 Cells; Rats; Rats, Inbred Dahl; S100 Calcium-Binding Protein A4; S100 Proteins; Transcriptome; Tumor Suppressor Protein p53 | 2013 |
Central AT1 receptors are involved in the enhanced cardiac sympathetic afferent reflex in rats with chronic heart failure.
Topics: Anesthetics, Local; Angiotensin II; Animals; Anti-Arrhythmia Agents; Bradykinin; Capsaicin; Heart Failure; Heart Ventricles; Hemodynamics; Injections, Intravenous; Injections, Intraventricular; Lidocaine; Ligation; Losartan; Male; Myocardial Infarction; Myocardium; Neurons, Afferent; Organ Size; Pericardium; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Reflex; Renin; Sympathetic Nervous System; Ventricular Function | 2002 |
[Gene expression of Ang II receptors in myocardium in congestive heart failure].
Topics: Adult; Aged; Angiotensin II; Female; Gene Expression; Heart Failure; Humans; Male; Middle Aged; Myocardium; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; RNA, Messenger | 2002 |
L-Carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure.
Topics: Angiotensin II; Animals; Apoptosis; Carnitine; Caspase 3; Caspase 9; Caspases; Cell Nucleus; Cells, Cultured; Cytoprotection; Disease Models, Animal; Disease Progression; Drug Evaluation, Preclinical; Glucose Transporter Type 4; Heart Failure; In Situ Nick-End Labeling; Liver Function Tests; Male; Monocrotaline; Monosaccharide Transport Proteins; Muscle Proteins; Muscle, Skeletal; Muscular Disorders, Atrophic; Myosin Heavy Chains; Protein Isoforms; Rats; Rats, Sprague-Dawley; Sphingolipids; Staurosporine; Tumor Necrosis Factor-alpha | 2002 |
[Addition of an angiotensin II receptor blocker to maximal dose of ACE inhibitors in heart failure].
Topics: Adult; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Antihypertensive Agents; Data Interpretation, Statistical; Echocardiography; Female; Heart Failure; Hemodynamics; Humans; Losartan; Male; Middle Aged; Oxygen Consumption; Time Factors; Ventricular Dysfunction, Left | 2002 |
Parathyroid hormone-related protein is produced in the myocardium and increased in patients with congestive heart failure.
Topics: Adult; Angiotensin II; Aorta; Atrial Natriuretic Factor; Coronary Vessels; Diastole; Echocardiography; Endothelin-1; Female; Heart Failure; Hemodynamics; Humans; Male; Myocardium; Natriuretic Peptide, Brain; Norepinephrine; Parathyroid Hormone-Related Protein; Peptide Fragments; Protein Biosynthesis; Proteins; Stroke Volume; Systole; Ventricular Function, Left | 2002 |
Impaired responsiveness of renal mechanosensory nerves in heart failure: role of endogenous angiotensin.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Dinoprostone; Heart Failure; Kidney; Losartan; Male; Models, Animal; Natriuresis; Neurons, Afferent; Pressure; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Sodium; Sodium, Dietary; Substance P | 2003 |
Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Female; Heart Failure; Humans; Male; Middle Aged; Quality of Life; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2002 |
Angiotensin receptor blockers in heart failure: a work in progress.
Topics: Angiotensin II; Heart Failure; Humans; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan | 2002 |
Tissue angiotensin II during progression or ventricular hypertrophy to heart failure in hypertensive rats; differential effects on PKC epsilon and PKC beta.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Disease Progression; Echocardiography; Enzyme Activation; Heart Failure; Hypertension; Male; Myocardium; Organ Size; Protein Kinase C; Protein Kinase C beta; Protein Kinase C-epsilon; Protein Transport; Rats; Rats, Inbred Dahl; Stress, Mechanical; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2002 |
Angiotensin II and oxidative stress in Dahl Salt-sensitive rat with heart failure.
Topics: Albuminuria; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blotting, Western; Disease Models, Animal; Gene Expression; Heart Failure; Heart Ventricles; Hydrogen Peroxide; Imidazoles; Imidazolidines; Kidney; Male; NADPH Oxidases; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Oxidative Stress; Phosphoproteins; Rats; Rats, Inbred Dahl; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2002 |
Inhaled nitric oxide modifies left ventricular diastolic stress in the presence of vasoactive agents in heart failure.
Topics: Acetylcholine; Administration, Inhalation; Angiotensin II; Animals; Diastole; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Female; Heart Failure; Hemodynamics; Infusions, Intravenous; Isoproterenol; Male; Nitric Oxide; Nitroglycerin; Norepinephrine; Procainamide; Pulmonary Circulation; Random Allocation; Stroke Volume; Vascular Resistance; Vasoconstrictor Agents; Vasodilator Agents; Ventricular Function, Left | 2003 |
How to induce severe electrolyte disturbances in the elderly?
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzothiadiazines; Calcium Channel Blockers; Data Collection; Diuretics; Drug Resistance; Drug Therapy, Combination; Female; Heart Failure; Humans; Hypertension; Hypokalemia; Hyponatremia; Male; Middle Aged; Practice Guidelines as Topic; Prognosis; Risk Factors; Sex Factors; Sodium Chloride Symporter Inhibitors; Time Factors | 2002 |
Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure.
Topics: Aldosterone; Angiotensin II; Animals; Cardiac Output; Cardiac Pacing, Artificial; Disease Models, Animal; Dogs; Drug Evaluation, Preclinical; Glomerular Filtration Rate; Guanylate Cyclase; Heart; Heart Failure; Heart Function Tests; Hemodynamics; Injections, Intravenous; Kidney; Kidney Function Tests; Male; Nitroglycerin; Pyrazoles; Pyridines; Receptors, Cytoplasmic and Nuclear; Renin; Renin-Angiotensin System; Soluble Guanylyl Cyclase | 2003 |
Decreased facilitation by angiotensin II of noradrenergic neurotransmission in isolated mesenteric artery of rabbits with chronic heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Chronic Disease; Electric Stimulation; Heart Failure; In Vitro Techniques; Male; Mesenteric Arteries; Neural Inhibition; Norepinephrine; Rabbits; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Synaptic Transmission; Vasoconstriction | 2003 |
Urinary aquaporin-2 in healthy humans and patients with liver cirrhosis and chronic heart failure during baseline conditions and after acute water load.
Topics: Adult; Aldosterone; Angiotensin II; Aquaporin 2; Aquaporin 6; Aquaporins; Arginine Vasopressin; Atrial Natriuretic Factor; Chronic Disease; Drinking; Female; Heart Failure; Humans; Liver Cirrhosis; Male; Middle Aged; Natriuretic Peptide, Brain; Osmolar Concentration; Renin; Urine; Water-Electrolyte Balance | 2003 |
Are angiotensin II receptor antagonists indicated in chronic heart failure?
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Losartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Hypoxia, angiotensin-II, and norepinephrine mediated apoptosis is stimulus specific in canine failed cardiomyocytes: a role for p38 MAPK, Fas-L and cyclin D1.
Topics: Angiotensin II; Animals; Apoptosis; Cyclin D1; Disease Models, Animal; Dogs; Fas Ligand Protein; Follow-Up Studies; Heart Failure; Hypoxia; Incidence; Membrane Glycoproteins; Mitogen-Activated Protein Kinases; Models, Cardiovascular; Myocytes, Cardiac; Norepinephrine; p38 Mitogen-Activated Protein Kinases | 2003 |
Patterns of pharmacotherapy in patients hospitalised for congestive heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cohort Studies; Diuretics; Drug Utilization Review; Female; Fibrinolytic Agents; Follow-Up Studies; Heart Failure; Hospitalization; Humans; Male; Netherlands; Nitrates; Practice Guidelines as Topic; Treatment Outcome | 2003 |
Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure.
Topics: Angiotensin II; Animals; Chymases; Collagen Type I; Collagen Type III; Diastole; Disease Models, Animal; Disease Progression; Dogs; Enzyme Inhibitors; Fibrosis; Heart Failure; Hemodynamics; Mast Cells; Myocardium; Peptidyl-Dipeptidase A; RNA, Messenger; Serine Endopeptidases; Transforming Growth Factor beta; Ventricular Dysfunction, Left | 2003 |
Role for chymase in heart failure: angiotensin II-dependent or -independent mechanisms?
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Chymases; Disease Models, Animal; Dogs; Enzyme Inhibitors; Extracellular Space; Heart Failure; Humans; In Vitro Techniques; Mast Cells; Mice; Myocardium; Peptidyl-Dipeptidase A; Serine Endopeptidases; Transforming Growth Factor beta | 2003 |
Losartan corrects abnormal frequency response of renal vasculature in congestive heart failure.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Heart Failure; Kidney; Losartan; Male; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renal Circulation; Sympathetic Nervous System; Vasoconstrictor Agents | 2003 |
Myogenic constriction is increased in mesenteric resistance arteries from rats with chronic heart failure: instantaneous counteraction by acute AT1 receptor blockade.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Captopril; Chronic Disease; Coronary Vessels; Disease Models, Animal; Endothelium-Dependent Relaxing Factors; Endothelium, Vascular; Fatty Acids, Unsaturated; Heart; Heart Failure; Hydrazines; Imidazoles; Indomethacin; Lisinopril; Losartan; Male; Mesenteric Arteries; Nitric Oxide; omega-N-Methylarginine; Pyridines; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Superoxide Dismutase; Sympathetic Nervous System; Tetrazoles; Tetrodotoxin; Vascular Resistance | 2003 |
Expression of bradykinin receptors in the left ventricles of rats with pressure overload hypertrophy and heart failure.
Topics: Angiotensin II; Animals; Aorta; Blood Pressure; Disease Models, Animal; Echocardiography; Fibrosis; Gene Expression; Heart Failure; Hypertrophy, Left Ventricular; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Bradykinin B2; Receptors, Bradykinin; RNA, Messenger; Vasoconstrictor Agents | 2003 |
REDUCED VASCULAR RESPONSE TO ANGIOTENSIN II IN SECONDARY HYPERALDOSTERONISM.
Topics: Angiotensin II; Angiotensins; Blood Pressure; Heart Failure; Humans; Hyperaldosteronism; Liver Cirrhosis; Nephrotic Syndrome; Pharmacology | 1963 |
Hormones and the pathogenesis of congestive heart failure: vasopressin, aldosterone, and angiotensin II. Further evidence for renal-adrenal interaction from studies in hypertension and in cirrhosis.
Topics: Aldosterone; Angiotensin Amide; Angiotensin II; Heart Defects, Congenital; Heart Failure; Humans; Hypertension; Kidney; Vasopressins | 1962 |
Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction.
Topics: Angiotensin II; Animals; Chemokine CCL2; Cytokines; Disease Models, Animal; Disease Progression; Gene Expression Regulation; Genetic Therapy; Heart Failure; Humans; Immunohistochemistry; Male; Matrix Metalloproteinases; Mice; Muscle, Skeletal; Myocardial Infarction; Myocardium; Sequence Deletion; Survival Rate; Tumor Necrosis Factor-alpha; Ventricular Dysfunction, Left; Ventricular Remodeling | 2003 |
Reinduction of T-type calcium channels by endothelin-1 in failing hearts in vivo and in adult rat ventricular myocytes in vitro.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Bosentan; Calcium Channels, T-Type; Cells, Cultured; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Heart Ventricles; Male; Myocytes, Cardiac; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; Sulfonamides | 2003 |
Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Atrial Fibrillation; bcl-2-Associated X Protein; Biomarkers; Cardiac Pacing, Artificial; Caspase 3; Caspases; DNA Fragmentation; Dogs; Enalapril; Heart Atria; Heart Failure; In Situ Nick-End Labeling; Mitogen-Activated Protein Kinase Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2 | 2003 |
Nitric oxide's role in heart failure: pathophysiology and treatment. Introduction.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Black or African American; Heart Failure; Humans; Nitric Oxide; Ventricular Remodeling | 2003 |
Impaired neuronal and vascular responses to angiotensin II in a rabbit congestive heart failure model.
Topics: Acrylates; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Dose-Response Relationship, Drug; Electric Stimulation; Heart Failure; Imidazoles; In Vitro Techniques; Male; Osmolar Concentration; Rabbits; Sympathetic Nervous System; Thiophenes | 2003 |
Valsartan restores sarcoplasmic reticulum function with no appreciable effect on resting cardiac function in pacing-induced heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium Signaling; Calcium-Transporting ATPases; Cardiac Pacing, Artificial; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dobutamine; Dogs; Drug Evaluation, Preclinical; Heart Failure; Myocardial Contraction; Norepinephrine; Phosphorylation; Protein Processing, Post-Translational; Receptors, Adrenergic, beta; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum; Tachycardia, Ventricular; Tacrolimus Binding Proteins; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2004 |
Effect of exercise on natriuretic peptides in plasma and urine in chronic heart failure.
Topics: Angiotensin II; Aquaporin 2; Aquaporins; Arginine Vasopressin; Atrial Natriuretic Factor; Case-Control Studies; Exercise; Exercise Test; Exercise Tolerance; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Natriuretic Peptide, C-Type; Osmolar Concentration; Radioimmunoassay | 2004 |
Angiotensin AT2 receptor: the younger sibling attracts attention.
Topics: Action Potentials; Angiotensin II; Animals; Heart Failure; Humans; Hypertrophy, Left Ventricular; Myocardium; Receptor, Angiotensin, Type 2 | 2004 |
Dynamic 123I-BMIPP single-photon emission computed tomography in patients with congestive heart failure: effect of angiotensin II type-1 receptor blockade.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Case-Control Studies; Fatty Acids; Female; Heart Failure; Humans; Iodine Radioisotopes; Iodobenzenes; Male; Middle Aged; Receptor, Angiotensin, Type 1; Time Factors; Tomography, Emission-Computed, Single-Photon | 2004 |
[Effects of shenqifuxin oral liquid on the plasma kaliuretic peptide, the myocardial contractility and relaxation of left ventricle and the left ventricular remodeling in experimental rats with heart failure].
Topics: Administration, Oral; Angiotensin II; Animals; Astragalus propinquus; Atrial Natriuretic Factor; Cardiotonic Agents; Drug Combinations; Drugs, Chinese Herbal; Endothelins; Heart Failure; Male; Myocardial Contraction; Ophiopogon; Panax; Plants, Medicinal; Protein Precursors; Rats; Rats, Sprague-Dawley; Ventricular Function, Left; Ventricular Remodeling | 2003 |
Remodeling of the chronic severely failing ischemic sheep heart after coronary microembolization: functional, energetic, structural, and cellular responses.
Topics: Aldosterone; Angiotensin II; Animals; Atrial Natriuretic Factor; Caspase 2; Caspase 3; Caspase 8; Caspases; Chronic Disease; Collagen; Coronary Vessels; Embolism; Extracellular Matrix; Fas Ligand Protein; Female; Heart Failure; Male; Membrane Glycoproteins; Microcirculation; Microspheres; Myocardial Contraction; Myocardial Ischemia; Myocardium; Severity of Illness Index; Sheep; Stroke Volume; Ventricular Remodeling | 2004 |
Defining "culprit mechanisms" in arrhythmogenic cardiac remodeling.
Topics: Angiotensin II; Animals; Arrhythmias, Cardiac; Atrial Fibrillation; Dogs; Fibrosis; Heart Atria; Heart Failure; Humans; Mice; Mice, Transgenic; Models, Animal; Myocardium; Transforming Growth Factor beta; Transforming Growth Factor beta1; Ventricular Remodeling | 2004 |
Left ventricular reconstruction: the aim and the reality after twenty years.
Topics: Angiotensin II; Biomarkers; Cardiac Surgical Procedures; Cardiomyopathies; Heart Failure; Heart Ventricles; Humans; Myocardial Ischemia; Natriuretic Peptide, Brain; Neurotransmitter Agents; Norepinephrine; Renin; Stroke Volume; Ventricular Function, Left | 2004 |
Neurohormonal response to left ventricular reconstruction surgery in ischemic cardiomyopathy.
Topics: Aged; Angiotensin II; Biomarkers; Cardiac Surgical Procedures; Cardiomyopathies; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Male; Middle Aged; Myocardial Ischemia; Natriuretic Peptide, Brain; Neurotransmitter Agents; Norepinephrine; Renin; Statistics as Topic; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2004 |
Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure.
Topics: Angiotensin II; Animals; Apoptosis; Blotting, Western; Cardiac Pacing, Artificial; Cell Death; Dogs; Fibrosis; Heart Atria; Heart Failure; Heart Ventricles; Humans; Leukocytes; Mitogen-Activated Protein Kinases; Transforming Growth Factor beta; Ventricular Remodeling | 2004 |
[Neurohormonal activation in congestive heart failure: does it normalize after heart transplantation?].
Topics: Adult; Aged; Angiotensin II; Atrial Natriuretic Factor; Endothelins; Female; Heart Failure; Heart Transplantation; Humans; Male; Middle Aged; Neurosecretory Systems; Neurotransmitter Agents; Renin-Angiotensin System; Treatment Outcome; Vasoconstrictor Agents | 2004 |
Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aortic Valve Stenosis; Apoptosis; Cardiomegaly; Cells, Cultured; Disease Models, Animal; Disease Progression; Endoplasmic Reticulum; Gene Expression Regulation; Heart Failure; Humans; Imidazoles; Ligation; Male; Mice; Mice, Inbred C57BL; Molecular Chaperones; Myocytes, Cardiac; Natriuretic Peptide, Brain; Olmesartan Medoxomil; Rats; Rats, Inbred WKY; RNA, Messenger; Signal Transduction; Stress, Physiological; Tetrazoles; Thapsigargin; Tunicamycin | 2004 |
Unequal effects of renin-angiotensin system inhibitors in acute cardiac dysfunction induced by isoproterenol.
Topics: Acute Disease; Aldosterone; Angiotensin II; Animals; Atrial Natriuretic Factor; Dogs; Dose-Response Relationship, Drug; Female; Heart Failure; Isoproterenol; Lipid Peroxidation; Male; Receptors, Adrenergic, beta; Renin; Renin-Angiotensin System; Sympathomimetics; Ventricular Function, Left | 2004 |
Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Atrial Natriuretic Factor; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Collagen Type I; Disease Models, Animal; DNA-Binding Proteins; Enzyme Activation; Enzyme Inhibitors; Fibrosis; Heart Failure; Homozygote; Hypertrophy, Left Ventricular; Imidazoles; Immunohistochemistry; Male; Mitogen-Activated Protein Kinases; Myocardium; Protein-Tyrosine Kinases; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Renin; Smad Proteins; Tetrazoles; Time Factors; Trans-Activators; Tyrphostins | 2004 |
Mechanisms of heart failure with well preserved ejection fraction in dogs following limited coronary microembolization.
Topics: Angiotensin II; Animals; Blood Volume; Dogs; Echocardiography; Heart Failure; Hemodynamics; Microcirculation; Myocardial Infarction; Natriuretic Peptide, Brain; Phosphopyruvate Hydratase; Time Factors; Ventricular Function | 2004 |
Changes in skeletal muscle SR Ca2+ pump in congestive heart failure due to myocardial infarction are prevented by angiotensin II blockade.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Calcium; Calcium-Transporting ATPases; Captopril; Cyclic AMP-Dependent Protein Kinases; Enalapril; Heart Failure; Imidazolidines; Losartan; Male; Muscle, Skeletal; Muscular Atrophy; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Sarcoplasmic Reticulum; Time Factors | 2004 |
Superoxide mediates sympathoexcitation in heart failure: roles of angiotensin II and NAD(P)H oxidase.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Ditiocarb; Heart Failure; Heart Rate; Injections, Intraventricular; Kidney; Losartan; Male; Medulla Oblongata; NADPH Oxidases; Protein Subunits; Rabbits; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; RNA, Messenger; Superoxides; Sympathetic Nervous System; Tachycardia, Ventricular; Telemetry | 2004 |
[Effect of fosinopril on the rate of neurohumoral and proinflammatory activation in patients with heart failure].
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; C-Reactive Protein; Data Interpretation, Statistical; Echocardiography; Fosinopril; Heart Failure; Humans; Immunoenzyme Techniques; Middle Aged; Natriuretic Peptide, Brain; Radioimmunoassay; Time Factors; Tumor Necrosis Factor-alpha | 2004 |
Inhibition of catecholamine-induced cardiac fibrosis by an aldosterone antagonist.
Topics: Adrenergic beta-Agonists; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Canrenoic Acid; Fibrosis; Heart Failure; Isoproterenol; Losartan; Male; Mineralocorticoid Receptor Antagonists; Myocardial Infarction; Myocardium; Rats; Rats, Wistar; Receptors, Adrenergic, beta | 2005 |
Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting.
Topics: Angiotensin II; Animals; Cachexia; Heart Failure; Insulin-Like Growth Factor I; Male; Mice; Mice, Transgenic; Muscle Proteins; Muscle, Skeletal; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; SKP Cullin F-Box Protein Ligases; TOR Serine-Threonine Kinases; Tripartite Motif Proteins; Ubiquitin-Protein Ligases; Vasoconstrictor Agents; Wasting Syndrome | 2005 |
Hyperglycemia activates JAK2 signaling pathway in human failing myocytes via angiotensin II-mediated oxidative stress.
Topics: Angiotensin II; Animals; Female; Heart; Heart Failure; Humans; Janus Kinase 2; Kinetics; Male; Middle Aged; Muscle Cells; Oxidative Stress; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Rats; Signal Transduction; Tissue Donors | 2005 |
Activation of calcineurin in human failing heart ventricle by endothelin-1, angiotensin II and urotensin II.
Topics: Adult; Angiotensin II; Blotting, Western; Calcineurin; Endothelin-1; Female; Heart Failure; Heart Ventricles; Humans; In Vitro Techniques; Male; Middle Aged; Myocardial Contraction; Peptides; Phosphates; Protein Kinase C; Tacrolimus; Urotensins | 2005 |
Clinical implications of an accurate problem list on heart failure treatment.
Topics: Aged; Aged, 80 and over; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Community Health Centers; Cross-Sectional Studies; Drug Utilization Review; Evidence-Based Medicine; Female; Heart Failure; Humans; Logistic Models; Male; Medical Records, Problem-Oriented; Middle Aged; Oregon; Practice Patterns, Physicians'; Retrospective Studies | 2005 |
Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Angiotensin II; Animals; Apoptosis; Case-Control Studies; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Enzyme Inhibitors; Heart Failure; Heart Ventricles; Humans; Isoproterenol; Mice; Myocytes, Cardiac | 2005 |
Angiotensin II and cell-matrix adhesion: PKCepsilon is essential.
Topics: Angiotensin II; Cell Adhesion; Cell-Matrix Junctions; Collagen; Heart Failure; Humans; Integrin beta1; Myocardium; Signal Transduction; Ventricular Remodeling | 2005 |
[Calpain involved in signal transduction of myocardial remodeling in patients with congestive heart failure].
Topics: Adaptor Proteins, Signal Transducing; Adult; Angiotensin II; Calcineurin; Calpain; Female; Heart Failure; Humans; Male; Middle Aged; Myocardium; Signal Transduction; Ventricular Remodeling | 2005 |
Protein kinase C epsilon mediates angiotensin II-induced activation of beta1-integrins in cardiac fibroblasts.
Topics: Angiotensin II; Animals; Blotting, Western; Cell Adhesion; Cell-Matrix Junctions; Collagen; Enzyme Activation; Fluorescent Antibody Technique; Heart Failure; Integrin beta1; Mice; Mice, Knockout; Models, Animal; Myocytes, Cardiac; Phosphorylation; Rats; Rats, Sprague-Dawley; Ventricular Remodeling | 2005 |
Angiotensin II, but not aldosterone and renin, correlates positively with increased concentrations of N-terminal pro-brain natriuretic peptide in patients with chronic heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Biomarkers; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Renin | 2005 |
[Effect of the polymorphism of the angiotensin-converting enzyme gene on the plasma angiotensin II levels and the risk of chronic heart failure].
Topics: Adolescent; Adult; Aged; Alleles; Angiotensin II; Female; Genotype; Heart Failure; Humans; Male; Middle Aged; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Risk Factors | 2004 |
Risk-treatment mismatch in the pharmacotherapy of heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Drug Utilization; Female; Heart Failure; Humans; Male; Middle Aged; Ontario; Risk; Survival Analysis | 2005 |
A positive feedback loop contributes to the deleterious effects of angiotensin.
Topics: Angiotensin II; Apoptosis; Feedback, Physiological; Heart Failure; Humans; Models, Biological | 2005 |
Changes of chymase, angiotensin converting enzyme and angiotensin II type 1 receptor expressions in the hamster heart during the development of heart failure.
Topics: Angiotensin II; Animals; Body Weight; Chymases; Cricetinae; Heart Failure; Male; Myocardium; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serine Endopeptidases; Ventricular Function, Left | 2005 |
[Cardiac oxidative stress: interaction between angiotensin and adrenaline receptors].
Topics: Angiotensin II; Animals; Enzyme Activation; Heart Failure; Isoproterenol; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Myocardium; Oxidative Stress; Rats; Receptors, Adrenergic; Receptors, Angiotensin | 2005 |
Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
Topics: Aged; Aged, 80 and over; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Feedback, Physiological; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Peptidyl-Dipeptidase A; Renin; Renin-Angiotensin System; Spironolactone | 2006 |
Risk-treatment mismatch for heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Agents; Heart Failure; Humans; Risk; Survival Analysis | 2005 |
Cardiac remodeling and angiotensin II-forming enzyme activity of the left ventricle in hamsters with chronic pressure overload induced by ascending aortic stenosis.
Topics: Angiotensin II; Animals; Aortic Valve Stenosis; Body Weight; Chymases; Cricetinae; Disease Models, Animal; Dog Diseases; Dogs; Echocardiography; Heart Failure; Heart Ventricles; Histocytochemistry; Male; Mesocricetus; Myocardium; Organ Size; Peptidyl-Dipeptidase A; Serine Endopeptidases; Ventricular Remodeling | 2006 |
Modification of the pulmonary renin-angiotensin system and lung structural remodelling in congestive heart failure.
Topics: Angiotensin II; Animals; Blood Pressure; Cell Proliferation; Cells, Cultured; Fibroblasts; Heart Failure; Lung; Male; Microscopy, Confocal; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System | 2006 |
Angiotensin II enhances carotid body chemoreflex control of sympathetic outflow in chronic heart failure rabbits.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blotting, Western; Carotid Body; Chemoreceptor Cells; Heart Failure; Hypoxia; Imidazoles; Immunohistochemistry; Kidney; Male; Models, Animal; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; Stimulation, Chemical; Sympathetic Nervous System; Tetrazoles | 2006 |
Contribution of reactive oxygen species to the pathogenesis of left ventricular failure in Dahl salt-sensitive hypertensive rats: effects of angiotensin II blockade.
Topics: Angiotensin II; Animals; Blood Pressure; Collagen; Connective Tissue Growth Factor; Diastole; Gene Expression; Heart Failure; Heart Ventricles; Hypertension; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Ion Channels; Lung; Male; Membrane Transport Proteins; Mitochondrial Proteins; Myocardium; NADPH Oxidases; Natriuretic Peptide, Brain; Organ Size; Rats; Rats, Inbred Dahl; Reactive Oxygen Species; Thiobarbituric Acid Reactive Substances; Transforming Growth Factor beta; Uncoupling Protein 2; Ventricular Dysfunction, Left | 2006 |
Effects of KR-31378, a novel ATP-sensitive potassium channel activator, on hypertrophy of H9c2 cells and on cardiac dysfunction in rats with congestive heart failure.
Topics: Analysis of Variance; Angiotensin II; Animals; Atrial Natriuretic Factor; Blotting, Western; Cell Enlargement; Cell Line; Dose-Response Relationship, Drug; Enzyme Activation; Guanidines; Heart; Heart Failure; Hypertrophy; Mitogen-Activated Protein Kinases; Myoblasts; Myocardial Infarction; Myocardium; Organ Size; Potassium Channels, Inwardly Rectifying; Protein Precursors; Pyrans; Rats; Rats, Sprague-Dawley | 2006 |
Enhanced sensitivity of Kv channels to hypoxia in the rabbit carotid body in heart failure: role of angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Carotid Body; Cell Hypoxia; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Heart Failure; Imidazoles; Male; Membrane Potentials; Patch-Clamp Techniques; Potassium Channels, Voltage-Gated; Rabbits; Tetrazoles | 2006 |
[Protein kinase Cdelta is possibly involved in the transition from hypertrophy to apoptosis of myocardiocytes].
Topics: Angiotensin II; Animals; Animals, Newborn; Apoptosis; Cardiomegaly; Cell Enlargement; Endothelin-1; Heart Failure; Myocytes, Cardiac; Primary Cell Culture; Protein Kinase C-delta; Rats; Rats, Sprague-Dawley | 2006 |
Novel roles of a local angiotensin-generating system in the carotid body.
Topics: Angiotensin II; Animals; Carotid Body; Heart Failure; Hypoxia; Potassium Channels, Voltage-Gated; Receptor, Angiotensin, Type 1; Renin-Angiotensin System | 2006 |
Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patients.
Topics: Aged; Aldosterone; AMP Deaminase; Angiotensin II; Atrial Natriuretic Factor; Endothelin-1; Epinephrine; Female; Genotype; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Natriuretic Peptide, Brain; Norepinephrine; Polymorphism, Genetic; Proportional Hazards Models; Retrospective Studies | 2006 |
Cardiac energy metabolism alterations in angiotensin II induced hypertrophy.
Topics: Angiotensin II; Animals; Disease Progression; Energy Metabolism; Fatty Acids; Heart Failure; Humans; Hypertrophy; Mice; Models, Biological; Myocardium; Oxygen | 2006 |
Pathophysiological characteristics of heart rate recovery in heart failure.
Topics: Analysis of Variance; Angiotensin II; Atrial Natriuretic Factor; Chi-Square Distribution; Echocardiography; Exercise Test; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Respiratory Function Tests; Risk Factors | 2006 |
Down-regulation of cardiac apelin system in hypertrophied and failing hearts: Possible role of angiotensin II-angiotensin type 1 receptor system.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Apelin; Cardiomegaly; Carrier Proteins; Down-Regulation; Heart Failure; Intercellular Signaling Peptides and Proteins; Male; Rats; Rats, Inbred Dahl; Receptor, Angiotensin, Type 1; RNA, Messenger; Signal Transduction | 2006 |
Angiotensin II, oxidative stress, and extracellular matrix degradation during transition to LV failure in rats with hypertension.
Topics: Angiotensin II; Animals; Base Sequence; Enzyme Activation; Extracellular Matrix; Heart Failure; Hypertension; Male; Matrix Metalloproteinases; Microscopy, Electron, Scanning; NADH, NADPH Oxidoreductases; NF-kappa B; Oxidative Stress; Rats; Rats, Inbred Dahl; RNA, Messenger; Ventricular Remodeling | 2006 |
A "love triangle" elicited by electrochemistry: complex interactions among cardiac sympathetic afferent, chemo-, and baroreflexes.
Topics: Angiotensin II; Animals; Baroreflex; Cardiovascular Physiological Phenomena; Cardiovascular System; Chemoreceptor Cells; Heart Conduction System; Heart Failure; Humans; Neurons, Afferent; Pressoreceptors; Rats; Receptor, Angiotensin, Type 1; Solitary Nucleus; Sympathetic Nervous System | 2007 |
Mechanisms of angiotensin II-dependent progression to heart failure.
Topics: Angiotensin II; Animals; Apoptosis; Heart Diseases; Heart Failure; Mice; Mice, Transgenic; Mitochondria; Muscle Cells; Myocardium; Promoter Regions, Genetic; Proto-Oncogene Proteins c-bcl-2; Transgenes; Up-Regulation | 2006 |
Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.
Topics: Aldosterone; Angiotensin II; Animals; Blotting, Western; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP11B2; Diastole; Eplerenone; Heart Failure; Heart Ventricles; Male; Mass Spectrometry; Mineralocorticoid Receptor Antagonists; Myocardial Contraction; Myocardium; Rats; Rats, Inbred Dahl; Receptors, Mineralocorticoid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Steroids; Stroke Volume; Ventricular Function, Left | 2007 |
[Angiotensin II up-regulates expression of inducible nitric oxide synthase in human umbilical endothelial cells: roles of AT1 and AT2].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Cell Line; Endothelial Cells; Heart Failure; Humans; NF-kappa B; Nitric Oxide Synthase Type II; Reverse Transcriptase Polymerase Chain Reaction; Umbilical Veins; Up-Regulation | 2006 |
A case of ACTH-independent bilateral macronodular adrenal hyperplasia and severe congestive heart failure.
Topics: Adrenal Glands; Aldosterone; Angiotensin II; Heart Failure; Humans; Hydrocortisone; Hyperplasia; Male; Middle Aged; Pituitary ACTH Hypersecretion; Receptor, Melanocortin, Type 2 | 2006 |
Ventricular unloading, tissue angiotensin II, matrix modulation, and function during left ventricular assist device support.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Extracellular Matrix; Female; Forecasting; Heart Failure; Heart-Assist Devices; Humans; Male; Matrix Metalloproteinase 1; Risk Assessment; Sensitivity and Specificity; Stroke Volume; Survival Analysis; Ventricular Remodeling | 2007 |
NADPH oxidase-derived superoxide anion mediates angiotensin II-enhanced carotid body chemoreceptor sensitivity in heart failure rabbits.
Topics: Action Potentials; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Arsenicals; Blotting, Western; Carotid Body; Chemoreceptor Cells; Cyclic N-Oxides; Heart Failure; Male; Models, Animal; NADPH Oxidases; Rabbits; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Spin Labels; Superoxides | 2007 |
Comparison of active renin concentration and plasma renin activity as a prognostic predictor in patients with heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Norepinephrine; Predictive Value of Tests; Prognosis; Renin; Retrospective Studies; Survival Rate; Ventricular Function, Left | 2007 |
Loss of myocardial LIF receptor in experimental heart failure reduces cardiotrophin-1 cytoprotection. A role for neurohumoral agonists?
Topics: Aldosterone; Angiotensin II; Animals; Apoptosis; Cells, Cultured; Cytokines; Cytoprotection; Endothelin-1; Heart Failure; In Situ Nick-End Labeling; Leukemia Inhibitory Factor; Myocardium; Myocytes, Cardiac; Norepinephrine; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptors, OSM-LIF; RNA, Messenger | 2007 |
Inhibition of apoptosis-regulated signaling kinase-1 and prevention of congestive heart failure by estrogen.
Topics: Acetophenones; Angiotensin II; Animals; Apoptosis; Cardiomyopathy, Dilated; Cell Size; Cytosol; Dicarboxylic Acids; Drug Implants; Estradiol; Estrogen Receptor Modulators; Fulvestrant; GTP-Binding Protein alpha Subunits, Gq-G11; Heart Failure; Hydrogen Peroxide; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase Kinase 5; Membrane Proteins; Mice; Mice, Transgenic; Mitochondria; Myocytes, Cardiac; NADPH Oxidases; Neuropeptides; Oxidation-Reduction; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; rac GTP-Binding Proteins; rac1 GTP-Binding Protein; Rats; Superoxides; Thioredoxin Reductase 1; Thioredoxin Reductase 2; Thioredoxin-Disulfide Reductase; Thioredoxins | 2007 |
Exercise training in chronic heart failure: how to harmonize oxidative stress, sympathetic outflow, and angiotensin II.
Topics: Angiotensin II; Chronic Disease; Exercise; Exercise Therapy; Heart Failure; Humans; Oxidative Stress; Sympathetic Nervous System | 2007 |
Forever young?: nerve growth factor, sympathetic fibers, and right ventricle pressure overload.
Topics: Adrenergic Fibers; Angiotensin II; Animals; Calcium; Endothelin-1; Heart Failure; Humans; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Mice; Nerve Growth Factor; Rats; Tyrosine 3-Monooxygenase; Vasoconstriction; Ventricular Dysfunction, Right | 2007 |
[Comparative study on early application of the recipe for activating blood circulation and the recipe for supplementing qi for inhibiting left ventricular remodeling and apoptosis in rats with heart failure].
Topics: Angiotensin II; Animals; Apoptosis; Astragalus propinquus; Drug Combinations; Drugs, Chinese Herbal; Heart Failure; Male; Myocardial Infarction; Myocardium; Myocytes, Cardiac; Plants, Medicinal; Qi; Random Allocation; Rats; Rats, Sprague-Dawley; Salvia miltiorrhiza; Ventricular Remodeling | 2007 |
Reactive oxygen species in the paraventricular nucleus mediate the cardiac sympathetic afferent reflex in chronic heart failure rats.
Topics: Afferent Pathways; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Heart; Heart Failure; Losartan; Male; Models, Animal; Paraventricular Hypothalamic Nucleus; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Superoxides; Sympathetic Nervous System; Vasoconstrictor Agents | 2007 |
Chronic baroreceptor activation enhances survival in dogs with pacing-induced heart failure.
Topics: Angiotensin II; Animals; Blood Pressure; Cardiac Pacing, Artificial; Carotid Sinus; Chronic Disease; Dogs; Echocardiography; Electric Stimulation Therapy; Electrocardiography; Electrodes, Implanted; Heart Failure; Heart Rate; Male; Norepinephrine; Pressoreceptors; Stroke Volume; Survival Analysis | 2007 |
The role of local and systemic renin angiotensin system activation in a genetic model of sympathetic hyperactivity-induced heart failure in mice.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Blood Pressure; Disease Models, Animal; Heart Failure; Heart Rate; Losartan; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Models, Genetic; Myocytes, Cardiac; Norepinephrine; Physical Conditioning, Animal; Receptors, Adrenergic, alpha-2; Renin-Angiotensin System; Sympathetic Nervous System | 2008 |
"Don't flog the heart!" - development of specific drug therapies for heart failure.
Topics: Angiotensin II; Animals; Disease Models, Animal; Heart Failure; Humans; Myocardial Contraction; Myocardial Ischemia; Myocardium; Myocytes, Cardiac; Receptors, Adrenergic, beta-3; Renin-Angiotensin System; Sodium-Potassium-Exchanging ATPase; Up-Regulation | 2007 |
Exercise training enhances baroreflex sensitivity by an angiotensin II-dependent mechanism in chronic heart failure.
Topics: Angiotensin II; Animals; Baroreflex; Chronic Disease; Disease Models, Animal; Down-Regulation; Exercise Therapy; Heart Failure; Hemodynamics; Infusion Pumps, Implantable; Kidney; Male; Medulla Oblongata; Nitroprusside; Phenylephrine; Physical Conditioning, Animal; Rabbits; Receptor, Angiotensin, Type 1; RNA, Messenger; Sympathetic Nervous System; Time Factors; Vasoconstrictor Agents; Vasodilator Agents | 2008 |
Exercise training in heart failure: reduction in angiotensin II, sympathetic nerve activity, and baroreflex control.
Topics: Angiotensin II; Animals; Baroreflex; Chronic Disease; Disease Models, Animal; Down-Regulation; Exercise Therapy; Heart Failure; Hemodynamics; Humans; Kidney; Medulla Oblongata; Receptor, Angiotensin, Type 1; RNA, Messenger; Sympathetic Nervous System | 2008 |
New twist to the role of the renin-angiotensin system in heart failure: aldosterone upregulates renin-angiotensin system components in the brain.
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Brain; Disease Models, Animal; Heart Failure; Hemostasis; Rats; Renin-Angiotensin System; Up-Regulation | 2008 |
Does aldosterone upregulate the brain renin-angiotensin system in rats with heart failure?
Topics: Aldosterone; Angiotensin II; Animals; Blood Pressure; Brain; Disease Models, Animal; Heart Failure; Hemostasis; Hypothalamus; Male; Paraventricular Hypothalamic Nucleus; Peptidyl-Dipeptidase A; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Renin-Angiotensin System; Superoxides; Up-Regulation | 2008 |
Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress.
Topics: Angiogenic Proteins; Angiotensin II; Animals; Aorta, Thoracic; Apoptosis; Blotting, Western; Constriction; Disease Models, Animal; Disease Progression; Energy Metabolism; Fibrosis; Heart Failure; Hypertrophy, Left Ventricular; Male; Mechanotransduction, Cellular; Mice; Mice, Knockout; Mitogen-Activated Protein Kinases; Myocardium; Neovascularization, Physiologic; Phosphorylation; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; Stress, Mechanical; Ventricular Function, Left; Ventricular Remodeling | 2008 |
Mechanical stretch and angiotensin II increase interleukin-13 production and interleukin-13 receptor alpha2 expression in rat neonatal cardiomyocytes.
Topics: Angiotensin II; Animals; Animals, Newborn; Base Sequence; Cells, Cultured; DNA Primers; Heart Failure; Humans; Immunohistochemistry; Interleukin-13; Interleukin-13 Receptor alpha2 Subunit; Myocytes, Cardiac; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Stress, Mechanical; Up-Regulation | 2008 |
Inhibition of brain proinflammatory cytokine synthesis reduces hypothalamic excitation in rats with ischemia-induced heart failure.
Topics: Action Potentials; Adrenocorticotropic Hormone; Angiotensin II; Animals; Anti-Inflammatory Agents; Cyclooxygenase 2; Cytokines; Dinoprostone; Disease Models, Animal; Heart Failure; Hypothalamo-Hypophyseal System; Hypothalamus; Inflammation Mediators; Infusions, Parenteral; Interleukin-1beta; Male; Myocardial Ischemia; Norepinephrine; Paraventricular Hypothalamic Nucleus; Pentoxifylline; Pituitary-Adrenal System; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Superoxides; Tumor Necrosis Factor-alpha; Ultrasonography | 2008 |
Acute hemodynamic and hormonal effects of MK-521 in congestive heart failure.
Topics: Adult; Aged; Aldosterone; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Dipeptides; Female; Heart Failure; Hemodynamics; Hormones; Humans; Lisinopril; Male; Middle Aged; Renin; Time Factors | 1984 |
Role of angiotensin II in the altered renal function of congestive heart failure.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Glomerular Filtration Rate; Heart Failure; Hemodynamics; Kidney; Kidney Glomerulus; Kidney Tubules; Male; Myocardial Infarction; Rats; Renal Circulation | 1984 |
Acute haemodynamic, hormonal and electrolyte effects and short-term clinical response to enalapril in heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Blood Pressure; Chronic Disease; Electrolytes; Enalapril; Female; Furosemide; Heart Failure; Heart Rate; Hemodynamics; Humans; Kinetics; Male; Middle Aged; Renin; Vascular Resistance | 1983 |
Mechanism of action of enalapril in experimental hypertension and acute left ventricular failure.
Topics: Adrenalectomy; Angiotensin II; Animals; Blood Pressure; Captopril; Dogs; Enalapril; Female; Heart Failure; Heart Ventricles; Hindlimb; Hypertension; Hypertension, Renal; Kidney; Male; Muscles; Rats; Rats, Inbred SHR; Renin; Sodium; Vasoconstriction | 1983 |
Haemodynamic, hormonal, and electrolyte responses to withdrawal of long-term captopril treatment for heart failure.
Topics: Aged; Angiotensin II; Captopril; Cardiac Output; Female; Heart Failure; Heart Rate; Hemodynamics; Hormones; Humans; Male; Middle Aged; Potassium; Proline; Sodium; Substance Withdrawal Syndrome; Time Factors | 1981 |
Angiotensin-converting enzyme inhibitors.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Captopril; Heart Failure; Humans; Hypertension; Oligopeptides; Proline; Renin; Teprotide | 1980 |
Angiotensin-converting enzyme inhibition in congestive heart failure: the concept.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Captopril; Creatinine; Heart Failure; Hemodynamics; Humans; Norepinephrine; Oligopeptides; Proline; Renin; Renin-Angiotensin System; Sodium; Teprotide; Water-Electrolyte Balance | 1982 |
Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Urea Nitrogen; Captopril; Cardiac Output; Creatinine; Glomerular Filtration Rate; Heart Failure; Hemodynamics; Humans; Kidney; Length of Stay; Male; Middle Aged; Proline; Renin; Vascular Resistance | 1980 |
Role of the renin-angiotensin-aldosterone system in the regulation of blood pressure.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Diet, Sodium-Restricted; Dogs; Heart Failure; Humans; Hypertension, Renovascular; Hypotension; Norepinephrine; Renin | 1980 |
Clinical improvement and hormonal changes in severe cardiac failure after captopril treatment.
Topics: Administration, Oral; Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Body Weight; Captopril; Heart Failure; Heart Rate; Humans; Hypokalemia; Male; Middle Aged; Natriuresis; Potassium; Proline; Renin; Renin-Angiotensin System; Stroke Volume | 1981 |
The renin-angiotensin system in refractory heart failure: clinical, hemodynamic and hormonal effects of captopril and enalapril.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Captopril; Dipeptides; Enalapril; Epinephrine; Heart Failure; Hemodynamics; Humans; Norepinephrine; Proline; Renin; Renin-Angiotensin System | 1983 |
Haemodynamic, hormonal, and electrolyte effects of enalapril in heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Dipeptides; Dose-Response Relationship, Drug; Enalapril; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Norepinephrine; Physical Exertion; Potassium; Renin; Sodium | 1983 |
Estimation of angiotensin II receptor activity in chronic congestive heart failure.
Topics: Adult; Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chronic Disease; Female; Heart Failure; Hemodynamics; Humans; Hypotension, Orthostatic; Male; Middle Aged; Receptors, Angiotensin; Receptors, Cell Surface; Renin; Saralasin; Sodium | 1984 |
The renin-angiotensin system in congestive cardiac failure: a selective review.
Topics: Aldosterone; Angiotensin II; Animals; Captopril; Heart Failure; Hemodynamics; Humans; Renin; Renin-Angiotensin System; Sodium | 1983 |
Neurohumoral mechanisms in heart failure: role in pathogenesis, therapy, and drug tolerance.
Topics: Angiotensin II; Blood Urea Nitrogen; Captopril; Creatinine; Drug Tolerance; Extracellular Space; Heart Failure; Humans; Renin; Renin-Angiotensin System; Sympathetic Nervous System; Vasoconstriction; Vasodilator Agents | 1983 |
Renin, renin substrate, angiotensin II, and vasopressin in plasma during treatment with captopril in hypertension and heart failure.
Topics: Adult; Aged; Angiotensin II; Angiotensinogen; Angiotensins; Blood Pressure; Captopril; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Proline; Renin; Time Factors; Vasopressins | 1983 |
Endogenous prostaglandin E2 metabolite levels, renin-angiotensin system and catecholamines versus acute hemodynamic response to captopril in chronic congestive heart failure.
Topics: Adult; Aged; Angiotensin II; Captopril; Chronic Disease; Coronary Disease; Dinoprostone; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Norepinephrine; Proline; Prostaglandins E; Renin; Renin-Angiotensin System | 1983 |
Relationships between plasma epinephrine, norepinephrine, dopamine and angiotensin II concentrations, renin activity, hemodynamic state and prognosis in acute heart failure.
Topics: Acute Disease; Adult; Aged; Angiotensin II; Cardiac Output; Catecholamines; Dopamine; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Prognosis; Pulmonary Wedge Pressure; Renin | 1984 |
Angiotensin II levels, hemodynamics, and sympathoadrenal function after low-dose captopril in heart failure.
Topics: Aged; Angiotensin II; Captopril; Epinephrine; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Norepinephrine; Proline; Renin | 1984 |
Acute and chronic effects of captopril therapy in patients with refractory heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Captopril; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Proline; Renin | 1982 |
[Captopril - profile of a new antihypertensive (author's transl)].
Topics: Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Captopril; Heart Failure; Hemodynamics; Humans; Hypertension; Hypertension, Renovascular; Proline; Rats; Rats, Inbred Strains; Renin | 1981 |
Hemodynamic and hormonal responses during captopril therapy for heart failure: acute, chronic and withdrawal studies.
Topics: Aged; Aldosterone; Angiotensin II; Captopril; Dose-Response Relationship, Drug; Female; Heart Failure; Hemodynamics; Humans; Hydrocortisone; Long-Term Care; Male; Middle Aged; Proline; Renin; Substance Withdrawal Syndrome | 1982 |
[Treatment of acute left cardiac insufficiency: a labyrinth without the thread of Ariane?].
Topics: Aldosterone; Angiotensin II; Blood Pressure; Cardiac Output; Heart Failure; Heart Ventricles; Hemodynamics; Humans; Myocardial Contraction; Perfusion; Pulmonary Edema; Systole | 1981 |
The renin-angiotensin-aldosterone system and catecholamines in chronic congestive heart failure. Effect of angiotensin I converting enzyme inhibitor SQ 14225 (Captopril).
Topics: Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Blood Pressure; Captopril; Catecholamines; Chronic Disease; Heart Failure; Heart Rate; Humans; Middle Aged; Norepinephrine; Proline; Renin; Sympathetic Nervous System; Time Factors; Vascular Resistance | 1980 |
Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Female; Furosemide; Heart Failure; Hemodynamics; Humans; Hydrocortisone; Male; Middle Aged; Potassium; Renin; Sodium; Time Factors | 1980 |
Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Blood Pressure; Blood Urea Nitrogen; Creatinine; Female; Heart Failure; Humans; Male; Middle Aged; Potassium; Pulmonary Wedge Pressure; Renin; Sodium | 1981 |
Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy.
Topics: Administration, Oral; Adult; Aged; Aldosterone; Angiotensin II; Captopril; Cardiac Output; Female; Heart Failure; Hemodynamics; Humans; Leg; Male; Middle Aged; Norepinephrine; Proline; Pulmonary Wedge Pressure; Regional Blood Flow; Renin; Vascular Resistance | 1981 |
Angiotensin II is more potent than potassium in regulating aldosterone in cardiac failure: evidence during captopril therapy.
Topics: Aged; Aldosterone; Angiotensin II; Captopril; Heart Failure; Humans; Kinetics; Male; Middle Aged; Potassium; Proline | 1981 |
Evidence against an interaction of angiotensin II with the sympathetic nervous system in man.
Topics: Adult; Aged; Angiotensin II; Captopril; Epinephrine; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Norepinephrine; Renin; Sympathetic Nervous System | 1981 |
Haemodynamic reaction to exercise and increased afterload in the detection of right heart failure in pulmonary diseases.
Topics: Adult; Angiotensin II; Blood Pressure; Cardiac Output; Heart Failure; Heart Rate; Hemodynamics; Humans; Lung Diseases, Obstructive; Middle Aged; Physical Exertion; Stroke Volume; Vascular Resistance | 1980 |
Modulation of norepinephrine release in adriamycin-induced heart failure in rabbits: role of presynaptic alpha 2-adrenoceptors and presynaptic angiotensin II receptors.
Topics: Anesthesia; Angiotensin II; Animals; Captopril; Catecholamines; Decerebrate State; Doxorubicin; Electric Stimulation; Female; Heart Failure; Male; Nitroprusside; Norepinephrine; Pentobarbital; Rabbits; Receptors, Adrenergic, alpha-2; Receptors, Angiotensin; Receptors, Presynaptic; Sympathetic Nervous System; Yohimbine | 1994 |
Expression of renin-angiotensin system components in the heart, kidneys, and lungs of rats with experimental heart failure.
Topics: Angiotensin II; Animals; Blotting, Western; Gene Expression; Heart Failure; Kidney; Lung; Male; Myocardium; Peptidyl-Dipeptidase A; Polymerase Chain Reaction; Rats; Rats, Sprague-Dawley; Receptors, Angiotensin; Renin; Renin-Angiotensin System; RNA, Messenger | 1995 |
Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Bradykinin; Disease Models, Animal; Heart; Heart Failure; Hemodynamics; Imidazoles; Isoquinolines; Losartan; Male; Myocardial Contraction; Myocardial Infarction; Myocardium; Organ Size; Rats; Rats, Wistar; Tetrahydroisoquinolines; Tetrazoles | 1994 |
Theoretical basis for the use of angiotensin II antagonists in the treatment of heart failure.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans | 1994 |
Cardiac renin-angiotensin system: role in development of pressure-overload hypertrophy.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Aortic Valve Stenosis; Blood Pressure; Cardiomegaly; Disease Models, Animal; Heart Failure; Humans; Myocardial Contraction; Rats; Renin-Angiotensin System; Ventricular Function, Left | 1995 |
[Medical angiotensin II-receptor blockade in hypertension and heart failure].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Agents; Heart Failure; Humans; Hypertension; Imidazoles; Losartan; Renin; Tetrazoles | 1995 |
Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart.
Topics: Adolescent; Adult; Angiotensin II; Base Sequence; Blotting, Southern; Chymases; Endothelium; Female; Heart Failure; Heart Ventricles; Humans; In Situ Hybridization; Male; Mast Cells; Microscopy, Electron; Middle Aged; Molecular Sequence Data; Myocardium; RNA; Serine Endopeptidases; Subcellular Fractions | 1993 |
ACE inhibitors in heart failure. What dose?
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Drug Administration Schedule; Heart Failure; Humans | 1995 |
Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure.
Topics: Alanine; Angiotensin II; Animals; Biphenyl Compounds; Blood Pressure; Blood Volume; Bradykinin; Cricetinae; Drug Synergism; Enalaprilat; Heart Failure; Irbesartan; Male; Neprilysin; Tetrazoles; Vasodilation; Ventricular Function, Left | 1995 |
Human cardiac fibroblasts express an angiotensin receptor with unusual binding characteristics which is coupled to cellular proliferation.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Cell Division; Cells, Cultured; Culture Media, Serum-Free; Fibroblasts; Heart Failure; Humans; Imidazoles; Kinetics; Losartan; Myocardium; Pyridines; Radioligand Assay; Receptors, Angiotensin; Tetrazoles | 1994 |
Discrepancy between plasma and lung angiotensin-converting enzyme activity in experimental congestive heart failure. A novel aspect of endothelium dysfunction.
Topics: Analysis of Variance; Angiotensin II; Animals; Atrial Natriuretic Factor; Cell Membrane; Disease Models, Animal; Endothelium, Vascular; Gene Expression; Heart; Heart Failure; Kidney; Lung; Male; Myocardial Infarction; Organ Size; Peptidyl-Dipeptidase A; Pleural Effusion; Rats; Rats, Wistar; Renin; RNA, Messenger | 1994 |
Hemodynamic and neurohumoral responses to exercise in patients with congestive heart failure.
Topics: 6-Ketoprostaglandin F1 alpha; Angiotensin II; Atrial Natriuretic Factor; Exercise; Exercise Test; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Neurotransmitter Agents; Rest | 1993 |
Relationship between hemostatic abnormalities and neuroendocrine activity in heart failure.
Topics: Adult; Aged; Angiotensin II; Blood Coagulation; Blood Viscosity; Chronic Disease; Endothelins; Exercise Test; Female; Fibrin Fibrinogen Degradation Products; Fibrinopeptide A; Heart Failure; Humans; Male; Middle Aged; Neurosecretory Systems; Platelet Activation; Radionuclide Ventriculography; Thromboembolism; von Willebrand Factor | 1994 |
[A clinical study of intravenous captopril in heart failure].
Topics: Adult; Angiotensin II; Blood Urea Nitrogen; Captopril; Female; Heart Failure; Hemodynamics; Humans; Injections, Intravenous; Male; Middle Aged | 1993 |
Short- and long-term neurohormonal activation following acute myocardial infarction.
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Case-Control Studies; Epinephrine; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Norepinephrine; Posture; Renin-Angiotensin System; Sympathetic Nervous System; Thrombolytic Therapy; Time Factors | 1993 |
Regulation of intrarenal and circulating renin-angiotensin systems in severe heart failure in the rat.
Topics: Angiotensin II; Angiotensinogen; Animals; Blotting, Northern; Disease Models, Animal; Heart Failure; Kidney; Male; Myocardial Infarction; Rats; Rats, Sprague-Dawley; Renin; Renin-Angiotensin System | 1993 |
Low-dose atrial natriuretic factor and furosemide in experimental acute congestive heart failure.
Topics: Acute Disease; Angiotensin II; Animals; Atrial Natriuretic Factor; Dogs; Drug Synergism; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Male; Natriuresis; Pulmonary Edema; Renin-Angiotensin System | 1993 |
Invasive pharmacodynamics of fosinopril in patients with congestive heart failure.
Topics: Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Blood Pressure; Chromatography, High Pressure Liquid; Female; Fosinopril; Half-Life; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Peptidyl-Dipeptidase A; Pulmonary Wedge Pressure; Renin | 1995 |
[Effect of cilazapril on exercise tolerance and neurohumoral factors in patients with asymptomatic chronic heart failure after myocardial infarction].
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Chronic Disease; Cilazapril; Exercise Tolerance; Female; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Neurotransmitter Agents; Norepinephrine; Renin; Stroke Volume | 1995 |
Plasma neuro-endocrine activity in very elderly subjects and patients with and without heart failure.
Topics: Aged; Aged, 80 and over; Aging; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Diuretics; Female; Heart Failure; Humans; Linear Models; Male; Norepinephrine; Reference Values; Renin; Renin-Angiotensin System | 1995 |
Altered ventricular and myocyte response to angiotensin II in pacing-induced heart failure.
Topics: Angiotensin II; Animals; Cardiac Pacing, Artificial; Dogs; Heart; Heart Failure; Heart Rate; Heart Ventricles; Myocardial Contraction; Myocardium; Ventricular Function, Left | 1996 |
Acute and chronic neutral endopeptidase inhibition in rats with aortocaval shunt.
Topics: Alanine; Angiotensin II; Animals; Aorta, Abdominal; Arteriovenous Shunt, Surgical; Atrial Natriuretic Factor; Cyclic GMP; Diuresis; Enzyme Inhibitors; Heart Failure; Hemodynamics; Male; Natriuresis; Neprilysin; Rats; Rats, Wistar; Renin; Vena Cava, Inferior | 1996 |
Renin-angiotensin system and cell communication in the failing heart.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Cells, Cultured; Cricetinae; Enalapril; Gap Junctions; Heart Conduction System; Heart Failure; Imidazoles; Losartan; Male; Membrane Potentials; Mesocricetus; Patch-Clamp Techniques; Renin-Angiotensin System; Tetrazoles | 1996 |
Angiotensin II in the evolution of experimental heart failure.
Topics: Angiotensin II; Animals; Aorta; Dogs; Heart Failure; Hemodynamics; Hormones; Kidney; Male; Myocardium; Natriuresis; Ventricular Function, Left | 1996 |
Responses of plasma norepinephrine and renin-angiotensin-aldosterone system to dynamic exercise in patients with congestive heart failure.
Topics: Aldosterone; Angiotensin II; Exercise; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Norepinephrine; Oxygen Consumption; Pulmonary Ventilation; Renin; Renin-Angiotensin System; Sympathetic Nervous System | 1996 |
Local stress, not systemic factors, regulate gene expression of the cardiac renin-angiotensin system in vivo: a comprehensive study of all its components in the dog.
Topics: Angiotensin II; Animals; Cardiomegaly; Chymases; Dogs; Gene Expression; Heart Failure; Myocardium; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin; RNA, Messenger; Serine Endopeptidases | 1996 |
Blockade of the renin-angiotensin system in heart failure in conscious dogs.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Binding, Competitive; Biphenyl Compounds; Captopril; Dogs; Heart Failure; Hemodynamics; Imidazoles; Losartan; Male; Myocardium; Pyridines; Reference Values; Renin-Angiotensin System; Tetrazoles | 1995 |
Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Body Weight; Dog Diseases; Dogs; Echocardiography; Enalapril; Female; Furosemide; Heart Failure; Heart Rate; Hydralazine; Male; Mitral Valve Insufficiency; Renin-Angiotensin System; Vasodilator Agents; Water-Electrolyte Balance | 1996 |
Effects of naturally acquired decompensated mitral valve regurgitation on the renin-angiotensin-aldosterone system and atrial natriuretic peptide concentration in dogs.
Topics: Aldosterone; Angiotensin II; Animals; Atrial Natriuretic Factor; Blood Pressure; Creatinine; Dog Diseases; Dogs; Echocardiography; Female; Heart Failure; Hematocrit; Male; Mitral Valve Insufficiency; Radiography, Thoracic; Renin-Angiotensin System | 1997 |
Effects of long-term treatment with trandolapril on augmented vasoconstriction in rats with chronic heart failure.
Topics: Analysis of Variance; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Coronary Vessels; Culture Techniques; Disease Models, Animal; Drug Interactions; Heart Failure; Hemodynamics; Indoles; Male; Muscle, Smooth, Vascular; Norepinephrine; Prostaglandins F; Rats; Rats, Wistar; Reference Values; Vasoconstriction; Vasoconstrictor Agents | 1996 |
Cardiac angiotensin converting enzyme and endothelin receptor in rats with chronic myocardial infarction.
Topics: Angiotensin II; Animals; Autoradiography; Cardiomegaly; Chronic Disease; Endothelin-1; Female; Heart Failure; Image Processing, Computer-Assisted; Iodine Radioisotopes; Ligation; Myocardial Infarction; Myocardium; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Receptors, Endothelin; Renin; Ventricular Function, Left | 1996 |
Plasma levels of atrial natriuretic peptide and of other vasoconstricting hormones in patients with chronic heart failure: relationship to exercise capacity.
Topics: Adult; Aged; Angiotensin II; Atrial Natriuretic Factor; Chronic Disease; Epinephrine; Exercise Test; Exercise Tolerance; Female; Heart Failure; Humans; Male; Middle Aged; Norepinephrine; Oxygen Consumption; Prognosis; Radioimmunoassay; Renin; Sensitivity and Specificity; Severity of Illness Index; Vasoconstrictor Agents; Vasopressins | 1996 |
Selective downregulation of the angiotensin II AT1-receptor subtype in failing human ventricular myocardium.
Topics: Adult; Angiotensin II; Cardiomyopathy, Dilated; Cell Membrane; Down-Regulation; Female; Heart Failure; Heart Ventricles; Humans; Kinetics; Male; Myocardium; Polymerase Chain Reaction; Radioligand Assay; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Receptors, Angiotensin; Reference Values | 1997 |
Early versus delayed angiotensin-converting enzyme inhibition in experimental chronic heart failure. Effects on survival, hemodynamics, and cardiovascular remodeling.
Topics: Analysis of Variance; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Diastole; Femoral Artery; Heart; Heart Failure; Hemodynamics; In Vitro Techniques; Lisinopril; Male; Muscle, Smooth, Vascular; Myocardial Infarction; Myocardium; Rats; Rats, Wistar; Survival Rate; Vascular Resistance; Ventricular Function, Left | 1997 |
Reversing congestive heart failure with endothelin receptor antagonists.
Topics: Aging; Angiotensin II; Animals; Bosentan; Cells, Cultured; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Humans; Mice; Mice, Transgenic; Rabbits; Receptors, Endothelin; Sulfonamides | 1997 |
Chronic effects of ANG II antagonist in heart failure: improvement of cGMP generation from ANP.
Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Benzimidazoles; Biphenyl Compounds; Cyclic GMP; Dogs; Female; Glomerular Filtration Rate; Heart Failure; Hemodynamics; Kidney; Male; Norepinephrine; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles; Time Factors; Vascular Resistance | 1997 |
Increased cardiomyocyte apoptosis during the transition to heart failure in the spontaneously hypertensive rat.
Topics: Angiotensin II; Animals; Apoptosis; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA Fragmentation; Gene Expression; Heart Failure; Hypertension; Myocardium; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; RNA, Messenger | 1997 |
[Angiotensin II antagonist for heart insufficiency].
Topics: Adrenergic beta-Antagonists; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Biphenyl Compounds; Heart Failure; Humans; Imidazoles; Losartan; Prognosis; Tetrazoles | 1997 |
Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Baroreflex; Benzazepines; Blood Pressure; Coronary Circulation; Female; Heart Failure; Humans; Male; Middle Aged; Norepinephrine; Pressoreceptors; Renin; Sympathetic Nervous System | 1997 |
[New therapeutic principle in the management of cardiac insufficiency: A II antagonists. Results of the ELITE study (Evaluation of Losartan In The Elderly)].
Topics: Aged; Angiotensin II; Anti-Arrhythmia Agents; Female; Heart Failure; Humans; Losartan; Male; Renin-Angiotensin System | 1997 |
[Angiotensin-II-antagonism: new hope for the management of cardiac insufficiency].
Topics: Age Factors; Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Dose-Response Relationship, Drug; Heart Failure; Humans; Losartan | 1997 |
Impaired nitric oxide-mediated renal vasodilation in rats with experimental heart failure: role of angiotensin II.
Topics: Acetylcholine; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aortic Diseases; Arteriovenous Fistula; Enzyme Inhibitors; Heart Failure; Hemodynamics; Kidney; Male; Nitric Oxide; Nitric Oxide Synthase; Penicillamine; Rats; Rats, Wistar; Renal Circulation; S-Nitroso-N-Acetylpenicillamine; Vasodilation; Vasodilator Agents; Venae Cavae | 1997 |
Hemodynamic effect of amrinone depends on pretreatment vascular resistance in patients with evolving congestive heart failure: correlation between vascular resistance and neurohormonal activity.
Topics: Aged; Amrinone; Angiotensin II; Biomarkers; Cardiotonic Agents; Endothelin-1; Female; Heart Failure; Hemodynamics; Humans; Male; Norepinephrine; Statistics as Topic; Vascular Resistance | 1998 |
Combined neutral endopeptidase and angiotensin-converting enzyme inhibition in heart failure: role of natriuretic peptides and angiotensin II.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Cyclic GMP; Female; Heart Failure; Hemodynamics; Myocardium; Neprilysin; Peptidyl-Dipeptidase A; Sheep; Time Factors; Ventricular Function | 1998 |
Evaluation of Losartan in the Elderly (ELITE) Trial: clinical implications.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Heart Failure; Humans; Losartan; Randomized Controlled Trials as Topic; Treatment Outcome | 1997 |
Angiotensin receptor antagonist improves cardiac reflex control of renal sodium handling in heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Baroreflex; Blood Pressure; Heart; Heart Failure; Kidney; Losartan; Male; Rats; Rats, Sprague-Dawley; Sodium; Sodium Chloride; Sodium, Dietary; Solutions; Sympathetic Nervous System; Vagus Nerve | 1998 |
[Beta-blockers and new drugs for cardiac failure].
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Cardiotonic Agents; Endothelin Receptor Antagonists; Heart Failure; Humans; Receptors, Angiotensin; Receptors, Endothelin | 1997 |
Synergistic exacerbation of diastolic stiffness from short-term tachycardia-induced cardiodepression and angiotensin II.
Topics: Angiotensin I; Angiotensin II; Animals; Diastole; Dogs; Enzyme Activation; Female; Heart Failure; Heart Rate; Hemodynamics; Male; Metalloendopeptidases; Myocardial Contraction; Tachycardia; Time Factors | 1998 |
Pharmacological profile of nicardipine hydrochloride in anesthetized dogs with acute heart failure. Part 1: Hemodynamic effects in normal dogs and dogs with acute heart failure.
Topics: Acute Disease; Adrenergic beta-Agonists; Anesthesia; Angiotensin II; Animals; Blood Pressure; Calcium Channel Blockers; Dobutamine; Dogs; Female; Heart Conduction System; Heart Failure; Heart Rate; Hemodynamics; Male; Nicardipine; Nitroglycerin; Vasodilator Agents | 1998 |
Mesangiolytic glomerulopathy in severe congestive heart failure.
Topics: Adult; Aged; Angiotensin II; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Capillaries; Female; Glomerulonephritis, Membranoproliferative; Heart Failure; Hematocrit; Humans; Hypertension; Kidney Glomerulus; Macrophages; Male; Middle Aged; Oxygen; Periodic Acid-Schiff Reaction | 1998 |
Effects of epanolol, a selective beta1-blocker with intrinsic sympathomimetic activity, in patients with ischemic left ventricular dysfunction.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II; Benzeneacetamides; Cardiac Pacing, Artificial; Coronary Circulation; Electrocardiography; Epinephrine; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Myocardial Ischemia; Norepinephrine; Propanolamines; Sympathomimetics; Ventricular Dysfunction, Left | 1998 |
The activated immune system and the renin-angiotensin-aldosterone system in congestive heart failure.
Topics: Adult; Aldosterone; Angiotensin II; Antigens, CD; Female; Heart Failure; Humans; Male; Middle Aged; Neopterin; Peptidyl-Dipeptidase A; Radioimmunoassay; Receptors, Interleukin-2; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type I; Renin; Renin-Angiotensin System; Severity of Illness Index | 1998 |
Angiotensin II receptor antagonists for heart failure.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bradykinin; Captopril; Clinical Trials as Topic; Heart Failure; Humans; Losartan; Receptors, Angiotensin | 1998 |
[Value of angiotensin II-antagonists].
Topics: Angiotensin II; Anti-Arrhythmia Agents; Antihypertensive Agents; Heart Failure; Humans; Losartan; Renin-Angiotensin System; Vasodilator Agents | 1998 |
Combined effects of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism in conscious pigs with congestive heart failure.
Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enalaprilat; Female; Heart Failure; Hemodynamics; Imidazoles; Male; Swine; Tetrazoles | 1998 |
Renal hemodynamic effects in patients with moderate to severe heart failure during chronic treatment with trandolapril.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Digoxin; Diuretics; Epinephrine; Female; Heart Failure; Heart Rate; Humans; Indoles; Kidney; Male; Middle Aged; Neurotransmitter Agents; Norepinephrine; Pulmonary Wedge Pressure; Renal Circulation; Renin; Time Factors | 1998 |
Regulation of regional norepinephrine spillover in heart failure: the effect of angiotensin II and beta-adrenergic agonists in the forearm circulation.
Topics: Adult; Aged; Angiotensin II; Forearm; Heart Failure; Humans; Isoproterenol; Male; Middle Aged; Norepinephrine; Regional Blood Flow; Sympathetic Nervous System; Sympathomimetics | 1998 |
AT1 angiotensin II receptor inhibition in pacing-induced heart failure: effects on left ventricular performance and regional blood flow patterns.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cardiac Pacing, Artificial; Coronary Vessels; Disease Models, Animal; Exercise Test; Heart Failure; Hemodynamics; Male; Regional Blood Flow; Swine; Tetrazoles; Valine; Valsartan; Vascular Resistance; Ventricular Function, Left | 1998 |
Angiotensin AT1 receptor inhibition, angiotensin-converting enzyme inhibition, and combination therapy with developing heart failure: cellular mechanisms of action.
Topics: Action Potentials; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Cardiac Pacing, Artificial; Disease Models, Animal; Drug Therapy, Combination; Evaluation Studies as Topic; Heart Failure; Myocardium; Random Allocation; Swine; Ventricular Function, Left | 1998 |
Relationship between endothelin-1 extraction in the peripheral circulation and systemic vascular resistance in patients with severe congestive heart failure.
Topics: Adolescent; Adult; Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Biomarkers; Blood Pressure; Endothelin-1; Female; Femoral Artery; Femoral Vein; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Norepinephrine; Pulmonary Wedge Pressure; Severity of Illness Index; Vascular Resistance | 1999 |
The role of angiotensin II AT1 receptor in the maintenance of hemodynamics in a canine model of coronary microembolization-induced heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzofurans; Blood Pressure; Coronary Disease; Dogs; Embolism; Female; Heart Failure; Heart Rate; Male; Receptors, Angiotensin | 1999 |
Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Biphenyl Compounds; Blood Pressure; Body Weight; Captopril; Cardiomegaly; Dose-Response Relationship, Drug; Echocardiography; Gene Expression; Heart Failure; Irbesartan; Isoenzymes; Male; Myosin Heavy Chains; Organ Size; Rats; Rats, Inbred Strains; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin; RNA, Messenger; Systole; Tetrazoles | 1999 |
Renal function in high-output heart failure in rats: role of endogenous natriuretic peptides.
Topics: Analysis of Variance; Angiotensin II; Animals; Atrial Natriuretic Factor; Cyclic GMP; Disease Models, Animal; Glomerular Filtration Rate; Heart Failure; Kidney Function Tests; Male; Polysaccharides; Rats; Rats, Wistar; Reference Values; Renal Circulation; Statistics, Nonparametric; Urodynamics | 1999 |
An experimental study of cardiac natriuretic peptides as markers of development of congestive heart failure.
Topics: Aldosterone; Angiotensin II; Animals; Atrial Natriuretic Factor; Biomarkers; Endothelin-1; Epinephrine; Female; Heart Failure; Male; Myocardium; Natriuretic Peptide, Brain; Norepinephrine; Pacemaker, Artificial; Protein Precursors; Renin; Swine | 1998 |
Heart failure induced by pheochromocytoma: laparoscopic treatment and intraoperative changes of several new cardiovascular hormones.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adult; Angiotensin II; Atrial Natriuretic Factor; Blood Pressure; Endothelin-1; Epinephrine; Female; Heart Failure; Humans; Laparoscopy; Monitoring, Intraoperative; Norepinephrine; Pheochromocytoma; Protein Precursors | 1999 |
Vascular alterations during the development and progression of experimental heart failure.
Topics: Angiotensin II; Animals; Cricetinae; Disease Models, Animal; Disease Progression; Heart Failure; Male; Mesocricetus; Norepinephrine; Vasoconstriction; Vasoconstrictor Agents | 1999 |
High-dose enoximone to evaluate reversibility of pulmonary hypertension: is there a diagnostic value of neurohormonal measurements?
Topics: Angiotensin II; Atrial Natriuretic Factor; Biomarkers; Cardiac Catheterization; Catecholamines; Endothelin-1; Enoximone; Female; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Male; Middle Aged; Peptidyl-Dipeptidase A; Phosphodiesterase Inhibitors; Prognosis; Pulmonary Artery; Pulmonary Veins; Severity of Illness Index | 1999 |
AT1-receptor antagonists for the treatment of chronic heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biphenyl Compounds; Captopril; Dogs; Heart Failure; Humans; Irbesartan; Losartan; Rats; Tetrazoles | 1999 |
Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats.
Topics: Analysis of Variance; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Dose-Response Relationship, Drug; Heart Failure; Heart Rate; Irbesartan; Male; Rats; Rats, Wistar; Survival Rate; Tetrazoles; Vascular Resistance; Ventricular Pressure; Ventricular Remodeling | 1999 |
Comparison between angiotensin receptor antagonism and converting enzyme inhibition in heart failure. Differential acute effects according to the renin-angiotensin system activation.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Dogs; Enalaprilat; Female; Heart Failure; Hemodynamics; Imidazoles; Losartan; Male; Renin; Renin-Angiotensin System; Tetrazoles; Vasodilation | 1999 |
Concentrations of angiotensin II, endothelin-1, and BNP in the coronary sinus and ascending aorta of patients with heart disease.
Topics: Aged; Angiotensin II; Aorta; Biomarkers; Cardiac Catheterization; Coronary Vessels; Endothelin-1; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain | 1999 |
Anomalous origin of the left coronary artery from the pulmonary artery.
Topics: Angiotensin II; Biomarkers; Endothelin-1; Female; Heart Failure; Humans; Natriuretic Peptide, Brain | 1999 |
Brain renin-angiotensin system and sympathetic hyperactivity in rats after myocardial infarction.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Baroreflex; Blood Pressure; Brain; Cardiotonic Agents; Enzyme Inhibitors; Guanabenz; Heart Failure; Heart Rate; Injections, Intraventricular; Losartan; Male; Myocardial Infarction; Nitroprusside; Ouabain; Phenylephrine; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Stress, Physiological; Sympathetic Nervous System | 1999 |
The circulating renin-angiotensin system during treatment with metoprolol or captopril in patients with heart failure due to non-ischaemic dilated cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Captopril; Cardiomyopathy, Dilated; Exercise; Female; Heart Failure; Humans; Male; Metoprolol; Middle Aged; Renin; Rest | 1999 |
How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Captopril; Enalapril; Female; Fosinopril; Heart Failure; Humans; Indoles; Lisinopril; Male; Peptidyl-Dipeptidase A; Perindopril; Treatment Failure | 1999 |
ANG II and baroreflex function in rabbits with CHF and lesions of the area postrema.
Topics: Angiotensin II; Animals; Baroreflex; Cerebral Ventricles; Heart Failure; Hemodynamics; Kidney; Male; Rabbits; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Sympathetic Nervous System | 1999 |
Increased superoxide in heart failure: a biochemical baroreflex gone awry.
Topics: Angiotensin II; Animals; Baroreflex; Endothelium, Vascular; Heart Failure; Nitric Oxide; Rats; Renin; Superoxides | 1999 |
Improving outcomes in congestive heart failure: Val-HeFT. Valsartan in Heart Failure Trial.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials as Topic; Heart Failure; Humans; Quality of Life; Tetrazoles; Valine; Valsartan | 1999 |
ACE inhibitors or AT(1) receptor blockers in heart failure?
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Heart Failure; Humans; Renin-Angiotensin System | 1999 |
Effects of the angiotensin II antagonist losartan on endothelin-1 and norepinephrine plasma levels during cold pressor test in patients with chronic heart failure.
Topics: Aged; Aged, 80 and over; Angiotensin II; Antihypertensive Agents; Blood Pressure; Chronic Disease; Cold Temperature; Endothelin-1; Exercise Test; Female; Heart Failure; Heart Rate; Humans; Losartan; Male; Middle Aged; Norepinephrine; Sympathetic Nervous System; Vasoconstriction | 1999 |
Angiotensin inhibition and atrial natriuretic peptide release after acute volume expansion in rats with aortocaval shunt.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Blood Volume; Cyclic GMP; Diuresis; Heart Failure; Male; Myocardium; Ramipril; Rats; Rats, Wistar; Renin-Angiotensin System; Statistics, Nonparametric; Tetrazoles; Valine; Valsartan | 1999 |
Comment on "Effects of long-term angiotensin II AT-1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats".
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Biphenyl Compounds; Chronic Disease; Heart Failure; Irbesartan; Rats; Tetrazoles | 1999 |
Increased bradykinin levels accompany the hemodynamic response to acute inhibition of angiotensin-converting enzyme in dogs with heart failure.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Bradykinin; Cardiac Output; Cardiac Pacing, Artificial; Disease Models, Animal; Dogs; Enalaprilat; Heart Failure; Indoles; Norepinephrine; Peptide Fragments; Ventricular Function, Left | 1999 |
Structural and functional assessment of small arteries in patients with chronic heart failure.
Topics: Acetylcholine; Adult; Aged; Analysis of Variance; Angiotensin II; Arteries; Bradykinin; Case-Control Studies; Dose-Response Relationship, Drug; Endothelin-1; Epoprostenol; Female; Heart Failure; Humans; Male; Middle Aged; Muscle, Skeletal; Myography; Natriuretic Peptide, Brain; Nitroprusside; Norepinephrine; Vascular Resistance; Vasoconstrictor Agents; Vasodilator Agents | 1999 |
Blockade of the renin angiotensin system in heart failure: the potential place of angiotensin II receptor blockers.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Heart Failure; Humans; Losartan; Receptors, Angiotensin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2000 |
Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiomyopathy, Dilated; Heart Failure; Humans; Middle Aged; Regression Analysis; Renin-Angiotensin System; Survival Analysis; Ventricular Dysfunction, Left | 2000 |
Angiotensin II type 1 receptor blockade prevents cardiac remodeling in bradykinin B(2) receptor knockout mice.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Female; Fibrosis; Heart Failure; Heart Rate; Heart Ventricles; Hypertension; Hypertrophy, Left Ventricular; Male; Mice; Mice, Knockout; Myocardium; Nicotinic Acids; Organ Size; Phenotype; Pregnancy; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptor, Bradykinin B2; Receptors, Bradykinin; Tetrazoles | 2000 |
Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enalapril; Female; Fosinopril; Heart Failure; Humans; Lisinopril; Male; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Treatment Failure; Valine; Valsartan | 2000 |
ELITE II. AT1-blockers not better, but more tolerable than ACE-inhibitors.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Female; Heart Failure; Humans; Losartan; Male; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2000 |
[Chronic cardiac insufficiency. Treatment with angiotensin I converting enzyme inhibitors and angiotensin II receptor antagonists].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Output, Low; Heart Failure; Humans | 2000 |
Prognostic value of serum cytokines in patients with congestive heart failure.
Topics: Adult; Aged; Angiotensin II; Antigens, CD; Atrial Natriuretic Factor; Biomarkers; Cytokines; Echocardiography, Doppler; Heart Failure; Heart Transplantation; Humans; Interleukin-1; Interleukin-6; Middle Aged; Prognosis; Receptors, Cytokine; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Renin; Survival Rate | 2000 |
Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antidiuretic Hormone Receptor Antagonists; Atrial Natriuretic Factor; Blood Pressure; Heart Failure; Hemodynamics; Male; Myocardial Contraction; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Sodium; Swine; Vasopressins; Ventricular Function, Left | 2000 |
Reverse remodeling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin-angiotensin system.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Cardiomegaly; Echocardiography; Enalapril; Female; Heart Failure; Hypertension, Renal; Imidazoles; Muscle Fibers, Skeletal; Myocardium; Organ Size; Rats; Rats, Inbred Strains; Renin-Angiotensin System; Tetrazoles; Ventricular Remodeling | 2000 |
Blockade of central angiotensin II does not affect the reduction in renal sympathetic nerve activity following a volume load in heart failure rabbits.
Topics: Angiotensin II; Animals; Antibiotics, Antineoplastic; Blood Pressure; Blood Volume; Doxorubicin; Electrodes; Heart Failure; Heart Rate; Injections, Intraventricular; Kidney; Losartan; Male; Rabbits; Sympathetic Nervous System | 2000 |
Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Circadian Rhythm; Drug Interactions; Enalapril; Fibrinolysis; Heart Failure; Humans; Losartan; Randomized Controlled Trials as Topic; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System | 2000 |
Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Captopril; Female; Heart Failure; Humans; Longitudinal Studies; Male; Peptidyl-Dipeptidase A; Renin | 1999 |
Update of recent clinical trials in heart failure and myocardial infarction.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Heart Failure; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Research Design | 1999 |
Clinical implications of increased plasma angiotensin II concentrations despite ACE inhibitor therapy in patients with congestive heart failure: the issue of non-compliance with therapy.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Patient Compliance | 2000 |
Plasma brain natriuretic peptides and renal hypertension.
Topics: Adolescent; Angiotensin I; Angiotensin II; Atrophy; Blood Pressure; Child; Child, Preschool; Female; Heart Failure; Humans; Hypertension, Renal; Kidney; Male; Natriuretic Peptide, Brain; Neuroblastoma; Renin; Ventricular Function, Left | 2000 |
Effects of combined angiotensin II and endothelin receptor blockade with developing heart failure: effects on left ventricular performance.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Bosentan; Cardiac Pacing, Artificial; Combined Modality Therapy; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Myocardial Contraction; Norepinephrine; Receptor, Endothelin A; Renin; Sulfonamides; Swine; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2000 |
Transcardiac extraction of circulating endothelin-1 across the failing heart.
Topics: Angiotensin II; Aorta; Coronary Vessels; Endothelin-1; Heart Failure; Hemodynamics; Humans; Norepinephrine; Peptide Fragments; Procollagen; Reference Values; Ventricular Function, Left | 2000 |
Chronic exercise reduces sympathetic nerve activity in rabbits with pacing-induced heart failure: A role for angiotensin II.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Baroreflex; Heart Failure; Hemodynamics; Male; Physical Conditioning, Animal; Physical Exertion; Rabbits; Sympathetic Nervous System | 2000 |
Effects of ACE inhibitor, AT1 antagonist, and combined treatment in mice with heart failure.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Cardiac Output; Chronic Disease; Echocardiography; Female; Heart; Heart Failure; Imidazoles; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocardium; Organ Size; Ramipril; Stroke Volume; Tetrazoles; Ventricular Remodeling | 2000 |
Beneficial renal and hemodynamic effects of omapatrilat in mild and severe heart failure.
Topics: Aldosterone; Angiotensin II; Animals; Atrial Natriuretic Factor; Blood Pressure; Cardiac Output; Cardiovascular Agents; Cross-Over Studies; Cyclic GMP; Disease Models, Animal; Glomerular Filtration Rate; Heart Failure; Hemodynamics; Injections, Intravenous; Kidney; Natriuretic Peptide, Brain; Pyridines; Renin; Sheep; Sodium; Thiazepines | 2000 |
Congestive heart failure: fifty years of progress.
Topics: Angiotensin II; Apoptosis; Calcium; Cardiomegaly; Cardiomyopathies; Cytokines; Heart Failure; History, 20th Century; Humans; Models, Cardiovascular; Myocardial Contraction; Myocardial Ischemia; Signal Transduction | 2000 |
Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro.
Topics: Active Transport, Cell Nucleus; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Cardiomegaly; Cell Nucleus; Cells, Cultured; Collagen; Cytosol; DNA-Binding Proteins; Fibroblasts; Heart Failure; In Vitro Techniques; Losartan; Male; Myocardial Infarction; Myocardium; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Smad2 Protein; Smad4 Protein; Trans-Activators; Transforming Growth Factor beta; Vimentin | 2000 |
Myocardial cell death in human diabetes.
Topics: Angiotensin II; Apoptosis; Cardiomegaly; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Oxidative Stress; Reactive Oxygen Species; Renin-Angiotensin System; Tyrosine | 2000 |
Enhancement of Rho/Rho-kinase system in regulation of vascular smooth muscle contraction in tachycardia-induced heart failure.
Topics: Amides; Analysis of Variance; Angiotensin II; Animals; Calcium; Calcium Channel Blockers; Cardiac Pacing, Artificial; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Femoral Artery; Heart Failure; Immunoblotting; In Vitro Techniques; Intracellular Signaling Peptides and Proteins; Male; Muscle, Smooth, Vascular; Nifedipine; Protein Serine-Threonine Kinases; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; rho-Associated Kinases; rhoA GTP-Binding Protein | 2001 |
Canine ventricular myocytes possess a renin-angiotensin system that is upregulated with heart failure.
Topics: Actins; Angiotensin II; Animals; Binding, Competitive; Blotting, Western; Cardiac Pacing, Artificial; Cathepsin D; Chymases; Dogs; Heart Failure; Heart Ventricles; Immunohistochemistry; Microscopy, Confocal; Peptidyl-Dipeptidase A; Protein Binding; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serine Endopeptidases; Tumor Suppressor Protein p53; Up-Regulation; Ventricular Function | 2001 |
The role of ANG II and endothelin-1 in exercise-induced diastolic dysfunction in heart failure.
Topics: Acetamides; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atrial Function, Left; Diastole; Disease Models, Animal; Dogs; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Losartan; Nitroprusside; Physical Exertion; Reference Values; Vasodilation; Ventricular Function, Left | 2001 |
Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease.
Topics: Acetylcholine; Aged; Angina Pectoris; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Arteries; Bradykinin; Chymases; Enalaprilat; Female; Heart Failure; Humans; In Vitro Techniques; Losartan; Male; Middle Aged; Oligopeptides; Peptidyl-Dipeptidase A; Serine Endopeptidases; Vascular Resistance; Vasoconstriction | 2001 |
Stage-specific differential activation of mitogen-activated protein kinases in hypertrophied and failing rat hearts.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Enzyme Activation; Gene Expression; Heart; Heart Failure; Heart Ventricles; Hemodynamics; Hypertrophy, Left Ventricular; In Vitro Techniques; JNK Mitogen-Activated Protein Kinases; Male; Mitogen-Activated Protein Kinases; Myocardium; p38 Mitogen-Activated Protein Kinases; Peptidyl-Dipeptidase A; Rats; RNA, Messenger | 2001 |
[Val-HeFT-Valsartan Heart Failure Trial].
Topics: Adult; Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Female; Heart Failure; Humans; International Cooperation; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Quality of Life; Randomized Controlled Trials as Topic | 2001 |
Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure.
Topics: Angiotensin II; Animals; Apoptosis; Biphenyl Compounds; Calcium Channel Blockers; Drug Evaluation, Preclinical; Gene Expression Regulation; Heart Failure; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Infusion Pumps, Implantable; Irbesartan; Male; Monocrotaline; Muscle Fibers, Fast-Twitch; Muscle Fibers, Slow-Twitch; Muscle Proteins; Muscle, Skeletal; Muscular Atrophy; Nifedipine; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Tetrazoles; Tumor Necrosis Factor-alpha | 2001 |
[Bilateral renal artery stenosis--a cause of acute pulmonary edema].
Topics: Acute Kidney Injury; Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diagnosis, Differential; Enalapril; Heart Failure; Humans; Hypertension; Hypertension, Renovascular; Male; Pulmonary Edema; Renal Artery Obstruction | 2001 |
Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophic left ventricular myocardium during transition to heart failure.
Topics: Angiotensin II; Angiotensinogen; Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Disease Progression; Endothelin-1; Endothelins; Gene Expression Regulation; Heart Failure; Heart Ventricles; Hemodynamics; Hypertrophy, Left Ventricular; Male; Organ Size; Peptidyl-Dipeptidase A; Protein Precursors; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides; Survival Analysis; Thiazepines; Time Factors | 2001 |
[ACE inhibitors for therapy of cardiac and kidney insufficiency].
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Constriction, Pathologic; Contraindications; Creatinine; Heart Failure; Humans; Renal Insufficiency | 2001 |
Effects of ACE inhibition and angiotensin II type 1 receptor blockade on cardiac function and G proteins in rats with chronic heart failure.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Body Weight; Chronic Disease; Collagen; Dose-Response Relationship, Drug; Fibroblasts; GTP-Binding Proteins; Heart; Heart Failure; Heart Septum; Heart Ventricles; Hemodynamics; Imidazoles; Indoles; Lung; Male; Organ Size; Peptidyl-Dipeptidase A; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Tetrazoles | 2001 |
Apoptosis in the skeletal muscle of rats with heart failure is associated with increased serum levels of TNF-alpha and sphingosine.
Topics: Angiotensin II; Animals; Apoptosis; Blotting, Western; Cells, Cultured; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Heart Failure; Heart Ventricles; Hypertrophy, Right Ventricular; In Situ Nick-End Labeling; Male; Muscle, Skeletal; Rats; Rats, Sprague-Dawley; Sphingosine; Tumor Necrosis Factor-alpha | 2001 |
Relationship between plasma level of cardiotrophin-1 and left ventricular mass index in patients with dilated cardiomyopathy.
Topics: Adolescent; Adult; Aged; Angiotensin II; Cardiomyopathy, Dilated; Case-Control Studies; Cytokines; Female; Heart Failure; Hemodynamics; Humans; Hypertrophy, Left Ventricular; Linear Models; Male; Middle Aged; Multivariate Analysis; Norepinephrine; Predictive Value of Tests; Radioimmunoassay; Severity of Illness Index; Signal Transduction; Stroke Volume; Ventricular Remodeling | 2001 |
AT(2) receptor-mediated vasodilation in the heart: effect of myocardial infarction.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Cardiac Output; Coronary Circulation; Heart Failure; Heart Rate; Imidazoles; Irbesartan; Male; Myocardial Infarction; Pyridines; Rats; Rats, Wistar; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renal Circulation; Survival Rate; Tetrazoles; Vasoconstriction; Vasoconstrictor Agents; Vasodilation | 2001 |
[Diastolic heart failure. Treatment].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Diastole; Diuretics; Heart Failure; Humans | 2000 |
Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Fibrillation; Dogs; Electrophysiology; Enalapril; Endomyocardial Fibrosis; Heart Atria; Heart Failure; Hemodynamics; Hydralazine; Isosorbide Dinitrate; Mitogen-Activated Protein Kinases; Renin-Angiotensin System; Signal Transduction; Tachycardia, Ventricular | 2001 |
beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure.
Topics: Adrenergic beta-Antagonists; Analysis of Variance; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Case-Control Studies; Drug Therapy, Combination; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Treatment Outcome | 2001 |
[Effects of angiotensin-converting enzyme inhibitors and cosaar on quality of life of patients with pulmonary tuberculosis and chronic heart failure].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Emotions; Heart Failure; Hemodynamics; Humans; Perindopril; Pulmonary Heart Disease; Quality of Life; Ramipril; Socioeconomic Factors; Surveys and Questionnaires; Tuberculosis, Pulmonary | 2001 |
[Changes of myocardial tissue and plasma angiotensin II in rats with pressure overload and effect of lujiao prescription].
Topics: Angiotensin II; Animals; Aorta, Abdominal; Constriction, Pathologic; Drugs, Chinese Herbal; Heart Failure; Hypertrophy, Left Ventricular; Male; Myocardium; Random Allocation; Rats; Rats, Wistar; Renin-Angiotensin System | 2000 |
Cardiac and renal effects of growth hormone in volume overload-induced heart failure: role of NO.
Topics: Angiotensin II; Animals; Atrial Natriuretic Factor; Body Weight; Cyclic GMP; Enzyme Inhibitors; Growth Hormone; Heart; Heart Failure; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Kidney; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type III; Organ Size; Rats; Rats, Wistar; Recombinant Proteins; RNA, Messenger; Ventricular Dysfunction, Left | 2002 |
Combined endopeptidase inhibition and adrenomedullin in sheep with experimental heart failure.
Topics: Adrenomedullin; Angiotensin II; Animals; Atrial Natriuretic Factor; Cyclic AMP; Cyclic GMP; Dipeptides; Drug Synergism; Female; Heart Failure; Hemodynamics; Kidney; Natriuretic Peptide, Brain; Neprilysin; Peptides; Protease Inhibitors; Renin; Sheep; Vasodilator Agents | 2002 |
Treatment of heart failure: state of the art and prospectives.
Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Cardiomegaly; Drug Therapy; Endothelins; Heart Failure; Humans; Norepinephrine; Review Literature as Topic; Spironolactone; Tumor Necrosis Factor-alpha; Ventricular Dysfunction, Left | 2001 |
Neurohormonal activation does not explain elevated tissue factor expression in heart failure.
Topics: Adult; Aged; Angiotensin II; Endothelin-1; Female; Gene Expression Regulation; Heart Failure; Humans; Male; Middle Aged; Monocytes; Norepinephrine; Thromboplastin | 2002 |
Activation of vascular tissue angiotensin-converting enzyme (ACE) in heart failure. Effects of ACE inhibitors.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Vessels; Heart Failure; Humans | 2002 |
Treatment of congestive heart failure.
Topics: Angioedema; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Heart Failure; Humans; Hydralazine; Nitrates; Vasodilator Agents | 2002 |
[Aldosterone blockade in heart failure. So much for so little].
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Clinical Trials as Topic; Coronary Circulation; Diuretics; Heart Failure; Hemodynamics; Humans; Microcirculation; Mineralocorticoid Receptor Antagonists; Placebos; Rats; Rats, Inbred WKY; Spironolactone | 2002 |
Humoral regulation of vascular resistance after 30 days of pulmonary artery constriction.
Topics: Angiotensin II; Animals; Cardiomegaly; Catecholamines; Dopamine; Epinephrine; Guinea Pigs; Heart Failure; Norepinephrine; Papaverine; Phentolamine; Phenylephrine; Saralasin; Sympathetic Nervous System; Tyrosine 3-Monooxygenase; Vascular Resistance | 1979 |
Differences in the regulation of vascular resistance in guinea pigs with right and left heart failure.
Topics: Angiotensin II; Animals; Aorta; Arterial Occlusive Diseases; Blood Gas Analysis; Cardiomegaly; Electric Stimulation; Guinea Pigs; Heart Failure; Heart Ventricles; Hemodynamics; Hindlimb; Male; Norepinephrine; Papaverine; Pulmonary Artery; Sympathectomy; Vascular Resistance; Vasomotor System | 1977 |
The renin-angiotensin-aldosterone system in congestive failure in conscious dogs.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Constriction, Pathologic; Dogs; Heart Failure; Oligopeptides; Pulmonary Artery; Renin; Sodium; Vena Cava, Inferior; Water-Electrolyte Balance | 1976 |
Aldosterone and renin-angiotensin responses to stimuli in patients with treated congestive heart failure.
Topics: Adrenocorticotropic Hormone; Aged; Aldosterone; Angiotensin II; Circadian Rhythm; Dose-Response Relationship, Drug; Female; Heart Failure; Humans; Hydrocortisone; Infusions, Parenteral; Male; Middle Aged; Posture; Potassium; Renin; Sodium | 1976 |
Effects of the oral converting enzyme inhibitor SQ 14225 in experimental high output failure.
Topics: Administration, Oral; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Dogs; Female; Heart Failure; Proline; Renin | 1979 |
Effects of the oral converting enzyme inhibitor, SQ 14225, in a model of low cardiac output in dogs.
Topics: Administration, Oral; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Ascites; Blood Pressure; Cardiac Output; Constriction; Creatinine; Disease Models, Animal; Dogs; Edema; Female; Heart Failure; Kidney; p-Aminohippuric Acid; Proline; Renin; Sodium; Vena Cava, Superior | 1979 |
[Infusion therapy in cardio-pulmonary insufficiency (author's transl)].
Topics: Angiotensin II; Blood Proteins; Cardiac Output; Heart Failure; Humans; Intensive Care Units; Mechanoreceptors; Parenteral Nutrition; Renin; Respiration, Artificial; Respiratory Insufficiency; Thoracic Injuries; Water-Electrolyte Imbalance | 1977 |
RAA in CHF.
Topics: Aldosterone; Angiotensin II; Edema; Heart Failure; Humans; Renin | 1979 |
Ultrasonodiagnosis of subclinical heart failure by increasing afterload with angiotensin II.
Topics: Adult; Aged; Angiotensin II; Blood Pressure; Cardiac Catheterization; Cardiac Output; Echocardiography; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Ultrasonography | 1979 |
Angiotensin II inhibition. Treatment of congestive cardiac failure in a high-renin hypertension.
Topics: Angiotensin II; Cardiac Output; Cardiac Volume; Coronary Circulation; Heart Failure; Humans; Hypertension, Renal; Male; Middle Aged; Oxygen Consumption; Pulmonary Circulation; Renin; Saralasin; Vascular Resistance | 1977 |
Angiotensin II blockade in congestive heart failure.
Topics: Adult; Aged; Angiotensin II; Cardiac Catheterization; Cardiac Output; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Saralasin; Vascular Resistance | 1978 |
Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure.
Topics: Adult; Aged; Angiotensin II; Blood Pressure; Cardiac Output; Female; Heart Failure; Humans; Male; Middle Aged; Norepinephrine; Pulmonary Circulation; Renin; Teprotide; Vascular Resistance; Vasoconstriction | 1978 |
Congestive heart failure in normotensive man. Haemodynamics, renin, and angiotensin II blockade.
Topics: Adult; Aged; Angiotensin II; Blood Pressure; Cardiac Output; Female; Heart; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Renin; Saralasin | 1978 |
The renin-angiotensin-aldosterone system in rabbits with congestive heart failure produced by aortic constriction.
Topics: Aldosterone; Angiotensin II; Animals; Aorta, Abdominal; Blood Pressure; Constriction, Pathologic; Dexamethasone; Disease Models, Animal; Heart Failure; Hematocrit; Lung; Male; Natriuresis; Pulmonary Edema; Rabbits; Renin; Sodium | 1977 |
Pharmacology of the renal circulation.
Topics: Angiotensin II; Animals; Blood Pressure; Diuresis; Epinephrine; Glomerular Filtration Rate; Heart Failure; Homeostasis; Humans; Kidney; Norepinephrine; Pharmacology; Prostaglandins E; Regional Blood Flow; Renin; Vascular Resistance; Vasoconstrictor Agents; Vasodilator Agents; Vasomotor System | 1977 |
Renin and aldosterone in the cardiomyopathic hamster in congestive heart failure.
Topics: Adrenal Glands; Aldosterone; Angiotensin II; Animals; Body Weight; Cricetinae; Heart; Heart Failure; Male; Mesocricetus; Muscles; Organ Size; Potassium; Renin; Sodium | 1977 |
Effect of potassium-sparing diuretics on the renin-angiotensin-aldosterone system and potassium retention in heart failure.
Topics: Adult; Aged; Aldosterone; Amiloride; Angiotensin II; Digoxin; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Potassium; Renin; Sodium; Spironolactone; Urea | 1976 |
Changes of blood pressure, plasma renin activity and plasma aldosterone concentration following the infusion of Sar1-Ile8-angiotensin II in hypertensive, fluid and electrolyte disorders.
Topics: Acidosis, Renal Tubular; Aldosterone; Angiotensin II; Bartter Syndrome; Blood Pressure; Cushing Syndrome; Edema; Heart Failure; Humans; Hyperaldosteronism; Hypertension; Hypertension, Malignant; Hypertension, Renal; Kidney Failure, Chronic; Liver Cirrhosis; Nephrotic Syndrome; Pheochromocytoma; Renin; Sodium; Time Factors; Water-Electrolyte Imbalance | 1976 |
The relationship between elevated water intake and oedema associated with congestive cardiac failure in the dog.
Topics: Angiotensin II; Animals; Blood Proteins; Dogs; Edema; Extracellular Space; Female; Heart Failure; Hematocrit; Ligation; Male; Osmolar Concentration; Plasma Volume; Potassium; Saralasin; Sodium; Thirst; Vena Cava, Inferior; Water Deprivation | 1975 |
High-output heart failure in the dog: systemic and intrarenal role of angiotensin II.
Topics: Angiotensin II; Animals; Blood Pressure; Creatinine; Dogs; Female; Glomerular Filtration Rate; Heart Failure; Kidney; Regional Blood Flow; Renin; Saralasin; Sodium | 1975 |
Renal blockade to angiotensin II in acute and chronic sodium-retaining states.
Topics: Angiotensin II; Animals; Constriction; Dogs; Female; Glomerular Filtration Rate; Heart Failure; Hemodynamics; Kidney; Kidney Cortex; Metabolic Clearance Rate; Regional Blood Flow; Renin; Saralasin; Sodium; Time Factors; Vena Cava, Inferior | 1975 |
The kidney in congestive heart failure.
Topics: Aldosterone; Angiotensin II; Heart Failure; Hematuria; Humans; Kidney; Kidney Failure, Chronic; Natriuresis; Renin; Vasopressins | 1975 |
[The fole of the renin-angiotensin system in secondary aldosteronism (author's transl)].
Topics: Adolescent; Adult; Aged; Angiotensin II; Female; Heart Failure; Humans; Hyperaldosteronism; Hypertension, Malignant; Hypertension, Renal; Liver Cirrhosis; Male; Middle Aged; Nephrotic Syndrome; Renin | 1975 |
Impact of enalapril therapy on in vitro coronary artery responsiveness in pacing-induced heart failure.
Topics: Acetylcholine; Adrenergic alpha-Agonists; Angiotensin I; Angiotensin II; Animals; Cardiac Pacing, Artificial; Coronary Vessels; Disease Models, Animal; Dogs; Enalapril; Endothelium, Vascular; Heart Failure; In Vitro Techniques; Male; Vasoconstriction | 1992 |
Comparison of the effect of renin inhibition and angiotensin-converting enzyme inhibition in ovine heart failure.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Captopril; Catheterization; Heart Failure; Hemodynamics; Male; Oligopeptides; Renin; Sheep | 1992 |
Enhanced urinary excretion of albumin in congestive heart failure: effect of ACE-inhibition.
Topics: Adult; Aged; Albuminuria; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; beta 2-Microglobulin; Captopril; Female; Heart Failure; Humans; Male; Middle Aged; Reference Values; Renin | 1992 |
Contrasting patterns of arterial and venous dilatation after intravenous captopril in patients with chronic cardiac failure and their relationship to plasma angiotensin II concentrations.
Topics: Aged; Angiotensin II; Arteries; Blood Pressure; Captopril; Female; Heart Atria; Heart Failure; Humans; Injections, Intravenous; Male; Middle Aged; Renin; Vascular Resistance; Vasodilation; Veins | 1992 |
[Vasoactive substances and growth].
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomegaly; Cell Division; Heart Failure; Humans | 1992 |
Determinants of the renal response to ACE inhibition in patients with congestive heart failure.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Female; Heart Failure; Humans; Isoquinolines; Kidney; Kidney Function Tests; Male; Middle Aged; Quinapril; Renal Circulation; Renin; Renin-Angiotensin System; Risk Factors; Tetrahydroisoquinolines | 1992 |
The relationship between diuretic dose, and the haemodynamic response to captopril in patients with cardiac failure.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Blood Pressure; Captopril; Cardiac Output; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Furosemide; Heart Failure; Hemodynamics; Humans; Infusions, Intravenous; Male; Middle Aged; Renin | 1992 |
Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure.
Topics: Alanine; Angiotensin II; Animals; Atrial Natriuretic Factor; Cyclic GMP; Dogs; Heart Failure; Hemodynamics; Kidney; Male; Neprilysin; Sodium | 1991 |
A lack of effect of captopril on platelet aggregation in patients with congestive heart failure.
Topics: Angiotensin II; Captopril; Heart Failure; Humans; Male; Platelet Aggregation; Renin; Serotonin | 1991 |
Modulation of coronary circulation and the cardiac matrix by the renin-angiotensin system.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Cardiac; Coronary Circulation; Heart Failure; Humans; Renin-Angiotensin System; Vasoconstriction | 1991 |
Cardiac remodelling and myocardial contractility in patients with congestive heart failure treated with furosemide and enalapril.
Topics: Aged; Angiotensin II; Cardiomegaly; Drug Therapy, Combination; Enalapril; Furosemide; Heart Failure; Humans; Male; Middle Aged; Myocardial Contraction | 1991 |
[Endothelin in arterial hypertension].
Topics: Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Endothelins; Heart Failure; Humans; Hypertension; Radioimmunoassay; Reference Values; Renin | 1991 |
[Symptoms complex of traditional Chinese medicine in patients with congestive heart failure].
Topics: Adult; Aged; Aged, 80 and over; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Female; Heart Failure; Humans; Male; Medicine, Chinese Traditional; Middle Aged; Yin-Yang | 1991 |
Acute administration of captopril lowers the natriuretic and diuretic response to a loop diuretic in patients with chronic cardiac failure.
Topics: Aged; Aged, 80 and over; Aldosterone; Angiotensin II; Blood Pressure; Captopril; Creatinine; Diuresis; Drug Interactions; Furosemide; Heart Failure; Humans; Male; Middle Aged; Natriuresis | 1991 |
Long-term treatment of congestive heart failure with oral ibopamine. Effects of rhythm disorders and neurohormonal alterations.
Topics: Administration, Oral; Aged; Aldosterone; Angiotensin II; Arrhythmias, Cardiac; Cardiotonic Agents; Deoxyepinephrine; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Heart Failure; Hemodynamics; Humans; Long-Term Care; Male; Middle Aged; Neurotransmitter Agents; Norepinephrine; Renin; Vasodilator Agents | 1990 |
Vasopressin and angiotensin II contribute equally to the increased afterload in rabbits with heart failure.
Topics: Angiotensin II; Animals; Arginine Vasopressin; Blood Pressure; Captopril; Cardiac Output; Disease Models, Animal; Female; Heart Failure; Male; Rabbits; Vascular Resistance; Vasopressins | 1991 |
[Effects of captopril on plasma renin activity angiotensin II and aldosterone level in cardiac failure patients].
Topics: Adult; Aged; Aldosterone; Angiotensin II; Captopril; Female; Heart Failure; Humans; Male; Middle Aged; Renin | 1991 |
Effect of captopril on congestive heart failure.
Topics: Aldosterone; Angiotensin I; Angiotensin II; Captopril; Epinephrine; Female; Half-Life; Heart Failure; Humans; Male; Metabolic Clearance Rate; Middle Aged; Norepinephrine; Renin | 1990 |
Atrial natriuretic factor. Is it physiologically important?
Topics: Angiotensin II; Animals; Atrial Natriuretic Factor; Blood Circulation; Drug Interactions; Heart Failure; Humans; Pressoreceptors; Vasodilation | 1990 |
Role of angiotensin II in altered glomerular hemodynamics in congestive heart failure.
Topics: Angiotensin II; Animals; Arterioles; Glomerular Filtration Rate; Heart Failure; Kidney Glomerulus; Male; Rats; Renal Circulation | 1990 |
[The role of the renin-angiotensin-aldosterone system and vasopressin in the development of heart failure during continuous electric stimulation of the heart].
Topics: Aldosterone; Angiotensin II; Blood Volume; Heart Failure; Hemodynamics; Humans; Pacemaker, Artificial; Renin-Angiotensin System; Sick Sinus Syndrome; Time Factors; Vascular Resistance; Vasopressins | 1990 |
Conceptual and therapeutic approaches to inhibition of the renin-angiotensin system in chronic heart failure.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Enalapril; Enalaprilat; Enzyme Activation; Heart Failure; Heart Rate; Hemodynamics; Humans; Renin-Angiotensin System; Saralasin; Sodium; Vasoconstriction | 1986 |
Clinical studies with a vascular vasopressin antagonist.
Topics: Angiotensin II; Arginine Vasopressin; Heart Failure; Hemodynamics; Humans; Hypertension; Smoking; Steam Bath; Vasopressins | 1986 |
Neuroendocrine activation in acute myocardial infarction.
Topics: Aged; Angiotensin II; Heart Failure; Hemodynamics; Humans; Middle Aged; Myocardial Infarction; Myocardium; Neurosecretory Systems; Renin-Angiotensin System | 1987 |
Haemodynamic effects of captopril in acute left ventricular failure complicating myocardial infarction.
Topics: Angiotensin II; Blood Pressure; Captopril; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Myocardial Infarction; Pulmonary Wedge Pressure; Renin | 1987 |
Captopril in congestive cardiac failure.
Topics: Angiotensin II; Captopril; Heart Failure; Humans; Vasodilation | 1989 |
Molecular biology and pathophysiology of the intrarenal renin-angiotensin system.
Topics: Angiotensin II; Angiotensinogen; Animals; Blotting, Northern; Gene Expression; Heart Failure; Hypertension, Renal; Kidney; Peptidyl-Dipeptidase A; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renin; Renin-Angiotensin System; RNA, Messenger | 1989 |
Neuroendocrine response in acute heart failure and the influence of treatment.
Topics: Acute Disease; Aged; Aldosterone; Angiotensin II; Arginine Vasopressin; Atrial Natriuretic Factor; Catecholamines; Cyclic GMP; Diuretics; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Neurotransmitter Agents | 1989 |
[The effect of bunazosin vs captopril on hemodynamic and neurohumoral parameters in patients with congestive heart failure].
Topics: Adrenergic alpha-Antagonists; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Captopril; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Quinazolines; Renin | 1989 |
[Echocardiography with angiotensin administration in the diagnosis of adriamycin-induced cardiomyopathy].
Topics: Adolescent; Adult; Angiotensin II; Cardiomyopathies; Dose-Response Relationship, Drug; Doxorubicin; Echocardiography; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Neoplasms | 1989 |
[Receptors for vasoactive peptides in experimental hypertension and cardiac insufficiency].
Topics: Angiotensin II; Animals; Atrial Natriuretic Factor; Heart Failure; Humans; Hypertension; Receptors, Angiotensin; Receptors, Atrial Natriuretic Factor; Receptors, Cell Surface; Receptors, Vasopressin; Vasopressins | 1988 |
Neurohumoral vasoconstrictor systems in heart failure.
Topics: Angiotensin II; Animals; Arginine Vasopressin; Captopril; Cardiac Output; Dogs; Heart; Heart Failure; Neurotransmitter Agents; Norepinephrine; Osmolar Concentration; Prazosin; Rats; Rats, Inbred Strains; Renin-Angiotensin System; Vascular Resistance; Vasoconstriction | 1985 |
Hemodynamic effects of synthetic atrial natriuretic factor (ANF) in dogs with acute left ventricular failure.
Topics: Angiotensin II; Animals; Atrial Natriuretic Factor; Coronary Disease; Creatinine; Dogs; Electrolytes; Female; Heart Failure; Hemodynamics; Kidney Function Tests; p-Aminohippuric Acid; Renal Circulation; Time Factors | 1985 |
Antidiuretic hormone and atrial natriuretic peptide in congestive heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Captopril; Female; Heart Failure; Humans; Male; Middle Aged; Renin; Tachycardia, Paroxysmal; Vasopressins | 1986 |
[Acute and long-term effect of captopril in severe chronic heart failure].
Topics: Adult; Aged; Angiotensin I; Angiotensin II; Captopril; Chronic Disease; Drug Evaluation; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Peptidyl-Dipeptidase A; Proline; Time Factors | 1985 |
Hormone and haemodynamic effects of angiotensin II infusion during captopril treatment for heart failure.
Topics: Adrenocorticotropic Hormone; Aged; Angiotensin II; Captopril; Female; Heart Failure; Hemodynamics; Hormones; Humans; Hydrocortisone; Male; Middle Aged; Norepinephrine; Proline | 1985 |
The kidney in heart failure.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Volume; Captopril; Diuresis; Glomerular Filtration Rate; Heart Failure; Homeostasis; Humans; Hyponatremia; Kidney; Kidney Tubules; Natriuresis; Natriuretic Agents; Prostaglandins; Renal Circulation; Renin; Renin-Angiotensin System; Sodium; Sympathetic Nervous System | 1986 |
Effects of ACE inhibition on renal regulation of salt and water.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Cholinesterase Inhibitors; Dinoprostone; Diuresis; Epoprostenol; Heart Failure; Humans; Hyponatremia; Natriuresis; Peptidyl-Dipeptidase A; Prostaglandins E; Renin; Renin-Angiotensin System | 1986 |
Plasma concentrations of angiotensin II and aldosterone during acute left ventricular failure in the dog. Effect of converting enzyme inhibition.
Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Dogs; Enalapril; Enalaprilat; Heart Failure; Hemodynamics | 1986 |
Angiotensin II, aldosterone and arginine vasopressin in plasma in congestive heart failure.
Topics: Aged; Aldosterone; Angiotensin II; Arginine Vasopressin; Drinking; Female; Heart Failure; Humans; Kidney Concentrating Ability; Male; Middle Aged; Renin-Angiotensin System; Water-Electrolyte Balance | 1986 |
Role of the kidney in congestive heart failure.
Topics: Angiotensin II; Animals; Blood Pressure; Glomerular Filtration Rate; Heart Failure; Heart Ventricles; Hemodynamics; Male; Myocardial Infarction; Natriuresis; Rats; Rats, Inbred Strains; Renal Circulation | 1986 |
Role of angiotensin II in the altered renal function of heart failure.
Topics: Angiotensin II; Animals; Denervation; Glomerular Filtration Rate; Heart Failure; Kidney; Kidney Cortex; Male; Microcirculation; Myocardial Infarction; Rats; Rats, Inbred Strains; Renin-Angiotensin System | 1987 |
Bicyclo-prostaglandin E2 metabolite in congestive heart failure and relation to vasoconstrictor neurohumoral principles.
Topics: Adult; Aged; Angiotensin II; Dinoprostone; Epinephrine; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Norepinephrine; Potassium; Prostaglandins E; Renin; Sodium; Vasoconstriction | 1986 |
Systemic and regional hemodynamic effects of isomazole in awake dogs with congestive heart failure.
Topics: Angiotensin II; Animals; Cardiac Output; Catecholamines; Dogs; Heart Failure; Heart Rate; Hemodynamics; Imidazoles; Isoproterenol; Myocardial Contraction; Propranolol; Regional Blood Flow; Sympathetic Nervous System; Vascular Resistance; Vasodilation | 1987 |
[Hemofiltration and the neurohumoral system in patients with severe heart failure].
Topics: Adult; Aldosterone; Angiotensin II; Blood; Catecholamines; Female; Heart Failure; Humans; Male; Middle Aged; Neurosecretory Systems; Renin; Sympathetic Nervous System; Ultrafiltration | 1985 |
[Blood plasma content of angiotensinogen in arterial hypertension, circulatory insufficiency, myocardial infarct and liver cirrhosis].
Topics: Adrenal Glands; Alpha-Globulins; Angiotensin II; Chronic Disease; Glomerulonephritis; Glucocorticoids; Heart Failure; Humans; Hypertension; Liver; Liver Cirrhosis; Myocardial Infarction; Renin | 1972 |
[Influence of intravenous perfusion of angiotensin II on the urinary elimination of sodium in edematous cardiac patients].
Topics: Angiotensin II; Heart Failure; Humans; In Vitro Techniques; Natriuresis | 1966 |
Angiotensin blood levels in hypertensive and non-hypertensive diseases.
Topics: Acute Kidney Injury; Angiotensin II; Glomerulonephritis; Heart Failure; Humans; Hyperaldosteronism; Hypertension; Hypertension, Renal; Liver Cirrhosis; Pyelonephritis | 1966 |
[Angiotensin intradermoreaction in patients with liver cirrhosis in the ascitic phase. Results and interpretation in relation to the pathogenesis of the altered hydrosaline metabolism in cirrhogenic liver diseases].
Topics: Aldosterone; Angiotensin II; Ascites; Diabetes Insipidus; Heart Failure; Humans; Hypertension; Jaundice; Liver Cirrhosis; Renin; Skin Tests; Sodium Chloride; Water | 1966 |
[The effect of an angiotensin infusion on the renal water-electrolyte excretion in liver cirrhosis and hydropic heart insufficiency].
Topics: Angiotensin II; Heart Failure; Humans; Infusions, Parenteral; Kidney Function Tests; Liver Cirrhosis; Water-Electrolyte Balance | 1965 |
Role of aldosterone in edema formation.
Topics: Aldosterone; Angiotensin II; Edema; Heart Failure; Humans; Hyperaldosteronism; Kidney; Liver; Liver Cirrhosis; Natriuresis; Nephrotic Syndrome; Renin; Secretory Rate | 1966 |
[The value of the angiotensin infusion test in differential diagnosis].
Topics: Angiotensin II; Glomerulonephritis; Heart Failure; Humans; Hypertension; Liver Cirrhosis; Metaraminol | 1967 |
Drug effects on cardiac myosin adenosine triphosphatase activity.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Angiotensin II; Animals; Binding Sites; Calcium; Chloralose; Cyclopropanes; Digoxin; Dogs; Epinephrine; Ethers; Heart; Heart Failure; In Vitro Techniques; Isoproterenol; Lidocaine; Magnesium; Muscle Contraction; Muscle Proteins; Myocardium; Nitrous Oxide; Norepinephrine; Ouabain; Pentobarbital; Pharmacology; Procainamide; Protein Binding; Quinidine; Secobarbital | 1967 |
[Results of the determination of plasma renin].
Topics: Anemia; Angiotensin II; Cushing Syndrome; Diagnosis, Differential; Female; Heart Failure; Humans; Hyperaldosteronism; Hypertension, Renal; Hyperthyroidism; Liver Cirrhosis; Nephritis; Pregnancy; Pregnancy Complications; Pyelonephritis; Renin; Sodium | 1967 |
[Hormonal interference with water and electrolyte metabolism in congestive heart failure].
Topics: Aldosterone; Angiotensin II; Estrogens; Glucocorticoids; Heart Failure; Humans; Kidney; Progesterone; Vasopressins; Water-Electrolyte Balance | 1966 |
[Clinical study of cardiac asthma].
Topics: Aged; Angiotensin II; Blood Pressure; Bradycardia; Cardiac Output; Cardiomegaly; Circadian Rhythm; Dyspnea, Paroxysmal; Epinephrine; Exercise Test; Female; Heart Failure; Heart Valve Diseases; Hemodynamics; Humans; Hypertension; Infusions, Parenteral; Male; Middle Aged; Norepinephrine; Posture; Pulmonary Circulation; Serum Albumin, Radio-Iodinated | 1967 |
Deoxycorticosterone secretion in chronic experimental heart failure and during infusion of angiotensin II.
Topics: Aldosterone; Angiotensin II; Animals; Carbon Isotopes; Chromatography, Paper; Corticosterone; Desoxycorticosterone; Dogs; Female; Heart Failure; Infusions, Parenteral; Tritium | 1968 |
Electrical pacing of the heart with observations on the single and paired electrical stimuli during acute reversible experimental heart failure in the anaesthetized dog.
Topics: Angiotensin II; Animals; Cardiac Output; Dogs; Electric Stimulation; Electrocardiography; Heart Atria; Heart Failure; Heart Rate; Heart Ventricles; Methods; Models, Theoretical; Pacemaker, Artificial | 1968 |
Plasma renin and angiotensinogen levels in pathological states associated with oedema.
Topics: Adolescent; Angiotensin II; Child; Child, Preschool; Edema; Glomerulonephritis; Heart Failure; Humans; Infant; Liver Cirrhosis; Liver Diseases; Nephrotic Syndrome; Protein-Losing Enteropathies; Renin | 1968 |
[The physiological relationship between the renin-angiotensin system and aldosterone].
Topics: Adult; Aldosterone; Angiotensin II; Diet, Sodium-Restricted; Female; Heart Failure; Humans; Hyperaldosteronism; Liver Cirrhosis; Nephrotic Syndrome; Norepinephrine; Pregnancy; Radiography; Renal Artery Obstruction; Renin; Sodium | 1965 |
Systemic effects of intestinal revascularization.
Topics: Adult; Aged; Angiotensin II; Embolism; Female; Heart Failure; Hepatic Encephalopathy; Humans; Male; Mesenteric Vascular Occlusion; Middle Aged; Postoperative Complications; Pulmonary Edema; Thrombosis; Urination; Water-Electrolyte Balance | 1969 |
[Clinical aspects of intrarenal hemodynamics].
Topics: Angiotensin II; Animals; Autoradiography; Catecholamines; Deficiency Diseases; Heart Failure; Humans; Kidney; Krypton; Regional Blood Flow; Renin; Shock, Hemorrhagic; Sodium | 1969 |
[Observations on the behavior of plasma angiotensin activity during congestive cardiac failure].
Topics: Adult; Aged; Angiotensin II; Female; Heart Failure; Heart Valve Diseases; Humans; Male; Middle Aged; Renin | 1967 |
[Secondary hyperaldosteronisms].
Topics: Aldosterone; Angiotensin II; Heart Failure; Hyperaldosteronism; Hyperkalemia; Hypertension, Malignant; Hypertension, Renal; Hypokalemia; Kidney Failure, Chronic; Liver Cirrhosis; Norepinephrine; Pheochromocytoma; Potassium; Renin; Stimulation, Chemical | 1969 |
[Importance of the angiotensin perfusion for the diagnosis of renovascular diseases].
Topics: Adolescent; Adult; Aged; Angiotensin II; Diagnosis, Differential; Female; Glomerulonephritis; Heart Failure; Humans; Hypertension; Hypertension, Malignant; Hypertension, Renal; Male; Methods; Middle Aged; Perfusion | 1968 |
Plasma renin in congestive heart failure in man.
Topics: Aged; Aldosterone; Angiotensin II; Diet, Sodium-Restricted; Digoxin; Female; Furosemide; Heart Failure; Humans; Male; Middle Aged; Renin; Sodium; Time Factors | 1970 |
[Physiopathology of the kidney in congestive heart insufficiency].
Topics: Aldosterone; Angiotensin II; Heart Failure; Hemodynamics; Humans; Kidney; Sodium | 1970 |
Effect of furosemide and hydrochlorothiazide on plasma renin activity in man.
Topics: Administration, Oral; Aldosterone; Angiotensin II; Furosemide; Heart Failure; Humans; Hydrochlorothiazide; Renin; Sodium | 1970 |
Plasma renin activity and the effects of deoxycorticosterone acetate in dogs with chronic left ventricular overload.
Topics: Acetates; Angiotensin II; Animals; Aorta, Thoracic; Chronic Disease; Desoxycorticosterone; Disease Models, Animal; Dogs; Heart; Heart Atria; Heart Failure; Methods; Natriuresis; Pulmonary Edema; Renin | 1970 |
[The kidney and adrenal glands in experimental heart failure].
Topics: Adrenal Glands; Aldosterone; Angiotensin II; Animals; Cricetinae; Heart Failure; Kidney; Renin; Water-Electrolyte Balance | 1971 |
Left ventricular function in chronic obstructive lung disease.
Topics: Angiotensin II; Blood Pressure; Bronchitis; Carbon Dioxide; Cardiac Catheterization; Cardiac Output; Cardiomegaly; Cineangiography; Coronary Angiography; Heart Failure; Heart Function Tests; Heart Ventricles; Hemodynamics; Humans; Hypercapnia; Lung Diseases; Lung Diseases, Obstructive; Oxygen; Pulmonary Emphysema; Spirometry | 1971 |
[Orthostatic hypotension following cyclazenine medication].
Topics: Angiotensin II; Antihypertensive Agents; Electrocardiography; Ergoloid Mesylates; Ergotamine; Female; Heart Failure; Humans; Hypertension; Hypotension, Orthostatic; Methyldopa; Middle Aged; Norepinephrine; Phytotherapy; Piperidines; Plants, Medicinal; Pulmonary Edema; Rauwolfia; Sympatholytics | 1970 |
[Radioimmunologic determination of angiotensin 2. Study on healthy individuals and on patients with congestive heart failure].
Topics: Adolescent; Adult; Aged; Angiotensin II; Animals; Antibodies; Chromatography; Diet, Sodium-Restricted; Heart Failure; Humans; Iodine Isotopes; Middle Aged; Rabbits; Radioimmunoassay | 1971 |
Mesenteric vasoconstriction after endotoxin administration in cats pretreated with aspirin.
Topics: Angiotensin II; Animals; Aspirin; Blood Platelets; Blood Pressure; Cats; Endotoxins; Heart Failure; Hypophysectomy; Hypotension; Ischemia; Mesenteric Arteries; Nephrectomy; Phenoxybenzamine; Pulmonary Edema; Time Factors; Vasoconstrictor Agents; Vasopressins | 1971 |
A steady-state control analysis of the renin-angiotensin-aldosterone system.
Topics: Absorption; Aldosterone; Angiotensin II; Animals; Blood Pressure; Constriction; Diet; Feedback; Heart Failure; Hemorrhage; Homeostasis; Kidney Glomerulus; Kidney Tubules; Models, Biological; Pressoreceptors; Renin; Sodium; Sympathetic Nervous System; Vena Cava, Inferior | 1972 |
[Regulation of the renin-angiotensin system in congestive heart failure: indications for a total body sodium-dependent regulation of the renin secretion].
Topics: Adult; Aged; Angiotensin II; Female; Furosemide; Heart Failure; Humans; Injections, Intravenous; Male; Middle Aged; Natriuresis; Potassium; Radioimmunoassay; Renin; Sodium; Time Factors; Water-Electrolyte Balance | 1972 |
Mechanisms regulating renin release in dogs with thoracic caval constriction.
Topics: Angiotensin II; Animals; Ascites; Blood Pressure; Constriction; Creatinine; Disease Models, Animal; Dogs; Female; Glomerular Filtration Rate; Heart Failure; Kidney; Natriuresis; Papaverine; Potassium; Propranolol; Receptors, Drug; Regional Blood Flow; Renal Artery; Renin; Sodium; Sympathetic Nervous System; Vena Cava, Inferior | 1972 |
[Plasma renin in patients with congestive heart failure].
Topics: Angiotensin II; Heart Failure; Humans; Renin | 1970 |
Adrenergic control of the peripheral circulation in cardiomyopathic hamsters with heart failure.
Topics: Angiotensin II; Animals; Aorta; Arteries; Blood Flow Velocity; Blood Pressure; Blood Vessels; Catecholamines; Cricetinae; Electric Stimulation; Fluorometry; Heart; Heart Failure; Heart Rate; Myocardium; Nerve Crush; Norepinephrine; Vascular Resistance; Vasomotor System | 1973 |
Proceedings: Increased drinking in dogs during congestive heart failure.
Topics: Angiotensin II; Animals; Body Weight; Constriction; Dogs; Drinking Behavior; Extracellular Space; Heart Failure; Isoproterenol; Time Factors; Vena Cava, Inferior; Water | 1973 |
Editorial: Analysis of congestive heart failure in terms of ventricular function curves.
Topics: Angiotensin II; Blood Pressure; Cardiac Output; Heart Failure; Heart Function Tests; Heart Ventricles; Humans; Stimulation, Chemical | 1973 |
Left ventricular function in chronic obstructive pulmonary disease with and without cardiac failure.
Topics: Age Factors; Angiotensin II; Blood Circulation; Blood Pressure; Carbon Dioxide; Cardiac Catheterization; Cardiac Output; Female; Heart; Heart Failure; Heart Rate; Heart Ventricles; Humans; Lung Diseases, Obstructive; Male; Middle Aged; Oxygen; Physical Exertion | 1973 |
Response of plasma aldosterone to postural change, diuretica, angiotensin II, sodium restriction or loading and prostaglandin.
Topics: Adrenocortical Hyperfunction; Aldosterone; Angiotensin II; Ascites; Cushing Syndrome; Diet; Diet, Sodium-Restricted; Furosemide; Heart Failure; Humans; Hyperaldosteronism; Hypertension; Liver Cirrhosis; Posture; Prostaglandins; Radioimmunoassay; Sodium; Uremia | 1973 |
The renin-angiotensin system (second of two parts).
Topics: Angiotensin II; Arteries; Extracellular Space; Female; Heart Failure; Humans; Hyperaldosteronism; Hypertension; Hypertension, Malignant; Hypertension, Renal; Kidney Failure, Chronic; Kidney Neoplasms; Liver Diseases; Mineralocorticoids; Pre-Eclampsia; Pregnancy; Renin; Sodium; Wilms Tumor | 1974 |
[Symposium on pathophysiology of congestive heart failure. 1. Relationship of renin-angiotensin-aldosterone system to cardio-renal hemodynamics on chronic congestive heart failure (author's transl)].
Topics: Aldosterone; Angiotensin II; Chronic Disease; Heart; Heart Failure; Hemodynamics; Humans; Kidney; Renin; Sodium | 1973 |